AMYOTROPHIC LATERAL SCLEROSIS A
3-in-1
Medical
Reference
A Bibliography and Dictionary for Physicians, Patients, and Genome Researchers TO INTERNET REFERENCES
AMYOTROPHIC LATERAL SCLEROSIS A BIBLIOGRAPHY AND DICTIONARY FOR PHYSICIANS, PATIENTS, AND GENOME RESEARCHERS
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 7404 Trade Street San Diego, CA 92121 USA Copyright ©2007 by ICON Group International, Inc. Copyright ©2007 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher’s note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Amyotrophic Lateral Sclerosis: A Bibliography and Dictionary for Physicians, Patients, and Genome Researchers/ James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-497-11327-9 1. Amyotrophic Lateral Sclerosis-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on amyotrophic lateral sclerosis. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Chaired Professor of Management Science at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 7404 Trade Street San Diego, CA 92121 USA Fax: 858-635-9414 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON AMYOTROPHIC LATERAL SCLEROSIS ....................................................... 3 Overview........................................................................................................................................ 3 Genetics Home Reference ............................................................................................................... 3 What Is Amyotrophic Lateral Sclerosis?........................................................................................ 3 How Common Is Amyotrophic Lateral Sclerosis? ......................................................................... 4 What Genes Are Related to Amyotrophic Lateral Sclerosis?......................................................... 4 How Do People Inherit Amyotrophic Lateral Sclerosis? ............................................................... 5 Where Can I Find Additional Information about Amyotrophic Lateral Sclerosis? ....................... 5 References....................................................................................................................................... 7 What Is the Official Name of the ALS2 Gene? .............................................................................. 8 What Is the Normal Function of the ALS2 Gene? ......................................................................... 8 What Conditions Are Related to the ALS2 Gene?......................................................................... 8 Where Is the ALS2 Gene Located?................................................................................................. 9 References....................................................................................................................................... 9 What Is the Official Name of the SETX Gene?............................................................................ 10 What Is the Normal Function of the SETX Gene? ...................................................................... 10 What Conditions Are Related to the SETX Gene? ...................................................................... 10 Where Is the SETX Gene Located? .............................................................................................. 11 References..................................................................................................................................... 11 What Is the Official Name of the SOD1 Gene? ........................................................................... 12 What Is the Normal Function of the SOD1 Gene?...................................................................... 12 What Conditions Are Related to the SOD1 Gene?...................................................................... 12 Where Is the SOD1 Gene Located?.............................................................................................. 13 References..................................................................................................................................... 13 What Is the Official Name of the VAPB Gene? ........................................................................... 14 What Is the Normal Function of the VAPB Gene?...................................................................... 14 What Conditions Are Related to the VAPB Gene?...................................................................... 14 Where Is the VAPB Gene Located?.............................................................................................. 15 References..................................................................................................................................... 15 What Is the Official Name of the NEFH Gene? ........................................................................... 16 What Is the Normal Function of the NEFH Gene? ..................................................................... 16 What Conditions Are Related to the NEFH Gene? ..................................................................... 16 Where Is the NEFH Gene Located? ............................................................................................. 16 References..................................................................................................................................... 17 What Is the Official Name of the SMN1 Gene?........................................................................... 18 What Is the Normal Function of the SMN1 Gene? ..................................................................... 18 What Conditions Are Related to the SMN1 Gene? ..................................................................... 18 Where Is the SMN1 Gene Located? ............................................................................................. 19 References..................................................................................................................................... 19 What Is the Official Name of the SMN2 Gene?........................................................................... 20 What Is the Normal Function of the SMN2 Gene? ..................................................................... 20 What Conditions Are Related to the SMN2 Gene? ..................................................................... 21 Where Is the SMN2 Gene Located? ............................................................................................. 21 References..................................................................................................................................... 22 Federally Funded Research on Amyotrophic Lateral Sclerosis .................................................... 23 The National Library of Medicine: PubMed ................................................................................ 79 CHAPTER 2. ALTERNATIVE MEDICINE AND AMYOTROPHIC LATERAL SCLEROSIS ..................... 125 Overview.................................................................................................................................... 125 National Center for Complementary and Alternative Medicine................................................ 125 Additional Web Resources ......................................................................................................... 138
viii Contents
General References ..................................................................................................................... 139 CHAPTER 3. PATENTS ON AMYOTROPHIC LATERAL SCLEROSIS .................................................. 140 Overview.................................................................................................................................... 140 Patent Applications on Amyotrophic Lateral Sclerosis ............................................................. 140 Keeping Current ........................................................................................................................ 143 CHAPTER 4. BOOKS ON AMYOTROPHIC LATERAL SCLEROSIS...................................................... 144 Overview.................................................................................................................................... 144 Book Summaries: Online Booksellers......................................................................................... 144 The National Library of Medicine Book Index ........................................................................... 145 CHAPTER 5. MULTIMEDIA ON AMYOTROPHIC LATERAL SCLEROSIS ........................................... 147 Overview.................................................................................................................................... 147 Bibliography: Multimedia on Amyotrophic Lateral Sclerosis.................................................... 147 APPENDIX A. HELP ME UNDERSTAND GENETICS ....................................................................... 149 Overview.................................................................................................................................... 149 The Basics: Genes and How They Work..................................................................................... 149 Genetic Mutations and Health................................................................................................... 160 Inheriting Genetic Conditions ................................................................................................... 166 Genetic Consultation ................................................................................................................. 174 Genetic Testing .......................................................................................................................... 176 Gene Therapy ............................................................................................................................. 182 The Human Genome Project and Genomic Research................................................................. 185 APPENDIX B. PHYSICIAN RESOURCES ........................................................................................... 188 Overview.................................................................................................................................... 188 NIH Guidelines.......................................................................................................................... 188 NIH Databases........................................................................................................................... 189 Other Commercial Databases..................................................................................................... 192 The Genome Project and Amyotrophic Lateral Sclerosis ........................................................... 192 APPENDIX C. PATIENT RESOURCES .............................................................................................. 197 Overview.................................................................................................................................... 197 Patient Guideline Sources.......................................................................................................... 197 Finding Associations.................................................................................................................. 202 Resources for Patients and Families........................................................................................... 203 ONLINE GLOSSARIES................................................................................................................ 204 Online Dictionary Directories ................................................................................................... 207 AMYOTROPHIC LATERAL SCLEROSIS DICTIONARY.................................................... 208 INDEX .............................................................................................................................................. 271
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: “The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading.”1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with amyotrophic lateral sclerosis is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about amyotrophic lateral sclerosis, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to amyotrophic lateral sclerosis, from the essentials to the most advanced areas of research. Special attention has been paid to present the genetic basis and pattern of inheritance of amyotrophic lateral sclerosis. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on amyotrophic lateral sclerosis. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to amyotrophic lateral sclerosis, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. We hope these resources will prove useful to the widest possible audience seeking information on amyotrophic lateral sclerosis. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/.
3
CHAPTER 1. STUDIES ON AMYOTROPHIC LATERAL SCLEROSIS Overview In this chapter, we will show you how to locate peer-reviewed references and studies on amyotrophic lateral sclerosis. For those interested in basic information about amyotrophic lateral sclerosis, we begin with a condition summary published by the National Library of Medicine.
Genetics Home Reference Genetics Home Reference (GHR) is the National Library of Medicine’s Web site for consumer information about genetic conditions and the genes or chromosomes responsible for those conditions. Here you can find a condition summary on amyotrophic lateral sclerosis that describes the major features of the condition, provides information about the condition’s genetic basis, and explains its pattern of inheritance. In addition, a summary of the gene or chromosome related to amyotrophic lateral sclerosis is provided. 2 The Genetics Home Reference has recently published the following summary for amyotrophic lateral sclerosis:
What Is Amyotrophic Lateral Sclerosis?3 Amyotrophic lateral sclerosis is a progressive disease that affects the control of muscle movement by damaging motor neurons, which are specialized nerve cells in the spinal cord and the part of the brain that is connected to the spinal cord (the brainstem). More than 90 percent of amyotrophic lateral sclerosis cases occur in people with no family history of the disorder (sporadic cases). The cause of sporadic cases remains largely unknown. Only a
2 3
This section has been adapted from the National Library of Medicine: http://ghr.nlm.nih.gov/.
Adapted from the Genetics Home Reference of the National Library of Medicine: http://ghr.nlm.nih.gov/condition=amyotrophiclateralsclerosis.
4
Amyotrophic Lateral Sclerosis
small percentage of amyotrophic lateral sclerosis cases are caused by a known genetic mutation; these cases are referred to as inherited or familial. The first signs and symptoms of amyotrophic lateral sclerosis may be so subtle that they are overlooked. The earliest symptoms include muscle twitching, cramping, stiffness, or weakness. Speech may become slurred, and later there is difficulty chewing or swallowing. The muscles become weaker as the disease progresses, and arms and legs begin to look thinner as muscle tissue wastes away (atrophies). Individuals with this disorder lose their strength, the ability to walk, and use of their hands and arms. In late stages of the disease, breathing becomes difficult because the muscles of the respiratory system weaken. Most people with amyotrophic lateral sclerosis die from respiratory failure. Different types of familial amyotrophic lateral sclerosis are distinguished by genetic cause, pattern of inheritance, age when symptoms begin, and disease progression. Onset of symptoms in adulthood is characteristic of amyotrophic lateral sclerosis types 1 and 8. Symptoms of type 1 usually begin between 40 and 60 years of age and progress rapidly. Most individuals with type 1 amyotrophic lateral sclerosis die of respiratory failure within 3 to 5 years of the onset of symptoms. Symptoms of type 8 amyotrophic lateral sclerosis begin earlier than type 1 (between 25 and 44 years of age) but progress slowly over several years to several decades. Juvenile or early onset of symptoms is characteristic of amyotrophic lateral sclerosis types 2 and 4. Type 2 symptoms usually begin in early childhood or adolescence and slowly worsen for 10 to 15 years. Symptoms of type 4 amyotrophic lateral sclerosis typically begin before age 25 and slowly progress over several decades. Additional types of amyotrophic lateral sclerosis have been reported, but the responsible mutations have not been adequately described.
How Common Is Amyotrophic Lateral Sclerosis? An estimated 5,000 people in the United States are diagnosed with amyotrophic lateral sclerosis each year. Worldwide, this disorder occurs in 4 to 8 per 100,000 individuals. Only a small percentage of cases arise from a known genetic cause. About 3 percent of sporadic cases and 20 percent of familial cases are considered type 1. Types 2, 4, and 8 are rare disorders, reported in a small number of families.
What Genes Are Related to Amyotrophic Lateral Sclerosis? Mutations in the ALS2 (http://ghr.nlm.nih.gov/gene=als2), SETX (http://ghr.nlm.nih.gov/gene=setx), SOD1 (http://ghr.nlm.nih.gov/gene=sod1), and VAPB (http://ghr.nlm.nih.gov/gene=vapb) genes cause amyotrophic lateral sclerosis. Variations of the NEFH (http://ghr.nlm.nih.gov/gene=nefh), SMN1 (http://ghr.nlm.nih.gov/gene=smn1), and SMN2 (http://ghr.nlm.nih.gov/gene=smn2) genes increase the risk of developing amyotrophic lateral sclerosis. Each type of familial amyotrophic lateral sclerosis is caused by mutations in a specific gene. Type 1 is caused by mutations in the SOD1 gene, type 2 by ALS2 mutations, type 4 by mutations in the SETX gene, and type 8 by VAPB mutations. These mutations contribute to the decline and death of motor neurons, which leads to muscle weakness and atrophy. Not
Studies
5
all familial cases are due to SOD1, ALS2, SETX, or VAPB mutations. Other genes are thought to cause amyotrophic lateral sclerosis, but they have not been identified or fully characterized. Mutations in the NEFH gene appear to increase the risk of developing amyotrophic lateral sclerosis. Research findings also suggest that a decrease in the number of SMN1 or SMN2 genes leads to an increased chance of developing this disorder. It is unclear how variations in these gene lead to an increased risk.
How Do People Inherit Amyotrophic Lateral Sclerosis? The pattern of inheritance varies with the type of amyotrophic lateral sclerosis. Type 2 amyotrophic lateral sclerosis is inherited in an autosomal recessive pattern, which means two copies of the gene in each cell are altered. Most often, the parents of an individual with an autosomal recessive disorder are carriers of one copy of the altered gene but do not show signs and symptoms of the disorder. Amyotrophic lateral sclerosis types 1, 4, and 8 are inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. Studies in Sweden and Finland, however, revealed a small number of type 1 cases that are inherited in an autosomal recessive pattern.
Where Can I Find Additional Information about Amyotrophic Lateral Sclerosis? You may find the following resources about amyotrophic lateral sclerosis helpful. These materials are written for the general public. NIH Publications - National Institutes of Health •
National Center for Biotechnology Information: Genes and Disease: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View.ShowSection&rid=gn d.section.194
•
National Institute of Neurological Disorders and Stroke: ALS fact sheet: http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_amyotrophicl ateralsclerosis.htm
•
National Institute of Neurological Disorders and Stroke: Senataxin gene linked to juvenile-onset ALS: http://www.ninds.nih.gov/news_and_events/news_articles/news_article_als4.htm MedlinePlus - Health Information
•
Encyclopedia: Amyotrophic lateral sclerosis: http://www.nlm.nih.gov/medlineplus/ency/article/000688.htm
•
Health Topic: Amyotrophic Lateral Sclerosis: http://www.nlm.nih.gov/medlineplus/amyotrophiclateralsclerosis.html
6
Amyotrophic Lateral Sclerosis
Educational Resources - Information Pages •
American Speech-Language-Hearing Association: http://www.asha.org/public/speech/disorders/Amyotrophic-lateral-sclerosis.htm
•
Duke Center for Human Genetics: http://www.chg.duke.edu/diseases/als.html
•
KidsHealth (Nemours Foundation): http://kidshealth.org/kid/grownup/conditions/als.html
•
Mayo Clinic: http://www.mayoclinic.org/lou-gehrigs-disease/index.html
•
New York Online Access to Health (NOAH): http://www.noah-health.org/en/bns/disorders/lougehrig/index.html
•
Orphanet: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=803
•
World Federation of Neurology-ALS: http://www.wfnals.org Patient Support - for Patients and Families
•
Les Turner Amyotrophic Lateral Sclerosis Foundation: http://www.lesturnerals.org/als.htm
•
Muscular Dystrophy Association: http://als.mdausa.org/
•
National Organization for Rare Disorders (NORD): http://www.rarediseases.org/search/rdbdetail_abstract.html?disname=Amyotrophic+L ateral+Sclerosis
•
Project ALS: http://www.projectals.org
•
The ALS Association: http://www.alsa.org/als
•
The ALS Society of Canada: http://www.als.ca/ Professional Resources
You may also be interested in these resources, which are designed for healthcare professionals and researchers. •
Gene Reviews - Clinical summary: http://ghr.nlm.nih.gov/condition=amyotrophiclateralsclerosis/show/Gene+Reviews;js essionid=62691805C4C5F3409543E26AE3172532
•
Gene Tests - DNA tests ordered by healthcare professionals: http://ghr.nlm.nih.gov/condition=amyotrophiclateralsclerosis/show/Gene+Tests;jsessi onid=62691805C4C5F3409543E26AE3172532
Studies
7
•
ClinicalTrials.gov - Linking patients to medical research: http://clinicaltrials.gov/search/condition=%22amyotrophic+lateral+sclerosis%22?recru iting=false
•
PubMed - Recent literature: http://ghr.nlm.nih.gov/condition=amyotrophiclateralsclerosis/show/PubMed;jsessioni d=62691805C4C5F3409543E26AE3172532
•
OMIM - Genetic disorder catalog: http://ghr.nlm.nih.gov/condition=amyotrophiclateralsclerosis/show/OMIM;jsessionid =62691805C4C5F3409543E26AE3172532
References These sources were used to develop the Genetics Home Reference condition summary on amyotrophic lateral sclerosis. •
Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, Dierick I, Abel A, Kennerson ML, Rabin BA, Nicholson GA, Auer-Grumbach M, Wagner K, De Jonghe P, Griffin JW, Fischbeck KH, Timmerman V, Cornblath DR, Chance PF. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004 Jun;74(6):1128-35. Epub 2004 Apr 21. PubMed citation
•
Gene Reviews: Amyotrophic lateral sclerosis overview
•
Hand CK, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve. 2002 Feb;25(2):135-59. Review. PubMed citation
•
Jackson M, Llado J, Rothstein JD. Therapeutic developments in the treatment of amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2002 Oct;11(10):1343-64. Review. PubMed citation
•
Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet. 2004 Dec;75(6):933-47. Epub 2004 Oct 11. No abstract available. PubMed citation
•
Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion. 2005 Apr;5(2):77-87. Review. PubMed citation
•
National Institute of Neurological Disorders and Stroke: ALS fact sheet
•
Rao SD, Weiss JH. Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci. 2004 Jan;27(1):17-23. Review. No abstract available. PubMed citation
•
Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol. 2005 Aug;64(8):649-64. Review. PubMed citation
•
Veldink JH, Kalmijn S, Van der Hout AH, Lemmink HH, Groeneveld GJ, Lummen C, Scheffer H, Wokke JH, Van den Berg LH. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology. 2005 Sep 27;65(6):820-5. Epub 2005 Aug 10. PubMed citation
8
Amyotrophic Lateral Sclerosis
A summary of the genes related to amyotrophic lateral sclerosis is provided below:
What Is the Official Name of the ALS2 Gene?4 The official name of this gene is “amyotrophic lateral sclerosis 2 (juvenile).” ALS2 is the gene's official symbol. The ALS2 gene is also known by other names, listed below.
What Is the Normal Function of the ALS2 Gene? The ALS2 gene provides instructions for making a protein called alsin. Alsin is produced in a wide range of tissues, with highest amounts in the brain. It is also abundant in motor neurons, the specialized nerve cells in the brain and spinal cord that control the movement of muscles. The function of alsin, however, is unknown. It may play a role in regulating cell membrane organization, movement of molecules inside the cell, and assembly of the network of filaments and tubules (cytoskeleton) that gives shape and structure to the cell contents.
What Conditions Are Related to the ALS2 Gene? Amyotrophic Lateral Sclerosis - Caused by Mutations in the ALS2 Gene Two ALS2 mutations that cause type 2 amyotrophic lateral sclerosis have been identified. These mutations delete a single DNA building block (base pair), which disrupts the instructions for producing alsin. As a result, alsin is unstable and decays rapidly, or it is disabled and cannot function properly. It is unknown how the loss of functional alsin protein causes the death of motor neurons and the symptoms of amyotrophic lateral sclerosis, type 2. Infantile-Onset Ascending Hereditary Spastic Paralysis - Caused by Mutations in the ALS2 Gene Two ALS2 mutations that cause type 2 amyotrophic lateral sclerosis have been identified. These mutations delete a single DNA building block (base pair), which disrupts the instructions for producing alsin. As a result, alsin is unstable and decays rapidly, or it is disabled and cannot function properly. It is unknown how the loss of functional alsin protein causes the death of motor neurons and the symptoms of amyotrophic lateral sclerosis, type 2.
4
Adapted from the Genetics Home Reference of the National Library of Medicine: http://ghr.nlm.nih.gov/gene=als2;jsessionid=62691805C4C5F3409543E26AE3172532.
Studies
9
Juvenile Primary Lateral Sclerosis - Caused by Mutations in the ALS2 Gene Several ALS2 mutations have been identified in patients with infantile-onset ascending hereditary spastic paralysis. These mutations change or delete one or more DNA building blocks (base pairs), which disrupts the instructions for producing alsin. As a result, alsin is unstable and decays rapidly, or it is disabled and cannot function properly. It is unknown how the loss of functional alsin protein causes the death of motor neurons and the symptoms of infantile-onset hereditary spastic paralysis.
Where Is the ALS2 Gene Located? Cytogenetic Location: 2q33.2 Molecular Location on chromosome 2: base pairs 202,273,521 to 202,353,982
The ALS2 gene is located on the long (q) arm of chromosome 2 at position 33.2. More precisely, the ALS2 gene is located from base pair 202,273,521 to base pair 202,353,982 on chromosome 2.
References These sources were used to develop the Genetics Home Reference gene summary on the ALS2 gene. •
Devon RS, Helm JR, Rouleau GA, Leitner Y, Lerman-Sagie T, Lev D, Hayden MR. The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. Clin Genet. 2003 Sep;64(3):210-5. PubMed citation
•
Eymard-Pierre E, Lesca G, Dollet S, Santorelli FM, di Capua M, Bertini E, BoespflugTanguy O. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet. 2002 Sep;71(3):518-27. PubMed citation
•
Gros-Louis F, Meijer IA, Hand CK, Dube MP, MacGregor DL, Seni MH, Devon RS, Hayden MR, Andermann F, Andermann E, Rouleau GA. An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Ann Neurol. 2003 Jan;53(1):144-5. No abstract available. PubMed citation
•
Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, Miyamoto N, Showguchi-Miyata J, Okada Y, Singaraja R, Figlewicz DA, Kwiatkowski T, Hosler BA,
10
Amyotrophic Lateral Sclerosis
Sagie T, Skaug J, Nasir J, Brown RH Jr, Scherer SW, Rouleau GA, Hayden MR, Ikeda JE. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet. 2001 Oct;29(2):166-73. PubMed citation •
Kress JA, Kuhnlein P, Winter P, Ludolph AC, Kassubek J, Muller U, Sperfeld AD. Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis. Ann Neurol. 2005 Nov;58(5):800-3. PubMed citation
•
Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet. 2004 Dec;75(6):933-47. Epub 2004 Oct 11. No abstract available. PubMed citation
•
Millecamps S, Gentil BJ, Gros-Louis F, Rouleau G, Julien JP. Alsin is partially associated with centrosome in human cells. Biochim Biophys Acta. 2005 Aug 15;1745(1):84-100. Epub 2005 Jan 19. PubMed citation
•
Otomo A, Hadano S, Okada T, Mizumura H, Kunita R, Nishijima H, Showguchi-Miyata J, Yanagisawa Y, Kohiki E, Suga E, Yasuda M, Osuga H, Nishimoto T, Narumiya S, Ikeda JE. ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. Hum Mol Genet. 2003 Jul 15;12(14):1671-87. PubMed citation
•
Yamanaka K, Vande Velde C, Eymard-Pierre E, Bertini E, Boespflug-Tanguy O, Cleveland DW. Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16041-6. Epub 2003 Dec 10. PubMed citation
What Is the Official Name of the SETX Gene?5 The official name of this gene is “senataxin.” SETX is the gene's official symbol. The SETX gene is also known by other names, listed below.
What Is the Normal Function of the SETX Gene? The SETX gene provides instructions for making a protein called senataxin. Senataxin is produced in a wide range of tissues, including the brain, spinal cord, and muscles. Its function is unknown. On the basis of its structure, senataxin is thought to play a role in processing RNA, a molecule similar to DNA. RNA makes up the cellular machinery that produces proteins from information contained in DNA. Senataxin may help ensure that protein production is error-free.
What Conditions Are Related to the SETX Gene? Amyotrophic Lateral Sclerosis - Caused by Mutations in the SETX Gene Researchers have identified three SETX mutations that cause type 4 amyotrophic lateral sclerosis. These mutations change one of the protein building blocks (amino acids) used to 5
Adapted from the Genetics Home Reference of the National Library of Medicine: http://ghr.nlm.nih.gov/gene=setx.
Studies
11
make senataxin. It is unknown how mutations in the SETX gene lead to the signs and symptoms of type 4 amyotrophic lateral sclerosis. Other Disorders - Caused by Mutations in the SETX Gene Researchers have identified three SETX mutations that cause type 4 amyotrophic lateral sclerosis. These mutations change one of the protein building blocks (amino acids) used to make senataxin. It is unknown how mutations in the SETX gene lead to the signs and symptoms of type 4 amyotrophic lateral sclerosis.
Where Is the SETX Gene Located? Cytogenetic Location: 9q34.3 Molecular Location on chromosome 9: base pairs 134,129,103 to 134,220,192
The SETX gene is located on the long (q) arm of chromosome 9 at position 34.3. More precisely, the SETX gene is located from base pair 134,129,103 to base pair 134,220,192 on chromosome 9.
References These sources were used to develop the Genetics Home Reference gene summary on the SETX gene. •
Blair IP, Bennett CL, Abel A, Rabin BA, Griffin JW, Fischbeck KH, Cornblath DR, Chance PF. A gene for autosomal dominant juvenile amyotrophic lateral sclerosis (ALS4) localizes to a 500-kb interval on chromosome 9q34. Neurogenetics. 2000 Sep;3(1):1-6. PubMed citation
•
Chance PF, Rabin BA, Ryan SG, Ding Y, Scavina M, Crain B, Griffin JW, Cornblath DR. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet. 1998 Mar;62(3):633-40. PubMed citation
•
Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, Dierick I, Abel A, Kennerson ML, Rabin BA, Nicholson GA, Auer-Grumbach M, Wagner K, De Jonghe P, Griffin JW,
12
Amyotrophic Lateral Sclerosis
Fischbeck KH, Timmerman V, Cornblath DR, Chance PF. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004 Jun;74(6):1128-35. Epub 2004 Apr 21. PubMed citation •
Duquette A, Roddier K, McNabb-Baltar J, Gosselin I, St-Denis A, Dicaire MJ, Loisel L, Labuda D, Marchand L, Mathieu J, Bouchard JP, Brais B. Mutations in senataxin responsible for Quebec cluster of ataxia with neuropathy. Ann Neurol. 2005 Mar;57(3):408-14. PubMed citation
•
Entrez Gene
•
Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet. 2004 Dec;75(6):933-47. Epub 2004 Oct 11. No abstract available. PubMed citation
•
Moreira MC, Klur S, Watanabe M, Nemeth AH, Le Ber I, Moniz JC, Tranchant C, Aubourg P, Tazir M, Schols L, Pandolfo M, Schulz JB, Pouget J, Calvas P, Shizuka-Ikeda M, Shoji M, Tanaka M, Izatt L, Shaw CE, M'Zahem A, Dunne E, Bomont P, Benhassine T, Bouslam N, Stevanin G, Brice A, Guimaraes J, Mendonca P, Barbot C, Coutinho P, Sequeiros J, Durr A, Warter JM, Koenig M. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet. 2004 Mar;36(3):225-7. Epub 2004 Feb 08. PubMed citation
•
OMIM: senataxin
What Is the Official Name of the SOD1 Gene?6 The official name of this gene is “superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)).” SOD1 is the gene's official symbol. The SOD1 gene is also known by other names, listed below.
What Is the Normal Function of the SOD1 Gene? The SOD1 gene provides instructions for making an enzyme called superoxide dismutase, which is abundant in cells throughout the body. This enzyme neutralizes supercharged oxygen molecules (called superoxide radicals). Superoxide radicals, which are byproducts of normal cell processes, can damage cells if their levels are not controlled by superoxide dismutase. To function properly, the superoxide dismutase enzyme must bind to copper and zinc.
What Conditions Are Related to the SOD1 Gene? Amyotrophic Lateral Sclerosis - Caused by Mutations in the SOD1 Gene More than 100 SOD1 mutations that cause type 1 amyotrophic lateral sclerosis have been identified. Most of these mutations change one of the building blocks (amino acids) used to 6
Adapted from the Genetics Home Reference of the National Library of Medicine: http://ghr.nlm.nih.gov/gene=sod1;jsessionid=62691805C4C5F3409543E26AE3172532.
Studies
13
make the enzyme superoxide dismutase. The most common change, which occurs in 50 percent of Americans with type 1 amyotrophic lateral sclerosis, replaces the amino acid arginine with the amino acid valine at position 4 in the enzyme. (This mutation is written as Arg4Val). Other types of mutations result in an enzyme of abnormal size.
Where Is the SOD1 Gene Located? Cytogenetic Location: 21q22.1 Molecular Location on chromosome 21: base pairs 31,953,805 to 31,963,114
The SOD1 gene is located on the long (q) arm of chromosome 21 at position 22.1. More precisely, the SOD1 gene is located from base pair 31,953,805 to base pair 31,963,114 on chromosome 21.
References These sources were used to develop the Genetics Home Reference gene summary on the SOD1 gene. •
Gene Review: Amyotrophic Lateral Sclerosis
•
Giess R, Holtmann B, Braga M, Grimm T, Muller-Myhsok B, Toyka KV, Sendtner M. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am J Hum Genet. 2002 May;70(5):1277-86. PubMed citation
•
Hand CK, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve. 2002 Feb;25(2):135-59. Review. PubMed citation
•
Jonsson PA, Ernhill K, Andersen PM, Bergemalm D, Brannstrom T, Gredal O, Nilsson P, Marklund SL. Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain. 2004 Jan;127(Pt 1):73-88. Epub 2003 Oct 08. PubMed citation
•
Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet. 2004 Dec;75(6):933-47. Epub 2004 Oct 11. No abstract available. PubMed citation
14
Amyotrophic Lateral Sclerosis
•
Rao SD, Weiss JH. Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci. 2004 Jan;27(1):17-23. Review. No abstract available. PubMed citation
•
Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001 May 31;344(22):1688-700. Review. No abstract available. PubMed citation
•
Selverstone Valentine J, Doucette PA, Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem. 2005;74:563-93. Review. PubMed citation
•
Siddique T, Lalani I. Genetic aspects of amyotrophic lateral sclerosis. Adv Neurol. 2002;88:21-32. Review. No abstract available. PubMed citation
What Is the Official Name of the VAPB Gene?7 The official name of this gene is “VAMP (vesicle-associated membrane protein)-associated protein B and C.” VAPB is the gene's official symbol. The VAPB gene is also known by other names, listed below.
What Is the Normal Function of the VAPB Gene? The VAPB gene provides instructions for making a protein that is found in cells throughout the body. Little is known about the role of the VAPB protein. Research indicates that this protein is associated with the membrane that surrounds the endoplasmic reticulum, a specialized structure within cells. Among its many functions, the endoplasmic reticulum folds newly formed proteins and prepares them for transit within the cell or to the cell surface. To function efficiently, the endoplasmic reticulum relies on a system that detects a buildup of unfolded or misfolded proteins. The cell's response to prevent or correct this buildup is called the unfolded protein response. Researchers suggest that the VAPB protein may play an important role in the unfolded protein response.
What Conditions Are Related to the VAPB Gene? Amyotrophic Lateral Sclerosis - Caused by Mutations in the VAPB Gene Researchers have identified one VAPB mutation in people with amyotrophic lateral sclerosis type 8. This mutation changes one of the building blocks (amino acids) used to make the VAPB protein. In this protein's string of amino acids, the 56th amino acid, proline, is replaced with the amino acid serine. This mutation is written as Pro56Ser or P56S. It is unclear how the VAPB mutation leads to the loss of nerve cells that control muscle movement, a characteristic feature of amyotrophic lateral sclerosis. Researchers suggest that the P56S mutation impairs the unfolded protein response. As a result, misfolded and unfolded proteins may accumulate to a level that is toxic to nerve cells.
7
Adapted from the Genetics Home Reference of the National Library of Medicine: http://ghr.nlm.nih.gov/gene=vapb.
Studies
15
Spinal Muscular Atrophy - Caused by Mutations in the VAPB Gene Researchers have identified one VAPB mutation in people with amyotrophic lateral sclerosis type 8. This mutation changes one of the building blocks (amino acids) used to make the VAPB protein. In this protein's string of amino acids, the 56th amino acid, proline, is replaced with the amino acid serine. This mutation is written as Pro56Ser or P56S. It is unclear how the VAPB mutation leads to the loss of nerve cells that control muscle movement, a characteristic feature of amyotrophic lateral sclerosis. Researchers suggest that the P56S mutation impairs the unfolded protein response. As a result, misfolded and unfolded proteins may accumulate to a level that is toxic to nerve cells.
Where Is the VAPB Gene Located? Cytogenetic Location: 20q13.33 Molecular Location on chromosome 20: base pairs 56,397,650 to 56,455,368
The VAPB gene is located on the long (q) arm of chromosome 20 at position 13.33. More precisely, the VAPB gene is located from base pair 56,397,650 to base pair 56,455,368 on chromosome 20.
References These sources were used to develop the Genetics Home Reference gene summary on the VAPB gene. •
Kanekura K, Nishimoto I, Aiso S, Matsuoka M. Characterization of amyotrophic lateral sclerosis-linked pro56ser mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8). J Biol Chem. 2006 Aug 4; [Epub ahead of print]. PubMed citation
•
Nishimura AL, Al-Chalabi A, Zatz M. A common founder for amyotrophic lateral sclerosis type 8 (ALS8) in the Brazilian population. Hum Genet. 2005 Sep 27;:1-2 [Epub ahead of print]. PubMed citation
•
Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, Kok F, Oliveira JR, Gillingwater T, Webb J, Skehel P, Zatz M. A mutation in the vesicletrafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004 Nov;75(5):822-31. Epub 2004 Sep 15. PubMed citation
16
•
Amyotrophic Lateral Sclerosis
OMIM
What Is the Official Name of the NEFH Gene?8 The official name of this gene is “neurofilament, heavy polypeptide 200kDa.” NEFH is the gene's official symbol. The NEFH gene is also known by other names, listed below.
What Is the Normal Function of the NEFH Gene? The NEFH gene provides instructions for making a protein component (subunit) of neurofilaments. Neurofilaments, which are assembled from light, medium, and heavy subunits, are essential for normal nerve function. The NEFH gene produces the heavy subunit. Neurofilaments form a structural framework that helps to define the shape and size of nerve cells. Cross-linking or bridging between neurofilaments maintains the diameter of nerve cells, which is important for the conduction of nerve impulses. Neurofilaments are the most abundant structural protein in motor neurons, the specialized nerve cells in the brain and spinal cord that control muscle movement. The heavy subunit is made up of three regions: the head, which regulates assembly of neurofilaments; a coiled midsection; and a tail with branches that interact with other proteins and neurofilaments. The tail region has a segment called the KSP motif that plays an important role in regulating the functions of neurofilaments.
What Conditions Are Related to the NEFH Gene? Amyotrophic Lateral Sclerosis - Increased Risk from Variations of the NEFH Gene NEFH gene mutations have been detected in a small percentage of individuals with amyotrophic lateral sclerosis. In some cases, unaffected family members of people with this disorder also have a NEFH mutation. Based on these observations, a mutation in the NEFH gene appears to increase the risk of developing amyotrophic lateral sclerosis but does not directly cause this disorder.
Where Is the NEFH Gene Located? Cytogenetic Location: 22q12.2 Molecular Location on chromosome 22: base pairs 28,206,218 to 28,217,278 8
Adapted from the Genetics Home Reference of the National Library of Medicine: http://ghr.nlm.nih.gov/gene=nefh;jsessionid=62691805C4C5F3409543E26AE3172532.
Studies
17
The NEFH gene is located on the long (q) arm of chromosome 22 at position 12.2. More precisely, the NEFH gene is located from base pair 28,206,218 to base pair 28,217,278 on chromosome 22.
References These sources were used to develop the Genetics Home Reference gene summary on the NEFH gene. •
Al-Chalabi A, Andersen PM, Nilsson P, Chioza B, Andersson JL, Russ C, Shaw CE, Powell JF, Leigh PN. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet. 1999 Feb;8(2):157-64. PubMed citation
•
Al-Chalabi A, Miller CC. Neurofilaments and neurological disease. Bioessays. 2003 Apr;25(4):346-55. PubMed citation
•
Garcia ML, Singleton AB, Hernandez D, Ward CM, Evey C, Sapp PA, Hardy J, Brown RH Jr, Cleveland DW. Mutations in neurofilament genes are not a significant primary cause of non-SOD1-mediated amyotrophic lateral sclerosis. Neurobiol Dis. 2005 Aug 2; [Epub ahead of print]. PubMed citation
•
Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet. 2004 Dec;75(6):933-47. Epub 2004 Oct 11. No abstract available. PubMed citation
•
Lariviere RC, Julien JP. Functions of intermediate filaments in neuronal development and disease. J Neurobiol. 2004 Jan;58(1):131-48. Review. PubMed citation
•
Omary MB, Coulombe PA, McLean WH. Intermediate filament proteins and their associated diseases. N Engl J Med. 2004 Nov 11;351(20):2087-100. No abstract available. PubMed citation
•
Tomkins J, Usher P, Slade JY, Ince PG, Curtis A, Bushby K, Shaw PJ. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport. 1998 Dec 1;9(17):3967-70. PubMed citation
18
Amyotrophic Lateral Sclerosis
What Is the Official Name of the SMN1 Gene?9 The official name of this gene is “survival of motor neuron 1, telomeric.” SMN1 is the gene's official symbol. The SMN1 gene is also known by other names, listed below.
What Is the Normal Function of the SMN1 Gene? The SMN1 gene provides instructions for making a protein called SMN, which stands for "survival of motor neuron." The SMN protein is found throughout the body, with high levels in the spinal cord. This protein is particularly important for the survival of specialized nerve cells, called motor neurons, located in the spinal cord and the part of the brain that is connected to the spinal cord (the brainstem). Healthy motor neurons are critical because they control muscle movement. In cells, the SMN protein plays an important role in processing molecules called messenger RNA (mRNA), which serve as genetic blueprints for making proteins. Messenger RNA begins as a rough draft (pre-mRNA) and goes through several processing steps to a mature form. The SMN protein helps to assemble the cellular machinery needed to process premRNA. The SMN protein may have additional functions in nerve cells. Research findings indicate that the SMN protein is important for the specialized outgrowths from nerve cells called dendrites and axons. Dendrites and axons are required for the transmission of impulses from nerve to nerve and from nerves to muscles.
What Conditions Are Related to the SMN1 Gene? Spinal Muscular Atrophy - Caused by Mutations in the SMN1 Gene Normally, each cell has two copies of the SMN1 gene. About 95 percent of individuals with spinal muscular atrophy have mutations that delete all or some of the DNA in both copies of this gene. As a result, little or no SMN protein is made. In about 5 percent of people with this disorder, one copy of the SMN1 gene has a deletion, and the other copy has a mutation that affects the building blocks (amino acids) used to make the SMN protein. Researchers have identified nearly 30 mutations that affect amino acids and impair the function of the SMN protein. Amyotrophic Lateral Sclerosis - Increased Risk from Variations of the SMN1 Gene Normally, each cell has two copies of the SMN1 gene. About 95 percent of individuals with spinal muscular atrophy have mutations that delete all or some of the DNA in both copies of this gene. As a result, little or no SMN protein is made. In about 5 percent of people with this disorder, one copy of the SMN1 gene has a deletion, and the other copy has a mutation that affects the building blocks (amino acids) used to make the SMN protein. Researchers
9
Adapted from the Genetics Home Reference of the National Library of Medicine: http://ghr.nlm.nih.gov/gene=smn1.
Studies
19
have identified nearly 30 mutations that affect amino acids and impair the function of the SMN protein.
Where Is the SMN1 Gene Located? Cytogenetic Location: 5q13 Molecular Location on chromosome 5: base pairs 70,256,523 to 70,284,592
The SMN1 gene is located on the long (q) arm of chromosome 5 at position 13. More precisely, the SMN1 gene is located from base pair 70,256,523 to base pair 70,284,592 on chromosome 5.
References These sources were used to develop the Genetics Home Reference gene summary on the SMN1 gene. •
Boda B, Mas C, Giudicelli C, Nepote V, Guimiot F, Levacher B, Zvara A, Santha M, LeGall I, Simonneau M. Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells. Eur J Hum Genet. 2004 Sep;12(9):729-37. PubMed citation
•
Briese M, Esmaeili B, Sattelle DB. Is spinal muscular atrophy the result of defects in motor neuron processes? Bioessays. 2005 Sep;27(9):946-57. Review. PubMed citation
•
Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet. 2006 Jan;78(1):63-77. Epub 2005 Nov 16. PubMed citation
•
Frugier T, Nicole S, Cifuentes-Diaz C, Melki J. The molecular bases of spinal muscular atrophy. Curr Opin Genet Dev. 2002 Jun;12(3):294-8. Review. PubMed citation
•
Gubitz AK, Feng W, Dreyfuss G. The SMN complex. Exp Cell Res. 2004 May 15;296(1):51-6. Review. PubMed citation
•
Jablonka S, Sendtner M. Molecular and cellular basis of spinal muscular atrophy. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):144-9. Review. PubMed citation
20
Amyotrophic Lateral Sclerosis
•
Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, Burghes AH, Prior TW. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002 Jan-Feb;4(1):20-6. PubMed citation
•
Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. 2002 Dec;111(6):477-500. Epub 2002 Oct 03. Review. PubMed citation
•
Ogino S, Wilson RB. Spinal muscular atrophy: molecular genetics and diagnostics. Expert Rev Mol Diagn. 2004 Jan;4(1):15-29. Review. PubMed citation
•
OMIM
•
Paushkin S, Gubitz AK, Massenet S, Dreyfuss G. The SMN complex, an assemblyosome of ribonucleoproteins. Curr Opin Cell Biol. 2002 Jun;14(3):305-12. Review. PubMed citation
•
Pellizzoni L, Yong J, Dreyfuss G. Essential role for the SMN complex in the specificity of snRNP assembly. Science. 2002 Nov 29;298(5599):1775-9. PubMed citation
•
Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A. 2004 Oct 15;130(3):307-10. PubMed citation
•
Veldink JH, Kalmijn S, Van der Hout AH, Lemmink HH, Groeneveld GJ, Lummen C, Scheffer H, Wokke JH, Van den Berg LH. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology. 2005 Sep 27;65(6):820-5. Epub 2005 Aug 10. PubMed citation
•
Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A, Heller R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006 May;119(4):422-8. Epub 2006 Mar 1. PubMed citation
•
Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15(3):228-37. Review. PubMed citation
What Is the Official Name of the SMN2 Gene?10 The official name of this gene is “survival of motor neuron 2, centromeric.” SMN2 is the gene's official symbol. The SMN2 gene is also known by other names, listed below.
What Is the Normal Function of the SMN2 Gene? The SMN2 gene provides instructions for making a protein called SMN, which stands for "survival of motor neuron." The SMN protein is found throughout the body, with high levels in the spinal cord. This protein is particularly important for the survival of specialized 10
Adapted from the Genetics Home Reference of the National Library of Medicine: http://ghr.nlm.nih.gov/gene=smn2;jsessionid=62691805C4C5F3409543E26AE3172532.
Studies
21
nerve cells, called motor neurons, located in the spinal cord and the part of the brain that is connected to the spinal cord (the brainstem). Healthy motor neurons are critical because they control muscle movements. Several different versions of the SMN protein are produced from the SMN2 gene, but only one version (called isoform d) is full size and fully functional. The other versions are smaller and unstable. The full-size SMN protein made from the SMN2 gene is identical to the protein made from a similar gene called SMN1. A much smaller amount of full-size SMN protein is produced from the SMN2 gene compared to the SMN1 gene, however. In cells, the SMN protein plays an important role in processing molecules called messenger RNA (mRNA), which serve as genetic blueprints for making proteins. Messenger RNA begins as a rough draft (pre-mRNA) and goes through several processing steps to a mature form. The SMN protein helps to assemble the cellular machinery needed to process premRNA. The SMN protein may have additional functions in nerve cells. Research findings indicate that the SMN protein is important for the specialized outgrowths from nerve cells called dendrites and axons. Dendrites and axons are required for the transmission of impulses from nerve to nerve and from nerves to muscles.
What Conditions Are Related to the SMN2 Gene? Amyotrophic Lateral Sclerosis - Increased Risk from Variations of the SMN2 Gene Some studies suggest that a decreased number of SMN2 genes in each cell may be associated with an increased risk of developing amyotrophic lateral sclerosis. These studies found that people with amyotrophic lateral sclerosis were more likely to have only one copy of the SMN2 gene in each cell, instead of the usual two copies, compared to people unaffected by this disorder. Less SMN protein is produced as a result of the reduced number of SMN2 genes. Researchers propose that people with a reduced amount of SMN protein have an increased chance of developing amyotrophic lateral sclerosis. Spinal Muscular Atrophy - Course of Condition Modified by Extra Copies of the SMN2 Gene Some studies suggest that a decreased number of SMN2 genes in each cell may be associated with an increased risk of developing amyotrophic lateral sclerosis. These studies found that people with amyotrophic lateral sclerosis were more likely to have only one copy of the SMN2 gene in each cell, instead of the usual two copies, compared to people unaffected by this disorder. Less SMN protein is produced as a result of the reduced number of SMN2 genes. Researchers propose that people with a reduced amount of SMN protein have an increased chance of developing amyotrophic lateral sclerosis.
Where Is the SMN2 Gene Located? Cytogenetic Location: 5q13 Molecular Location on chromosome 5: base pairs 69,381,105 to 69,409,174
22
Amyotrophic Lateral Sclerosis
The SMN2 gene is located on the long (q) arm of chromosome 5 at position 13. More precisely, the SMN2 gene is located from base pair 69,381,105 to base pair 69,409,174 on chromosome 5.
References These sources were used to develop the Genetics Home Reference gene summary on the SMN2 gene. •
Boda B, Mas C, Giudicelli C, Nepote V, Guimiot F, Levacher B, Zvara A, Santha M, LeGall I, Simonneau M. Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells. Eur J Hum Genet. 2004 Sep;12(9):729-37. PubMed citation
•
Briese M, Esmaeili B, Sattelle DB. Is spinal muscular atrophy the result of defects in motor neuron processes? Bioessays. 2005 Sep;27(9):946-57. Review. PubMed citation
•
Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet. 2006 Jan;78(1):63-77. Epub 2005 Nov 16. PubMed citation
•
Gubitz AK, Feng W, Dreyfuss G. The SMN complex. Exp Cell Res. 2004 May 15;296(1):51-6. Review. PubMed citation
•
Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, Burghes AH, Prior TW. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002 Jan-Feb;4(1):20-6. PubMed citation
•
Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. 2002 Dec;111(6):477-500. Epub 2002 Oct 03. Review. PubMed citation
•
Ogino S, Wilson RB. Spinal muscular atrophy: molecular genetics and diagnostics. Expert Rev Mol Diagn. 2004 Jan;4(1):15-29. PubMed citation
•
Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A. 2004 Oct 15;130(3):307-10. PubMed citation
•
Veldink JH, Kalmijn S, Van der Hout AH, Lemmink HH, Groeneveld GJ, Lummen C, Scheffer H, Wokke JH, Van den Berg LH. SMN genotypes producing less SMN protein
Studies
23
increase susceptibility to and severity of sporadic ALS. Neurology. 2005 Sep 27;65(6):820-5. Epub 2005 Aug 10. PubMed citation •
Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A, Heller R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006 May;119(4):422-8. Epub 2006 Mar 1. PubMed citation
•
Wirth B. Spinal muscular atrophy: state-of-the-art and therapeutic perspectives. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Jun;3(2):87-95. Review. PubMed citation
Federally Funded Research on Amyotrophic Lateral Sclerosis The U.S. Government supports a variety of research studies relating to amyotrophic lateral sclerosis. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.11 CRISP (Computerized Retrieval of Information on Scientific Projects) CRISP is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to amyotrophic lateral sclerosis. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore amyotrophic lateral sclerosis. The following is typical of the type of information found when searching the CRISP database for amyotrophic lateral sclerosis: •
Project Title: ABERRANT MITOCHONDRIAL HANDLING OF CALCIUM IN ALS Principal Investigator & Institution: Garcia-Chacon, Luis E.; Physiology and Biophysics; University of Miami-Medical School 1507 Levante Avenue Coral Gables, Fl 33124 Timing: Fiscal Year 2006; Project Start 01-APR-2006; Project End 31-MAR-2008 Summary: (provided by applicant): This project will study the role of abnormal mitochondrial function in motor nerve terminals in the pathogenesis of amyotrophic lateral sclerosis (ALS). Mitochondria take up cytosolic Ca2+ during repetitive stimulation at mouse motor nerve terminals. Studies have detected abnormalities in mitochondrial Ca2+ handling and abnormal mitochondrial depolarizations following repetitive stimulation of motor terminals in a mouse model for ALS: Stimulationinduced changes in mitochondrial [Ca2+] and in mitochondrial membrane potential using fluorescent indicator dyes and confocal microscopy will be measured. Proposed experiments will compare mutant and wild-type mice, and also carry out these
11 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
24
Amyotrophic Lateral Sclerosis
measurements in normal mice with partially inhibited electron transport chain activity, one of the proposed mechanisms for ALS pathogenesis. Young mice that have yet to develop signs of disease will be used and compared to previous results from older, affected mice. Finally, the degree of denervation of motor end-plates after marked neuronal activity will be measured with fluorescent markers for both the nerve terminal cytoplasm and the muscle end-plate. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACTIVITY-DEPENDENT REGULATION OF SYNAPSES BY SHANK Principal Investigator & Institution: Hung, Albert Y.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2004; Project Start 01-AUG-2001; Project End 31-JUL-2006 Summary: (provided by applicant): The goal of this project is to investigate the role of a newly discovered postsynaptic protein, Shank, in the regulation of dendritic spine morphology and cytoskeleton. Local electrical stimulation induces growth of dendritic spines, suggesting that synaptic activity directly modulates neuronal architecture and circuitry. The molecular basis for these activitydependent changes is not known, but probably involves postsynaptic proteins that interact with receptors and/or cytoskeletal elements. Shank acts as a putative scaffold for multiple glutamate receptor subtypes and also binds to the actinbinding protein cortactin, which has been implicated in dynamic cytoskeletal rearrangement and translocates to synapses in response to glutamate. This study examines the role of Shank in the regulation of dendritic spines and its in vivo function through three specific aims. First a combination of cell biological, biochemical, and dominant inhibitory approaches will be used to determine the mechanism for glutamateregulated cortactin translocation to synapses, and to identify if Shankcortactin interaction is required for this response. Second, how Shank induces spine growth will be studied by structurefunction analysis. Finally, a genetic approach, generation of a Shank1 "knockout" mouse, will be used to investigate the role of Shank proteins in brain development, in postsynaptic receptor organization, and in learning and memory. The longterm goal of the candidate is to understand how aberrant synaptic transmission contributes to neurologic disease. Synapses are the signal processing units of the brain, and overexcitation of synapses by glutamate is thought to play a role in both acute neuronal injury (such as stroke and seizure) and chronic neurodegenerative conditions (including Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis). Understanding how postsynaptic proteins, such as Shank, regulate activitydependent synaptic plasticity may shed light on mechanisms of glutamate toxicity. The immediate goal is to obtain training in the most uptodate techniques in molecular genetics, protein biochemistry, and cellular neurobiology, sponsored by Dr. Morgan Sheng, which will enable him to become a productive, independent molecular neurologist. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MICRONESIA
AGE
RELATED
NEURODEGENERATIVE
DISEASES
IN
Principal Investigator & Institution: Galasko, Douglas R.; Associate Professor; Neurosciences; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 920930934 Timing: Fiscal Year 2004; Project Start 01-MAR-1997; Project End 31-MAR-2007 Summary: (provided by applicant): In this renewal of the program project Grant, we will continue to investigate neurodegenerative disorders on Guam, namely Parkinson-
Studies
25
Dementia Complex (PDC), Amyotrophic Lateral Sclerosis (ALS) and late-life dementia. The unifying feature among these disorders is the pathological finding of neurofibrillary tangles. We hypothesize that interactions between aging, genetics and environment may determine which type of clinical phenotype results. We will use a multidisciplinary approach to determine rates of disease and risk factors, identify susceptibility genes and potential mechanisms of disease, investigate biochemical and radiological markers that may assist in early diagnosis and differential diagnosis, and carry out clinicopathological studies. There will be 3 cores: Administrative and Data core; Clinical core (on Guam and in San Diego), and: Neuropathology-Brain Bank core, in New York. There will be 4 research subprojects. Subproject by Galasko: 'Prevalence and incidence of dementia among elderly Chamorros' aims to measure the prevalence and incidence of PDC and dementia among Chamorros and assess risk factors. Subproject by Schellenberg: 'Genetic studies of ALS, PDC and Dementia on Guam' aims to perform genome-wide searches for genetic alterations associated with ALS and PDC, and to examine candidate genes for PDC and dementia. Subproject by Kaye: 'MRI of Neurodegenerative Disease among aging Chamorros' aims to carry out volumetric analyses of the hippocampus and other brain regions to identify markers of disease and assist in early diagnosis. Subproject by Lee: 'PHF-tau in neurodegenerative diseases of Guam' will assess oxidative markers related to brain lesions in ALS, PDC and dementia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AGGREGATION OF PROTEINS IN AGE-RELATED DISEASES Principal Investigator & Institution: Sherman, Michael Y.; Professor; Biochemistry; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 021182394 Timing: Fiscal Year 2004; Project Start 01-JUN-2004; Project End 31-MAY-2006 Summary: The cause of many age-related neurodegenerative disorders, including Parkinson's disease, ALS, and several polyglutamine expansion diseases, is accumulation in neurons of various mutant or damaged polypeptides. These toxic abnormal proteins can aggregate in cells and form large inclusion bodies, and there is an ongoing discussion in the field how aggregation of these proteins influences neurotoxicity. Recently it became clear that in contrast to protein aggregation in a test tube, aggregation of damaged or mutant polypeptides in vivo is a complicated tightly regulated process that involves many cellular factors. This proposal is designed to identify cellular components that promote aggregation of abnormal proteins. The proposal is based on a yeast model of human polyglutamine (polyQ) expansion diseases. This model allowed us to demonstrate that there are two distinct steps in polyQ aggregation - (1) seeding and (2) growth of aggregates. These steps require two distinct sets of cellular components, including a prion-like protein Rnql in a prion conformation. This model will be used for screens for cellular mutations that affect various steps of polyQ aggregation. Mutants with defects in polyQ aggregation will be tested for their ability to carry out various steps of the aggregation process. Then, it will be established which of the newly identified cellular factors that promote polyQ aggregation are also involved in aggregation of mutant proteins important for development of other agerelated diseases, including synphilin 1, ataxin 1 and PABP2. This work will lay the basis for further study of mechanisms of protein aggregation in neurons and aged mammalian cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
26
•
Amyotrophic Lateral Sclerosis
Project Title: ANDROGEN TARGETS IN A SIMPLE BEHAVIORAL SYSTEM. Principal Investigator & Institution: Jordan, Cynthia L.; Associate Professor; Psychology; Michigan State University 301 Administration Bldg East Lansing, Mi 48824 Timing: Fiscal Year 2006; Project Start 15-DEC-2002; Project End 31-DEC-2009 Summary: (provided by applicant): Androgens influence the survival and growth of a neuromuscular system, the spinal nucleus of the bulbocavernosus (SNB) and its target muscles, the levator ani (LA) and the bulbocavernosus (BC). Proposed experiments will test whether LA/BC muscle fibers are direct cellular targets for androgens. Focus will be on LA/BC muscle fibers as prime mediators of androgenic influences on the SNB system because 1) androgens act directly on LA/BC muscles to regulate their survival and growth, and the survival and growth of SNB motoneurons and 2) androgen receptors (ARs) are enriched in muscle fibers of the LA/BC compared to other skeletal muscles. Proposed experiments will utilize two newly created transgenic mouse models that either over or under express ARs in their muscle fibers. These two models will be used to evaluate whether ARs in muscle fibers are necessary and/or sufficient for androgens to rescue the SNB system from death in development and promote expression of calcitonin gene-related peptide by SNB motoneurons in adulthood. Transgenic males will be compared to controls males (wild-type males and/or males that have a dysfunctional AR gene) and standard cellular approaches will be applied to answer these questions. Finally, males in some transgenic lines that overexpress ARs in muscle fibers show a progressive, late-onset neuromuscular degenerative disease that mimics Spinal Bulbar Muscular Atrophy (SBMA), a neurodegenerative disease in humans caused by a mutation in the AR gene (expansion of CAG repeats). SBMA afflicts primarily men in mid-life. Some proposed experiments are aimed at characterizing the emergent phenotype and the underlying pathology of this disease, and its liganddependence using behavioral, cellular and molecular methods. Relevance: Despite the essential role motoneurons have in all aspects of human life, motoneurons are susceptible to disease, and undergo selective demise in diseases such as Spinal Bulbar Muscular Atrophy (SBMA) and Amyotrophic Lateral Sclerosis (ALS). As part of the normal course of development, androgenic hormones prevent some motoneurons from dying and curiously, these same motoneurons are selectively spared in SBMA and ALS. We propose to study transgenic mouse models that have an altered expression of androgen receptors in skeletal muscle fibers to better understand how hormones regulate the survival of motoneurons. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DISORDERS
ARTICULATORY
KINEMATICS
IN
NEUROGENIC
SPEECH
Principal Investigator & Institution: Weismer, Gary G.; Professor; Waisman Ctr/Mr & Human Devlmt; University of Wisconsin Madison Suite 6401 Madison, Wi 537151218 Timing: Fiscal Year 2004; Project Start 01-DEC-1998; Project End 31-MAR-2009 Summary: (provided by applicant): This is a proposal to study the articulatory underpinnings of speech intelligibility deficits in the neurogenic speech disorders associated with Parkinson disease (PD) and amyotrophic lateral sclerosis (ALS). The proposed work uses x-ray microbeam (articulatory kinematic), speech acoustic, and speech intelligibility measures to address a major descriptive need, as well as a clinically- and theoretically-relevant hypothesis. Very little is known about lingual behavior in dysarthrias, and what is known about labial and mandibular behavior in dysarthria is confined to a limited type of speech material and measurement strategy.
Studies
27
The present proposal includes a variety of speech materials to allow a broad characterization of articulatory kinematics (and the speech acoustic and intelligibility results of those motions) for speech production behavior. One way in which the articulatory kinematics will be characterized is by means of a measure of articulatory working space (i.e., parameterization of ranges). A central hypothesis is that there is a relationship between the size of these articulatory working spaces defined kinematically on the one hand, and the size of the acoustic working spaces and speech intelligibility on the other hand. Specifically, we test the idea, in several ways, that articulatory reduction is the primary segmental reason for reduced intelligibility in persons with ALS and PD. The hypothesis has been shown in the first funding period to hold across speakers within each of the two disorder groups, and will now be studied within neurologicallyimpaired speakers who are asked to control speech variables such as rate, loudness, and clarity so as to create variation in the magnitude of articulatory movements. Another major area of study is to identify the nature and possible disorder of articulatory coordination in dysarthria. Dysarthria is often described as having a prominent component of articulatory dyscoordination, but the small amount of relevant data that exist have not revealed the kind of frank coordination disorder that might be expected from typical textbook descriptions. A finding from the first funding cycle of small abnormalities in the degree of coordination, but an essentially-normal 'form' of coordination for a particular phonetic sequence will be followed up with analyses of additional sequences, as well as with the inclusion of analyses of articulatory scale in these patients and in neurologically-healthy controls. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ASTROCYTES AND MOTOR NEURON APOPTOSIS Principal Investigator & Institution: Beckman, Joseph S.; Director; None; Oregon State University P.O. Box 1086 Corvallis, or 973391086 Timing: Fiscal Year 2004; Project Start 01-AUG-2004; Project End 31-JUL-2006 Summary: (provided by applicant) Through a long lasting collaboration between Dr. Luis Barbeito, we have made major progress towards l unraveling how oxidative stress involving peroxynitrite formation causes the death of motor neurons in Amyotrophic Lateral Sclerosis (ALS). We have proposed a novel mechanism to explain how Zndeficient SOD may cause motor neuron disease and have together coauthored 12 papers on these subjects over the past 7 years. Most recently, we have found that astroglia can play a pathogenic role in motor neuron degeneration. It is well known that reactive astrocytes surround degenerating motor neurons in ALS patients as well as in transgenic mice and rats over-expressing ALS mutant SOD-1. We found that peroxynitrite triggers a long-lasting phenotypic transformation in astrocytes, which promotes apoptosis of motor neurons cultured on the monolayers by mechanisms dependent on nitric oxide (NO) and peroxynitrite formation. Preliminary data implicates astrocytic synthesis of nerve growth factor (NGF) and its precursor form proNGF in triggering motor neuron apoptosis through activation of the "low affinity" NGF receptor p75NTR. We hypothesize that zinc-deficient SOD plus nitric oxide will activate astrocytes and contribute to the progression of motor neuron death through activating NGF/p75NTR signaling. To test this hypothesis, we propose to characterize whether zinc deficient SOD can make astrocytes reactive and induce NGF synthesis and secretion. The pro-apoptotic activity of the different NGF forms will be tested on cultured motor neurons and in vivo studies will be performed to analyze whether blockade of NGF/p75NTR pathway in G93A transgenic mice affect disease progression. These additional studies will provide important insight into astrocytes could contribute
28
Amyotrophic Lateral Sclerosis
to the progressive death of motor neurons in ALS. Halting the progressive death of motor neurons in ALS could be of huge clinical significance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AXONAL TRANSPORT OF NEUROFILAMENTS Principal Investigator & Institution: Brown, Anthony; Associate Neuroscience; Ohio State University 1960 Kenny Road Columbus, Oh 43210
Professor;
Timing: Fiscal Year 2004; Project Start 01-APR-1999; Project End 31-MAR-2008 Summary: (provided by applicant): Cytoplasmic accumulations of neurofilaments are a hallmark pathological feature of a number of human neurodegenerative diseases, most notably amyotrophic lateral sclerosis. These neurofilamentous accumulations are thought to be caused by changes in the mechanisms of slow axonal transport, which move cytoskeletal and cytosolic proteins along axons from their site of synthesis in the nerve cell body. We have recently observed the slow axonal transport of neurofilament protein in cultured nerve cells. The proteins move in the form of filamentous structures that may represent single neurofilament polymers. Contrary to the widely held view that slow axonal transport is a slow, synchronous and exclusively anterograde movement, we found that the filaments actually move at very fast rates, approaching the rate of fast axonal transport, and that the movements are also infrequent, bidirectional and highly asynchronous. Based on these observations, we have proposed a new model for slow axonal transport in which the actual rate of movement is fast, but the overall rate is slow because the rapid movements are interrupted by prolonged pauses. In this application, we propose to use live-cell fluorescence imaging strategies to test specific aspects of this hypothesis. In Aim 1 we will test the hypothesis that the moving filaments represent single neurofilament polymers. We expect that these experiments will also reveal the tracks along which the filaments move. In Aim 2 we will test the hypothesis that moving and stationary filaments differ in their phosphorylation state at specific epitopes and that they differ in their association with specific microtubule motor proteins. In Aim 3 we will test the hypothesis that rapidly moving filaments are delivered to the tip of growing axons in sufficient quantity to support the elaboration of the axonal neurofilament array during axon growth. We will also test the hypothesis that the growth cone is a site of frequent reversals in the direction of filament movement and that the frequency and/or directionality of filament movements in the distal axon is regulated in response to the rate of axon growth. The long-term goal of our research is to determine the mechanism and regulation of neurofilament protein transport along axons and the mechanisms that lead to the accumulation of neurofilaments in neurofilamentous neuropathies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BICARBONATE ENHANCES PEROXIDATION OF SOD/ALS MUTANTS Principal Investigator & Institution: Kalyanaraman, Balaraman; Professor and Chairman; Biophysics; Medical College of Wisconsin 8701 Watertown Plank Rd Milwaukee, Wi 532260509 Timing: Fiscal Year 2005; Project Start 01-JUL-2000; Project End 31-JAN-2009 Summary: (provided by applicant): Long-term goal: The broad long-term objectives of this revised application are to understand the direct and indirect mechanisms by which human copper, zinc superoxide dismutase (hSOD1) mutants associated with familial and sporadic amyotrophic lateral sclerosis (ALS) disease cause selective toxicity to
Studies
29
motor neurons. Hypotheses: (i) Bicarbonate anion (HCO3-) enhances the covalent aggregation of hSOD1 and hSOD1-ALS mutants via carbonate radical anion (CO3 -)mediated oxidative degradation of tryptophan residue (Trp-32) to kynurenine-type products, and (ii) Transfection of motor neuron cells (NSC-34) and neuroblastoma cells (SH-SY5Y) with familial ALS mutants (e.g., G93A) stimulates ceramide signaling, mitochondrial reactive oxygen species (ROS), transferrin iron uptake, proteasomal dysfunction and apoptosis or programmed death of neuronal cells. Specific Aims: Initially, the direct mechanism of covalent aggregation of isolated hSOD1 and ALS hSOD1 mutant mediated by CO3 - radical will be determined. Next, we will assess mitochondrial generation of ROS, transferrin iron signaling, protein aggregation, proteasome inhibition, and apoptosis in ALS hSOD1-transfected cells. Finally, the influence of ceramide, a bioactive lipid second messenger, on ROS generation in hSOD1WT and hSOD1G93A-transfected cells will be determined. The effects of iron supplementation and mitochondria-targeted spin probes on ALS disease progression and survival in ALS mutant mice will be assessed. Methods: Analytical techniques to be used will include EPR spin-trapping, MALDI-TOF, NMR, and fluorescence. Novel targeted oxidant-specific probes will be used. Significance: The proposed research will merge the oxidation and aggregation hypotheses in ALS SOD1-dependent toxicity using isolated hSOD1 proteins, and explore ceramide-induced oxidant signaling in G93Atransfected cells, and G93A mutant mice. Understanding the molecular basis of ALS SOD1 mutant toxicity will help improve overall strategies for developing effective drug therapy for ALS. Novelty: The use of state-of-the-art analytical techniques coupled with syntheses of mitochondria-targeted spin probes and fluorescent probes should yield new insights on the molecular mechanism for increased toxicity of ALS SOD1 mutants in motor neuron cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOSYNTHESIS AMINOCYCLITOLS
APPROACH
TO
NOVEL
BIOACTIVE
Principal Investigator & Institution: Mahmud, Taifo; Professor; Pharmaceutical Sciences; Oregon State University P.O. Box 1086 Corvallis, or 973391086 Timing: Fiscal Year 2004; Project Start 01-JUN-2004; Project End 31-MAY-2008 Summary: (provided by applicant): The increase of multi drug resistance (MDR) among pathogenic bacteria and fungi towards currently used antibiotics coupled with the lack of effective and safe medications to combat various physiological and regulatory disorders such as autoimmune diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, etc.) and cancer urgently require new drug discovery. The CTN aminocyclitols, a relatively newly recognized class of microbial secondary metabolites, has great potential to be developed as drugs for various physiological disorders and infectious diseases. This is due to their resemblance to sugar moieties, which are widely involved in various ways in structural and physiological systems in living organisms. In this application, we propose to study the biosynthesis of C7N aminocyclitol-containing natural products and to use the knowledge obtained to develop pharmaceutically important leads via biosynthetic-based structure modifications. The study will be carried out with three different compounds: (1) the antifungal agent validamycin (in S. hygroscopicus); (2) the antibiotic pyralomicin (in Nonomuraea spiralis); and (3) the antitumor cetoniacytone (in Actinomyces sp.). The long-term objectives of this study include developing new CTN aminocyclitol-based drugs to combat infectious diseases and physiological disorders, improving production yields and/or providing alternative production strategies of clinically important CTN aminocyclitol compounds, and
30
Amyotrophic Lateral Sclerosis
providing insights about the occurrence and distribution of this class of natural products in nature. The approach employs molecular genetics, enzymology, and chemistry to access, utilize and manipulate CTN aminocyclitol biosynthesis genes that direct precursor formation and other genes involved in the tailoring processes to create novel biologically active compounds. The study includes cloning and elucidation of the biosynthetic gene clusters of validamycin, pyralomicin, and cetoniacytone; elucidation of the newly discovered 2-epi-5-epi-valiolone pathway; characterization of the key biosynthetic enzymes; and use the information obtained to create novel bioactive aminocyclitols. The knowledge and methods that arise from these studies will be directly applicable to expanding the chemical diversity in other families of bioactive natural products. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: APOPTOSIS
CASPASE
CLEAVAGE
OF
MEF2
MEDIATES
NEURONAL
Principal Investigator & Institution: Lipton, Stuart A.; Professor and Director; Burnham Institute for Medical Research 10901 North Torrey Pines Road La Jolla, Ca 92037 Timing: Fiscal Year 2004; Project Start 01-AUG-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Apoptotic neuronal cell death may play a role in many acute and chronic neurologic disorders. These disorders range from acute stroke, head trauma and epilepsy to more chronic states, such as Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, HIV-associated dementia, and glaucoma. Moreover, a contributing factor to such damage is excessive excitation of glutamate receptors, particularly (but not exclusively) the N-methyI-D-aspartate (NMDA) subtype of glutamate receptor because of its high permeability to Ca 2+ and subsequent free radical generation. The aim of this proposed research project is to uncover the role of myocyte enhancer factor-2 (MEF2) transcription factors in this excitotoxic/apoptotic process in neurons during ischemic stroke in vivo. MEF2 transcription factors are activated by p38 mitogen-activated protein kinase during neuronal and myogenic differentiation. Recent work has shown that stimulation of this pathway is anti-apoptotic in stem cells but pro-apoptotic in mature neurons exposed to mild excitotoxic or other stresses. Here, preliminary data in vitro show that mild excitotoxic (NMDA) insults to mature cerebrocortical neurons activate caspases-3, -7, in turn cleaving MEF2A, C and D isoforms. Endogenous MEF2 cleavage fragments containing a truncated transactivation domain but preserved DNA binding domain are shown to block MEF2 transcriptional activity via dominant interference. In vitro transfection of constitutively-active/uncleavable MEF2 (MEF2-CA) rescues MEF2 transcriptional activity following NMDA insult and prevents neuronal apoptosis. Conversely, dominant-interfering MEF2 (MEF2-DN) abrogates neuroprotection by MEF2C-CA. Our underlying hypothesis is that these results obtained in vitro can now be applied in vivo using tetracycline (or doxycycline, "dox")-controlled transgenic mice expressing these MEF2-CA and MEF2-DN transgenes. This grant will define a novel pathway to neuronal apoptosis in ischemia via caspase-catalyzed cleavage of MEF2. The Specific Aims are as follows: 1. To characterize anti-apoptotic effects of MEF2-CA in stroke using dox-controlled transgenic mice. 2. To characterize the effect of caspase cleavage fragments of MEF2 as dominant interfering forms that contribute to stroke damage using dox-controlled transgenic mice that express doxycycline-controlled, MEF2 cleavage products. 3. To characterize MEF2 transcriptional activity in vivo after an hypoxic/ischemic (stroke) insult but prior to cell loss using a MEF2-indicator mouse
Studies
31
that has been engineered to activate the LacZ gene in accord with the degree of MEF2 transcriptional activity (designated des-mef2-LacZ). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CER ON CAM ANTIOXIDANT THERAPIES (CERCAT) Principal Investigator & Institution: Frei, Balz B.; Professor and Endowed Chair; None; Oregon State University P.O. Box 1086 Corvallis, or 973391086 Timing: Fiscal Year 2004; Project Start 26-SEP-2003; Project End 31-MAY-2008 Summary: This Program Project is based in the Linus Pauling Institute, an emerging international leader in research and education on micronutrients and antioxidants, and one of a few centers in the US to focus entirely on health promotion and disease prevention by dietary and CAM approaches. The Center of Excellence for Research on Complementary and Alternative Medicine (CAM) Antioxidant Therapies (CERCAT) will investigate two specific categories of CAM antioxidants: (i) Antioxidants that modulate the cellular redox environment and, thus, cell signaling and transcriptional activation, e.g. by affecting critical thiols with a low pKa or upregulating endogenous antioxidant systems. The CAM antioxidants to be investigated from this category are dithiol compounds (e.g. alpha-Iipoic acid) and metal chelators (e.g. EDTA and desferrioxamine). (ii) Highly conjugated or aromatic compounds that inhibit tyrosine nitration by peroxynitrite and other reactive nitrogen species. The principal antioxidant to be examined in this category is uric acid. Using cell culture studies and relevant animal models, CERCAT will determine the molecular and cellular mechanisms of action of these CAM antioxidants, and their safety and efficacy in treating amyotrophic lateral sclerosis (ALS) and cardiovascular diseases (CVD) and reversing the loss of cellular resistance to stress that occurs with aging. These goals of CERCAT are buttressed by NCCAM's "increased emphasis on studies of the mechanism underlying CAM approaches" and its "FY 2003 Research Priorities" of "studies of the biology of EDTA chelation therapy in animal models of CVD" and "neurodegenerative disorders using in vitro studies and animal models." CERCAT's research goals will be accomplished through three highly interactiveprojects: 1) "Metal chelators and thiols in endothelial function, and CVD" (Balz Frei); 2) "Lower vulnerability to toxins in aging by treatment with lipoic acid" (Tory Hagen); and 3) "CAM antioxidants and ALS" (Joseph Beckman). Center Investigators will be aided by an Administrative Core, which handles budgetary, reporting, and external advisory needs. In summary, CERCAT will investigate the efficacy of CAM antioxidants in ALS, CVD and aging, and provide the essential knowledge about the underlying mechanisms, dose-response effects, and relevant biological targets to advance these CAM therapies to human trials; equally important, the studies will test for untoward effects that might discourage CAM antioxidant therapies from proceeding to human studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CLINICAL TRIAL OF AMYOTROPHIC LATERAL SCLEROSIS.
CELEBREX
IN
SUBJECTS
WITH
Principal Investigator & Institution: Pestronk, Alan; Professor; Clinical Research Center; Washington University 1 Brookings Dr, Campus Box 1054 Saint Louis, Mo 631304899 Timing: Fiscal Year 2004; Project Start 06-MAY-2004; Project End 31-MAR-2005 Summary: There is no text on file for this abstract. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
32
•
Amyotrophic Lateral Sclerosis
Project Title: CLINICAL TRIAL OF HIGH DOSE COQ10 IN ALS - QALS-CLIN Principal Investigator & Institution: Kaufmann, Petra; Neurology; Columbia University Health Sciences Research Administration New York, Ny 100323702 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2008 Summary: (provided by applicant): Amyotrophic Lateral Sclerosis (ALS) is one of the most devastating neurological diseases leading to death typically in 3 years of onset. Treatment is severely limited, and no cure is available. Oxidative stress and mitochondrial dysfunction have been implicated in ALS pathophysiology. Coenzyme Q 10 (CoQ 10), a mitochondrial cofactor and powerful antioxidant, prolongs survival in the transgenic ALS mouse model and slows functional decline in other human neurodegenerative disease. CoQ 10 is a nonprescription dietary supplement with an excellent safety profile and central nervous system penetration. Thus, we propose to conduct a 2-stage phase II, randomized, placebo-controlled, double-blind, multi-center clinical trial of high-dose, solubilized CoQ 10 against placebo (target enrollment 185 patients at 18 clinical sites). This project will test the hypothesis that CoQ 10 reduces functional decline in patients with ALS. Aim 1 will consist of two stages. Stage 1 identifies which of two CoQ 10 doses is preferable (1000 mg. or 2000 mg. daily). Stage 2 compares the selected dose against placebo to assess whether evidence of efficacy is sufficient to justify proceeding to a future phase III trial. The primary outcome measure is the change in ALS Functional Rating Scale revised (ALSFRSr) score from baseline (randomization) to 9 months. We chose the ALSFRSr because: (1) It measures daily living functional abilities, a clinically meaningful outcome; (2) it is a validated predictor of survival; and (3) its ease of administration will minimize subject dropout. Aim 2 will determine whether CoQ 10 affects secondary measures: (1) forced vital capacity, (2) fatigue severity, (3) health-related quality-of-life, and (4) serum oxidative stress markers. Because median disease duration is short, the pool of ALS clinical trial participants at any given time is quite limited. Survival as an outcome measure is the gold standard for phase HI trials, but requires a large sample size. Because several new agents will soon be available for clinical testing, it is vital to reduce the number of patients required for phase II trials if these agents are to be tested in a timely, effective way. Aim 3 will evaluate alternative outcome measures to determine if their use can decrease the sample size required for ALS trials (see QALS-STAT). If CoQ 10 is effective in reducing functional decline in ALS, after phase III confirmation this knowledge will have an immediate impact on clinical practice and our understanding of ALS pathophysiology. This application is the clinical part (QALS-CLIN) of two separate, but highly coordinated units, which together constitute QALS (Clinical Trial of High Dose CoQ 10 in ALS). A separate R01 grant proposal (QALS-STA T, PI JLP Thompson) has been submitted for conduct of the statistical operations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CLINICAL TRIAL OF HIGH DOSE COQ10 IN ALS-QALS-=STAT Principal Investigator & Institution: Thompson, John L.; Biostatistics; Columbia University Health Sciences Research Administration New York, Ny 100323702 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2008 Summary: (provided by applicant): QALS-CLIN and QALS-STAT are two independent, but highly coordinated units, which together constitute QALS, a two-stage, phase II, randomized, placebo-controlled, double-blind, multi-center clinical trial of Coenzyme Q10 against placebo (target enrollment 185 patients at 18 clinical sites). The first stage identifies, which of two doses of CoQ10 is preferred (1,000 mg. or 2,000 mg. daily), using
Studies
33
a selection procedure to hold the number of patients required to a minimum. The second stage compares the preferred dose against placebo to assess whether there is sufficient evidence of efficacy to justify proceeding to a phase III trial. The primary outcome measure is the change in Amyotrophic Lateral Sclerosis Functional Rating Scale revised (ALSFRSr) score from baseline (randomization) to 9 months, which preliminary research has validated as a surrogate for the gold standard of survival. Four pre-specified secondary supporting hypotheses are also tested. Alternative outcome measures, based on ALSFRSr subscores that may prove more sensitive, will be explored in tertiary analyses as candidates for future trials. The goals of QALS-STAT are: 1) To minimize follow-up-time and number of patients required. 2) To conduct, efficiently integrate, and be responsible for all QALS data management and statistical operations. 3) To transmit to the Clinical Coordinating Center (CCC) in a timely fashion all of the data which the principal investigator of QALS CLIN needs to meet her responsibilities, in terms of ensuring patient safety and directing all clinical operations. Goal 1 is accomplished by the selection procedure, and the use of a surrogate endpoint, which cuts follow-up time by 50%. Goal 2 is achieved by a Statistical Analysis Center, whose personnel have extensive experience in coordination, data management, and programming for clinical trials, as well as their statistical requirements. Goal 3 is ensured by an Operations Committee of QALS-CLIN and QALS-STAT investigators and senior coordinators, which meets frequently under tightly specified and controlled communication protocols. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DISEASES
COMPARATIVE
MODELING
OF
NEURODEGENERATIVE
Principal Investigator & Institution: Link, Christopher D.; Professor; Inst for Behavioral Genetics; University of Colorado at Boulder 572 Ucb Boulder, Co 80309 Timing: Fiscal Year 2004; Project Start 01-JUN-2003; Project End 31-MAY-2007 Summary: (provided by applicant): Numerous age-associated neurodegenerative diseases [e.g., Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD), etc.] are associated with aggregation of disease-specific proteins. The finding that the genes encoding these proteins are mutated in some familial forms of these diseases strongly argues that these aggregating proteins cause these diseases. However, for all these diseases the relationship between protein aggregation and cellular pathology has not been clearly established. It is also unknown if the common association of protein aggregation with these diseases reflects a common underlying toxic mechanism, or, alternatively, a common downstream result of cell pathology. We will seek to identify the molecular consequences resulting from the aggregation of three different disease-associated proteins by individually expressing these proteins in a transgenic Caenorhabditis elegans model system. These molecular consequences will be determined by DNA microarray-based gene expression studies and co-immunoprecipitation analyses. Comparison of the molecular responses to expression of different disease-associated proteins will allow identification of common and disease-specific responses. We will then use the molecular genetic tools available in C. elegans to manipulate these molecular responses to determine their role in disease protein toxicity. These studies will directly test whether there is a common underlying toxic mechanism for these neurodegenerative diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
34
•
Amyotrophic Lateral Sclerosis
Project Title: CONTROL OF SYNAPTIC GLUTAMATE RELEASE Principal Investigator & Institution: Mennerick, Steven J.; Assistant Professor; Psychiatry; Washington University 1 Brookings Dr, Campus Box 1054 Saint Louis, Mo 631304899 Timing: Fiscal Year 2006; Project Start 01-JUL-2000; Project End 31-MAY-2011 Summary: (provided by applicant): In the central nervous system (CNS), glutamate and gamma-aminobutyric acid (GABA) are major excitatory and inhibitory neurotransmitters respectively. Balance between glutamate and GABA actions is critical for proper CNS function. Excessive glutamate accumulation has been associated with neuronal damage in a myriad of neurological and neuropsychiatric disorders including epilepsy, stroke, amyotrophic lateral sclerosis and others. We hypothesize that the CNS may have endogenous mechanisms by which glutamate release is selectively dampened, thereby maintaining or resetting the balance between excitation and inhibition during excessive activity. Novel ameliorative strategies might arise from better understanding and exploiting endogenous mechanisms that the nervous system itself uses to restore balance between excitation and inhibition. We explore two homeostatic mechanisms that, at the level of presynaptic vesicle release, depress glutamate release selectively over GABA release. The first synaptic adaptation is an acute change in vesicle release probability at glutamate but not GABA synapses. Glutamate synapses possess more "reluctant vesicles" than GABA synapses, identifiable with short trains of action potentials that fail to release otherwise accessible vesicles. Reluctant vesicles may be present at a distinct set of presynaptic terminals from willing vesicles or may arise within terminals as a result of stimulus-dependent factors. We propose to study the mechanisms and regulation of reluctant vesicles. We hypothesize a rapid-onset, calciumdependent feedback mechanism is particularly important in vesicle reluctance. The second synaptic adaptation is a persistent change in glutamate vesicle availability that outlives the inducing stimulus. We show that normal action potential activity suffices to inactivate a small percentage of glutamate vesicles, and that the number of inactivated vesicles is increased by augmenting neuronal activity. We hypothesize that the persistent changes differ mechanistically from other more commonly studied forms of persistent synaptic plasticity and that the changes are induced by local presynaptic calcium influx, which alters the number of functionally active presynaptic terminals. By better understanding the modulation of vesicle release probability and availability, we may learn to exploit the mechanisms for clinical benefit in disorders of excitotoxicity, and we will broaden our understanding of the reliability and malleability of glutamate synapses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORD BLOOD CELLS IN ALS: REPLACEMENT OF PROTECTION? Principal Investigator & Institution: Garbuzova-Davis, Svitlana N.; Assistant Professor; Saneron Ccel Therapeutics, Inc. 3802 Spectrum Blvd. Tampa, Fl 33612 Timing: Fiscal Year 2004; Project Start 01-AUG-2004; Project End 31-JUL-2006 Summary: (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease affecting motor neurons in the spinal cord, brainstem and cortex. We have previously shown that transplanting neuronal cells into the spinal cord delays the onset of motor symptoms in the G93A mouse model of ALS, but developing a potential treatment strategy around a committed neuronal cell or cell-line is not appropriate when there is widespread neurodegeneration as in ALS. Stem cells with their putative migratory abilities and multipotentiality may be able to protect dying
Studies
35
motor neurons and prevent disease progression. However, the mechanism behind these effects is unknown. We hypothesize that stem cells from umbilical cord blood (hUCB) will have a neuroprotective effect through modulation of immune effectors. The purpose of this project is to determine whether the mononuclear hUCB (MNC hUCB) cell population can serve as a novel source of transplant cells to ameliorate behavioral deficits and extend lifespan in the G93A mouse model of ALS. In Aim 1 we will determine a dose response relationship between MNC hUCB transplantation in the ALS mouse and motor function and lifespan of the mouse. In Aim 2 we will determine the distribution and migration potential of the transplanted MNC hUCB cells to areas of degeneration and if they may adopt immune phenotypes in vivo. In Aim 3 we will determine the effect of the transplanted cells on host immune inflammatory response by examining cytokine expression in G93A mice. The results of this study may provide the basis for developing a novel, non-invasive therapy, easily accessed by ALS patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CREATINE IN AMYOTROPHIC LATERAL SCLEROSIS Principal Investigator & Institution: Rosenfeld, Jeffrey; Carolinas Medical Center Box 32861, 1000 Blythe Blvd Charlotte, Nc 282322861 Timing: Fiscal Year 2004; Project Start 15-SEP-2002; Project End 31-MAY-2006 Summary: (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder selectively affecting motor neurons resulting in progressive weakness. Currently there is no known cure and a specific etiology has not been identified. Creatine is a nutritional supplement that improves mitochondrial function and has been shown to protect motor neurons in animal models of ALS. Based on our preliminary results presented in this proposal, creatine may also improve strength in patients with ALS.The Specific Aims of this proposal are to: 1) Determine whether treatment with creatine results in an acute increase in muscle strength and whether that effect is sustained with chronic therapy. 2) Determine whether chronic treatment with creatine will slow the progressive deterioration of motor and pulmonary function in patients with ALS. 3) Determine whether administration of loading doses of creatine followed by chronic treatment is safe in patients with ALS.This will be a phase III, double-blind, placebo-controlled, multi-center safety and efficacy study of creatine in 100 patients with ALS treated for nine months. The primary outcome measures are changes in disease progression rate as measured by 1) the maximum voluntary isometric contraction (MVIC) strength of ten arm muscle groups (bilateral shoulder and elbow flexion-extension and grip strength and 2) manual muscle testing (MMT) of the same ten arm muscle groups. Secondary endpoints include the rate of decline of forced vital capacity (FVC, percent predicted), the change in the ALS functional rating scale (ALSFRS-R), the SF-12 (quality of life instrument), and the safety and tolerability of creatine. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CYCLOOXYGENASE 2 AND ISCHEMIC NEURONAL INJURY Principal Investigator & Institution: Graham, Steven H.; Professor & Vice Chairman; Neurology; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2004; Project Start 01-JUN-1999; Project End 31-MAY-2008 Summary: (provided by applicant): Cyclooxygenase, the enzyme that catalyzes the production of prostaglandins from arachidonic acid, has long been thought to play a
36
Amyotrophic Lateral Sclerosis
role in exacerbating injury due to cerebral ischemia via its vascular and inflammatory effects. Recently it has been found that the inducible isoform of the enzyme, cyclooxygenase 2 (COX2), is expressed in high levels within neurons. We hypothesize that COX2 activity within the neuron itself promotes cell death after hypoxia/ischemia. The proposed experiments are designed to test whether COX2 activity exacerbates anoxic injury by oxidative stress, production of prostaglandins including the cyclopentenone prostaglandins, or both. The following specific aims are proposed: 1. Test whether COX2 activity exacerbates anoxic injury through production of oxidative stress via peroxidase activity. 2. Test whether COX2 activity exacerbates anoxic injury through production of prostaglandins via cyclooxygenase activity. 3. Test whether 15deoxy-delta(12,14) -PGJ2 or other prostaglandins activate PPARgamma receptor binding and exacerbate anoxic neuronal death via activation of the PPARgamma receptor. COX2 activity has been implicated in the pathogenesis of stroke and neurodegenerative diseases, including Atzheimer's disease and amyotrophic lateral sclerosis. The current studies will address the mechanisms by which COX2 activity can directly injure neurons and thus could lead to new therapeutic strategies for stroke and neurodegenerative diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEPLETION OF MITOCHONDRIAL S-NITROSOTHIOLS IN ALS Principal Investigator & Institution: Mannick, Joan B.; Associate Professor; Medicine; Univ of Massachusetts Med Sch Worcester 55 Lake Avenue North Worcester, Ma 01655 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): There is increasing evidence that mitochondrial dysfunction contributes to amyotrophic lateral sclerosis (ALS) pathogenesis. However the causes of mitochondrial dysfunction in ALS are not known. We hypothesize that familial ALS-associated SOD1 mutants aberrantly deplete S-nitrosothiols (SNOs) in mitochondria leading to mitochondrial degeneration and motor neuron death. Snitrosothiols are peptides and proteins that have an NO group attached to a cysteine residue. Peptide SNOs are potent antioxidants and neuroprotective. S-nitrosylation of critical cysteine residues on proteins is emerging as a mechanism of signal transduction regulation. Therefore aberrant depletion of mitochondrial SNOs is likely to be a toxic gain-of-function of SOD1 mutants. This is a novel testable working hypothesis in a virtually unexplored area in the ALS field. In support of our hypothesis, our preliminary data indicate that peptide and protein SNOs are located primarily in the mitochondria of cell lines expressing wild-type SOD1. Moreover, SNO levels are significantly decreased in the mitochondria of cells expressing SOD1 mutants. In specific aim 1 of the proposed studies we will extend our preliminary studies in cell lines to an in vivo animal model and determine if mitochondrial SNO levels are decreased in the spinal cord of mutant SOD1 transgenic mice before or at the time of onset of muscle weakness. In specific aim 2 we will determine if restoration of mitochondrial SNO levels improves mitochondrial function and the viability of cells expressing mutant SOD1. If we confirm our hypothesis, then in future studies we will determine if SNO donor compounds improve the survival of mutant SOD1 transgenic mice. Our long term goal is to determine if SNO donor compounds (which have been used for decades in the treatment of coronary artery disease with limited toxicity) have therapeutic efficacy in patients with ALS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
37
Project Title: DIAGNOSTIC AND SURROGATE MARKERS FOR ALS Principal Investigator & Institution: Paige, Lisa A.; Metabolon, Inc. Durham, Nc 277134409 Timing: Fiscal Year 2005; Project Start 01-FEB-2005; Project End 31-JUL-2006 Summary: (PROVIDED BY APPLICANT): Environmental and genetic factors are believed to contribute to Neurodegenerative disorders such as Amyotrophic Lateral Sclerosis, Parkinson's, Huntington and Alzheimer's diseases. In general, these diseases are poorly understood at the molecular and biochemical levels with no effective therapies. A better understanding of environmental triggers that influence disease development and the interplay between these exposures and a person's underlying genetic susceptibility will result in earlier detection, better understanding of disease mechanisms, and ultimately the design of prevention strategies. Metabolomics is a powerful new technology platform for the comprehensive study of the metabolome, the repertoire of bio-chemicals (or small molecules) present in cells, tissue and body fluid. It can provide signatures for disease states in ways not possible before and maps these changes to aberrent biochemical pathways. Environmental insults and genetic mutations leave long lasting changes in the metabolome that can be captured in modified signatures. In the proposed studies we will extend our current observations of biochemical abnormalities (signatures) in the sera of ALS patients, both familial and sporadic, but using the new chemically capable metabolomic platform. We will confirm the specificity of these signatures by comparing them to signatures from patients with general neuropathies, myopathies and other neurodegenerative diseases. Specific aims for Phase I: 1. Collect clinical data and plasma samples from subjects with ALS and disease and non-disease comparison groups. 2. Begin to identify unique metabolomic profiles for sporadic ALS (SALS) and familial ALS (FALS) by comparing to those from patients with peripheral nervous system disorders, other neurodegenerative disorders and healthy controls. In Phase II we will propose to develop diagnostic and surrogate marker products for ALS. Long-term goals are to use metabolomics as a powerful tool to map environmental factors that contribute to the development of neurodegnerative diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DISCOVERING SMALL MOLECULES TO RESCUE SOD-1 FOLDING Principal Investigator & Institution: Wigley, William C.; Reata Pharmaceuticals, Inc. Suite 150 Irving, Tx 75063 Timing: Fiscal Year 2005; Project Start 15-FEB-2005; Project End 31-JAN-2006 Summary: (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a fatal adultonset neurodegenerative disease characterized by selective loss of motor neurons and atrophy of skeletal muscle. ALS is the most common motor neuron disease in the adult population, affecting 30,000 in the United States alone. Approximately 15% to 20% of familial ALS cases are associated with dominant missense mutations in the Cu/Zn superoxide dismutase 1 (SOD1) gene. A pathologic feature of both sporadic and familial ALS is the accumulation of potentially toxic proteinaceous inclusions containing misfolded SOD1 in the cytosol of degenerating neurons. A series of recent studies strongly suggest that ALS results from a gain of toxic function, which arises either during early steps of inclusion formation or from the inclusions themselves. In this regard, the discovery of compounds that affect SOD1 misfolding would be a major step toward the development of drugs for the treatment and prevention of ALS. To date however, the search for such compounds has been hindered by a lack of appropriate
38
Amyotrophic Lateral Sclerosis
high-throughput screening (HTS) methods. Reata Discovery, Inc., the applicant organization, has obtained an exclusive license to a novel, proprietary cell-based HTS method that directly monitors SOD1 folding and solubility in live cells. Using this method, we have established a tight correlation between reporter signal and the published effects of disease-associated mutations on the stability of SOD1. Notably, this system is sensitive and has excellent dynamic range in mammalian cells, providing up to a 50-fold difference in signal between wild type SOD1 and the most severe mutations. Based upon this robust assay, Reata has initiated a program to identify small drug-like compounds that impact SOD1 misfolding. The proposed funding will significantly enhance this effort by expanding the scope of compound libraries and supplementing internal funds that Reata has already committed to the program. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFECTS OF STARGAZIN ON AMPA RECEPTOR CHANNEL FUNCTION Principal Investigator & Institution: Patneau, Doris K.; Anatomy and Cell Biology; Osu Center of Health Sciences 1111 W 17Th St Tulsa, Ok 741071898 Timing: Fiscal Year 2006; Project Start 01-JAN-2006; Project End 31-DEC-2008 Summary: (provided by applicant): The ionotropic glutamate receptors are critical for the normal development and function of the nervous system, and for the processes underlying learning and memory. Glutamate receptors have also been implicated in the etiology of several pathological conditions, including Alzheimer's, Huntington's and Parkinson's diseases, amyotrophic lateral sclerosis, epilepsy and brain damage following stroke. The proposed experiments will provide significant new information regarding regulation of the channel properties of AMPA receptors, the major glutamate receptor subtype mediating fast excitatory synaptic transmission in the brain. Stargazin is a transmembrane protein that is known to act as a molecular chaperone in trafficking of AMPA receptors to the cell surface. However, as an associated membrane protein, stargazin could also affect AMPA receptor channel function. Preliminary data document significant effects of stargazin on AMPA receptor desensitization that appear to be distinct from its effects on trafficking. Studies are proposed that will (1) identify the specific effects of stargazin on gating and desensitization of the AMPA channel; (2) identify the regions of interaction between stargazin and the AMPA receptor that mediate these functional effects, and; (3) determine the underlying mechanism for TARP modulation of AMPA receptors. Stargazin will be co-expressed with recombinant AMPA receptors in HEK 293 cells, as well as native AMPA receptors in cultured rat hippocampal neurons and mouse cerebellar granule cells. Functional effects on agonistevoked and synaptic responses will be examined using patch-clamp recording from single cells. Molecular techniques will be applied to determine whether the regions of the stargazin protein that mediate trafficking and effects on channel function can be distinguished. Further experiments will involve manipulations of AMPA receptor proteins to attempt to disrupt the effects of stargazin on channel function. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FLUORESCENT NEUROCHEMISTRY
SENSORS
TO
INVESTIGATE
ZINC
Principal Investigator & Institution: Lippard, Stephen J.; Professor of Chemistry; Chemistry; Massachusetts Institute of Technology 77 Massachusetts Ave Cambridge, Ma 02139
Studies
39
Timing: Fiscal Year 2004; Project Start 01-APR-2002; Project End 31-MAR-2006 Summary: (provided by applicant): The long-term goal of this research is to provide bright fluorescent sensors for zinc to investigate its neurochemistry. Zinc occurs at high concentrations in vesicles located in presynaptic neurons of the hippocampus and is released into the synaptic cleft in response to a physiological signal. We hypothesize that such zinc release can be used to map neural networks by following the temporal and positional pattern of fluorescence changes that occur following stimulation. Uncontrolled release of neuronal zinc, for example in response to ischemia, leads to Zninduced death of cortical neurons. The sensors devised here will provide a powerful tool for tracking zinc levels suspected to correlate with such events as well as neurological diseases, including familial amyotrophic lateral sclerosis and Alzheizemer's disease. The proposal focuses on the design and synthesis of three classes of ligands for selective zinc binding, each giving rise to a fluorescent response. The sensors are all derivatives of fluorescein, chosen for its high quantum yield, long wavelength excitation and emission properties, and ability to be manipulated chemically. The first class of ligands improves the brightness of the fluorescence upon Zn2+-binding, which is quenched by photoinduced electron transfer (PET) until zinc binding restores it. This kind of sensor is typified by preliminary work with the "Zinpyr" family of molecules, which contain fluorescein functionalized at the 4' and 5' positions with bis(2-pyridylmethyl)aminomethyl zinc-binding moieties. A second approach affords ratioable fluorophores by coordination of zinc to the nitrogen atom of a hybrid rhodamine/fluorescein skeleton that we designate as "rhodafluor" ligands. Here, both the unbound and bound sensors fluoresce, but emit at different wavelengths. The third class of molecules to be synthesized and investigated positions the zinc-binding moiety as a spacer between pendant fluorescent donor/acceptor pairs that undergo resonance energy transfer (ET) more efficiently upon zinc binding. All the synthetic routes are modular and convergent, allowing for systematic variation of the Zn2+-binding unit to access a wide range of dissociation constants and solubility properties. The structures, formation constants, rates of formation and dissociation, solubility, solution stability, and fluorescence lifetimes of the zinc complexes of these sensors will be investigated. Their cellular localization will be studied by one- and two-photon microscopic methods. A strategy for attaching the sensors to the extracellular surface of post-synaptic neurons to monitor zinc arrival after synaptic firing will be pursued. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTIONAL DISSECTION OF RET SIGNALING PATHWAYS Principal Investigator & Institution: Jain, Sanjay; Surgery; Washington University 1 Brookings Dr, Campus Box 1054 Saint Louis, Mo 631304899 Timing: Fiscal Year 2004; Project Start 15-AUG-2004; Project End 31-JUL-2009 Summary: (provided by applicant): RET is a single membrane tyrosine kinase receptor that mediates signaling of GDNF family ligands (GFLs) in association with GFRalpha coreceptors. Aberrant RET signaling results in a number of human diseases and developmental abnormalities, including multiple endocrine neoplasia type 2 syndromes, Hirschsprung disease (intestinal ganglionosis), and developmental abnormalities of the peripheral nervous and urogenital systems in mice. GFL signaling is also important for the survival of neuronal populations such as midbrain dopaminergic neurons and spinal cord motor neurons, which degenerate in Parkinson disease and amyotrophic lateral sclerosis (ALS), respectively. The molecular defects in the signaling pathways that result in the wide variety of RET-mediated abnormalities are largely unknown. This lack of knowledge is an impediment for the creation of rationally designed medical
40
Amyotrophic Lateral Sclerosis
interventions for these conditions. Similar to other receptor tyrosine kinases (RTKs), RET signals through interactions between key phosphotyrosine docking sites and their cognate adaptor proteins. Signals emanating from these interactions are important in RET-mediated regulation of cellular processes such as proliferation, migration, and axonal outgrowth, whereas the perturbation of these processes ultimately leads to diseases. The candidate proposes to characterize mice expressing RET mutants lacking key adaptor docking sites in order to associate these mutations with alterations in key cellular processes that lead to developmental deficits in the peripheral nervous and urogenital systems. As aberrations in RET-stimulated proliferation is central to its role in tumorigenesis and developmental abnormalities, the candidate will utilize engineered fibroblast cell lines to study this aspect of RET biology in further detail. These in vitro assays will be used in conjunction with lentivirus delivery of specific siRNAs to identify signaling components (adaptor proteins) and pathways (MAPK, PLCgamma) that signal through particular RET docking sites to regulate proliferation. The identification of specific components of this signaling pathway will be helpful ultimately in developing targeted therapeutics for these tumors and in enhancing our understanding of nervous system development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTIONAL GENOMICS OF C.ELEGANS USED TO STUDY DISEASE Principal Investigator & Institution: Buttner, Edgar A.; Molecular and Cellular Biology; Harvard University 1350 Massachusetts Avenue Cambridge, Ma 02138 Timing: Fiscal Year 2004; Project Start 01-AUG-2001; Project End 31-JUL-2007 Summary: (Applicant's Abstract): My long-term objective is to develop and analyze invertebrate models to obtain a mechanistic understanding of hereditary human neurological diseases. The nematode Caenorhabditis elegans will be used for genetic analysis of loss-of-function diseases such as lissencephaly (LIS), and gain-of-function diseases, such as familial amyotrophic lateral sclerosis (FALS). Loss-of-function neurological diseases will be modeled by disrupting C. elegans disease gene homololues. Gain-of-function neurodegenerative disorders will be modeled by generating transgenic worms carrying gain-of-function disease transgenes. The powerful genetics of C. elegans will then be applied to analyze the molecular basis of neuronal cell death or dysfunction in these disorders. Suppressor and enhancer screens will be performed to identify novel genes that interact with loss-of-function disease gene homologues or gain-of-function disease transgenes, an approach not possible in transgenic mice. Such novel genes may not only provide insight into the molecular mechanisms of action of neurological disease genes, but may also constitute potential therapeutic targets. Genetic analysis of diverse aspects of C. elegans development has identified genes and pathways relevant to disease. Studies of apoptosis in C. elegans defined genes composing a programmed cell death pathway that is conserved in human. The creation of worm models of neurological diseases will provide an opportunity to study how upstream disease genes and downstream cell-death genes might interact. Because a large number of disease gene homologues have been identified in C. elegans, the project could in principal establish an approach with future applications to a wide range of neurological disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
41
Project Title: GAMMA - SECRETASE CLEAVAGE OF THE P75 RECEPTOR Principal Investigator & Institution: Chao, Moses V.; Professor; Skirball Institute; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2006; Project Start 30-SEP-2006; Project End 31-MAY-2011 Summary: (provided by applicant): The neurotrophins, NGF, BDNF, NT-3 and NT-4, represent a family of proteins essential for the development of the vertebrate nervous system. In addition to classical effects upon neuronal cell survival, neurotrophins also can regulate axonal and dendritic growth, synaptic structure and connections, neurotransmitter release, long-term potentiation and synaptic plasticity. Each neurotrophin can signal through two different cell surface receptors, Trk receptor tyrosine kinases and the p75 neurotrophin receptor, a member of the TNF receptor superfamily. Given the wide number of activities now associated with neurotrophins, it is likely additional regulatory events and signaling systems are involved. In this application, we will focus on a new and unexpected mechanism. Intramembraneous cleavage of the p75 receptor by ?-secretase results in the release of the intracellular domain. This is the first known example of this activity in the TNF receptor superfamily. Significantly, the cleavage of p75 has been mapped to the same location as amyloid precursor protein (APR). Cleavage-resistant forms of p75 have been created to test the functional significance of y-secretase cleavage and the effect on p75 signaling activities. The functional consequences of p75 cleavage will be tested upon Trk receptor signaling, as well as axonal regeneration events. The p75 receptor is known to interact with cytoplasmic proteins that can translocate to the nucleus. Among many proteins that interact with p75, we will follow SC-1, a novel zinc finger protein that translocates to the nucleus. Since p75 is frequently upregulated after injury, these studies will provide further insight into mechanisms responsible for neurotrophins during inflammation and neurodegenerative disease states, such as Alzheimer's dementia and amyotrophic lateral sclerosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETIC DETERMINANTS OF OXYGEN TOXICITY Principal Investigator & Institution: Culotta, Valeria C.; Associate Professor; Environmental Health Sciences; Johns Hopkins University W400 Wyman Park Building Baltimore, Md 212182680 Timing: Fiscal Year 2004; Project Start 01-AUG-1993; Project End 31-JUL-2005 Summary: This research focuses on Cu/Zn superoxide dismutase (SOD1), an important anti-oxidant enzyme that scavenges superoxide and predominantly localizes to the cytosol of eukaryotes. The function of SOD1 has been somewhat enigmatic because superoxide is thought to largely arise from mitochondria, where a second SOD (Mn SOD2) already exists. Through studies in bakers yeast, we have been exploring the biology of Cu/Zn SOD1. Previously, we discovered the CCS metallochaperone that inserts the catalytic Cu co-factor into SOD1. CCS co-localizes with SOD1 primarily in the cytosol, but recently we found that both proteins also reside in the intermembrane space of the mitochondria where active SOD1 may directly combat respiratory sources of superoxide. By exploiting yeast and mammalian systems, the current Aims are designed to unravel the striking link between SOD1 and the mitochondria. AIM l: To identify the sources of oxidative damage relevant to Cu/Zn SOD1. The role of mitochondria in causing rapid aging and oxidative damage to yeast lacking SOD1 will be determined. Metabolic sources of superoxide will be identified through a genetic screen. AIM 2: To understand the physiology of mitochondrial Cu/Zn SOD1. The functions of cytosolic
42
Amyotrophic Lateral Sclerosis
versus mitochondria SOD1 will be differentiated and the mechanism of mitochondrial import of SOD1 probed. We will also begin to address the possible implications for mitochondrial SOD1 in SOD1-linked cases of Amyotrophic Lateral Sclerosis. AIM 3: To define the CCS-independent pathway of copper delivery for SOD1. Mammalian SOD1 acquires a limited level of copper independent of CCS. We will now test whether this pathway occurs in mitochondria and will employ yeast genetics to identify factor(s) other than CCS that activate mammalian SOD1 with copper. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC EPIDEMIOLOGY OF ALS IN VETERANS Principal Investigator & Institution: Schmidt, Silke A.; Medicine; Duke University 2424 Erwin Rd. Durham, Nc 27705 Timing: Fiscal Year 2004; Project Start 19-AUG-2004; Project End 31-JUL-2009 Summary: (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a devastating, incurable and rapidly fatal disorder of the motor neurons responsible for voluntary muscle movement. Genes responsible for the familial form of ALS have been identified, but the majority of ALS is sporadic and has a complex etiology with contributions of both genetic and environmental factors. The hypothesis that geneenvironment (GxE) interaction may play a substantial role in ALS pathogenesis is supported by studies of high-risk clusters in the Western Pacific Islands. ALS is a disease of high priority for the Department of Veterans Affairs (VA) since an increased incidence of the disease has been reported in deployed compared to non-deployed Gulf War veterans. Recently, the VA has initiated a National Registry of veteran ALS patients, which is expected to recruit approximately 1,500 patients with blood samples over the next three years. Given this unique resource, the explosion of data from the Human Genome Project, and the development of new laboratory and statisticalgenetic analysis tools, the time is ripe for new approaches to dissecting the etiology of ALS, with an emphasis on uncovering complex GxE interactions. The specific aims of the study proposed here are to (1) ascertain 3,000 veteran controls frequency-matched to the ALS Registry patients by age, sex, ethnicity and branch of military service; (2) collect environmental risk factor information from ALS patients and controls, building upon an instrument currently used in other ALS studies, which will be modified and expanded to include military-specific exposure assessment; (3) genotype nuclear DNA of ALS patients and controls for single-nucleotide polymorphisms (SNPs) in a number of putative candidate genes, using an efficient DNA pooling strategy combined with highthroughput individual genotyping; (4) genotype mitochondrial haplogroups of ALS patients and controls; and (5) perform statistical analysis of case-control and case-only data to identify main effects of genetic and non-genetic risk factors for ALS as well as GxE interaction. Both traditional regression-based well as novel computationally intensive methods will be employed. Genetic and environmental effects on disease progression will also be examined. Our study will not only be of great relevance for the veteran population, but is also likely to improve our understanding of ALS in the general population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GLUTAMATE TRANSPORT REGULATION AND SYNAPTIC PLASTICITY Principal Investigator & Institution: Eskin, Arnold; Professor and Chair; Biology and Biochemistry; University of Houston 4800 Calhoun Rd Houston, Tx 772045037
Studies
43
Timing: Fiscal Year 2004; Project Start 01-AUG-2001; Project End 31-JUL-2006 Summary: A number of properties of a neuron change in a coordinated fashion to store a given type of memory. Our long- term goal is to determine which properties of neurons change, and how these properties are regulated during formation of memories. Regulation of glutamate transporter activity may be necessary during increases in synaptic efficacy to maintain the fidelity of synaptic transmission and to avoid toxicity that might occur if glutamate is elevated in the synaptic cleft for too long. Thus, we hypothesize that increases in glutamate transporter activity will accompany increases in synaptic efficacy at glutamatergic synapses, especially ones involving long-term changes in synaptic efficacy. This hypothesis will be tested in vitro by investigating regulation of glutamate uptake after induction of LTP and in vivo by investigating regulation of glutamate uptake after contextual fear conditioning. Area CA1 of the rat hippocampus will be used in most experiments. We will use a multidisciplinary approach including electrophysiology, biochemistry and behavioral analysis to investigate the regulation of glutamate uptake. The proposed research has four specific aims. Most of the experiments in Specific Aims 1-3 will investigate regulation of glutamate transport during two different forms of LTP (E- and L-LTP). Aim 1 is to characterize the mechanisms involved in the increase in glutamate uptake produced by high frequency stimulation. Aim 2 is to determine whether induction of LTP increases the expression of glutamate transporters, and what mechanisms are involved in the increase in expression. Aim 3 is to investigate the relationship between LTP and changes in glutamate uptake and expression of glutamate transporters. Aim 4 is to determine whether an associative learning paradigm, contextual fear conditioning, produces an increase in glutamate transport in the hippocampus in vivo. In our lab, recent studies have shown that glutamate uptake is regulated during long-term memory in Aplysia, and preliminary results indicate that glutamate uptake is regulated during LTP in the rat hippocampus as well. Thus, the results of these studies will likely indicate that regulation of glutamate transport is a general phenomenon at glutamatergic synapses involved in synaptic plasticity. As glutamate is a remarkably potent and rapidly acting neurotoxin, fundamental studies of long-term regulation of glutamate transport should aid solutions to brain trauma and diseases such as amyotrophic lateral sclerosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUTAMATE TRANSPORTERS IN THE CNS Principal Investigator & Institution: Robinson, Michael B.; Associate Professor; Children's Hospital of Philadelphia Joseph Stokes, Jr. Research Institute Philadelphia, Pa 191044318 Timing: Fiscal Year 2004; Project Start 01-MAY-1997; Project End 31-MAY-2006 Summary: (provided by applicant): The acidic amino acids, glutamate (Glu) and aspartate, are the predominant excitatory neurotransmitters in the mammalian central nervous system (CNS). Although there are millimolar concentrations of these excitatory amino acids (EAAs) in brain, extracellular concentrations are maintained in the low micromolar range to facilitate crisp synaptic transmission and to limit the neurotoxic potential of these EAAs. A family of Na+-dependent high affinity transporters is responsible for the regulation and clearance of extracellular EAAs. This project represents a collaborative effort between two laboratories that have defined the biochemical, pharmacological, and pathophysiological properties of these transporters. In this competitive renewal, we propose to focus on studies of one of the astroglial transporters, GLT-1/EAAT2. There is a substantial body of evidence to suggest that this transporter mediates the largest percentage of transport activity in the mammalian
44
Amyotrophic Lateral Sclerosis
forebrain. The expression (protein and mRNA) of this transporter is regulated in several interesting ways, increasing dramatically during the period of synaptogenesis and astrocyte differentiation. Unlike the two other forebrain transporters, expression of GLT1 is largely restricted to the CNS and astrocytic expression is dependent upon the presence of neurons both in vivo and in vitro. Finally, we and others have documented abnormal expression of this transporter in several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Essentially nothing is known about the mechanisms responsible for this regulation of GLT-1. Therefore in Specific Aims I-III, we propose a strategy to study the mechanisms that control GLT-1 expression and assembly. We and others have shown that inhibition of these transporters increases the susceptibility of the tissue to excitotoxic insults, but it is not known if overexpression can be neuroprotective. Therefore in Specific Aim IV, we propose to determine if overexpression of GLT-1 is neuroprotective in animals models of ALS and against excitotoxic insults using both in vitro and in vivo models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEALTH PREFERENCE ASSESSMENT IN PARKINSON'S DISEASE Principal Investigator & Institution: Siderowf, Andrew D.; Assistant Professor; Neurology; University of Pennsylvania Office of Research Services Philadelphia, Pa 19104 Timing: Fiscal Year 2004; Project Start 01-AUG-2000; Project End 31-JUL-2006 Summary: The candidate is a fellowship-trained neurologist dedicated to a career in the evaluation of health services for patients with Parkinson's Disease (PD) and other neurodegenerative diseases. This application proposes a comprehensive program designed to allow the candidate to become an independent investigator in this area. The University of Pennsylvania has outstanding clinical and academic resources to support this proposal. The training component entails formal graduate education in clinical epidemiology and medical economics, specifically focusing on health services research. This training will satisfy the degree requirements for a Master of Science in Clinical Epidemiology (MSCE). The research component is an evaluation of the validity, reliability and responsiveness of preference-based outcomes in PD. These outcomes are a type of health related quality-of-life measure in which the desirability of a given health state is explicitly valued relative to alternative health states. The main use of preferencebased outcomes is in cost-effectiveness analysis (CEA). In practice, societal preferences, which are the recommended metric for CEA, are difficult to measure. As a result, prescored multi-attribute health classification systems have been developed to approximate these preferences. The central hypothesis of the research component is that these prescored systems may not reflect societal preferences for health states encountered in PD. The specific aims of this study are: 1) To produce a series of vignettes describing PDrelated health states, and to elicit societal preference weights for these vignettes; 2) To conduct a cross sectional study comparing this set of preferences to values derived from pre-scored multi- attribute health classification systems, and to preferences elicited from patients and caregivers; and 3) To conduct a longitudinal study to measure the reliability and responsiveness of preference-based measures in PD patients and their caregivers. The results from this study will have a direct application to all future CEA for PD-related interventions. In addition, the insights gained may be applied to other neuro-degenerative diseases including Alzheimer's Disease and Amyotrophic Lateral Sclerosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
45
Project Title: HIGH RESOLUTION HYBRID FT-ICR MASS SPECTROMETER Principal Investigator & Institution: Loo, Joseph A.; Professor; Biological Chemistry; University of California Los Angeles Office of Research Administration Los Angeles, Ca 90024 Timing: Fiscal Year 2006; Project Start 01-AUG-2006; Project End 31-JUL-2007 Summary: (PROVIDED BY APPLICANT): A high-resolution hybrid Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer with capabilities for top-down protein sequencing and rapid duty-cycle LC-tandem MS measurements for bottom- up proteomics is requested. This instrument will be a vital component to support the specific aims of over 11 NIH-funded projects. The projects involve a variety of protein structure/function-related research, including the determination of protein-protein and protein-ligand interactions, protein phosphorylation, and the identification of protein biomarkers for disease detection and prognosis. The research will impact a range of human health issues, including neurodegenerative diseases, such as Huntington's disease, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), respiratory illnesses, cardiovascular and inflammatory diseases, and cancer. The hybrid FT-ICR mass spectrometer will be capable of sub-2 parts-per-million mass measurement accuracy for both intact peptides/proteins and product ions derived from MS/MS experiments. It will include a storage trapping device for increased dynamic range and have capabilities for rapid data dependent LC-MS/MS, and a resolving power sufficient to measure the isotope distribution of large, intact proteins for improved mass accuracy. Unique to this system will be capabilities for electron capture dissociation (ECD) and infrared multiphoton dissociation (IRMPD), ion activation methods advantageous for top-down protein sequencing and identification/localization of post-translational modifications. ECD greatly improves the ability to dissociate intact proteins to derive complete sequence information, as well as holding the promise of detection of post-translational modifications. An instrument with these unique capabilities is not available currently at UCLA. The instrument will be a centerpiece and will be supported and administered by the newly-created Molecular Instrumentation Center at UCLA, and it will serve researchers from across the institution. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HORMONAL EFFECTS ON BEHAVIOR AND SPINAL CORD MORPHOLOGY Principal Investigator & Institution: Breedlove, S Marc.; Professor; Psychology; Michigan State University 301 Administration Bldg East Lansing, Mi 48824 Timing: Fiscal Year 2004; Project Start 01-APR-1990; Project End 31-JUL-2009 Summary: (provided by applicant): We will examine the influence of steroid hormones, specifically androgens, on a neuromuscular system that responds to these hormones throughout life. Previous work has shown that androgens maintain the bulbocavernosus (BC) and levator ani (LA) muscles of developing male rats. These striated perineal muscles are normally present in females at birth but, in the absence of androgen, the muscles die. A single injection of androgen to newborn female rats will preserve the muscles for life. The BC/LA muscles are innervated by motoneurons in the spinal nucleus of the bulbocavernosus (SNB). Androgenic sparing of the BC/LA target muscles also indirectly spares the SNB motoneurons from developmental apoptosis. The present project will study the effects that androgenic hormones continue to exert on the SNB system in adulthood. Castration of adult male rats triggers a host of changes in the structure and function of the SNB system. For example, the somata and dendrites of
46
Amyotrophic Lateral Sclerosis
SNB motoneurons, as well as the neuromuscular junctions (NMJs) these motoneurons make upon the target muscles, shrink following castration. Testosterone (T) therapy can prevent and/or reverse this shrinkage. We have found that T cannot maintain SNB somata size when we pharmacologically block the N-methyl-d-aspartate (NMDA) type glutamate receptor. This effect of NMDA blockade seems to be specific to SNB motoneurons and to the effect of T. We propose to determine whether NMDA blockade also prevents the effects of T on SNB dendrites and NMJs. We have found that SNB motoneurons, but not other nearby motoneurons, increase their expression of the gene for the NMDA receptor subtype 1 (NMDAR1). So the androgen-induced increase in NMDA receptor stimulation of SNB motoneurons may contribute to maintaining soma size. We will use a mosaic analysis to ask whether androgen acts directly upon SNB motoneurons to increase their expression of the NMDAR1 message. We will also determine whether SNB motoneurons express a newly discovered NMDA receptor subtype (NMDAR3), whether androgen manipulations alter NMDAR3 expression, and if so whether this is a cell-autonomous response of the motoneurons. These studies should lead to a better understanding of neuromuscular systems, of the influence of steroid hormones on the spinal cord, and the etiology of several neuromuscular disorders including amyotrophic lateral sclerosis and Kennedy's syndrome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IDENTIFICATION AND CHARACTERIZATION OF THE ALS4 GENE Principal Investigator & Institution: Chance, Phillip F.; Professor and Chief; Pediatrics; University of Washington Office of Sponsored Programs Seattle, Wa 98105 Timing: Fiscal Year 2004; Project Start 01-AUG-2002; Project End 31-MAY-2007 Summary: (Adapted from applicant?s abstract): Amyotrophic lateral sclerosis (ALS) is an age-dependent neurodegenerative disorder associated with severe loss of motor neurons in the brain, brainstem and spinal cord. ALS typically has a rapid course and leads to death within 3 to 5 years after the onset of clinical symptoms. Approximately 10 percent of cases are thought to have a genetic basis and are referred to as "familial ALS." One form of familial ALS (ALS1) maps to chromosome 21q22 and is associated with mutations in the Cu/Zn superoxide dismutase (SOD1) gene. While ALS is a type is a disorder that is almost exclusively seen in adults, there are forms of ALS that have onset in childhood or adolescence, and manifest a chronic, slowly progressive course. This type of ALS is termed "juvenile ALS." We identified a region on chromosome 9q34 which harbors the gene for an autosomal dominant form of juvenile ALS. The various forms of ALS and juvenile ALS are devastating neurological disorders lacking a defined pathophysiological basis and any effective therapies. The purpose of this application is to identify and characterize the gene for juvenile ALS mapping to chromosome 9q34, also known as the ALS4 locus. Specific Aim (1) is to search for mutations in known candidate genes mapping within the ALS4 candidate region on chromosome 9q34 in order to identify the gene for ALS4. Specific Aim (2) is to search for additional transcripts as candidate genes for ALS4 by direct cDNA selection and other positional cloning methods, if our evaluation of the known candidate genes from the critical region fails to yield the causal gene. Specific Aim (3) is to characterize the genomic structure of the ALS4 gene by standard molecular genetic approaches and to determine the expression pattern of the ALS4 gene and the ALS protein by nucleic acid hybridization and immunohistochemical methods using specific probes and/or antibodies. Specific Aim (4) is to identify the functional domains of the ALS gene by sequence-similarity comparisons and analysis of homologous and orthologous genes from other species and by biochemical analysis. Specific Aim (5) is to develop an animal model of ALS4 by
Studies
47
introducing an identified disease-causing mutation into the germline of the mouse by employing either transgenesis or gene targeting. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IGF-I/ALS TRIAL Principal Investigator & Institution: Sorenson, Eric J.; Mayo Clinic Coll of Medicine, Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2004; Project Start 30-SEP-2002; Project End 31-JUL-2007 Summary: (provided by the applicant): The objective of this trial is to determine whether IGF-1 slows progression of weakness in ALS. 300 patients with ALS will be enrolled for 2 years of treatment with a study drug or Placebo. The study will be double-blind, with equal randomization of patients to Placebo or drug. The primary end-point will be the rate of change in Manual Muscle Testing score (MMT). Secondary end-points will be tracheotomy-free survival and change in the ALSFRS score over the 2-year study period. Enrollment will be limited to those with a disease duration of less than 24 months, and a Manual Muscle Testing score of less than 8. The study is designed to detect a 30% difference in survival over the two-year treatment period. Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder that causes progressive muscle weakness and death within 4 years of onset. Its overall incidence is about 2 cases/100,000 in the United States. Except for a very small minority of cases, the cause is unknown. The disease is incurable and only Riluzole has been proven to be effective in slowing the disease. Riluzole effects are modest and more effective treatments for ALS are desirable. IGF-1 had demonstrated neurotropic effects in animal and tissue culture models of motor neuron disease. These findings have led to an interest in its potential use in ALS patients. Clinical trials have been completed in the United States, Europe, and Japan with conflicting conclusions. Previous Clinical Trials in ALS have utilized global measures of function, electrophysiological measures of muscle function, mechanical measurement of maximum force generated by Voluntary Isometric Contraction of Muscle (MVIC) or Manual Muscle Testing (MMT). Loss-of-function and death in ALS is primarily due to loss of muscle strength. Muscle strength is directly related to the underlying pathology (loss-of-motor neurons). To obtain a definitive answer as to the beneficial effects of IGF-1 in ALS, we will assess the most direct and objective effects of the disease, directly, by assessing muscle strength testing, survival and functional performance. The preliminary data from our prior trial allows design of a Phase III treatment trial that will yield a definitive result about the treatment effect of IGF-1. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMAGING THE PATHOPHYSIOLOGY OF AMN IN MICE AND HUMANS Principal Investigator & Institution: Eichler, Florian S.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2006; Project Start 01-JUN-2006; Project End 31-MAY-2011 Summary: (provided by applicant): The proposed interdisciplinary study allows the candidate to further develop his knowledge of MR physics and expertise in imaging studies of adrenomyeloneuropathy (AMN), a form of adrenoleukodystrophy (ALD), while providing rigorous exposure to the clinical and biological side of this research. The goal is to increase the candidate's expertise in multiple areas necessary to his proposed research project and future career development. These areas include genetics
48
Amyotrophic Lateral Sclerosis
of peroxisomal disorders, lipid metabolism, and spatial aspects of nuclear magnetic resonance spectroscopy. The proposal builds nicely on the candidate's prior experience with Dr. Moser at Johns Hopkins and extends his studies to the animal model. The candidate is in a world-renown environment for both MR imaging and neuroscience. This Award will provide the guidance and tools necessary for him to become a successful, independent researcher. The 5 year research training program consists of 1) coursework and mentoring relationships on the science of high-field magnetic resonance that the candidate is currently lacking, 2) a 2 year rigorous training in animal imaging, and 3) collaborative translational studies with experts in the field of lipid metabolism and peroxisomal disorders. The research portion of this application will allow him to examine the histopathological and biochemical correlate of advanced MR techniques in the mouse model of ALD. This has never been done before and likely to reveal insight into the fundamental dynamics of demyelination. Further, the proposal encompasses application of novel therapeutics to normalize lipid metabolism and stabilize myelin membrane integrity. Hypotheses include: 1) in the animal model of ALD, measures of diffusion tensor imaging can assess the density of white matter tracts in the mouse and measures of single voxel proton MR spectroscopy reflect changes in lipid composition of the brain, and 2) in ALD patients, metabolic changes seen on proton MR spectroscopic imaging herald lesion development on conventional MRI. Our results will yield a noninvasive means of gauging the effects of experimental and therapeutic manipulations of lipid chemistry upon specific neuroanatomic structures. Ultimately, insights gained in these studies of ALD/AMN may prove beneficial to other neurodegenerative diseases, such as amyotrophic lateral sclerosis or Parkinson's and Alzheimer's diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INCREASED MOTONEURONS
PERSISTENT
SODIUM
CURRENT
IN
SOD1
Principal Investigator & Institution: Heckman, Charles J.; Professor; Physiology; Northwestern University 750 N. Lake Shore Drive, 7Th Chicago, Il 60611 Timing: Fiscal Year 2005; Project Start 01-APR-2005; Project End 31-MAR-2010 Summary: (provided by applicant): One of the leading hypotheses for motoneuron degeneration in ALS is excitotoxicity, in which excessive calcium entry leads to cell death. Most work on excitotoxicity has focused on ligand-gated channels activated by the excitatory neurotransmitter glutamate. In contrast, this proposal focuses on the possibility that ALS alters voltage-gated channels and thus alters the intrinsic excitability of the motoneuron. We have shown that a specific type of sodium (Na+) channel is markedly elevated in motoneurons cultured from a transgenic mouse model of ALS (the SOD1 model). This current is NaP, the persistent component of the total Na+ current generating the action potential. NaP is a major factor controlling the number of action potentials per time generated in response to a given amount of synaptic input. Because each action potential allows calcium to enter the cell, elevated NaP in ALS motoneurons could play a major role in excitotoxic death. The goals of this proposal are to investigate mechanisms of the aberrant upregulation of NaP in mutant SOD1 motoneurons and to assess how drugs that change NaP influence motoneuron survival. Studies are carried out in culture, in vitro in a slice preparation, and in vivo in the intact animal, all using the mutant SOD1 mouse. Aim 1 considers the issue of whether molecular subtypes or densities of the Na channels themselves change. Aim 2 focuses on potential changes in the regulation of NaP in response to acute and chronic drug administration. The monoamines serotonin and norepinephrine enhance NaP and likely
Studies
49
play a particularly important role in its normal regulation. In Aim 3, the effects of NaPspecific drugs studied in aim 2 are evaluated for their effect on motoneuron survival both in culture and in the intact mouse. A key question addressed by Aims 2 and 3 is whether the monoamines further increase NaP above its already high levels in mutant SOD1 motoneurons. If so, then standard anti-depressant drugs may actually exacerbate motoneuron degeneration. In Aim 4, we evaluate whether, as predicted from our cell culture work, NaP is upregulated at a very early stage in life. Presence of enhanced NaP in very young animals would indicate that this aberrant property may play a significant role in the disease onset. These studies will play an essential role in determining if NaP makes an important contribution to motoneuron degeneration in ALS. Moreover, the results may prove invaluable in establishing new therapeutic strategies Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INDUCIBLE SITE-SPECIFIC EXPRESSION OF MUTANT SOD1 Principal Investigator & Institution: Roos, Raymond P.; Professor; Neurology; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2004; Project Start 15-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the selective loss of motor neurons (MN). Approximately 10% of ALS cases are familial (known as FALS), and approximately 25% of FALS cases are caused by mutations in Cu/Zn superoxide dismutase type 1 (SOD1). There is convincing evidence that mutant (MT) SOD kills MN because of toxicity rather than a deficiency in dismutase activity. However, the basis for this toxicity remains unclear as does effective treatment for this devastating fatal disease. Surprisingly, although mice that carry MTSOD with its endogenous promoter as a transgene develop MN disease (MND), a restricted expression of MTSOD in neurons or astrocytes fails to induce MND. In this proposal, we hypothesize that MTSOD requires expression early in embryonic life in MN in order to cause an ALS phenotype. In order to test this hypothesis, we will generate a transgenic mouse that selectively expresses MTSOD in MN (and some interneurons) starting early in embryonic life. The MTSOD expression will be inducible so that we will also be able to determine how early expression must occur and how long this expression has to last in order to kill MN. In addition, these mice will also express a luciferase reporter gene in MN, so that the mice can provide a source for dissociated spinal cord cell cultures with tagged MN for use in screens for effective drugs in ALS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INDUCTION OF IMMUNE TOLERANCE TO FASL-EXPRESSING ES CELL Principal Investigator & Institution: Sonntag, Kai-Christian; Mc Lean Hospital (Belmont, Ma) 115 Mill Street Belmont, Ma 02478 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): The potential of pluripotent embryonic stem (ES) cells to develop into functional mature cells or tissue has high implication in finding new treatments for diseases including neurodegenerative disorders. This includes the potential use of ES cells as cell replacement therapy in neurological diseases, such as Parkinson's Disease (PD), Huntington's Disease (HD), Amyotrophic Lateral Sclerosis (ALS) and ischemia. However, survival of call grafts requires systemic immunosuppression, which severely compromises the entire host immune system
50
Amyotrophic Lateral Sclerosis
leading to complications in clinical transplantation. An optimal therapy would be, therefore, the induction of specific tolerance to the donor cells by otherwise preserving functional immune responses. Fas ligand (FasL, CD178, or CD95L) is a type II membrane protein and is expressed in activated lymphocytes and cells in "immuneprivileged" sites such as the testis, the eye, and the CNS. Its receptor Fas (CD95 or Apo1), a type I membrane protein and a member of the TNF receptor family, is expressed on various immune-reactive hematopoietic cell types including activated NK and T calls, non-lymphoid calls such as immature myeloid cells, monocytes, and polymorphic mononucleocytes. Fas-expressing cells undergo apoptosis upon interaction with FasL, a process that is involved in regulating cellular immunity and it has been shown that FasL can be used as an immunomodulatory tool to protect allogeneic or xenogeneic cells against cellular immune responses. Here, I hypothesize that ES cell grafts in the brain, which express FasL, are protected against the host cellular immune response abolishing the need for systemic immunosuppressive drug treatment. For this, I will genetically engineer mouse ES cells to express FasL and test their survival ability in the host brain of rats without further immunosuppression. Furthermore, I will analyze the effects of FasL expression on transplanted cells towards modulating the host immune response. Results from this work will have implications for immunomodulation of ES cell grafts in both allogeneic and xenogeneic transplantation settings. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF SELECTIVE TOXICITY OF SOD1 MUTANTS IN ALS Principal Investigator & Institution: Crow, John P.; Pharmacology and Toxicology; University of Arkansas Med Scis Ltl Rock 4301 W Markham St Little Rock, Ar 72205 Timing: Fiscal Year 2004; Project Start 15-JUN-2001; Project End 31-MAY-2006 Summary: (provided by applicant): In 1993, it was first reported that a mutation to the gene coding for Cu,Zn superoxide dismutase (SOD1) was associated with a form of familial amyotrophic lateral sclerosis (ALS). Since that time, more than 70 single amino acid mutations to SOD1 have been found to cause ALS in humans. Mice transgenic for any one of several of the human SOD1 mutants develop progressive and ultimately lethal paralysis in a time-dependent manner reminiscent of human ALS. Studies in transgenic mice clearly indicate that SOD1 is toxic via a gained function because the mutant produces disease even in the presence of marked increases in total SOD1 enzyme activity. Despite the overwhelming evidence for a gained toxic function, the exact nature of that function has remained elusive. Equally puzzling has been the fact that SOD1 mutants are toxic only to motor neurons even though they are expressed in all cell types. Based on published results, in vitro characterizations of SOD1 mutants, studies in cultured motor neurons, and preliminary data from transgenic mice, we have formulated a hypothesis which may explain how all ALS-associated SOD1 mutations can be toxic via a common mechanism and why toxicity is manifested only in motor neurons. HYPOTHESIS: We are proposing that zinc-deficient (copper-containing) SOD1 is the common toxic phenotype of ALS-associated SOD1 mutants, that zinc-deficient SOD1 is injurious via its ability to utilize ascorbate, oxygen, and nitric oxide to catalyze the formation of the cytotoxin peroxynitrite, and that neurofilament proteins--which avidly bind zinc and are very abundant in motor neurons--contribute to the formation of zinc-deficient SOD1 preferentially in motor neurons. This study proposes: Specific Aim 1) to measure zinc-deficient SOD1 in the most widely used animal model of ALS (G93A transgenic mice) and determine the factors responsible for its accumulation, Specific Aim 2) to determine the conditions which lead to SOD1-mediated oxidant generation
Studies
51
and its potential relationship to toxic protein aggregation, and Specific Aim 3) to evaluate the in vivo efficacy of two classes of compounds which protect cultured motor neurons from the toxic effects of zinc-deficient SOD1 and which enhance survival in G93A mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS FOR TAU INVOLVEMENT IN ALZHEIMER'S DISEASE Principal Investigator & Institution: Roberson, Erik D.; J. David Gladstone Institutes 1650 Owens St San Francisco, Ca 94158 Timing: Fiscal Year 2006; Project Start 01-APR-2006; Project End 31-MAR-2011 Summary: (provided by applicant): Alzheimer's disease (AD) and related neurodegenerative disorders are a major source of morbidity and mortality, particularly with the increasingly aged population of the United States. Pathology involving the microtubule-associated protein tau is a common feature of many such diseases, including AD, frontotemporal lobar degeneration, many forms of Parkinsonism, and amyotrophic lateral sclerosis. This proposal describes a training plan for the development of an academic neurologist interested in the molecular mechanisms of dementing diseases, particularly tau. The research plan focuses on the role of tau in AD pathology testing the hypothesis that tau is critical for the neuronal dysfunction induced by amyloid-beta (Abeta) in amyloid precursor protein (APP) transgenic mice. Preliminary studies indicate that tau removal prevents most behavioral and pathological abnormalities in APP mice at 4-7 months of age. Specific Aim 1 extends this observation, studying older APP mice to examine how long the effects of Abeta remain taudependent and determining the effect of changing tau expression after AD is produced and dysfunction is apparent. Specific Aim 2 considers signaling pathways that might mediate interactions between Abeta and tau, with an emphasis on the tyrosine kinase Fyn. Specific Aim 3 studies downstream mechanisms for tau's role, specifically regulation of axonal transport and APP processing. The candidate has a Ph.D. in neuroscience and an M.D. with residency training in neurology. He is committed to a career in academic medicine studying the basic mechanisms of neurodegenerative diseases. To that end, the research proposal and career development plan build on his prior training in basic neuroscience, biochemistry, electrophysiology, and clinical neurology to provide expertise in transgenic mouse models, behavioral analysis, histology, and viral vectors. Dr. Lennart Mucke, who specializes in transgenic mouse models of neurodegenerative disease, is the candidate's sponsor. The mentoring and research experience described in this proposal will facilitate the candidate's goal of an independent faculty research position. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF NEURONAL SPECIFIC TRANSCRIPTION Principal Investigator & Institution: Gill, Grace B.; Associate Professor; Pathology; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2004; Project Start 01-JUL-2003; Project End 31-MAY-2008 Summary: (provided by applicant): Transcription factors play essential roles in the processes of neuronal cell fate determination and expression of the mature neuronal phenotype that are necessary for normal development and function of the brain. My laboratory is investigating expression of the cyclin-dependent kinase 5 (cdk5) activator p35 as a model to understand the molecular mechanisms of cell type-specific
52
Amyotrophic Lateral Sclerosis
transcription in neurons. The heterodimeric cdk5/p35 kinase plays a role in many neuronal processes ranging from neuronal migration and axon guidance to synaptic plasticity and drug addiction. Furthermore, improper cdk5 activity, caused by association with a proteolytic fragment of p35, has been implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer's and amyotrophic lateral sclerosis. A repeated GC box element in the p35 promoter is necessary and sufficient for neuronspecific gene expression. The studies described in this proposal are designed to test the hypothesis that the mechanisms that regulate the levels and activity of the GC boxbinding transcription factors Sp1, Sp3 and Sp4 during neurogenesis contribute to neuronal-specific expression of p35. The specific aims of this research are to (1) determine which Sp transcription factors are important for GC box-dependent expression of p35 in neurons, (2) determine the mechanisms that regulate Sp transcription factor stability during neurogenesis, and (3) determine how SUMO-1 mediated repression of Sp3 is relieved in post-mitotic neurons. In addition to advancing our specific knowledge of the transcriptional mechanisms that regulate activity of the cdk5/p35 kinase, these studies will provide a paradigm for understanding how cell type-specific regulation of transcription factor levels and activity controls neuronal specific expression of many genes whose expression depends on GC box promoter elements. Since disturbances of the finely tuned transcriptional program in neurons are associated with developmental abnormalities and disease, it is imperative to increase our understanding of the molecular mechanisms that underlie cell type-specific gene expression in neurons. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: METABOTROPIC NEURODEGENERATION
GLUTAMATE
RECEPTORS
IN
Principal Investigator & Institution: Young, Anne B.; Professor; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2004; Project Start 15-AUG-1995; Project End 31-JUL-2005 Summary: Description (From the applicant's abstract): Human neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) are characterized by adult onset, progressive neurologic dysfunction, and a paucity of effective therapies. These common disorders produce substantial disability, and their importance to public health is expected to increase as the population ages. One or more causative genes have now been isolated for familial forms of each of these four devastating neurologic illnesses, making possible the development of transgenic mouse models. Although such animals now exist, the exact mechanisms by which mutant genes cause neurologic disease remains unclear. Unless the etiologic mechanisms underlying the neurodegenerative diseases are clearly identified, rational therapeutic interventions will be impossible. The neurotransmitter glutamate has been implicated as a causative factor in the etiology of neurodegenerative disorders. Specifically, one class of glutamate receptors, the metabotropic glutamate receptors (mGluRs), may be specifically abnormal in many of the neurodegenerative disorders. This project will examine metabotropic glutamate receptors in transgenic mouse models of AD, PD, HD, and ALS using ligand binding, in situ hybridization, immunohistochemistry, and Western blotting. Alteration of mGluR expression level is also predicted to have direct implications for the abnormal synaptic functioning which is characteristic of neurodegenerative diseases. Thus, we will also explore glutamate-related intracellular signaling pathways in the brains of transgenic mice. Finally, if mGluR dysfunction is an important part of disease etiology, drugs
Studies
53
targeting mGluRs may ameliorate symptoms in certain of these models. We will test if administration of mGluR-active medications improves clinical outcome in mouse models of these diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MICROGLIA: DEGENERATION/REGENERATION
ROLE
IN
MOTONEURON
Principal Investigator & Institution: Streit, Wolfgang J.; Professor of Neuroscience; Neuroscience; University of Florida 219 Grinter Hall Gainesville, Fl 32611 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): The causes that underlie primary degeneration of motoneurons in ALS remain unknown. This proposal will investigate a novel hypothesis regarding ALS pathogenesis, namely, that dysfunctional microglia are, in part, responsible for motoneuron degeneration. The rationale for this hypothesis is twofold: on one hand experimental studies in rodents suggest that microglial activation is essential for rescuing acutely injured motoneurons and for facilitating their regeneration, and on the other hand there is now evidence that microglial cells undergo structural deterioration in the aged and, particularly, in the Alzheimer's disease brain. The latter observations suggest that progressive structural deterioration of microglia over long periods of time results in microglial malfunction and dwindling glial support to neurons, which ultimately causes neurodegeneration. We now propose to investigate whether dystrophic microglia are present in motor neuron disease (MND). The specific aims are as follows: 1) To examine post-mortem human tissue specimens from individuals who died with ALS to determine if the incidence of dystrophic microglial cells is higher than in age-matched non-ALS individuals. 2) To determine if dystrophic microglial cells are present in the recently generated transgenic ALS rat carrying the SOD1/G93A mutation. 3) To determine the effect of minocycline treatment on axotomyinduced microglial activation in wildtype Sprague Dawley rats. This last set of studies is intended to represent a proof-of-principle experiment, which will test recent claims that minocycline delays the onset of MND by inhibiting microglial activation. If this claim is true, an attenuation of axotomy-induced microglial activation with minocycline should result in delayed or impaired motoneuron regeneration after axotomy. Collectively, these studies may provide a new lead into the pathogenesis of ALS, i.e. that dystrophy and dysfunction of microglia may be involved. In addition, the minocycline experiments will help to further assess the usefulness of this drug for possible treatment of ALS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODELS OF SBMA MOTOR NEURON DEGENERATION Principal Investigator & Institution: La Spada, Albert R.; Assistant Professor; Laboratory Medicine; University of Washington Office of Sponsored Programs Seattle, Wa 98105 Timing: Fiscal Year 2004; Project Start 01-JUN-2001; Project End 31-MAY-2005 Summary: X-linked spinal and bulbar muscular atrophy (SBMA or Kennedy's disease) is a progressive neuromuscular disorder characterized pathologically by degeneration of lower motor neurons. In 1991, expansion of a CAG trinucleotide repeat was identified in the coding region of the androgen receptor (AR) gene of SBMA patients. In addition to SBMA, seven other neurodegenerative disorders are caused by CAG repeat expansions that encode elongated polyglutamine tracts. Molecular and genetic studies of the CAG/polyglutamine repeat diseases suggest that the polyglutamine tract expansion has a toxic gain-of- function effect, the basis of which remains unknown. The purpose of this
54
Amyotrophic Lateral Sclerosis
grant proposal is to determine the molecular basis of neuronal cell death in SBMA. To achieve this goal, we have initiated studies aimed at recapitulating AR polyglutamine neurotoxicity in mice and in cell culture. For producing an in vivo model of SBMA, we have generated AR yeast artificial chromosomes (YACs) carrying 100 CAG repeats. These AR YACs have been introduced into the mouse germline by fusing yeast cells carrying the AR YACs with mouse embryonic stem (ES) cells. In addition to an in vivo model of SBMA, we are attempting to develop in vitro models of AR polyglutamine neurotoxicity. We have demonstrated cellular toxicity of mutant AR expression constructs in HEK-293T cells, a non-neuronal cell line. We are attempting to extend this finding to motor neuron-like cell lines, MN-1 and NSC-34, and are also establishing primary cultures of cortical, hippocampal, and spinal motor neurons. Once we have produced accurate in vivo and in vitro models of SBMA, we will examine the role of apoptotic pathways in SBMA pathogenesis by evaluating whether caspase activation and/or p53 participate in AR polyglutamine neurotoxicity. We will use our in vivo and in vitro models to determine what functions of the AR protein are required for SBMA disease pathogenesis. Animal and cell culture models of AR polyglutamine neurotoxicity will allow us to identify alterations in gene expression in diseased motor neurons and cell lines by performing microarray expression comparisons. As SBMA, amyotrophic lateral sclerosis and autosomal spinal muscular atrophy all show motor neuron cell death, any toxic factors or degenerative pathways that we identify in our studies may be relevant to these and other motor neuron diseases. In addition to allowing us to track the molecular events that lead to neuronal cell death, animal and cell culture models of SBMA will allow us to design novel treatments and test potential therapies for this motor neuron disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODULATION OF CASPASE PATHWAYS IN HUNTINGTON'S DISEASE Principal Investigator & Institution: Friedlander, Robert M.; Associate Director; Brigham and Women's Hospital Research Administration Boston, Ma 02115 Timing: Fiscal Year 2004; Project Start 01-JAN-2000; Project End 31-JAN-2005 Summary: The interleukin-1beta converting enzyme (caspase-1 or caspase-1) cell death gene family, also known as the caspase family, plays an important role in apoptosis. Evidence indicates that caspase- 1 is involved in mediating brain damange in ischemia, trauma, and in amyotrophic lateral sclerosis. We have evidence implicating caspase-1 as an important mediator of cell dysfunction and disease progression in Huntington s disease (HD). The broad objective of this project is to evaluate the mechanisms of caspase-1-mediates disease progression in HD. Preliminary results indicate that caspase1 is activated in human and mouse HD brain specimens. In addition, inhibiting caspase function slows the progression and delays the mortality in a mouse model of HD. The specific aims are: 1) evaluate the expression and activation status of different members of the caspase family in human and mouse HD brain specimens, 2) evaluate the role of mature IL-1beta, a product of caspase-1 activation, in the pathogenesis of HD, 3) determine whether bc1-2 might be a neuroprotector in HD, and whether its effects might be synergistic with caspase-1 inhibition, 4) evaluate pharmacological approaches to slow the progression of HD, and 5) evaluate the mechanism of inhibition of weight loss in HD mice by caspase-1 inhibition, 6) evaluate the impact of HD on neural stem cell proliferation and differentiation. Significance: To elucidate the mechanistic pathways by which caspase-1 mediates disease progression and death in HD. Since caspase-1-mediated cell death is a common pathway shared by a variety of neurological
Studies
55
disorders, understanding the mechanistic pathways mediating neurodegeneration in HD should provide important information for the development of treatments for diseases sharing this cell death pathway. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR BASIS OF GLUTAMATE TRANSPORT Principal Investigator & Institution: Grewer, Christof Theodor.; Physiology and Biophysics; University of Miami-Medical School 1507 Levante Avenue Coral Gables, Fl 33124 Timing: Fiscal Year 2004; Project Start 01-JUN-2004; Project End 31-MAY-2008 Summary: (provided by applicant): In the mammalian brain the extracellular concentration of the excitatory neurotransmitter glutamate is, among other factors, controlled by transporters, which actively take up glutamate into glial cells and neurons. The broad aim of this proposal is to investigate the molecular mechanisms by which these transporters accomplish this glutamate uptake. Recombinant glutamate transporters will be expressed in HEK293 cells and Xenopus oocytes, and currents that originate from electrogenic glutamate transport will be recorded using the patch clamp technique. Currents will be induced by glutamate concentration jumps generated within 100 mus, allowing the resolution of rapid transporter reaction steps in time. The hypotheses that guide this research are: Both inward and outward glutamate transport occur via a multistep electrogenic mechanism; charged amino acids in the transmembrane segments contribute to the function and electrogenicity of the transporter; translocation of glutamate across the membrane requires molecular movement of the transport protein. Experiments with the following specific aims will test these hypotheses: (1) To determine the reaction steps associated with outward glutamate transport, by investigating the sequence and voltage dependence of intracellular Na+ and glutamate binding. (2) To determine the contributions of conserved charged amino acids to transporter function and electrogenicity, by investigating transporters with specifically charge-neutralized amino acids. (3) To characterize molecular movement of the transporter machinery by determining which parts of the transporter move and at what steps during a complete transport cycle they move. Movement of the transporter will be detected by the movement of charges attached to the transporter at specific sites. Understanding the molecular mechanism of glutamate transport will give insight into the involvement of glutamate transporters in acute and slowly progressing neurodegenerative diseases, such as stroke, amyotrophic lateral sclerosis, and Alzheimer's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOTOR SYSTEM DEVELOPMENT IN THE ABSENCE OF CELL DEATH Principal Investigator & Institution: Oppenheim, Ronald W.; Professor; Anatomy and Neurobiology; Wake Forest University Health Sciences Medical Center Blvd WinstonSalem, Nc 27157 Timing: Fiscal Year 2004; Project Start 01-JUN-2004; Project End 31-MAY-2008 Summary: (provided by applicant): The major objective of the proposed research is to examine the development of the neuromuscular system in a mouse model in which programmed cell death (PCD) of motoneurons has been eliminated by genetic deletion of pro-apoptotic genes. The use of this model will allow us to address issues of basic biology such as the adaptive significance of PCD in the nervous system and whether
56
Amyotrophic Lateral Sclerosis
excess neurons can be functionally incorporated into the developing nervous system. Neuroanatomical, physiological and behavioural methods will be employed to examine both spinal and cranial motoneurons. We well determine whether rescued neurons differentiate normally; and whether physiological and behavioural assays of neuromuscular function are affected by the presence of tens of thousands of rescued motoneurons. Additionally, we plan to take advantage of the fact that even following injury, motoneurons in these mice can survive. Accordingly, we will cross these mice with a mouse model of Amyotrophic Lateral Sclerosis (ALS), the SOD1 mutant, and determine whether the pathological signs of motoneuron disease are ameliorated. In both the developmental and SOD1 studies, treatment with neurotrophic factors (NTFs) will be used in an attempt to optimize the development and maintenance of the neuromuscular system. The use of mice lacking motoneuron cell death provides a unique opportunity to examine: (1) the widely accepted but largely untested assumption that the PCD of neurons during development subserves essential adaptive functions that if perturbed would result in neurobehavioral dysfunction; and (2) the role of PCD and neurotrophic factors in a mouse model of ALS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MTOR ACTIVATION AND FUNCTION DURING CNTF SIGNALING Principal Investigator & Institution: Reeves, Steven A.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114
Assistant
Professor;
Timing: Fiscal Year 2004; Project Start 24-JUL-1998; Project End 31-JAN-2008 Summary: (provided by applicant): Signal transduction initiated by the neuroregulatory cytokine ciliary neurotrophic factor (CNTF) has been shown to promote neuronal survival in the injured or diseased nervous system. These findings have provided a basis for using CNTF as a therapeutic agent aimed at the treatment or prevention of a variety of neuropathological diseases, including amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, stroke, and several forms of cerebellar ataxias. The precise manner in which CNTF activates and coordinately regulates the signaling cascades it employs for its neuroprotective effects remains largely undefined. One important component in this cascade that we have recently identified is the mammalian target of rapamycin (mTOR). The TOR proteins have been shown to be key regulators of a diverse set of cell processes, and recent reports have indicated that mTOR may play a critical role in synaptic plasticity and memory. We hypothesize that mTOR is a critical link in one or more of the CNTF signal transduction pathways. Thus the research we are proposing in this application aims to determine the mechanism by which CNTF activates mTOR and to identify the role(s) that mTOR plays in CNTF-stimulated sympathetic neurons. This work could identify novel targets for therapies aimed at the treatment or prevention of a variety of central nervous system disorders as well as provide a sound scientific foundation for the clinical use of CNTF and CNTF analogues now being tested in clinical trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MUTANT GENE IDENTIFICATION IN THE DYSTONIC RAT Principal Investigator & Institution: Ledoux, Mark S.; Professor, Department of Neurology; Neurology; University of Tennessee Health Sci Ctr 62 S. Dunlap Memphis, Tn 38163 Timing: Fiscal Year 2005; Project Start 05-FEB-2005; Project End 31-JAN-2009
Studies
57
Summary: (provided by applicant): Dystonia is a syndrome of sustained muscle contractions, frequently causing twisting and repetitive movements, or abnormal postures. Dystonia is a relatively common neurological disease. For example, dystonia is more prevalent than the combination of Huntington disease, amyotrophic lateral sclerosis and Duchenne muscular dystrophy. There are no definitive cures for dystonia and treatments are expensive and often ineffective. Over fourteen chromosomal loci associated with a dystonia phenotype exist in humans. However, only a few genes clearly associated with the development of dystonia have been cloned to date. Identifying other defective genes in either humans or animal models should provide critical insights into the extremely complex molecular and neural network pathophysiology of dystonia. In addition, any effort to understand dystonia will likely contribute in important ways to our understanding of motor systems and neuronal plasticity. The genetically dystonic (dt) rat, an autosomal recessive mutant discovered in the Sprague-Dawley strain, exhibits a movement disorder that closely resembles the generalized dystonia seen in humans. Dystonic rats demonstrate twisting movements and abnormal postures by Postnatal Day 12. The mutation is fully penetrant. Even with supportive measures, "dt" rats die before 40 days of age. However, cerebellectomy can eliminate dystonia in the "dt" rat, extend its life into adulthood, and enable it to bear and rear offspring. Behavioral, biochemical, and electrophysiological studies indicate that olivocerebellar pathway dysfunction is critical to the dt rat motor syndrome. A systematic approach to finding the mutant gene associated with the dt rat phenotype was begun by crossing homozygote male "dt" rats to females of an inbred strain. The heterozygote first-generation offspring were crossbred to produce second-generation offspring. Rats were genotyped using a set of markers spaced across the rat genome and the responsible gene has been narrowed down to a region of less than 0.5 cM. We plan to locate and clone the mutant gene in the "dt" rat and fully characterize the temporal and spatial expression of this gene's transcriptional and translational products. Patients with dystonia will be screened for mutations in the human homologue. These proposed studies will likely increase our understanding of both dystonia and olivocerebellar motor systems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NANOSCALE IRON PHASES IN NEURODEGENERATIVE DISEASES Principal Investigator & Institution: Dobson, Jon P.; Keele University Keele St5 5Bg, England Keele, Timing: Fiscal Year 2004; Project Start 15-APR-2003; Project End 31-MAR-2006 Summary: (provided by applicant): AIMS:. To develop multi-modal imaging methods for high-resolution mapping of iron in neurodegenerative brain tissue. To examine the magnetic properties of neurodegenerative tissue for the possible presence of anomalous magnetic iron oxides. To examine the effects of biogenic, magnetic iron biominerals (primarily magnetite) on amyloid-beta aggregation in vitro. Research Design & Methods: The primary method for mapping iron distribution in tissue sections is via synchrotron x-ray scanning which will be conducted at Argonne National Laboratory. This technique will be used to identify iron anomalies eventually on a cellular level. And to compose composit images using a variety of imaing techniques. This work will enable correlation of iron anomalies and structural form to specific cellular and tissue structures for the first time. Examination of the magnetic properties of neurodegenerative tissue will be carried out pdmarily using Superconducting Quantum Interference Device (SQUID) magnetometry and Magnetic Force Microscopy (MFM). Using these methods the magnetic iron biominerals in the tissue will be characterized
58
Amyotrophic Lateral Sclerosis
and compared to published data on non-pathologic and epileptic tissue samples. This will provide information on the relative abundance and type of magnetic iron biomineral present in the tissue and will help to either confirm or refute preliminary studies of nanoscale magnetic iron biominerals in Alzheimer's disease (AD) tissue. The effects of strong, local magnetic fields generated by nanoscale magnetic iron biominerals on amyloid-beta peptide aggregation rates will be examined using thioflavin-T assay and TEM imaging of peptide aggregates. Aggregation rates will be assessed in control solutions, solutions of peptide with coated magnetic nanoparticles and sham solutions containing the same concentrations of non-magnetic nanoparticles with the same size distribution and surface chemistry. Gla: FOREIGN GRANT: As the PI is a US citizen based at Keele University in the United Kingdom, the project will be administered through a foreign institution - Keele. The PI has considerable and unique experience in the analysis of magnetic iron biominerals in the brain (he has led all of the previous work described in this proposal) and is one of the few people in the wodd working in this field. The proposed project is highly interdisciplinary, incorporating aspects of biophysics, chemistry, neurobiology and biomedical engineering. The PI has a uniquely diverse background related to the proposed research, having worked in physics, chemistry and biomedical engineering departments and the UF Brain Institute since obtaining his PhD in 1991. He has published extensively in nanoscale magnetic iron biomineralization in the brain and his work has been featured by the media in such journals as Science,The Economist, Fact/Switzerland, The Los Angeles Times/Washington Post wire service as well as newspaper, radio and television coverage in six countries. The Pl's combination of skills and experience related to the research proposed here is unique and unavailable in the US. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEURAL PROSTHESIS USING POSTERIOR PARIETAL REACH REGION Principal Investigator & Institution: Andersen, Richard A.; Professor of Neuroscience; None; California Institute of Technology Office of Sponsored Research, Mail Code 20115 Pasadena, Ca 91125 Timing: Fiscal Year 2004; Project Start 01-FEB-2001; Project End 31-JAN-2006 Summary: adapted from applicant's abstract) The purpose of this grant is to develop a neural prosthesis to help paralyzed patients. The prosthesis will be developed in nonhuman primates as a precursor to applying a similar approach in humans. The rationale of the prosthesis is to record from an area of the cerebral cortex that plans reach movements. If these plans can be read-out in real-time, then patients who are paralyzed from spinal cord section, ALS, or other peripheral neuropathies could still think about making movements, and these thoughts could be used to operate external devices. In the experiments, the activity from the parietal reach region (PRR) will be recorded using arrays of electrodes, an area that is responsible for the initial planning of reach movements. Decode algorithms will be developed that will allow these plans to be read out in real time. The output device will be a robot limb whose controller is designed to be instructed by high level signals and to compute many of the lower level aspects of the movement trajectory that are normally computed at levels of the brain closer to the motor output. This hybrid control system represents a new area of robotics research. Additionally, local field potentials will be used to convey similar information to the robotic controller and this should provide a breakthrough for long-term recordings. The specific aims will proceed from the simplest experiment of demonstrating that a monkey can control an animated limb on a computer screen to more complex experiments where
Studies
59
the experimenters will determine how PRR codes information about reaches in more natural situations. These later experiments will include neurophysiological studies of the coding of sequential movements, curved trajectories, combined hand-eye movements, and visua-motor plasticity. The concurrent engineering studies will develop alogorithms that can reconstruct the intended movements from neural record and develop supervisory control architectures that can move the robotic limb appropriately, all in real-time. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROBIOLOGY OF DISEASE -- TEACHING WORKSHOP Principal Investigator & Institution: Kriegstein, Arnold R.; Professor; Society for Neuroscience 11 Dupont Cir Nw, Ste 500 Washington, Dc 20036 Timing: Fiscal Year 2004; Project Start 01-AUG-1983; Project End 31-MAY-2006 Summary: The Society for Neuroscience (SFN) is the major professional organization for scientists who study the nervous system. An important goal of this organization is to encourage scientists in training to undertake research related to diseases of the nervous system. The objective of this grant application is to support teaching workshops that introduce young neuroscientists to current concepts about the etiology and pathogenesis of disorders of the nervous system. For each workshop, about 12 faculty are chosen by the Organizing Committee after eliciting proposals from the Society at large. Clinical presentations provide enrollees with an experience of the human dimension of particular diseases. Lectures cover both clinical research and relevant laboratory work. In addition to lectures, enrollees are given a choice of attending two of four small group workshops that emphasize either specific or methodological issues and encourage lively discussion. Since its inception, 20 workshops have been held, usually on the day prior to the start of the Society for Neuroscience meeting. Topics have included: Infections in the nervous system, epilepsy, Huntington's and Alzheimer's diseases, muscular dystrophy, multiple sclerosis, prion diseases, drug addiction, pain and affective disorders, stroke and excitotoxicity, neuromuscular diseases, amyotrophic lateral sclerosis, schizophrenia, migraine, mental retardation and developmental disorders, Tourette's syndrome and obsessive-compulsive disorder, and the neurobiology of brain tumors. Enrollment generally runs between 100 and 200 attendees. Most enrollees are graduate students or postdoctoral fellows. Current plans are to cover the following topics in the near future: Genes, free radicals, mitochondria and apoptosis in Parkinson's disease, AIDS dementia, peripheral neuropathy, pain, language disorders, and affective disorders. Other topics will be chosen depending on their potential interest to young neuroscientists, their impact on society and the quality of recent research related to that disease area. We are especially interested in covering diseases of the nervous system which are important clinically but which are in need of enhanced basic cellular and molecular understanding. Society members are encouraged to suggest topics in the SFN Newsletter. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NOGO'S ROLE IN INTRACELLULAR TRAFFICKING Principal Investigator & Institution: Harel, Noam Y.; Psychiatry; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2006; Project Start 15-SEP-2006; Project End 31-MAY-2011 Summary: (provided by applicant): Nogo inhibits neurite outgrowth by acting at the myelin surface through a neuronal surface receptor, NgR. Therapies targeting the Nogo-
60
Amyotrophic Lateral Sclerosis
NgR pathway show promise in the treatment of spinal cord injury and other central nervous system diseases. However, much remains unknown regarding Nogo's function in uninjured cells. Nogo is a member of the Reticulon family, a conserved set of endoplasmic reticulum (ER)-associated proteins with unclear functions. The bulk of Nogo expression is intracellular rather than surface-associated. Additionally, Nogo is prominently expressed in neurons as well as in oligodendrocytes. These facts argue for other roles played by Nogo besides inhibiting axon growth. We have obtained data suggesting that Nogo isoforms regulate intracellular traffic. Furthermore, Nogo levels affect the specialized neuronal trafficking pathway of axon transport. Nogo may mediate its effects on traffic through small GTPases of the Rab family. Additionally, Nogo may affect trafficking of its own receptor, thereby creating a form of NgR regulation that has not previously been explored. Finally, Nogo may enhance neuronal survival in the context of motor neuron disease. Better understanding of these roles is crucial as therapies are being developed to block the Nogo pathway in the treatment of central nervous system injury. The Aims of this proposal are to further explore the mechanisms of Nogo's involvement in intracellular trafficking using a variety of cell imaging and biochemical techniques. Nogo's effects on the specialized neuronal trafficking pathways of axon transport and synaptic vesicle recycling will be explored with live cell imaging studies in neurons from wild type and Nogo-knockout mice. These studies will be performed under the mentorship of Dr. Stephen M. Strittmatter, a leader in the field of neuroregeneration and axonal signal transduction. He and his extremely well-funded laboratory provide the optimal setting for developing expertise in the techniques required for successful neuroscientific research. Furthermore, Yale's Department of Neurology has committed to fostering the applicant's development by limiting clinical responsibilities to allow at least 85% effort devoted to research, and by keeping open laboratory space available as the applicant transitions to running an independent laboratory during the period of this proposal. The Nogo pathway is intensely studied for its role in blocking injured nerves in the brain and spinal cord from regenerating. However, this proposal shows that Nogo also plays important roles that may help uninjured nerves function. Insight into these roles will shed light on Nogo's involvement in diseases like amyotrophic lateral sclerosis, and will help guide the development of safer therapies to inhibit the Nogo pathway in the context of spinal cord injury and other devastating central nervous system diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NON-VIRAL DELIVERY OF NEUROTROPHIC FACTORS TO THE CNS Principal Investigator & Institution: Francis, Jonathan W.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2005; Project Start 19-APR-1999; Project End 31-DEC-2008 Summary: (provided by applicant): The development of new therapies to treat amyotrophic lateral sclerosis (ALS) is often hindered by the poor bioavailability of candidate drugs to affected motor neurons within the central nervous system (CNS). Thus, while both glial cell line-derived neurotrophic factor (GDNF) and insulin-like growth factor-1 (IGF-1) have had robust survival promoting effects on injured motor neurons in experimental animals, their success in treating ALS patients appears to have been thwarted by insufficient access to motor neurons in the much larger human CNS. We hypothesize that genetic or chemical fusion of tetanus toxin fragment C (TTC) to either GDNF or IGF-1 will improve growth factor delivery to motor neurons through one or more mechanisms related to the nerve cell binding properties of TTC. The
Studies
61
primary goal of this project, then, is to assess whether the neuroprotective activity of IGF-1:TTC and GDNF:TTC in an experimental animal model of ALS is superior to that of the respective growth factor alone. Our study has four specific aims: (1) optimize the design, expression, and purification of IGF-1:TTC and GDNF:TTC; (2) characterize the purity, stability, and basic functional activity of these fusion proteins; (3) examine the bioavailability and functional activity of the fusion proteins in rodent CNS following intracerebroventricular or intramuscular administration; and (4) investigate the neuroprotective activity of the fusion proteins in a transgenic rat model of amyotrophic lateral sclerosis (ALS). The experiments in Aim 1 will use recombinant protein expression and purification techniques to generate the fusion proteins, while the studies in Aims 2 and 3 will employ immunocytochemical, Western blot, enzyme immunoassay, and morphometric techniques to assess the functional properties of GDNF:TTC and IGF-1:TTC in cultured ceils and whole animals. Finally, the experiments in Aim 4 will employ transgenic animals in survival and behavioral experiments to assess the neuroprotective effects of GDNF:TTC and/or IGF-1 :TTC in vivo. While the present work may give rise to a new treatment for ALS, the information obtained from our characterization of IGF-1:TTC and GDNF:TTC may lead to the use of these fusion proteins in other neurological disorders as well. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL CEHC DERIVATIVES FOR NEUROINFLAMMATION Principal Investigator & Institution: Benaksas Schwartz, Pharmaceuticals, Inc. 18085 Gentian Ave Riverside, Ca 92508
Elaine
J.;
Encore
Timing: Fiscal Year 2005; Project Start 30-SEP-2003; Project End 31-JUL-2007 Summary: Experimental studies conducted under an SBIR Phase I (SBIR I) Grant, 1 R43 AG023510, have identified a compound that is a potential treatment for Amyotrophic Lateral Sclerosis (ALS). Encore Pharmaceuticals, Inc. (EncorePharma ) holds a composition of matter patent for the compound. The compound's mode of action in in vitro testing and its activity in preliminary studies in the G93A-SOD1 mouse model of ALS, suggest it may be the first drug candidate to have an overall impact on ALS disease progression. This SBIR Phase II Application (SBIR II) seeks support to further preclinical development of the compound in preparation for submission of an Investigational New Drug (IND) Application to the FDA, allowing initiation of clinical trials with the compound. The important preclinical development work defined in this SBIR II is the first step in commercialization of a potentially important new pharmaceutical agent. The successful scientific/business collaborations with the Oklahoma Medical Research Foundation (OMRF) in SBIR I will be further cultivated in SBIR II. The SBIR II Specific Aims are: to optimize the dose level and route of administration in concert with selecting the active enantiomer using well-defined rodent models of ALS; to conduct chemical process development and small to intermediate scale manufacture of compound (drug substance) according to Good Manufacturing Practices (GMP); to conduct appropriate supporting toxicology and pharmacology studies (including gene toxicity and metabolism) according to Good Laboratory Practices; to evaluate in ALS rodent models the utility of C-tau and other molecules as appropriate, as a biomarker for translation into the clinical setting. With a positive preclinical safety and efficacy profile, an IND will be prepared, filed with FDA and Orphan Drug Designation sought. As the compound may exert an effect against the neuroinflammatory component of ALS and many neurological diseases such as Huntington's, Parkinson's and Alzheimer's, EncorePharma will support, as appropriate, experimental studies with the compound and/or other related compounds in models
62
Amyotrophic Lateral Sclerosis
and systems relevant to these diseases. The need to move this potential therapeutic forward for a disease that has very few treatment alternatives cannot be understated. A total of 60,000 to 100,000 individuals are estimated to be affected with ALS worldwide at any given time, and the incidence of the disease is approximately five to nine persons per 100,000. The market potential for a therapeutic hi ALS alone is $100-300 million. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEROXYNITRITE AND SOD IN MOTOR NEURON APOPTOSIS Principal Investigator & Institution: Estevez, Alvaro G.; Director and Associate Professor; Physiology and Biophysics; University of Alabama at Birmingham 1530 3Rd Avenue South Birmingham, Al 35294 Timing: Fiscal Year 2004; Project Start 01-APR-1998; Project End 31-MAR-2006 Summary: (From the Applicant's Abstract): Our long-term goal is to understand how mutations to SOD can increase oxidative stress and cause the death of motor neurons in amyotrophic lateral sclerosis (ALS). We have shown that endogenous formation of the peroxynitrite by the diffusion-limited reaction between superoxide and nitric oxide induces apoptosis in cultured embryonic rat motor neurons deprived of trophic support. Both inhibitors of nitric oxide synthesis as well as Cu, Zn superoxide dismutase (SOD) delivered intracellularly with liposomes protect motor neurons from apoptosis. These data indicate that the interaction between nitric oxide and superoxide has a role in motor neuron apoptosis. Mutations to SOD are implicated in the selective degeneration of motor neurons in ALS and expression of ALS-SOD mutants in transgenic mice produces motor neuron disease. A common phenotype among the ALS-SOD mutations so far investigated is to decrease the affinity for zinc. We have shown that zinc-deficient SOD is both less efficient at scavenging superoxide and a better catalyst of tyrosine nitration. Furthermore, the copper in zinc-deficient SOD can act as a non-specific oneelectron oxidase, robbing electrons from antioxidants like ascorbate and glutathione that can be transferred to oxygen to produce superoxide. In the presence of NO, zincdeficient SOD can catalyze the formation of peroxynitrite. In the previous cycle of funding, we have shown that zinc-deficient SOD induces apoptosis in motor neurons by a nitric oxide-dependent mechanism. For the renewal, our first aim is to further investigate the mechanisms by which zinc-deficient SODs can kill cultured motor neurons and to determine what can protect motor neurons from this toxicity. Our second aim is to characterize the source or sources of superoxide induced in motor neurons by trophic factor is to characterize the source or sources of superoxide induced in motor neurons by trophic factor withdrawal. Our third aim is to test the role of tyrosine nitration by peroxynitrite in the death of motor neurons induced by either trophic factor deprivation or by zinc-deficient SOD. Completion of the specific aims will provide a mechanistic basis for explaining how motor neurons are particularly vulnerable to SOD mutations and establish a link between sporadic and familial SODs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PHASE III TRIAL OF MINOCYCLINE IN ALS:I-CLINICAL CENTER Principal Investigator & Institution: Gordon, Paul H.; Neurology; Columbia University Health Sciences Research Administration New York, Ny 100323702 Timing: Fiscal Year 2004; Project Start 25-AUG-2003; Project End 31-MAY-2007 Summary: (provided by the applicant): Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder leading to death on average in 3 years (1). There is no cure or known treatment that significantly improves function. Loss of motor neurons in the
Studies
63
brain and spinal cord of ALS patients causes the progressive symptoms. Motor nerve degeneration may result from a cascade of events including free radical toxicity, glutamate excitotoxicity and mitochondrial dysfunction (2-4), which lead to the activation of cell death pathways (5-9). Mitogen-Activated Protein (MAP) kinases, including p38, are up-regulated in response to cell stress, and promote pro-apoptotic and inflammatory mediators (10, 11). Caspase enzymes and inflammatory mediators regulate cell death pathways (12-14), and are activated in human and transgenic mousemodel ALS (15,16). Caspase enzyme inhibitors and anti-inflammatory agents have been shown to slow progression in the ALS model (6,7,17,18). Minocycline, FDA approved for treatment of infection, has high central nervous system penetration when taken orally, inhibits p38 MAP kinase, prevents activation of caspase-1, caspase-3 and inflammatory mediators (19,20), and delays disease progression in animal models of neurodegenerative disorders, including Huntington disease (19), Parkinson disease (21) and ALS (22) (Serge Przedborski, personal communication). It is well-tolerated as an oral treatment for outpatients. The objective of this clinical trial is to determine whether Minocycline slows disease progression and helps maintain function in patients with ALS. The study design selects patients early in the course of ALS when a neuroprotective therapy may be most beneficial, measures functional improvement from the medication, which patients and physicians consider most important, and minimizes subject drop out. The proposed study will be an IRB-approved, investigatorinitiated, multi-center, randomized, double-blind, placebo-controlled study of Minocycline in 400 subjects with ALS treated for 9 months. The primary outcome measure is the change in slope of the revised ALS Functional Rating Scale (ALSFRS-R). Secondary outcome measures consist of changes in disease progression rate, as measured by Manual Muscle Testing (MMT), forced vital capacity (percent predicted) and survival. Should Minocycline prove effective in slowing the rate of functional decline, it would have an immediate impact both clinically and from the perspective of understanding the underlying pathophysiology of human ALS. This application is the clinical part of a combined proposal to carry out the clinical trial. A Data Center will be established at the California Pacific Medical Center in San Francisco to carry out data management and statistical analyses (see companion grant application Phase III Trial of Minocycline in ALS: II Data Center. P.I. Dr. Robert Miller). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHASE III TRIAL OF MINOCYCLINE IN ALS-II DATA CENTER Principal Investigator & Institution: Miller, Robert G.; California Pacific Med Ctr Res Institute 475 Brannan Street, Suite 220 San Francisco, Ca 94107 Timing: Fiscal Year 2004; Project Start 15-AUG-2003; Project End 31-MAY-2007 Summary: (provided by the applicant): This proposal is designed to provide data management and statistical support for the companion application Phase III Trial of Minocycline in ALS: I-Clinical Center (P.I. Paul Gordon, University of New Mexico), which is a multi-center clinical trial of Minocycline in ALS. The clinical trial is a randomized (1:1), double-blind, placebo-controlled trial, which will enroll 400 patients during the first two years. Each patient will be followed monthly for a minimum of 13 months; the first four months without drug or placebo (monitoring phase) to measure rate of decline of a validated functional measure (ALS Functional Rating Scale-Revised, ALSFRS-R), followed by 9 months on drug or placebo (assigned by randomization). The primary test of drug efficacy will be based on comparing changes in slope, i.e., the slope after assignment (based on up to 9 monthly scores), minus the slope before assignment (based on 5 monthly scores), in the drug vs. placebo groups. A linear mixed effects
64
Amyotrophic Lateral Sclerosis
model will be used to estimate the average change of slope for patients in each group. The difference in average change, drug vs. placebo, will be tested using a mixed linear effects model. The study has 80% power to detect a change of 15% in slope, which corresponds to 4-5 months of prolonged survival. The companion application, Phase III Trial of Minocycline in ALS: I - Clinical Center (P.I. Paul Gordon, University of New Mexico), describes the details of background, clinical procedures and human subjects. This application describes the specific aims of the Data Management Center, and summarizes results of our previous clinical trials and studies in ALS. We provide data from our previous studies to justify the 4-month lead-in, thereby reducing sample size. We present an analysis of our previous results to support our choice of the primary and secondary efficacy variables. In particular, we demonstrate a close relationship between changes in ALSFRS and survival. We explain the selection of the effect size and development of the sample size in detail, based on analysis of our previous results. The details of data management are described, including the methods for quality control, security and information technology. Finally, the analytic plan is described in full. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROINFLAMMATORY ENZYMES IN AMYOTROPHIC LATERAL SCLEROSIS Principal Investigator & Institution: Przedborski, Serge E.; Professor; Neurology; Columbia University Health Sciences Research Administration New York, Ny 100323702 Timing: Fiscal Year 2004; Project Start 01-AUG-2001; Project End 31-JUL-2006 Summary: This proposal is submitted to pursue our investigation of the pathogenesis of amyotrophic lateral sclerosis (ALS) using transgenic mice expressing the glycine-93 yields arginine mutant copper/zinc superoxide dismutase (SOD1G93A). Pertinent to this goal, first, we have shown that inducible nitric oxide synthase (iNOS) is upregulated in glial cells in the spinal cords of affected transgenic SOD1G93A mice. To elucidate the role of iNOS in this model of ALS, Specific Aim (SA)-I will determine the effect of iNOS inhibition or ablation on SOD1G93A-mediated neurodegeneration. Second, we have evidence that the production of the highly-reactive tissue damaging species hypochlorous acid is increased in the spinal cords of affected transgenic SOD1G93A mice. To acquire a better understanding the cytotoxic role of hypochlorous acid in this model of ALS, SA-II will quantify spinal cord levels of chlorotyrosine and nitrotyrosine, the two main fingerprints of hypochlorous acid-induced protein oxidative attack, at different disease stages, in different lines of transgenic mice that express either mutant or wild-type SOD1 and, in transgenic SOD1G93A mice after ablation of neuronal NOS (nNOS), iNOS, or myeloperoxidase (MOP), which is the only mammalian enzyme which produced hypochlorous acid. To explore further the role of MPO. SA-III will (1) define spinal cord expression of MPO mRNA and protein, as in SA-II, at different disease stages and transgenic lines; and (2) assess the effect of MPO ablation on SOD1G93A-mediated neurodegeneration. Third, we have observed that cyclooxygenase-2 (Cox-2), a key enzyme in the synthesis of the pro-inflammatory prostaglandin PGE2, is also markedly increased in the spinal cord of affected transgenic SOD1G93A mice. To demonstrate whether Cox-2 upregulation plays a role in SOD1G93A-mediated neurodegeneration, SA-IV will (1) characterize spinal cord Cox-2 mRNA and protein expression, and PGE2 content, as in SA-II, at different disease stages, transgenic lines, and in transgenic SOD1G93A mice after ablation of iNOS; and (2) assess the effects of Cox-2 inhibition or ablation on SOD1G93A-mediated neurodegeneration. This proposal contains a comprehensive set of experiments, which
Studies
65
should provide insights into the role of iNOS, hypochlorous acid and its synthesizing enzyme MPO, as well as into Cox-2 in transgenic SOD1G93A mice. It should also shed light onto the mechanisms of neurodegeneration in ALS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROPERTIES OF DYNEIN ISOENZYMES Principal Investigator & Institution: Gibbons, Ian R.; Professor of Biophysics; Molecular and Cell Biology; University of California Berkeley 2150 Shattuck Avenue, Room 313 Berkeley, Ca 947045940 Timing: Fiscal Year 2004; Project Start 01-APR-1982; Project End 31-MAR-2008 Summary: (provided by applicant): Dyneins are motor proteins that move cellular cargos along microtubules toward their minus ends. There are two sub-classes of dynein. Cytoplasmic dynein is a single isoform that is involved in various essential cellular functions, including retrograde vesicle transport in the cytoplasm and in nerve axons, organellar movement, orientation of the mitotic spindle, disassembly of centromeric checkpoint proteins, and nuclear migration. Axonemal dynein occurs as approximately 12 isoforms, encoded by distinct genes, that are responsible for the beating movements of cilia and sperm flagella. In all dyneins the motor unit consists of six AAA protomers disposed in tandem on a single "heavy chain" polypeptide of unusually high molecular mass (>500 kDa). These AAA protomers form a hexameric ring from which the microtubule-binding domain protrudes on a short stalk. Binding and hydrolysis of ATP at certain of the AAA protomers is believed to cause cyclic changes in the angle of the protruding stalk and so translocate the dynein along the microtubule to which it is attached. Sequence analysis suggests that the structure of the AAA protomers in dynein resembles that of other members of the AAA ATPase family, with their closest relationship being to AAA protomers of the recently discovered protein, midasin. The long-term goal of this project is to understand the relationship between structure and function in dynein isoforms. The specific aims are to use techniques of cell and molecular biology: 1) to express individual structural domains of dynein in bacteria or in eukaryote cell cultures in order to obtain relatively low molecular weight forms of these proteins that retain subsets of their functional properties; 2) to use site-directed mutagenesis of the dynein motor to characterize the cooperative ATP-dependent structural changes in the AAA protomers and microtubulebinding stalk that are believed to underlie the ability of dynein to translocate along a microtubule; 3) to use antibodies to define an experimental map of the motor surface and of the changes that occur during the ATPase cycle; 4) to relate the structural and enzymatic properties of the AAA protomers in dynein to those of the AAA protomers in midasin. Defects in dynein underlie many human health problems, including male infertility, bronchiactosis, lissencephaly, primary cilia diskinesia, and defective retrograde transport in nerve axons that can result in amyotrophic lateral sclerosis (ALS). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PROSPECTIVE EPIDEMIOLOGICAL STUDY OF ALS Principal Investigator & Institution: Ascherio, Alberto; Associate Professor; Nutrition; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02115 Timing: Fiscal Year 2004; Project Start 01-APR-2003; Project End 31-MAR-2006 Summary: (provided by applicant): We propose to study prospectively the relationships between lifestyle factors and risk of amyotrophic lateral sclerosis (ALS) among
66
Amyotrophic Lateral Sclerosis
participants in the Cancer Prospective Study II (CPS II) of the American Cancer Society. The original cohort comprised 1,184,622 men and women from all 50 United States, the District of Columbia, and Puerto Rico, aged 30 years and older, who completed a lifestyle and dietary questionnaire in 1982. The proposed investigation will include the 1,098,726 participants who were alive on January 1, 1989, as reliable information on causes of death is only available after this date. During ten years of follow-up, 621 participants in this cohort died of ALS. Specifically, we will examine prospectively the associations between risk of ALS and cigarette smoking, use of antioxidant vitamins, education, occupation, and exposures to agricultural chemicals and solvents. Because of the large number of participants and long follow-up time this cohort provides a unique opportunity to examine prospectively the association between lifestyle variables and the risk of ALS among men and women. A further strength of the proposed investigation is the availability of information on several potential confounders, including past medical history, physical activity, and diet. Identification of the risk factors for ALS will provide clues about the etiology of the disease and contribute to identify those hypotheses that need more intense scrutiny in clinical or laboratory investigations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RETINOIDS AND THE SPECIFICATION OF SPINAL MOTOR NEURONS Principal Investigator & Institution: Sockanathan, Shanthini; Assistant Professor; Neuroscience; Johns Hopkins University W400 Wyman Park Building Baltimore, Md 212182680 Timing: Fiscal Year 2004; Project Start 01-JUN-2003; Project End 31-MAY-2007 Summary: The coordinated generation of specialized groups of spinal motor neurons during development of the central nervous system is essential for the assembly of functional neural circuits. Analysis to date hasfocused on the role of the signaling molecule shh in motor neuron specification however increasing evidencesuggests that other inductive molecules may play pivotal roles in their development. The dynamicspatiotemporal expression of RALDH2, the major synthetic enzyme for retinoic acid suggests that retinoidsignaling is required at defined stages in the sequential development of motor neurons. However, loss offunction studies have not been informative due to the early lethality of RALDH2 null embryos. This proposalaims to test the hypothesis that retinoids are required at specific stages of motor neuron development usinggenetic strategies in the mouse to bypass the early lethality of RALDH2 mutants. Tissue specific knockouts of RALDH2 will be constructed and analyzed to first assess the contribution of paraxial mesoderm derived retinoids to motor neuron generation and column induction and second, to determine if motor neuron derived retinoid signaling is necessary for motor column, motor division and motor pool determination. Finally, four prospective target genes for RALDH2 have been isolated using differential screening approaches and experiments outlined here will focus on functional analyses to determine the potential role of two of these genes in motor neuron specification. Taken together, these experiments aim to define the contribution of retinoic acid signaling to motor neuron development with the ultimate aim of assembling a molecular pathway of retinoid dependent events required for their specification during embryogenesis. Understanding the processes by which motor neuron specification occurs may provide insight into the basis of motor neuron degenerative diseases such as amyotrophic lateral sclerosis or the spinal muscular atrophies. This in turn may lead to the design of innovative treatments for these diseases in the future which may incorporate the use of stem cell technology.
Studies
67
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RILUZOLE MOA: TARGETS FOR IMPROVED NEUROPROTECTIVE DRUGS Principal Investigator & Institution: Sluder, Ann E.; Director, Genetics; Cambria Biosciences, Llc 8A Henshaw St Woburn, Ma 01801 Timing: Fiscal Year 2004; Project Start 30-SEP-2004; Project End 31-MAR-2006 Summary: (provided by applicant): Amyotrophic lateral sclerosis (ALS) is an aggressive neurodegenerative disease of motor neurons that results in progressive muscle weakness, paralysis, and ultimately death, usually within five years of disease onset. Late stage ALS patients require extensive supportive care, placing immense emotional and economic burdens on patients and their families. Riluzole, the only drug currently approved for the treatment of ALS, provides only a modest extension of 2 to 3 months in life expectancy for ALS patients, and hepatotoxicity is a significant side effect limiting the drug's use. Biochemical and cellular studies have suggested a wide variety of potential targets for riluzole action, but the precise molecular mechanism of action (MO A) of this drug remains poorly defined. A more complete understanding of riluzole's molecular target(s) would be of great value in guiding the discovery of safer and more effective therapies for ALS. Genetic studies in the model nematode Caenorhabditis elegans have been successfully utilized to identify the targets and mechanistic pathways of a number of human Pharmaceuticals. Preliminary studies have demonstrated a significant effect of riluzole on C. elegans, and multiple independent genetic mutants resistant to the drug have been isolated. This Phase I SBIR project will complete the genetic analysis of these riluzole-resistance alleles in C. elegans, with the goal of characterizing riluzole's MOA and identifying riluzole targets that can be exploited for therapeutic discovery efforts. Two specific aims will be pursued: (1) Genetic mapping of the riluzole-resistance alleles will employ a combination of genetic recombination mapping and single-nucleotide polymorphism analysis. (2) Identification of the riluzole-resistance gene(s). Based on the genetic mapping results, a combination of candidate gene sequencing and, as needed, genetic transformation experiments will be used to identify the specific mutations conferring riluzole resistance. The molecular characterization of the riluzole-resistance gene(s) will identify one or more pathways for riluzole's action in a living model animal with a well-characterized nervous system. Subsequent Phase II efforts will (a) identify and evaluate the function of homologous mammalian genes, and (b) develop and implement new bioassays for the rational discovery of next-generation therapeutics for ALS and other neurodegenerative diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DISMUTASE
RNAI-MEDIATED
SILENCING
OF
MUTANT
SUPEROXIDE
Principal Investigator & Institution: Maxwell, Michele M.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2007 Summary: (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder resulting from selective death of motor neurons in the brain and spinal cord. In approximately 20% of dominantly-inherited familial ALS cases, the disease is caused by mutations in the gene encoding cytosolic Cu,Zn superoxide dismutase (SOD1). The vast majority of ALS-linked variations in SOD1 are
68
Amyotrophic Lateral Sclerosis
point mutations yielding single amino acid substitutions. In cell culture and in rodent models of ALS, mutant SOD1 proteins exhibit dose dependent toxicity; thus, agents that reduce mutant protein expression would be useful therapeutic tools. The overall goal is this project is to evaluate the potential of RNA-mediated interference (RNAi) for silencing expression of mutant SOD1 in vitro and in vivo. Small interfering RNAs (siRNAs) capable of selectively inhibiting expression of mutant SOD1 will be identified. Transgenic mice expressing small hairpin RNAs directed against mutant SOD1 will be generated and crossed to mutant SOD1 transgenic mice; progeny will be monitored for changes in disease onset and progression. In addition, the therapeutic potential of RNAi will be assessed using viral delivery of shRNA to the spinal cords of mutant SOD1 transgenic mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF COPPER CHAPERONE FOR SOD1 IN MODELS OF ALS Principal Investigator & Institution: Wong, Philip C.; Associate Professor; Pathology; Johns Hopkins University W400 Wyman Park Building Baltimore, Md 212182680 Timing: Fiscal Year 2004; Project Start 10-APR-2000; Project End 31-MAR-2006 Summary: (Verbatim from the Applicant's Abstract) Cu/Zn superoxide dismutase (SOD1) mutations cause about 20 percent of cases of familial amyotrophic lateral sclerosis (FALS). Transgenic mice expressing mutant SOD1 develop a progressive motor neuron disease. A long term goal is to understand the molecular mechanisms by which SOD1 mutants cause selective motor neuron degeneration. Copper, an essential cofactor for SOD1 enzymatic activity, has been proposed to play a critical role in the pathogenesis of SOD1-linked ALS. Because free copper can be toxic in cells, the delivery of copper to specific proteins within various compartments of the cell is tightly regulated by specific copper chaperones like CCS. Previous efforts have demonstrated that CCS is necessary to deliver copper to SOD1, and CCS-deficient mice are viable and show no SOD1 activity. First, to test whether Cu in mutant SOD1 is required to cause motor neuron degeneration, CCS-deficient mice will be crossbred with a series of mutant SOD1 mice. If Cu participates in killing motor neurons, mutant SOD1 mice without CCS will show significant amelioration or rescue of motor neuron disease. Second, because 30 percent of SOD1 is not charged with Cu, transgenic mice overexpressing CCS will be generated to examine whether the level of active SOD1 can be increased in vivo by elevating the level of CCS. Finally, to determine the domains of CCS that are important for Cu delivery, a series of mutant CCS DNA constructs will be transfected into wild-type and CCS-deficient cells to identify CCS mutants that are able to inhibit the CCS Cu trafficking pathway. Taken together, these efforts will test Cubased neurotoxicity mechanisms in vivo. The results will have the potential to identify novel therapeutic targets and may have implications for the design of drug treatments for motor neuron disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLE OF YEAST SEN1P IN RNA MATURATION PATHWAYS Principal Investigator & Institution: Finkel, Jonathan S.; Lab of Molecular Biology; University of Wisconsin Madison Suite 6401 Madison, Wi 537151218 Timing: Fiscal Year 2006; Project Start 01-JAN-2006; Project End 31-DEC-2009 Summary: (provided by applicant): Sen1p in Saccharomyces cerevisiae is a Type I DNA/RNA helicase. Mutations in the helicase domain perturb accumulation of diverse RNA classes, and Sen1p has been implicated in 3' end formation of non- coding RNAs.
Studies
69
Mutations in the human ortholog of yeast SEN1 (SETX) have been implicated as a cause for the neurological disorders, ataxia-ocular apraxia 2 and Juvenile Amyotrophic Lateral Sclerosis (Lou Gehrig's disease). Speculation about the function of SETX in these diseases derives from work done on the yeast SEN1. Studies of sen1 mutants revealed defects in the processing of small nuclear RNA (snRNA). The aims of this proposal focus on the functional analysis of the interaction between Sen1p and Rnt1p and Sen1p and SmDSp. Rnt1p, which resembles E. coli RNase III, is an endoribonuclease required for RNA maturation. SmDSp is a subunit of the splicing complex. To investigate the potential roles of these interactions in RNA processing, mutations will be created in SEN1 that specifically disrupt the Sen1p-Rnt1p or Sen1p-SmD3p interactions. To assess the purpose of these protein-protein interactions, the non-interacting mutants will be assayed to determine the effects of loss of interaction on processing of the U5 snRNA. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROUTE 28 SUMMITS IN NEUROBIOLOGY Principal Investigator & Institution: Palmer, Theo D.; Assistant Professor; Neurosurgery; Stanford University 1215 Welch Road, Mod B Stanford, Ca 943055402 Timing: Fiscal Year 2005; Project Start 01-JUN-2005; Project End 31-MAY-2006 Summary: (provided by applicant): This proposal requests partial funding for the 5th workshop in a series of well optimized and uniquely effective training venues for graduate students and post-graduate fellows. The 2005 Route 28 Summit focuses on the emerging links between injury, inflammation and neurodegeneration in the central nervous system dysfunction. With the help of attending faculty, trainees work in small collaborative groups to competitively produce and present research strategies addressing current issues in multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and spinal cord injury. The workshop involves 45 trainees and formal lectures by 19 attending faculty members. Trainees and teaching faculty are drawn from the international research and clinical communities. The current organizing committee is well experienced and has produced four prior Route 28 Summits in 1999, 2001, 2002, and 2004. The organizers of the Route 28 Summits have made a commitment to attain four Aims: Aim 1. Provide outstanding student access to leading scientists in neurobiology and related disciplines. Aim 2. Promote long-lasting and rewarding crossdisciplinary interactions on the workshop topic. Aim 3. Educate trainees in the process of collaborative thinking and group planning of a competitive research proposal. Aim 4. Provide a cost package that does not discriminate against promising students with a limited travel budget. To our knowledge, the Route 28 Summit workshops provide the only graduate and post-graduate level training venue that purposefully highlights the strengths of collaborative multi-disciplinary research in the biomedical sciences. In addition, the workshop topics and trainee assignments provide a thorough introduction to cutting edge research in disease or injury processes and explore problems facing the translation of basic science into clinical application. These strengths are clearly called out in the newly generated NIH Roadmap and are fundamental to the programmatic goals of the NINDS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SOD1/BC1-2 COMPLEX: A ROLE IN REGULATING MOTOR NEURON CELL DEATH Principal Investigator & Institution: Pasinelli, Piera; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114
70
Amyotrophic Lateral Sclerosis
Timing: Fiscal Year 2006; Project Start 02-AUG-2006; Project End 31-JAN-2010 Summary: (provided by applicant): In this project we will define a role for copper-zinc superoxide dismutase (SOD1) in the regulation of cell survival and death. While the wild-type (WT) SOD1 is a pro-survival protein, amyotrophic lateral sclerosis (ALS)linked SOD1 mutants are toxic both in vitro and in vivo. We recently found that both WT and mutant SOD1 interact with the anti-apoptotic protein Bcl-2. However, the nature of the mutant SOD1 binding with Bcl-2 differs from WT SOD1. Contrary to WT SOD1, mutant SOD1 specifically localizes to spinal cord mitochondria where it forms SDS-resistant high molecular weight aggregates that bind and entrap Bcl-2. (Pasinelli et al, 2004, Neuron 43: 19-30). These studies suggest a potentially novel function for WT SOD1 in regulating cell survival and death, and a novel, toxic gain-of-function for mutant SOD1. Thus, while WT SOD1 may protect against cell death through its interaction with Bcl-2, mutant SOD1 may become toxic by aberrantly binding to Bcl-2 and converting Bcl-2 into a toxic or non-functional protein. In support of this hypothesis, we now have preliminary data indicating that both WT and mutant SOD1 might require Bcl-2 to exert their anti-and-pro apoptotic function respectively. With the present proposal we intend to characterize the anti and pro-death function of WT and mutant SOD1 and their respective interactions with Bcl-2. The ultimate goal is to understand the mechanism(s) of mutant SOD1-mediated toxicity and to define a potential role for the mitochondrial mutant SOD1/Bcl-2 complex in ALS pathogenesis. The specific aims are: 1) (A) To determine whether WT SOD1 pro-survival activity depends on its binding to Bcl-2, and (B) to determine whether mutant SOD 1-mediated toxicity depends on the aberrant interaction with Bcl-2. 2) (A) To identify the region(s) in SOD1 essential for the binding with Bcl-2, and (B) to study the difference in binding strength between WT SOD1 and Bcl-2 and mutant SOD1 and Bcl-2. 3) (A) To determine whether Bcl-2 undergoes conformational modifications upon binding with mutant SOD1 and.(B) to test the potential benefit of Bcl-2 and SOD1 like-peptides that abolish binding between Bcl-2 and mutant SOD1 on our cell culture model of mutant SOD1-linked ALS. 4) To determine whether Bcl-2 mediates mutant SOD1 mitochondrial translocation. 5) To study the correlation between mutant SOD1/Bcl-2-containing aggregates and ALS using transgenic ALS mice and patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURAL BIOLOGY OF COPPER HOMEOSTASIS Principal Investigator & Institution: Rosenzweig, Amy C.; Professor; Biochemistry, Molecular Biology and Cell Biology; Northwestern University Evanston, Il 602081110 Timing: Fiscal Year 2004; Project Start 01-FEB-1999; Project End 31-JAN-2008 Summary: (provided by applicant): The long-term goal of this research program is to understand the molecular mechanisms of human copper homeostasis in atomic detail. Copper serves as a cofactor for many key enzymes, but can also facilitate the formation of oxygen radicals, which can damage proteins, DNA, and lipids. The delivery of this essential yet potentially toxic metal ion to distinct cellular locations and particular target proteins is accomplished in part by metallochaperone proteins. Metallochaperones deliver copper ions to target proteins via specific protein-protein interactions. Three classes of eukaryotic copper chaperones have been identified: the Atx1-like chaperones, the copper chaperones for superoxide dismutase, and the copper chaperones for cytochrome c oxidase. The Atx1-like chaperones deliver copper to transport ATPases in the secretory pathway. These ATPases include the human Wilson and Menkes proteins, mutations in which lead to Wilson disease and Menkes syndrome, genetic disorders of copper metabolism. The copper chaperones for superoxide dismutase, known as the
Studies
71
CCS proteins, provide copper,zinc superoxide dismutase (SOD1) with its catalytic copper ion. Mutations in SOD1 have been linked to familial amyotrophic lateral sclerosis (FALS). The copper chaperones for cytochrome c oxidase, Sco1 and Cox17, help assemble the CuA site in subunit 2 (Cox2). In humans, defects in cytochrome c oxidase lead to fatal cardioencephalomyopathy. The objective of the proposed work is to elucidate on the molecular level how proteins in these pathways bind copper, recognize and dock with physiological partners, and facilitate metal ion transfer. The metal binding properties of the copper chaperones and their target proteins will be studied by biophysical and crystallographic methods. Interactions between chaperones and target proteins will be investigated by biochemical, biophysical, and X-ray crystallographic techniques. In addition, interactions among the multiple metal binding domains of the transport ATPases will be examined. These approaches are expected to reveal molecular details of copper trafficking and provide new insight into the causes and treatments of diseases related to copper metabolism. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURAL INVESTIGATIONS OF METALLOPROTEIN METAL SITES Principal Investigator & Institution: Penner-Hahn, James E.; Professor; Chemistry; University of Michigan at Ann Arbor 3003 South State Street, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2005; Project Start 01-APR-1987; Project End 31-MAR-2009 Summary: (provided by applicant): The long term objective of this proposal is to characterize in detail the structural and functional properties of zinc in biological systems. Zinc is the most common metal found in metalloproteins and is the only metal that is known to be required for every major class of enzyme catalysis. Hundreds of zinc proteins have been isolated and thousands of potential zinc binding sites have been identified in protein sequences. Imbalances in the levels of zinc or errors in its transport or regulation can have profound health consequence. Malfunctions in zinc homeostasis have been implicated in a wide range of diseases, including amyotrophic lateral sclerosis, Alzheimer's disease, and spongiform encephalopathies; as a modulator of synaptic transmission, zinc has been suggested to play a critical role in the proper functioning of the brain. Despite its importance, there is relatively little information available about biological zinc sites due to the difficulty of studying this spectroscopically "silent" metal. X-ray absorption spectroscopy, one of the few methods able to provide structural information for non-crystalline materials, will be used to determine the structures of zinc in a novel class of zinc-containing alkyl transfer enzymes and to characterize the relative importance of metal stereochemical preference and protein structure in defining the structure of a metal binding site. For the latter work, structures will be compared for a series of spectroscopically silent metal ions (Cu(l), Ag(l), Cd(ll), Hg(ll), Pb(ll), and As(lll), in addition to Zn(ll)). As a complement to "conventional" x-ray spectroscopy, new tools will be developed using high-resolution xray emission spectroscopy and zinc L-edge x-ray spectroscopy. In situ x-ray microprobe imaging and microspectroscopy will be used to characterize metal sites in intact biological tissue, and the newly developed tool of capillary electrophoresis/x-ray fluorescence will be used to determine the metal loading in metalloproteins, with particularly emphasis on the protein superoxide dismutase. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
72
•
Amyotrophic Lateral Sclerosis
Project Title: STRUCTURAL STUDIES ON DYNEIN-MICROTUBULE COMPLEX Principal Investigator & Institution: Kikkawa, Masahide; Assistant Profesor; Cell Biology; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2006; Project Start 01-JAN-2006; Project End 31-DEC-2010 Summary: (provided by applicant): Microtubule-based motors, dyneins, are nano-meter scale protein machineries and convert chemical energy derived from ATP hydrolysis to mechanical movement. The mechanical movement is employed for various essential intracellular motilities, such as axonal transport, chromosome segregation, and flagellar motility. The importance of dynein functions is underlined by several dynein-related diseases, such as Kartagener's syndrome and amyotrophic lateral sclerosis (ALS). However, little is known about how dynein mutations cause the primary cilia diskinesia or even how dyneins convert chemical energy to mechanical movement. Our long-term goal is to understand the structural basis of energy conversion by dynein and its regulation. To this end we will characterize the structure of dynein-microtubule complexes using cryo-electron microscopy and three-dimensional reconstruction. We have recently obtained two initial structures of dynein-microtubule complexes. One is a low resolution structure of the outer arm dynein-microtubule complex, and another is a medium resolution structure of the microtubule binding domain of dynein, the dynein stalk. Our immediate goals are to refine the structure of the outer arm dyneinmicrotubule complex to 25Angstroms resolution, and to extend the structure of the dynein stalk structure to 10Angstroms resolution. By studying several structures of these complexes in functionally important states, we would like to elucidate conformational changes essential to the energy conversion, motility and regulation of dynein. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TARGETED MOTOR NEURON GENE DELIVERY FOR SPASTICITY Principal Investigator & Institution: Boulis, Nicholas M.; Assistant Professor; Neurosurgery; Cleveland Clinic Lerner Col/Med-Cwru 9500 Euclid Avenue Cleveland, Oh 44195 Timing: Fiscal Year 2004; Project Start 15-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): Technological advancements have provided neurosurgery with new paradigms for the restoration of neural function. The dual emergence of accurate stereotaxis and deep brain stimulation (DBS) have generated a revolution in the application of targeted neuromodulation applied to movement disorders, epilepsy, eating disorders, obsessive compulsive disease, and pain (Appendix C). Nonetheless, because DBS depends on the focused delivery of electric current, it is incapable of pharmacological specificity. Rather than delivering electric current, viral vectors can alter synaptic function with molecular specificity. Further, vector tropism can be modified, creating the potential for system specific neuronal gene delivery. The experiments outlined in this proposal attempt to develop a vector capable of both neural tropism and neuromodulation. To test these concepts, we propose to develop a recombinant adeno-associated virus (rAAV) capable of synaptic inhibition and motor neuron tropism. We have chosen the spinal reflex arc as a simple mammalian functional system amenable to neuromodulation. In addition, the functional disorder, spasticity, provides a target for the study of applied neuromodulation. We hypothesize that an rAAV vector capable of specific motor neuron inhibition will have therapeutic efficacy in animal models of spasticity. In addition to providing a novel approach to spasticity, data from these studies will permit the rational design of rAAV vector(s) for application
Studies
73
to motor neuron disease (ALS) and stereotactic neuromodulation. There are 3 Aims: 1) Construct novel vectors capable of focused synaptic inhibition, 2) develop strategies for targeted gene delivery to motor neurons with rAAV, 3) apply targeted rAAV capable of synaptic inhibition in models of spasticity. The applicant has developed a focused interest in the neural basis for behavior in both normal and pathological states. His early training in simple systems neurophysiology, and later training in biochemistry and molecular biology have prepared him for a career in the study of focused gene-based neuromodulation. His appointment to the Cleveland Clinic Foundation will give him access to one of the most active programs in Functional Neurosurgery, and create opportunities for clinical application of his work. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE ALS LOCKED-IN COMMUNICATOR Principal Investigator & Institution: Schmidt, Robert N.; Scientist; Cleveland Medical Devices, Inc. Cleveland, Oh 44103 Timing: Fiscal Year 2006; Project Start 01-SEP-2006; Project End 31-JAN-2008 Summary: (provided by applicant): Standard Assistive Technology (AT) solutions do not help people with locked-in syndrome because most AT input devices depend on some form of small but reliable muscle movement, such as pressing a button, eye movements, or blinking. This program will provide a simple device to take standard AT technology to the next level with Biometric Interfaces. This program will develop a fourmode communication aid for disabled individuals. Since a large share of its market will be advanced stage Amyotrophic Lateral Sclerosis (Lou Gehrigs Disease, or ALS) patients and other locked-in patients, it will be referred to "The ALS Locked-ln COmmunicatoR, or TALCOR (pronounced "TALKER"). The goal of this program is to develop and validate a new device that allows severely disable individuals who cannot communicate to do so. TALCOR will provide four different methods of non-traditional communications: 1. Brain Computer Interface (BCI) using EEG; 2. Galvanic Skin Response (GSR). 3. pH changes in the mouth; and 4. Amplified and filtered muscle movement, EMG: In Phase I, we will build a prototype TALCOR that will demonstrate all four modes on the lab bench and with healthy volunteers, and at least one of these methods (or modes) of communication with a patient that currently does not have the ability to communicate. In Phase II, we will upgrade the selected communication modes, harden the device, improve the software, enhance the design toward manufacturing and commercialization, and test the device on patients in the modes selected in Phase I to show its utility. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THE HISTIDYL IMIDAZOLE LIGAND IN METALLOPROTEINS Principal Investigator & Institution: Valentine, Joan S.; Professor; Chemistry and Biochemistry; University of California Los Angeles Office of Research Administration Los Angeles, Ca 90024 Timing: Fiscal Year 2004; Project Start 01-JAN-1980; Project End 31-MAR-2006 Summary: (provided by applicant): Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive, fatal neurodegenerative disease that is characterized by degeneration of motor neurons in the cortex, brainstem, and spinal cord, leading to paralysis and eventual death. In approximately 10 percent of ALS cases, the disease is inherited; approximately one-fifth of these familial cases are associated with mutations in sod1, the gene that encodes the human antioxidant enzyme copper-zinc superoxide
74
Amyotrophic Lateral Sclerosis
dismutase (CuZnSOD). These mutations are the only known cause of ALS and therefore represent the strongest clues available in investigating what causes ALS, whether inherited or sporadic. Over 90 individual mutations in CuZnSOD are known to cause ALS, and it is widely accepted that they exert their toxic effects by a gain of function mechanism. Several plausible mechanisms have been suggested to explain the nature of the toxic function gained by CuZnSOD as a consequence of the ALS mutations. The proposed mechanisms include a new chemical reactivity for CuZnSOD, formation of CuZnSOD aggregates, co-aggregation of other unknown components with CuZnSOD, and disruption of metal ion homeostasis due to binding or release from CuZnSOD. Each of these mechanisms would appear to be dependent on a change in structure or on a change in conformational stability or flexibility of the mutant protein relative to the extremely stable wild-type protein. It is therefore important to determine the physical properties of the mutant enzymes, particularly with respect to structure, stability, dynamics, and metal binding and to assay new and potentially toxic chemical reactivities. The primary objective of this project is to discover how mutations in CuZnSOD cause ALS and to explore the possibility that CuZnSOD is also linked to sporadic, i.e., non inherited forms, of ALS. The specific aims are as follows: to expand numbers of isolated, properly metallated and N-acetylated ALS-mutant CuZnSOD proteins for structural and mechanistic characterization, to determine the thermal stabilities and thermodynamics of metal ion binding of wild type and ALS-mutant CuZnSOD, to compare the dynamic properties of wild type and ALS-mutant CuZnSOD, to isolate and characterize mixed dimers consisting of one subunit each of ALS-mutant and wild type CuZnSOD (analogous to the mixed dimers that are expected to occur in ALS patients), to prepare chemically modified wild type CuZnSODs for comparison of properties with ALS-mutant CuZnSOD as possible models for sporadic ALS, to study reactions of ALS-mutant CuZnSOD with ascorbate and with hydrogen peroxide, to continue whole cell studies of yeast strains expressing wild type and ALS mutant CuZnSODs as their only CuZnSODs, and to develop in vivo inhibitors of wild type and ALS-mutant CuZnSODs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE ROLE OF IDUNA IN NEUROPROTECTION Principal Investigator & Institution: Dawson, Valina L.; Professor; Clinical Research Center; Johns Hopkins University W400 Wyman Park Building Baltimore, Md 212182680 Timing: Fiscal Year 2006; Project Start 15-AUG-2006; Project End 31-JAN-2011 Summary: (provided by applicant): There are approximately 250 neurological - brain and nervous system - disorders. Combined, neurologic disorders are the leading cause of death, disability and loss of quality of life worldwide according to the World Health Organization. The incidence of these disorders ranges from stroke, epilepsy and Alzheimer's, which affect millions, to rare diseases such as amyotrophic lateral sclerosis and ataxia's. To address the problem of brain and nervous system disorders investigators have focused attention on describing cell injury mechanisms. However, discovery of cell survival strategies could have profound impact on the treatment of neurologic disorders and disease and is an area that has not yet been rigorously investigated. Recently we developed a strategy to discover neuroprotective genes from preconditioned neural tissue. Some of the first genes we have begun to characterize provide protection not only against ischemic and excitotoxic injury but are protective against classic apoptotic injury triggered by staurosporin or serum withdrawal. This is very exciting, suggesting that it might be possible to find molecules that are broadly
Studies
75
protective and therefore might provide treatment for stroke and perhaps even for other neurologic disorders such as Parkinson's disease, Huntington's disease or ALS. From this screen we identified a protein of unknown function that is potently neuroprotective that we have named Iduna and proposed the following aims to explore the biologic function of Iduna. Aim 1: What is the anatomical and cellular localization of Iduna in control and preconditioned tissues? Aim 2: What are the death programs against which Iduna protects neurons? Aim 3: Is Iduna neuroprotective in vivo? Aim 4: What is the neuroprotective network of Iduna? On completion of these studies we will have identified the biologic actions of Iduna and the survival pathways it mediates, as well as, identified potential disease targets that might benefit from expression of Iduna. Our long-term goal is to understand novel enodgenous survival pathways so that these pathways can be exploited for the treatment of neurologic injury and disease. The goal is to understand the function of Iduna so that translational therapy can be developed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THIRD INTERNATIONAL BCI MEETING Principal Investigator & Institution: Vaughan, Theresa M.; Wadsworth Center One University Pl Rensselaer, Ny 12144 Timing: Fiscal Year 2005; Project Start 01-JUN-2005; Project End 31-MAY-2007 Summary: (provided by applicant): Brain-computer interface (BCI) research seeks to give people with severe motor disabilities (e.g. amyotrophic lateral sclerosis, brainstem stroke, cerebral palsy, and spinal cord injury) communication and control technology that does not depend on neuromuscular output. BCI can provide people who are severely disabled with non-muscular methods for controlling cursor movements, selecting letters or icons, or even operating neuro-prostheses. Facilitated and encouraged by new understanding of brain function, by the advent of powerful low-cost computers, and by appreciation of the needs and potentials of people with disabilities, BCI research has grown rapidly through the past decade and its growth has greatly accelerated in the past two years. Effective BCI research requires interdisciplinary interactions involving neuroscience, psychology, engineering, mathematics, computer science, and clinical rehabilitation. No standard venue brings these groups together, in recognition of this, and of the growth in BCI research, the NIH sponsored and the Wadsworth Center organized in 1999 and 2002 the first two international BCI meetings. These meetings brought together researchers from all over the world and included all relevant disciplines. Foundation support allowed many graduate students and postdoctoral fellows to participate. The meetings were extremely successful. The first was reported in 18 peer-reviewed papers in a special section of IEEE Trans. Rehab. Eng, and the second in 28 peer-reviewed papers in a dedicated issue of IEEE Trans Neur. Syst. Rehab. Eng. In large part due to the interdisciplinary interactions fostered by these meetings, BCI research continues to grow even more rapidly. This proposal seeks core funding for the Third International BCI Meeting, June 14-19, 2005. The mornings of the first three days will provide concise updates from about 50 BCI laboratories, and the afternoons will be devoted to four parallel workshops addressing the four critical areas of BCI research: signals and recording methods; signal processing; clinical issues and applications; and software and hardware. The fourth day will be a plenary session comprised of summary presentations from each workshop. Evenings will offer a keynote address, poster sessions, and BCI demonstrations. Foundation support contingent on the success of this proposal will fund students and fellows. Proceedings will be published as a dedicated issue of IEEE Trans Neur. Syst. Rehab. Eng. By bringing together essentially all active BCI research groups, by focusing on the most important
76
Amyotrophic Lateral Sclerosis
issues, by involving students and fellows, and by producing a comprehensive state-ofthe-art set of papers, this Third International BCI Meeting should greatly encourage and facilitate continued BCI research and development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TROPHIC FACTOR SIGNALING AND MOTOR NEURON DEATH Principal Investigator & Institution: Kalb, Robert G.; Associate Professor; Children's Hospital of Philadelphia Joseph Stokes, Jr. Research Institute Philadelphia, Pa 191044318 Timing: Fiscal Year 2006; Project Start 15-FEB-2006; Project End 31-JAN-2011 Summary: (provided by applicant): The central pathologic event in Amyotrophic Lateral Sclerosis (ALS) is the selective degeneration of motor neurons. While most cases (-90%) are sporadic, the familial cases are due to mutations in a variety of different genes such as SOD1 and p150glued. Excessive activation of glutamate receptors (excitotoxicity) is an early triggering event. The death of motor neurons from excitotoxic insult or mutant gene expression can be studied in cell culture using dissociated rodent embryonic spinal cord tissue. Our previous in vitro work demonstrates that excitotoxic motor neuron death only occurs if Brain-derived neuronotrophic factor (BDNF) signaling via TrkB is intact. The phosphatidylinositol 3' kinase (PI3'K) signaling cascade is activated by TrkB and PI3'K signaling is necessary and sufficient for BDNF-induced excitotoxic death of motor neuron. Pharmacological manipulations that inhibit Trk activation can also protect motor neurons from the toxic effects of mutant SOD1 and p150glued. This can be accomplished using proprietary derivatives of K252a (made by Cephalon Pharmaceuticals) or by inhibiting the activation of adenosine A2A receptors. In specific aim #1 we will examine the alterations in intracellular signaling cascades that follow from administration of these agents. The potential interplay between mutant SOD1 and p150glued and Trk signaling events will also be studied. In specific aim #2, we will study the in vivo pharmacodynamics of these agents on Trk activation and signaling. This is a prelude to future studies in which we hope to examine the efficacy of these agents in animal models of ALS. In specific aim #3 we will study the signaling cascades downstream of activated PIS'K (two serine-theonine kinases (PDK1, Akt) and small monomeric GTP'ases of the RhoA and Arf families) to see which is needed to evoke excitotoxic sensitivity of motor neurons. This will define susceptibility-to-toxicity intracellular signaling pathways in motor neurons. Relevance: The proposed work attempts to translate basic science observations into new treatments for ALS. The development of new drug targets for ALS could guide the way for novel therapies for other, more prevalent, neuro-degenerative disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: UNDERSTANDING MECHANISM AND THERAPY OF ALS USING RNAI Principal Investigator & Institution: Xu, Zuoshang; Associate Professor; Biochemistry and Molecular Pharmacology; Univ of Massachusetts Med Sch Worcester 55 Lake Avenue North Worcester, Ma 01655 Timing: Fiscal Year 2004; Project Start 01-FEB-2004; Project End 31-JAN-2009 Summary: (provided by applicant): Diseases caused by dominant, gain-of-function mutations develop in people bearing one mutant and one wild-type copy of the gene. Some of the best known examples of this class are neurodegenerative diseases, including Huntington's, a subset of amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson's diseases. In all these diseases, the exact pathways whereby the mutant
Studies
77
proteins cause cell degeneration are not entirely clear, but the origin of the cellular toxicity is known to be the mutant protein. Thus, selectively lowering or eliminating the mutant protein is a key step in developing effective therapies. Until recently, it was not clear how specific down-regulation of a wide variety of mutant proteins could be achieved. But now, new advances in RNA interference (RNAi) raise the possibility that RNAi can be developed and eventually applied as a therapeutic means for these neurodegenerative diseases. RNAi can mediate sequence-selective suppression of gene expression in a wide variety of eukaryotes by introducing short RNA duplexes (called small interfering RNAs or siRNAs) with sequence homologies to the target gene. Recent experiments indicate that small hairpin RNAs (shRNAs) transcribed in vivo can trigger degradation of corresponding mRNAs similar to siRNA. These developments raise the possibility that siRNA duplexes or vectors expressing shRNAs may be used to block the expression of a toxic mutant gene. This proposal investigates in vivo efficacy of RNAi therapy using transgenic technology in a mouse model for ALS that is caused by mutations in Cu, Zn superoxide dismutase (SOD1). To determine the potential of RNAi therapy, we will express shRNAs targeting specifically the mutant mRNAs in transgenic mice. We will test how effective and how specific these shRNAs are in suppressing the mutant protein expression and alleviating the disease. To determine in which cell types the suppression of the mutant expression is most crucial, we will express shRNAs in selected cell types using Cre-lox recombination system, We will determine in which cell type suppression of mutant SOD1 expression has the largest impact in alleviating disease. To determine the optimal time for therapy, we will use the Tamoxifeninducible Cre recombinant system to determine at what stage of the disease induction of shRNA to suppress mutant SOD1expresion is most effective. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen NTIS (National Technical Information Service) The NTIS (www.ntis.gov), a service of the U.S. Department of Commerce, has published the following information on sponsored studies related to amyotrophic lateral sclerosis: •
"Bioenergetic Defects and Oxidative Damage in Transgenic Mouse Models of Neurodegenerative Disorders. - Annual rept. 1 May 2001-30 Apr 2002," published in May 2002. Sponsored by: Cornell Univ. Medical Coll., New York. Written by: S. E. Brown. Abstract: This project aimed to determine the contributions of bioenergetic dysfunction and oxidative stress to neurodegeneration in Huntington's disease (HE) and Amyotrophic lateral sclerosis (ALS). We found elevations in cerebral glucose utilization in two distinctly different mutant mouse models of HD: Hdh(Q92) and N171-82Q. Hypermetabolism preceded pathologic changes and symptoms, but was not accompanied by alterations in oxidative phosphorylation enzyme activities. We also found late increases in oxidative damage to DNA -and lipids in R6/2 and N171-82Q HD mice. Another approach to model HD is to inhibit mitochondrial complex II using the neurotoxin 3-nitropropionic acid (3-NP). In contrast to genetic models, reductions in glucose use following 3- NP coincided with neuronal loss, suggesting a different sequence of pathologic events in this model. In a model of ALS, G93A mice, we also found early metabolic changes preceding neuronal pathology and symptom onset. Reduced glucose utilization in brain and spinal cord at 60 days of age was concomitant with increased mitochondrial complex I activity and depletions in ATP levels. Elevated
78
Amyotrophic Lateral Sclerosis
free radical generation was evident by 90 days. Results clearly demonstrate the early involvement of metabolic changes in the pathologic events initiated by expression of the mutant disease gene in ALS and HD models. •
"Health Hazard Evaluation Report: University of Kentucky College of Pharmacy, Lexington, Kentucky," published in November 2000. Sponsored by: National Inst. for Occupational Safety and Health, Cincinnati, OH. Written by: C. K. Cook, H. Daftarian and V. Mortimer. Abstract: In June 1999, the National Institute for Occupational Safety and Health (NIOSH) received a request from management at the University of Kentucky Medical Center to conduct a health hazard evaluation (HHE) at the College of Pharmacy building. The request stated that two College of Pharmacy faculty personnel had been diagnosed with chronic neurological conditions (multiple sclerosis (MS) and Amyotrophic lateral sclerosis (ALS)), and that there were concerns that the development of these conditions may be work-related. Since the building was first occupied in 1985, faculty personnel often reported smelling chemical odors from research labs on the 4th floor. NIOSH investigators reviewed the facility's Chemical Hygiene Plan, chemical inventory lists, ventilation blueprints, and floor plans. A tracer gas evaluation of the building's ventilation system was conducted to evaluate potential pollutant pathways and airflow patterns on the 4th floor. The tracer gas study demonstrated how chemical odors generated in labs can enter each floor's common return-air plenum, then disperse to other areas in the building, and how air contaminants released from fume hood exhaust stacks and a plumbing vent could reenter the building's ventilation system. Some research labs were under positive pressure, which may allow chemical odors to disperse to areas outside the lab.
•
"New trace element determinations in the fingernails of ALS patients," published in 1996. Sponsored by: Oak Ridge National Lab., TN.; Department of Energy, Washington, DC. Written by: D. J. Van Dalsem, L. Robinson and W. D. Ehmann. Abstract: ORNL's High Flux Isotope Reactor was used in a neutron activation analysis experiment to determine selected elemental composition of fingernails from patients afflicted with Amyotrophic lateral sclerosis (ALS). While no statistical difference were found in aluminium, a significant difference was observed for copper concentrations.
•
"Public Health Assessment for Petitioned Public Health Assessment Great Lakes Chemical Corporation, El Dorado, Union County, Arkansas, Region 6. CERCLIS No. ARD043195429. - Final rept," published in June 2000. Abstract: The Great Lakes Chemical Company (GLCC) manufactures elemental bromine and brominated compounds from salt brines extracted from deep wells. Community members are concerned that emissions from Great Lakes Chemical Company are causing an increased incidence of motor neuron disease (in particular, Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease). Environmental sampling data before 1987 are not available to evaluate the potential health impact of Great Lakes Chemical Company emissions. However, a review of available environmental sampling data show that the on-site soil and groundwater are contaminated with brominated compounds. Human exposure to these media is limited because public access to the site is restricted and on-site groundwater is not being used for drinking water. No chemical contaminants detected in the nearest residence at levels of health concern. A review of blood samples showed no evidence of a correlation between blood bromide levels of nearby residents and adverse health effects. ATSDR also found no association between
Studies
79
environmental contamination from any source (including GLCC) and motor neuron disease mortality in El Dorado, Arkansas. The Agency for Toxic Substances and Disease Registry has classified this site as No Apparent Public Health Hazard based on the levels of contaminants found around Great Lakes Chemical Company.
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.12 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with amyotrophic lateral sclerosis, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type amyotrophic lateral sclerosis (or synonyms) into the search box, and click Go. The following is the type of output you can expect from PubMed for amyotrophic lateral sclerosis (hyperlinks lead to article summaries): •
A case of amyotrophic lateral sclerosis and breast cancer. Author(s): Kijima Y, Yoshinaka H, Higuchi I, Owaki T, Aikou T. Source: Breast Cancer. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15657525&query_hl=10&itool=pubmed_docsum
•
Advances in clinical trials for amyotrophic lateral sclerosis. Author(s): Gordon PH. Source: Curr Neurol Neurosci Rep. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15676108&query_hl=10&itool=pubmed_docsum
•
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Author(s): Kim K, Moore DH, Makriyannis A, Abood ME. Source: European Journal of Pharmacology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16781706&query_hl=10&itool=pubmed_docsum
12
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
80
Amyotrophic Lateral Sclerosis
•
Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking. Author(s): Lai C, Xie C, McCormack SG, Chiang HC, Michalak MK, Lin X, Chandran J, Shim H, Shimoji M, Cookson MR, Huganir RL, Rothstein JD, Price DL, Wong PC, Martin LJ, Zhu JJ, Cai H. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=17093100&query_hl=10&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis and gene therapy. Author(s): Miller TM, Smith RA, Cleveland DW. Source: Nat Clin Pract Neurol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16932606&query_hl=10&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis and sports: a case-control study. Author(s): Valenti M, Pontieri FE, Conti F, Altobelli E, Manzoni T, Frati L. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15693813&query_hl=10&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. Author(s): Furukawa Y, O'Halloran TV. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15691826&query_hl=10&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis: contemporary concepts in etiopathogenesis and pharmacotherapy. Author(s): Strong MJ. Source: Expert Opinion on Investigational Drugs. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15566317&query_hl=10&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis: possible role of environmental influences. Author(s): Wicklund MP. Source: Neurologic Clinics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15757793&query_hl=10&itool=pubmed_docsum
•
An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. Author(s): Xia XG, Zhou H, Zhou S, Yu Y, Wu R, Xu Z. Source: Journal of Neurochemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15663483&query_hl=10&itool=pubmed_docsum
Studies
81
•
Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Author(s): Qureshi MM, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D, Hilgenberg S, Smart R, Brown RH, Cudkowicz ME. Source: Amyotroph Lateral Scler. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16963407&query_hl=10&itool=pubmed_docsum
•
Another angiogenic gene linked to amyotrophic lateral sclerosis. Author(s): Lambrechts D, Lafuste P, Carmeliet P, Conway EM. Source: Trends in Molecular Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16843725&query_hl=10&itool=pubmed_docsum
•
Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease. Author(s): Orrell RW, Lane RJ, Ross M. Source: Cochrane Database Syst Rev. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15674899&query_hl=10&itool=pubmed_docsum
•
Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. Author(s): Li YJ, Pericak-Vance MA, Haines JL, Siddique N, McKenna-Yasek D, Hung WY, Sapp P, Allen CI, Chen W, Hosler B, Saunders AM, Dellefave LM, Brown RH, Siddique T. Source: Neurogenetics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15657798&query_hl=10&itool=pubmed_docsum
•
Are there causal relationships between the development of the inflammatory diseases amyotrophic lateral sclerosis and asthma? Author(s): Menendez A, Kuffler D. Source: P R Health Sci J. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16883679&query_hl=10&itool=pubmed_docsum
•
Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. Author(s): van Kan HJ, Groeneveld GJ, Kalmijn S, Spieksma M, van den Berg LH, Guchelaar HJ. Source: British Journal of Clinical Pharmacology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15752377&query_hl=10&itool=pubmed_docsum
•
Attitudes toward and desire for assisted suicide among persons with amyotrophic lateral sclerosis. Author(s): Achille MA, Ogloff JR. Source: Omega. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15688543&query_hl=10&itool=pubmed_docsum
82
Amyotrophic Lateral Sclerosis
•
Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Author(s): Mazzini L, Mareschi K, Ferrero I, Vassallo E, Oliveri G, Boccaletti R, Testa L, Livigni S, Fagioli F. Source: Neurological Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16808883&query_hl=10&itool=pubmed_docsum
•
Baroreflex stimulation shows impaired cardiovagal and preserved vasomotor function in early-stage amyotrophic lateral sclerosis. Author(s): Hilz MJ, Hecht MJ, Mittelhamm F, Neundorfer B, Brown CM. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12495575&query_hl=10&itool=pubmed_docsum
•
Basic and clinical research on amyotrophic lateral sclerosis and other motor neuron disorders in Italy: recent findings and achievements from a network of laboratories. Author(s): Beghi E, Mennini T; Italian Network for the Study of Motor Neuron Disease. Source: Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15197603&query_hl=10&itool=pubmed_docsum
•
Basic fibroblast growth factor does not prolong survival in a transgenic model of familial amyotrophic lateral sclerosis. Author(s): Upton-Rice MN, Cudkowicz ME, Warren L, Mathew RK, Ren JM, Finklestein SP, Brown RH Jr. Source: Annals of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10589551&query_hl=10&itool=pubmed_docsum
•
Basophilic cytoplasmic inclusions in a case of sporadic juvenile amyotrophic lateral sclerosis. Author(s): Aizawa H, Kimura T, Hashimoto K, Yahara O, Okamoto K, Kikuchi K. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10930592&query_hl=10&itool=pubmed_docsum
•
Behavioural and anatomical effects of systemically administered leukemia inhibitory factor in the SOD1(G93A G1H) mouse model of familial amyotrophic lateral sclerosis. Author(s): Azari MF, Lopes EC, Stubna C, Turner BJ, Zang D, Nicola NA, Kurek JB, Cheema SS. Source: Brain Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12915243&query_hl=10&itool=pubmed_docsum
Studies
83
•
Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Author(s): Nagano I, Shiote M, Murakami T, Kamada H, Hamakawa Y, Matsubara E, Yokoyama M, Moritaz K, Shoji M, Abe K. Source: Neurological Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16197815&query_hl=10&itool=pubmed_docsum
•
Beta-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients. Author(s): Calingasan NY, Chen J, Kiaei M, Beal MF. Source: Neurobiology of Disease. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15837590&query_hl=10&itool=pubmed_docsum
•
Bilirubin and amyotrophic lateral sclerosis. Author(s): Iwasaki Y, Igarashi O, Iwasa Y, Hirano K, Satoh R, Iwamoto K, Kawase Y, Aoyagi J, Ichikawa Y, Kawabe K, Ikeda K. Source: Clinical Neurology and Neurosurgery. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15708236&query_hl=10&itool=pubmed_docsum
•
Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Author(s): Di Matteo V, Esposito E. Source: Curr Drug Targets Cns Neurol Disord. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12769802&query_hl=10&itool=pubmed_docsum
•
Biochemical and ultrastructural study of neurofibrillary tangles in amyotrophic lateral sclerosis/parkinsonism-dementia complex in the Kii peninsula of Japan. Author(s): Itoh N, Ishiguro K, Arai H, Kokubo Y, Sasaki R, Narita Y, Kuzuhara S. Source: Journal of Neuropathology and Experimental Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12901704&query_hl=10&itool=pubmed_docsum
•
Biochemical characterization of plasma in amyotrophic lateral sclerosis: amino acid and protein composition. Author(s): Palma A, de Carvalho M, Barata N, Evangelista T, Chicau P, Regalla M, Costa J. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16036434&query_hl=10&itool=pubmed_docsum
84
Amyotrophic Lateral Sclerosis
•
Biomarkers for amyotrophic lateral sclerosis. Author(s): Bowser R, Cudkowicz M, Kaddurah-Daouk R. Source: Expert Review of Molecular Diagnostics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16706741&query_hl=10&itool=pubmed_docsum
•
Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Author(s): Kokic AN, Stevic Z, Stojanovic S, Blagojevic DP, Jones DR, Pavlovic S, Niketic V, Apostolski S, Spasic MB. Source: Redox Report : Communications in Free Radical Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16354415&query_hl=10&itool=pubmed_docsum
•
Blood oxidative stress in amyotrophic lateral sclerosis. Author(s): Bonnefont-Rousselot D, Lacomblez L, Jaudon M, Lepage S, Salachas F, Bensimon G, Bizard C, Doppler V, Delattre J, Meininger V. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11018250&query_hl=10&itool=pubmed_docsum
•
Blood transfusion in motor neurone disease (amyotrophic lateral sclerosis) Author(s): Burnett IB. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10399875&query_hl=10&itool=pubmed_docsum
•
Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Author(s): Verma A, Steele J. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16583370&query_hl=10&itool=pubmed_docsum
•
Brain-derived neurotrophic factor is not altered in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients. Author(s): Ilzecka J, Stelmasiak Z. Source: Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11976981&query_hl=10&itool=pubmed_docsum
•
Breaking the news in amyotrophic lateral sclerosis. Author(s): Chio A, Borasio GD. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15799546&query_hl=10&itool=pubmed_docsum
Studies
85
•
Bulbar-onset amyotrophic lateral sclerosis in a patient with Chiari I malformation. Author(s): Lo Coco D, Militello A, Piccoli F, La Bella V. Source: Acta Neurologica Scandinavica. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11589655&query_hl=10&itool=pubmed_docsum
•
Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals. Author(s): Pagani MR, Reisin RC, Uchitel OD. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16525045&query_hl=10&itool=pubmed_docsum
•
Calorimetric analysis of thermodynamic stability and aggregation for apo and holo amyotrophic lateral sclerosis-associated Gly-93 mutants of superoxide dismutase. Author(s): Stathopulos PB, Rumfeldt JA, Karbassi F, Siddall CA, Lepock JR, Meiering EM. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16407238&query_hl=10&itool=pubmed_docsum
•
Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? Author(s): de Carvalho M, Swash M. Source: Archives of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16606769&query_hl=10&itool=pubmed_docsum
•
Cerebral degeneration predicts survival in amyotrophic lateral sclerosis. Author(s): Kalra S, Vitale A, Cashman NR, Genge A, Arnold DL. Source: Journal of Neurology, Neurosurgery, and Psychiatry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16835288&query_hl=10&itool=pubmed_docsum
•
Changes in motor cortex excitability during muscle fatigue in amyotrophic lateral sclerosis. Author(s): Nardone R, Buffone E, Florio I, Tezzon F. Source: Journal of Neurology, Neurosurgery, and Psychiatry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15716542&query_hl=10&itool=pubmed_docsum
•
Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicleassociated membrane protein-associated protein B (VAPB/ALS8). Author(s): Kanekura K, Nishimoto I, Aiso S, Matsuoka M. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16891305&query_hl=10&itool=pubmed_docsum
86
Amyotrophic Lateral Sclerosis
•
Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Author(s): Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, Julien JP. Source: Nature Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16369483&query_hl=10&itool=pubmed_docsum
•
Chronological changes of sympathetic outflow to muscles in amyotrophic lateral sclerosis. Author(s): Shindo K, Shimokawa C, Watanabe H, Iida H, Ohashi K, Nitta K, Nagasaka T, Tsunoda S, Shiozawa Z. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15546595&query_hl=10&itool=pubmed_docsum
•
Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients. Author(s): Salauze L, van der Velden C, Lagroye I, Veyret B, Geffard M. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16319026&query_hl=10&itool=pubmed_docsum
•
Classification of amyotrophic lateral sclerosis cases at presentation in epidemiological studies. Author(s): Zoccolella S, Beghi E, Serlenga L, Logroscino G. Source: Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16388367&query_hl=10&itool=pubmed_docsum
•
Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future. Author(s): Choudry RB, Cudkowicz ME. Source: Journal of Clinical Pharmacology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16291708&query_hl=10&itool=pubmed_docsum
•
Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study in 52 patients. Author(s): Schreiber H, Gaigalat T, Wiedemuth-Catrinescu U, Graf M, Uttner I, Muche R, Ludolph AC. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15742104&query_hl=10&itool=pubmed_docsum
Studies
87
•
Cognitive functioning in sporadic amyotrophic lateral sclerosis: a six month longitudinal study. Author(s): Robinson KM, Lacey SC, Grugan P, Glosser G, Grossman M, McCluskey LF. Source: Journal of Neurology, Neurosurgery, and Psychiatry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16614030&query_hl=10&itool=pubmed_docsum
•
Commentary on: Return of the cycad hypothesis--does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health? Author(s): Wilson J, Shaw CA. Source: Neuropathology and Applied Neurobiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16640652&query_hl=10&itool=pubmed_docsum
•
Common dynamical signatures of familial amyotrophic lateral sclerosis-associated structurally diverse Cu, Zn superoxide dismutase mutants. Author(s): Khare SD, Dokholyan NV. Source: Proceedings of the National Academy of Sciences of the United States of America. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16488975&query_hl=10&itool=pubmed_docsum
•
Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Author(s): Goldknopf IL, Sheta EA, Bryson J, Folsom B, Wilson C, Duty J, Yen AA, Appel SH. Source: Biochemical and Biophysical Research Communications. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16516157&query_hl=10&itool=pubmed_docsum
•
Complexity of astrocyte-motor neuron interactions in amyotrophic lateral sclerosis. Author(s): Pehar M, Vargas MR, Cassina P, Barbeito AG, Beckman JS, Barbeito L. Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16909019&query_hl=10&itool=pubmed_docsum
•
Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Author(s): Deng HX, Shi Y, Furukawa Y, Zhai H, Fu R, Liu E, Gorrie GH, Khan MS, Hung WY, Bigio EH, Lukas T, Dal Canto MC, O'Halloran TV, Siddique T. Source: Proceedings of the National Academy of Sciences of the United States of America. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16636275&query_hl=10&itool=pubmed_docsum
88
Amyotrophic Lateral Sclerosis
•
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. Author(s): Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P. Source: Bmc Neurology [electronic Resource]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16512913&query_hl=10&itool=pubmed_docsum
•
Decreased galectin-1 immunoreactivity of the skin in amyotrophic lateral sclerosis. Author(s): Wada M, Ono S, Kadoya T, Kawanami T, Kurita K, Kato T. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12639727&query_hl=10&itool=pubmed_docsum
•
Decrement in surface-recorded motor unit potentials in amyotrophic lateral sclerosis. Author(s): Henderson RD, Daube JR. Source: Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15534253&query_hl=10&itool=pubmed_docsum
•
Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-superoxide dismutase proteins by macroautophagy and the proteasome. Author(s): Kabuta T, Suzuki Y, Wada K. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16920710&query_hl=10&itool=pubmed_docsum
•
Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis. Author(s): Parboosingh JS, Meininger V, McKenna-Yasek D, Brown RH Jr, Rouleau GA. Source: Archives of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10369311&query_hl=10&itool=pubmed_docsum
•
Depression and bulbar involvement in amyotrophic lateral sclerosis. Author(s): Hillemacher T, Grassel E, Tigges S, Bleich S, Neundorfer B, Kornhuber J, Hecht MJ. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15799555&query_hl=10&itool=pubmed_docsum
•
Descriptive epidemiology of amyotrophic lateral sclerosis in Japan, 1995-2001. Author(s): Okamoto K, Kobashi G, Washio M, Sasaki S, Yokoyama T, Miyake Y, Sakamoto N, Tanaka H, Inaba Y. Source: J Epidemiol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15678922&query_hl=10&itool=pubmed_docsum
Studies
89
•
Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Author(s): Kalra S, Hanstock CC, Martin WR, Allen PS, Johnston WS. Source: Archives of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16908742&query_hl=10&itool=pubmed_docsum
•
Development and implementation of the Dutch protocol for rehabilitative management in amyotrophic lateral sclerosis. Author(s): van den Berg JP, de Groot IJ, Joha BC, van Haelst JM, van Gorcom P, Kalmijn S. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15799551&query_hl=10&itool=pubmed_docsum
•
Development of a rat model of amyotrophic lateral sclerosis expressing a human SOD1 transgene. Author(s): Aoki M, Kato S, Nagai M, Itoyama Y. Source: Neuropathology : Official Journal of the Japanese Society of Neuropathology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16382787&query_hl=10&itool=pubmed_docsum
•
Different immunoreactivity against monoclonal antibodies between wild-type and mutant copper/zinc superoxide dismutase linked to amyotrophic lateral sclerosis. Author(s): Fujiwara N, Miyamoto Y, Ogasahara K, Takahashi M, Ikegami T, Takamiya R, Suzuki K, Taniguchi N. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15522870&query_hl=10&itool=pubmed_docsum
•
Diffusion tensor imaging in amyotrophic lateral sclerosis: volumetric analysis of the corticospinal tract. Author(s): Wang S, Poptani H, Bilello M, Wu X, Woo JH, Elman LB, McCluskey LF, Krejza J, Melhem ER. Source: Ajnr. American Journal of Neuroradiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16775271&query_hl=10&itool=pubmed_docsum
•
Diffusion tensor MRI as a diagnostic tool of upper motor neuron involvement in amyotrophic lateral sclerosis. Author(s): Hong YH, Lee KW, Sung JJ, Chang KH, Song IC. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15546594&query_hl=10&itool=pubmed_docsum
90
Amyotrophic Lateral Sclerosis
•
Diffusion-tensor MR imaging of corticospinal tract in amyotrophic lateral sclerosis and progressive muscular atrophy. Author(s): Cosottini M, Giannelli M, Siciliano G, Lazzarotti G, Michelassi MC, Del Corona A, Bartolozzi C, Murri L. Source: Radiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16183935&query_hl=10&itool=pubmed_docsum
•
Dissociated small hand muscle involvement in amyotrophic lateral sclerosis detected by motor unit number estimates. Author(s): Kuwabara S, Mizobuchi K, Ogawara K, Hattori T. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10398204&query_hl=10&itool=pubmed_docsum
•
Distal excitability changes in motor axons in amyotrophic lateral sclerosis. Author(s): Nakata M, Kuwabara S, Kanai K, Misawa S, Tamura N, Sawai S, Hattori T, Bostock H. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16765084&query_hl=10&itool=pubmed_docsum
•
Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Author(s): Jonsson PA, Graffmo KS, Andersen PM, Brannstrom T, Lindberg M, Oliveberg M, Marklund SL. Source: Brain; a Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16330499&query_hl=10&itool=pubmed_docsum
•
Does apoptosis occur in amyotrophic lateral sclerosis? TUNEL experience from human amyotrophic lateral sclerosis (ALS) tissues. Author(s): Tomik B, Adamek D, Pierzchalski P, Banares S, Duda A, Partyka D, Pawlik W, Kaluza J, Krajewski S, Szczudlik A. Source: Folia Neuropathol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16012908&query_hl=10&itool=pubmed_docsum
•
Does VEGF represent a potential treatment for amyotrophic lateral sclerosis? Author(s): Ilzecka J. Source: Curr Opin Investig Drugs. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16425672&query_hl=10&itool=pubmed_docsum
Studies
91
•
Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis. Author(s): Buttarelli FR, Circella A, Pellicano C, Pontieri FE. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16643322&query_hl=10&itool=pubmed_docsum
•
Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis. Author(s): Strey CW, Spellman D, Stieber A, Gonatas JO, Wang X, Lambris JD, Gonatas NK. Source: American Journal of Pathology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15509539&query_hl=10&itool=pubmed_docsum
•
Early abnormalities in transgenic mouse models of amyotrophic lateral sclerosis. Author(s): Durand J, Amendola J, Bories C, Lamotte d'Incamps B. Source: Journal of Physiology, Paris. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16448809&query_hl=10&itool=pubmed_docsum
•
Early or late appearance of "dropped head syndrome" in amyotrophic lateral sclerosis. Author(s): Gourie-Devi M, Nalini A, Sandhya S. Source: Journal of Neurology, Neurosurgery, and Psychiatry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12700323&query_hl=10&itool=pubmed_docsum
•
Effect of ubiquitin expression on neuropathogenesis in a mouse model of familial amyotrophic lateral sclerosis. Author(s): Gilchrist CA, Gray DA, Stieber A, Gonatas NK, Kopito RR. Source: Neuropathology and Applied Neurobiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15634228&query_hl=10&itool=pubmed_docsum
•
Effects of lumbar sympathetic ganglion block for a patient with amyotrophic lateral sclerosis (ALS). Author(s): Kitoh T, Kobayashi K, Ina H, Ofusa Y, Otagiri T, Tanaka S, Ono K. Source: Journal of Anesthesia. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16633768&query_hl=10&itool=pubmed_docsum
•
Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Author(s): Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Source: Lancet. Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16426990&query_hl=10&itool=pubmed_docsum
92
Amyotrophic Lateral Sclerosis
•
EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Author(s): Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, Pradat PF, Silani V, Tomik B; EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16324086&query_hl=10&itool=pubmed_docsum
•
Electromechanical coupling and synchronous firing of single wrist extensor motor units in sporadic amyotrophic lateral sclerosis. Author(s): Schmied A, Pouget J, Vedel JP. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10400212&query_hl=10&itool=pubmed_docsum
•
Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. Author(s): Koistinen H, Prinjha R, Soden P, Harper A, Banner SJ, Pradat PF, Loeffler JP, Dingwall C. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16856153&query_hl=10&itool=pubmed_docsum
•
Emotional responding in amyotrophic lateral sclerosis. Author(s): Lule D, Kurt A, Jurgens R, Kassubek J, Diekmann V, Kraft E, Neumann N, Ludolph AC, Birbaumer N, Anders S. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15977000&query_hl=10&itool=pubmed_docsum
•
Estimating the occurrence of amyotrophic lateral sclerosis among Gulf War (19901991) veterans using capture-recapture methods. Author(s): Coffman CJ, Horner RD, Grambow SC, Lindquist J; VA Cooperative Studies Program Project #500. Source: Neuroepidemiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15650320&query_hl=10&itool=pubmed_docsum
•
Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). Author(s): Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, Jin X, Reis J, Narvaez A, McGrath MS. Source: Journal of Neuroimmunology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15652422&query_hl=10&itool=pubmed_docsum
Studies
93
•
Evidence-based care in amyotrophic lateral sclerosis. Author(s): Piepers S, van den Berg LH. Source: Lancet. Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16426982&query_hl=10&itool=pubmed_docsum
•
Excitotoxicity and amyotrophic lateral sclerosis. Author(s): Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16909020&query_hl=10&itool=pubmed_docsum
•
Experimental therapies hold promise for treating amyotrophic lateral sclerosis. Author(s): Friedrich MJ. Source: Jama : the Journal of the American Medical Association. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15741517&query_hl=10&itool=pubmed_docsum
•
Expression of a familial amyotrophic lateral sclerosis-associated mutant human superoxide dismutase in yeast leads to decreased mitochondrial electron transport. Author(s): Gunther MR, Vangilder R, Fang J, Beattie DS. Source: Archives of Biochemistry and Biophysics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15488469&query_hl=10&itool=pubmed_docsum
•
Expression of leukaemia inhibitory factor in skin of patients with amyotrophic lateral sclerosis. Author(s): Hu J, Imai T, Shimizu N, Nakagawa H, Ono S. Source: Lancet. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10382701&query_hl=10&itool=pubmed_docsum
•
Expression of N19S-SOD1, an SOD1 mutant found in sporadic amyotrophic lateral sclerosis patients, induces low-grade motoneuronal toxicity. Author(s): Obata Y, Niikura T, Kanekura K, Hashimoto Y, Kawasumi M, Kita Y, Aiso S, Matsuoka M, Nishimoto I. Source: Journal of Neuroscience Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16035108&query_hl=10&itool=pubmed_docsum
•
Expression of ubiquitin and proteasome in motorneurons and astrocytes of spinal cords from patients with amyotrophic lateral sclerosis. Author(s): Mendonca DM, Chimelli L, Martinez AM. Source: Neuroscience Letters. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16806703&query_hl=10&itool=pubmed_docsum
94
Amyotrophic Lateral Sclerosis
•
Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. Author(s): Brockington A, Wharton SB, Fernando M, Gelsthorpe CH, Baxter L, Ince PG, Lewis CE, Shaw PJ. Source: Journal of Neuropathology and Experimental Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16410746&query_hl=10&itool=pubmed_docsum
•
Extensive exercise is not harmful in amyotrophic lateral sclerosis. Author(s): Liebetanz D, Hagemann K, von Lewinski F, Kahler E, Paulus W. Source: The European Journal of Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15579165&query_hl=10&itool=pubmed_docsum
•
F wave study in amyotrophic lateral sclerosis: assessment of balance between upper and lower motor neuron involvement. Author(s): Argyriou AA, Polychronopoulos P, Talelli P, Chroni E. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16678483&query_hl=10&itool=pubmed_docsum
•
Factors which predict physical and mental health status in patients with amyotrophic lateral sclerosis over time. Author(s): Norquist JM, Jenkinson C, Fitzpatrick R, Swash M; ALS-HPS Steering Group. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14506943&query_hl=10&itool=pubmed_docsum
•
Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex-tauopathy without mutations in the tau gene? Author(s): Kowalska A, Konagaya M, Sakai M, Hashizume Y, Tabira T. Source: Folia Neuropathol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12899197&query_hl=10&itool=pubmed_docsum
•
Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction. Author(s): Tiwari A, Hayward LJ. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12458194&query_hl=10&itool=pubmed_docsum
Studies
95
•
Familial amyotrophic lateral sclerosis with a point mutation (G37R) of the superoxide dismutase 1 gene: a clinicopathological study. Author(s): Inoue K, Fujimura H, Ogawa Y, Satoh T, Shimada K, Sakoda S. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12710516&query_hl=10&itool=pubmed_docsum
•
Familial amyotrophic lateral sclerosis with bulbar onset and a novel Asp101Tyr Cu/Zn superoxide dismutase gene mutation. Author(s): Tan CF, Piao YS, Hayashi S, Obata H, Umeda Y, Sato M, Fukushima T, Nakano R, Tsuji S, Takahashi H. Source: Acta Neuropathologica. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15235802&query_hl=10&itool=pubmed_docsum
•
Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Author(s): Vance C, Al-Chalabi A, Ruddy D, Smith BN, Hu X, Sreedharan J, Siddique T, Schelhaas HJ, Kusters B, Troost D, Baas F, de Jong V, Shaw CE. Source: Brain; a Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16495328&query_hl=10&itool=pubmed_docsum
•
Familial amyotrophic lateral sclerosis with His46Arg mutation in Cu/Zn superoxide dismutase presenting characteristic clinical features and Lewy body-like hyaline inclusions. Author(s): Ohi T, Nabeshima K, Kato S, Yazawa S, Takechi S. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15465081&query_hl=10&itool=pubmed_docsum
•
Familial amyotrophic lateral sclerosis: first report from India. Author(s): Nalini A, Yeshraj G, Veerendrakumar M. Source: Neurology India. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16936397&query_hl=10&itool=pubmed_docsum
•
Flail arm syndrome: a clinical variant of amyotrophic lateral sclerosis. Author(s): Czaplinski A, Steck AJ, Andersen PM, Weber M. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15272904&query_hl=10&itool=pubmed_docsum
96
Amyotrophic Lateral Sclerosis
•
Flip and flop splice variants of AMPA receptor subunits in the spinal cord of amyotrophic lateral sclerosis. Author(s): Tomiyama M, Rodriguez-Puertas R, Cortes R, Pazos A, Palacios JM, Mengod G. Source: Synapse (New York, N.Y.). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12125045&query_hl=10&itool=pubmed_docsum
•
Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis. Author(s): Kabashi E, Agar JN, Taylor DM, Minotti S, Durham HD. Source: Journal of Neurochemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15189335&query_hl=10&itool=pubmed_docsum
•
Folding of Cu, Zn superoxide dismutase and familial amyotrophic lateral sclerosis. Author(s): Khare SD, Ding F, Dokholyan NV. Source: Journal of Molecular Biology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14623191&query_hl=10&itool=pubmed_docsum
•
Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Author(s): Wilczak N, de Vos RA, De Keyser J. Source: Lancet. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12660059&query_hl=10&itool=pubmed_docsum
•
Frequency of a tau genotype in amyotrophic lateral sclerosis. Author(s): Munch C, Prechter F, Xu R, Linke P, Prudlo J, Kuzma M, Kwiecinski H, Ludolph AC, Meyer T. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16005901&query_hl=10&itool=pubmed_docsum
•
Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease--a record linkage study from the Scottish Motor Neurone Disease Register. Author(s): Forbes RB, Colville S, Swingler RJ; Scottish Motor Neurone Disease Research Group. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15258782&query_hl=10&itool=pubmed_docsum
Studies
97
•
Frontotemporal white matter changes in amyotrophic lateral sclerosis. Author(s): Abrahams S, Goldstein LH, Suckling J, Ng V, Simmons A, Chitnis X, Atkins L, Williams SC, Leigh PN. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15739047&query_hl=10&itool=pubmed_docsum
•
Functional motor compensation in amyotrophic lateral sclerosis. Author(s): Schoenfeld MA, Tempelmann C, Gaul C, Kuhnel GR, Duzel E, Hopf JM, Feistner H, Zierz S, Heinze HJ, Vielhaber S. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15750701&query_hl=10&itool=pubmed_docsum
•
F-Waves and the corticospinal lesion in amyotrophic lateral sclerosis. Author(s): de Carvalho M, Scotto M, Lopes A, Swash M. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12495574&query_hl=10&itool=pubmed_docsum
•
Gabapentin for the treatment of spasticity in patients with amyotrophic lateral sclerosis. Author(s): de Carvalho M. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11465933&query_hl=10&itool=pubmed_docsum
•
Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. Author(s): Kalra S, Cashman NR, Caramanos Z, Genge A, Arnold DL. Source: Ajnr. American Journal of Neuroradiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12637300&query_hl=10&itool=pubmed_docsum
•
Galectin-1 as a potential therapeutic agent for amyotrophic lateral sclerosis. Author(s): Kato T, Ren CH, Wada M, Kawanami T. Source: Current Drug Targets. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16026259&query_hl=10&itool=pubmed_docsum
98
Amyotrophic Lateral Sclerosis
•
Galectin-1 is a component of neurofilamentous lesions in sporadic and familial amyotrophic lateral sclerosis. Author(s): Kato T, Kurita K, Seino T, Kadoya T, Horie H, Wada M, Kawanami T, Daimon M, Hirano A. Source: Biochemical and Biophysical Research Communications. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11263987&query_hl=10&itool=pubmed_docsum
•
Gastrointestinal dysfunction in amyotrophic lateral sclerosis. Author(s): Toepfer M, Folwaczny C, Klauser A, Riepl RL, Muller-Felber W, Pongratz D. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12365061&query_hl=10&itool=pubmed_docsum
•
Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Author(s): Jiang YM, Yamamoto M, Kobayashi Y, Yoshihara T, Liang Y, Terao S, Takeuchi H, Ishigaki S, Katsuno M, Adachi H, Niwa J, Tanaka F, Doyu M, Yoshida M, Hashizume Y, Sobue G. Source: Annals of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15668976&query_hl=10&itool=pubmed_docsum
•
Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. Author(s): Alisky JM, Davidson BL. Source: Human Gene Therapy. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11096437&query_hl=10&itool=pubmed_docsum
•
Genetic aspects of amyotrophic lateral sclerosis. Author(s): Siddique T, Lalani I. Source: Adv Neurol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11908227&query_hl=10&itool=pubmed_docsum
•
Genetic epidemiology of amyotrophic lateral sclerosis. Author(s): Majoor-Krakauer D, Willems PJ, Hofman A. Source: Clinical Genetics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12630951&query_hl=10&itool=pubmed_docsum
•
Genetics of amyotrophic lateral sclerosis. Author(s): Robberecht W. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11200702&query_hl=10&itool=pubmed_docsum
Studies
99
•
Genotyping of presenilin-1 polymorphism in amyotrophic lateral sclerosis. Author(s): Panas M, Karadima G, Kalfakis N, Psarrou O, Floroskoufi P, Kladi A, Petersen MB, Vassilopoulos D. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11200686&query_hl=10&itool=pubmed_docsum
•
Geographical distribution of amyotrophic lateral sclerosis with neurofibrillary tangles in the Kii Peninsula of Japan. Author(s): Kokubo Y, Kuzuhara S, Narita Y. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11151416&query_hl=10&itool=pubmed_docsum
•
Glial cell line-derived neurotrophic factor protein prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Author(s): Manabe Y, Nagano I, Gazi MS, Murakami T, Shiote M, Shoji M, Kitagawa H, Abe K. Source: Neurological Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12635522&query_hl=10&itool=pubmed_docsum
•
Glial cells of the spinal cord and subcortical white matter up-regulate neuronal nitric oxide synthase in sporadic amyotrophic lateral sclerosis. Author(s): Anneser JM, Cookson MR, Ince PG, Shaw PJ, Borasio GD. Source: Experimental Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11573993&query_hl=10&itool=pubmed_docsum
•
Glial proliferation and metabotropic glutamate receptor expression in amyotrophic lateral sclerosis. Author(s): Anneser JM, Chahli C, Ince PG, Borasio GD, Shaw PJ. Source: Journal of Neuropathology and Experimental Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15330338&query_hl=10&itool=pubmed_docsum
•
Global loss of Na,K-ATPase and its nitric oxide-mediated regulation in a transgenic mouse model of amyotrophic lateral sclerosis. Author(s): Ellis DZ, Rabe J, Sweadner KJ. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12514200&query_hl=10&itool=pubmed_docsum
100
Amyotrophic Lateral Sclerosis
•
Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. Author(s): Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, Marouan A, Dib M, Meininger V. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11790386&query_hl=10&itool=pubmed_docsum
•
Glutamate release induced by activation of glycine and GABA transporters in spinal cord is enhanced in a mouse model of amyotrophic lateral sclerosis. Author(s): Raiteri L, Zappettini S, Stigliani S, Paluzzi S, Raiteri M, Bonanno G. Source: Neurotoxicology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15885796&query_hl=10&itool=pubmed_docsum
•
Glycation proceeds faster in mutated Cu, Zn-superoxide dismutases related to familial amyotrophic lateral sclerosis. Author(s): Takamiya R, Takahashi M, Myint T, Park YS, Miyazawa N, Endo T, Fujiwara N, Sakiyama H, Misonou Y, Miyamoto Y, Fujii J, Taniguchi N. Source: The Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12626432&query_hl=10&itool=pubmed_docsum
•
Golgi apparatus of the motor neurons in patients with amyotrophic lateral sclerosis and in mice models of amyotrophic lateral sclerosis. Author(s): Fujita Y, Okamoto K. Source: Neuropathology : Official Journal of the Japanese Society of Neuropathology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16382790&query_hl=10&itool=pubmed_docsum
•
Health-related quality of life in amyotrophic lateral sclerosis: determining a meaningful deterioration. Author(s): Norquist JM, Fitzpatrick R, Jenkinson C. Source: Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15503836&query_hl=10&itool=pubmed_docsum
•
Heterogeneous distribution of amyotrophic lateral sclerosis patients with SOD-1 gene mutations: preliminary data on an Italian survey. Author(s): Malaspina A, Zaman R, Mazzini L, Camana C, Poloni E, Curti D, Ceroni M. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10202988&query_hl=10&itool=pubmed_docsum
Studies
101
•
Hexosaminidase A deficiency is an uncommon cause of a syndrome mimicking amyotrophic lateral sclerosis. Author(s): Drory VE, Birnbaum M, Peleg L, Goldman B, Korczyn AD. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12811781&query_hl=10&itool=pubmed_docsum
•
High frequency of systemic mycoplasmal infections in Gulf War veterans and civilians with Amyotrophic Lateral Sclerosis (ALS). Author(s): Nicolson GL, Nasralla MY, Haier J, Pomfret J. Source: Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12383408&query_hl=10&itool=pubmed_docsum
•
Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Author(s): Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD. Source: Neurobiology of Disease. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11741389&query_hl=10&itool=pubmed_docsum
•
Histological recovery of the hepatocytes is based on the redox system upregulation in the animal models of mutant superoxide dismutase (SOD)1-linked amyotrophic lateral sclerosis. Author(s): Kato M, Kato S, Abe Y, Nishino T, Ohama E, Aoki M, Itoyama Y. Source: Histology and Histopathology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16598672&query_hl=10&itool=pubmed_docsum
•
Hoarseness due to bilateral vocal cord paralysis as an initial manifestation of familial amyotrophic lateral sclerosis. Author(s): Fukae J, Kubo S, Hattori N, Komatsu K, Kato M, Aoki M, Mizuno Y. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16036438&query_hl=10&itool=pubmed_docsum
•
Home mechanical ventilation in amyotrophic lateral sclerosis patients is not always a problem. Author(s): Servera E, Gomez-Merino E, Perez D, Marin J. Source: Chest. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10713039&query_hl=10&itool=pubmed_docsum
102
Amyotrophic Lateral Sclerosis
•
Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. Author(s): Hayward C, Brock DJ, Minns RA, Swingler RJ. Source: Journal of Medical Genetics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9556377&query_hl=10&itool=pubmed_docsum
•
Hospitalization in amyotrophic lateral sclerosis: causes, costs, and outcomes. Author(s): Lechtzin N, Wiener CM, Clawson L, Chaudhry V, Diette GB. Source: Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11274310&query_hl=10&itool=pubmed_docsum
•
How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of JeanMartin Charcot. Author(s): Rowland LP. Source: Archives of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11255459&query_hl=10&itool=pubmed_docsum
•
How beneficial is noninvasive ventilation in patients with amyotrophic lateral sclerosis? Author(s): Lechtzin N. Source: Nat Clin Pract Neurol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16932582&query_hl=10&itool=pubmed_docsum
•
HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) with amyotrophic lateral sclerosis-like manifestations. Author(s): Matsuzaki T, Nakagawa M, Nagai M, Nobuhara Y, Usuku K, Higuchi I, Takahashi K, Moritoyo T, Arimura K, Izumo S, Akiba S, Osame M. Source: Journal of Neurovirology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11175327&query_hl=10&itool=pubmed_docsum
•
Human CCS gene: genomic organization and exclusion as a candidate for amyotrophic lateral sclerosis (ALS). Author(s): Silahtaroglu AN, Brondum-Nielsen K, Gredal O, Werdelin L, Panas M, Petersen MB, Tommerup N, Tumer Z. Source: Bmc Genetics [electronic Resource]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11991808&query_hl=10&itool=pubmed_docsum
Studies
103
•
Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Author(s): Jaarsma D, Haasdijk ED, Grashorn JA, Hawkins R, van Duijn W, Verspaget HW, London J, Holstege JC. Source: Neurobiology of Disease. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11114261&query_hl=10&itool=pubmed_docsum
•
Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. Author(s): Janson CG, Ramesh TM, During MJ, Leone P, Heywood J. Source: Journal of Hematotherapy & Stem Cell Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11798518&query_hl=10&itool=pubmed_docsum
•
Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1. Author(s): Leger B, Vergani L, Soraru G, Hespel P, Derave W, Gobelet C, D'Ascenzio C, Angelini C, Russell AP. Source: The Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16507768&query_hl=10&itool=pubmed_docsum
•
Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Author(s): Ende N, Weinstein F, Chen R, Ende M. Source: Life Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10896029&query_hl=10&itool=pubmed_docsum
•
Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis. Author(s): Matsuoka M, Hashimoto Y, Aiso S, Nishimoto I. Source: Cns Drug Rev. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16958985&query_hl=10&itool=pubmed_docsum
•
Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. Author(s): Turner BJ, Atkin JD, Farg MA, Zang DW, Rembach A, Lopes EC, Patch JD, Hill AF, Cheema SS. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15634772&query_hl=10&itool=pubmed_docsum
104
Amyotrophic Lateral Sclerosis
•
Impairment of glutamate transport and increased vulnerability to oxidative stress in neuroblastoma SH-SY5Y cells expressing a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis. Author(s): Sala G, Beretta S, Ceresa C, Mattavelli L, Zoia C, Tremolizzo L, Ferri A, Carri MT, Ferrarese C. Source: Neurochemistry International. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15670639&query_hl=10&itool=pubmed_docsum
•
Implementation of X-ray fluorescence microscopy for investigation of elemental abnormalities in amyotrophic lateral sclerosis. Author(s): Tomik B, Chwiej J, Szczerbowska-Boruchowska M, Lankosz M, Wojcik S, Adamek D, Falkenberg G, Bohic S, Simionovici A, Stegowski Z, Szczudlik A. Source: Neurochemical Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16733809&query_hl=10&itool=pubmed_docsum
•
Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Author(s): Guillemin GJ, Meininger V, Brew BJ. Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16909022&query_hl=10&itool=pubmed_docsum
•
Inappropriate surgeries resulting from misdiagnosis of early amyotrophic lateral sclerosis. Author(s): Srinivasan J, Scala S, Jones HR, Saleh F, Russell JA. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16609978&query_hl=10&itool=pubmed_docsum
•
Increasing peak expiratory flow time in amyotrophic lateral sclerosis. Author(s): Wilson SR, Quantz MA, Strong MJ, Ahmad D. Source: Chest. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15653977&query_hl=10&itool=pubmed_docsum
•
Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. Author(s): Atkin JD, Farg MA, Turner BJ, Tomas D, Lysaght JA, Nunan J, Rembach A, Nagley P, Beart PM, Cheema SS, Horne MK. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16847061&query_hl=10&itool=pubmed_docsum
Studies
105
•
Informatics-assisted protein profiling in a transgenic mouse model of amyotrophic lateral sclerosis. Author(s): Lukas TJ, Luo WW, Mao H, Cole N, Siddique T. Source: Molecular & Cellular Proteomics : Mcp. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16571896&query_hl=10&itool=pubmed_docsum
•
Inhibition of chaperone activity is a shared property of several Cu,Zn-superoxide dismutase mutants that cause amyotrophic lateral sclerosis. Author(s): Tummala H, Jung C, Tiwari A, Higgins CM, Hayward LJ, Xu Z. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15753080&query_hl=10&itool=pubmed_docsum
•
Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice. Author(s): Basso M, Massignan T, Samengo G, Cheroni C, De Biasi S, Salmona M, Bendotti C, Bonetto V. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16943203&query_hl=10&itool=pubmed_docsum
•
Inter- and intracellular signaling in amyotrophic lateral sclerosis: role of p38 mitogenactivated protein kinase. Author(s): Bendotti C, Bao Cutrona M, Cheroni C, Grignaschi G, Lo Coco D, Peviani M, Tortarolo M, Veglianese P, Zennaro E. Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16909017&query_hl=10&itool=pubmed_docsum
•
Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. Author(s): Tanaka M, Kikuchi H, Ishizu T, Minohara M, Osoegawa M, Motomura K, Tateishi T, Ohyagi Y, Kira J. Source: Journal of Neuropathology and Experimental Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16896315&query_hl=10&itool=pubmed_docsum
•
Is motoneuronal cell death in amyotrophic lateral sclerosis apoptosis? Author(s): Yamazaki M, Esumi E, Nakano I. Source: Neuropathology : Official Journal of the Japanese Society of Neuropathology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16382789&query_hl=10&itool=pubmed_docsum
•
Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis? Author(s): Lindhorst S, Cudkowicz M. Source: Nat Clin Pract Neurol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16932586&query_hl=10&itool=pubmed_docsum
106
Amyotrophic Lateral Sclerosis
•
Is TNFalpha really a good therapeutic target in motoneuronal degeneration? A case of amyotrophic lateral sclerosis in a patient with RA receiving infliximab. Author(s): Dziadzio M, Reddy V, Rahman S, Mummery C, Keat A. Source: Rheumatology (Oxford, England). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16877458&query_hl=10&itool=pubmed_docsum
•
Japanese familial amyotrophic lateral sclerosis family with a two-base deletion in the superoxide dismutase-1 gene. Author(s): Watanabe Y, Adachi Y, Nakashima K. Source: Neuropathology : Official Journal of the Japanese Society of Neuropathology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11304044&query_hl=10&itool=pubmed_docsum
•
Juvenile amyotrophic lateral sclerosis with unusual presentation: a case report. Author(s): Panagariya A, Garg A, Sharma B. Source: Neurology India. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14652459&query_hl=10&itool=pubmed_docsum
•
Juvenile amyotrophic lateral sclerosis. Author(s): Aggarwal A, Shashiraj. Source: Indian J Pediatr. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16567917&query_hl=10&itool=pubmed_docsum
•
Juvenile familial amyotrophic lateral sclerosis: four cases with long survival. Author(s): Otero Siliceo E, Arriada-Mendicoa N, Balderrama J. Source: Developmental Medicine and Child Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9652786&query_hl=10&itool=pubmed_docsum
•
Juvenile familial amyotrophic lateral sclerosis: two siblings. Author(s): Ozge A, Kaleagas H, Tataroglu C, Unal O. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12495579&query_hl=10&itool=pubmed_docsum
•
Kif1Bbeta isoform is enriched in motor neurons but does not change in a mouse model of amyotrophic lateral sclerosis. Author(s): Conforti L, Dell'Agnello C, Calvaresi N, Tortarolo M, Giorgini A, Coleman MP, Bendotti C. Source: Journal of Neuroscience Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12584731&query_hl=10&itool=pubmed_docsum
Studies
107
•
Lactate stress testing in sporadic amyotrophic lateral sclerosis. Author(s): Finsterer J. Source: The International Journal of Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15809220&query_hl=10&itool=pubmed_docsum
•
L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Author(s): Kira Y, Nishikawa M, Ochi A, Sato E, Inoue M. Source: Brain Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16412993&query_hl=10&itool=pubmed_docsum
•
Lead exposure and amyotrophic lateral sclerosis. Author(s): Kamel F, Umbach DM, Munsat TL, Shefner JM, Hu H, Sandler DP. Source: Epidemiology (Cambridge, Mass.). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11964933&query_hl=10&itool=pubmed_docsum
•
Lead exposure as a risk factor for amyotrophic lateral sclerosis. Author(s): Kamel F, Umbach DM, Hu H, Munsat TL, Shefner JM, Taylor JA, Sandler DP. Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16909025&query_hl=10&itool=pubmed_docsum
•
Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold. Author(s): Armon C, Guiloff RJ, Bedlack R. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12495570&query_hl=10&itool=pubmed_docsum
•
Longitudinal analysis of progression of dysphagia in amyotrophic lateral sclerosis. Author(s): Higo R, Tayama N, Nito T. Source: Auris, Nasus, Larynx. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15364359&query_hl=10&itool=pubmed_docsum
•
Longitudinal effects of noninvasive positive-pressure ventilation in patients with amyotrophic lateral sclerosis. Author(s): Butz M, Wollinsky KH, Wiedemuth-Catrinescu U, Sperfeld A, Winter S, Mehrkens HH, Ludolph AC, Schreiber H. Source: American Journal of Physical Medicine & Rehabilitation / Association of Academic Physiatrists. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12872016&query_hl=10&itool=pubmed_docsum
108
Amyotrophic Lateral Sclerosis
•
Long-term safety of riluzole in amyotrophic lateral sclerosis. Author(s): Lacomblez L, Bensimon G, Leigh PN, Debove C, Bejuit R, Truffinet P, Meininger V; ALS Study Groups I and II. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12061945&query_hl=10&itool=pubmed_docsum
•
Loss of metabotropic glutamate receptor-mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis. Author(s): Vermeiren C, Hemptinne I, Vanhoutte N, Tilleux S, Maloteaux JM, Hermans E. Source: Journal of Neurochemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16371010&query_hl=10&itool=pubmed_docsum
•
Low concentrations of glutamate induce apoptosis in cultured neurons: implications for amyotrophic lateral sclerosis. Author(s): Cid C, Alvarez-Cermeno JC, Regidor I, Salinas M, Alcazar A. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12480091&query_hl=10&itool=pubmed_docsum
•
Measurement of decline of functioning in persons with amyotrophic lateral sclerosis: responsiveness and possible applications of the Functional Independence Measure, Barthel Index, Rehabilitation Activities Profile and Frenchay Activities Index. Author(s): De Groot IJ, Post MW, Van Heuveln T, Van Den Berg LH, Lindeman E. Source: Amyotroph Lateral Scler. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16963406&query_hl=10&itool=pubmed_docsum
•
Measures and markers in amyotrophic lateral sclerosis. Author(s): Cudkowicz M, Qureshi M, Shefner J. Source: Neurorx. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15717028&query_hl=10&itool=pubmed_docsum
•
Mitochondria in amyotrophic lateral sclerosis: a trigger and a target. Author(s): Dupuis L, Gonzalez de Aguilar JL, Oudart H, de Tapia M, Barbeito L, Loeffler JP. Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16908975&query_hl=10&itool=pubmed_docsum
Studies
109
•
Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Author(s): Carter GT, Weiss MD, Lou JS, Jensen MP, Abresch RT, Martin TK, Hecht TW, Han JJ, Weydt P, Kraft GH. Source: Am J Hosp Palliat Care. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15736608&query_hl=10&itool=pubmed_docsum
•
Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Author(s): Pasinelli P, Brown RH. Source: Nature Reviews. Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16924260&query_hl=10&itool=pubmed_docsum
•
Motor neuron protection in amyotrophic lateral sclerosis. Author(s): Carmichael G. Source: Lancet. Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15709223&query_hl=10&itool=pubmed_docsum
•
Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. Author(s): Shefner JM, Cudkowicz M, Brown RH Jr. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16892429&query_hl=10&itool=pubmed_docsum
•
MR imaging of upper motor neuron compromise in amyotrophic lateral sclerosis. Author(s): da Rocha AJ, Maia AC Jr, Fonseca RB. Source: Radiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16990687&query_hl=10&itool=pubmed_docsum
•
Mutant SOD1 instability: implications for toxicity in amyotrophic lateral sclerosis. Author(s): Tiwari A, Hayward LJ. Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16909016&query_hl=10&itool=pubmed_docsum
•
Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. Author(s): Vijayvergiya C, Beal MF, Buck J, Manfredi G. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15758154&query_hl=10&itool=pubmed_docsum
110
Amyotrophic Lateral Sclerosis
•
Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. Author(s): Weydt P, Moller T. Source: Neuroreport. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15812300&query_hl=10&itool=pubmed_docsum
•
Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Author(s): de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16036422&query_hl=10&itool=pubmed_docsum
•
Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis. Author(s): Chang-Hong R, Wada M, Koyama S, Kimura H, Arawaka S, Kawanami T, Kurita K, Kadoya T, Aoki M, Itoyama Y, Kato T. Source: Experimental Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15899257&query_hl=10&itool=pubmed_docsum
•
Neurotrophic factors and amyotrophic lateral sclerosis. Author(s): Ekestern E. Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16908980&query_hl=10&itool=pubmed_docsum
•
No evidence of linkage to chromosome 9q21-22 in a Swedish family with frontotemporal dementia and amyotrophic lateral sclerosis. Author(s): Ostojic J, Axelman K, Lannfelt L, Froelich-Fabre S. Source: Neuroscience Letters. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12672552&query_hl=10&itool=pubmed_docsum
•
Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Author(s): Jokic N, Gonzalez de Aguilar JL, Pradat PF, Dupuis L, Echaniz-Laguna A, Muller A, Dubourg O, Seilhean D, Hauw JJ, Loeffler JP, Meininger V. Source: Annals of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15786457&query_hl=10&itool=pubmed_docsum
•
Non-invasive ventilation in amyotrophic lateral sclerosis. Author(s): Servera E, Sancho J. Source: Lancet. Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16545744&query_hl=10&itool=pubmed_docsum
Studies
111
•
Normal chest radiograph in terminal respiratory failure due to amyotrophic lateral sclerosis. Author(s): Won C, Banerjee D, Stark P, Kuschner WG. Source: Southern Medical Journal. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16711329&query_hl=10&itool=pubmed_docsum
•
Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis. Author(s): Kress JA, Kuhnlein P, Winter P, Ludolph AC, Kassubek J, Muller U, Sperfeld AD. Source: Annals of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16240357&query_hl=10&itool=pubmed_docsum
•
Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Author(s): Di Lazzaro V, Oliviero A, Saturno E, Pilato F, Dileone M, Tonali PA. Source: Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15557544&query_hl=10&itool=pubmed_docsum
•
O-glycosylation of the tail domain of neurofilament protein M in human neurons and in spinal cord tissue of a rat model of amyotrophic lateral sclerosis (ALS). Author(s): Ludemann N, Clement A, Hans VH, Leschik J, Behl C, Brandt R. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16006557&query_hl=10&itool=pubmed_docsum
•
Only subtle cognitive deficits in non-bulbar amyotrophic lateral sclerosis patients. Author(s): Rottig D, Leplow B, Eger K, Ludolph AC, Graf M, Zierz S. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16208524&query_hl=10&itool=pubmed_docsum
•
Origin and distribution of bone marrow-derived cells in the central nervous system in a mouse model of amyotrophic lateral sclerosis. Author(s): Solomon JN, Lewis CA, Ajami B, Corbel SY, Rossi FM, Krieger C. Source: Glia. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16518833&query_hl=10&itool=pubmed_docsum
•
Oropharyngeal dysphagia in amyotrophic lateral sclerosis: neurological and dysphagia specific rating scales. Author(s): Kidney D, Alexander M, Corr B, O'toole O, Hardiman O. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15512903&query_hl=10&itool=pubmed_docsum
112
Amyotrophic Lateral Sclerosis
•
Overloading of stable and exclusion of unstable human superoxide dismutase-1 variants in mitochondria of murine amyotrophic lateral sclerosis models. Author(s): Bergemalm D, Jonsson PA, Graffmo KS, Andersen PM, Brannstrom T, Rehnmark A, Marklund SL. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16624935&query_hl=10&itool=pubmed_docsum
•
Oxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis (ALS). Author(s): Niebroj-Dobosz I, Dziewulska D, Kwiecinski H. Source: Folia Neuropathol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15535033&query_hl=10&itool=pubmed_docsum
•
Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Author(s): Ihara Y, Nobukuni K, Takata H, Hayabara T. Source: Neurological Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15829169&query_hl=10&itool=pubmed_docsum
•
Oximetry and indications for tracheotomy for amyotrophic lateral sclerosis. Author(s): Bach JR, Bianchi C, Aufiero E. Source: Chest. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15539719&query_hl=10&itool=pubmed_docsum
•
Paraoxonase-1 Q192R polymorphism and risk of sporadic amyotrophic lateral sclerosis. Author(s): Slowik A, Tomik B, Partyka D, Turaj W, Pera J, Dziedzic T, Szermer P, Figlewicz DA, Szczudlik A. Source: Clinical Genetics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16630171&query_hl=10&itool=pubmed_docsum
•
Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. Author(s): McGeer EG, McGeer PL. Source: Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15691215&query_hl=10&itool=pubmed_docsum
•
Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. Author(s): Chio A, Bottacchi E, Buffa C, Mutani R, Mora G; PARALS. Source: Journal of Neurology, Neurosurgery, and Psychiatry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16614011&query_hl=10&itool=pubmed_docsum
Studies
113
•
Predictors of psychological distress in carers of people with amyotrophic lateral sclerosis: a longitudinal study. Author(s): Goldstein LH, Atkins L, Landau S, Brown R, Leigh PN. Source: Psychological Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16490122&query_hl=10&itool=pubmed_docsum
•
Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. Author(s): Ciccarelli O, Behrens TE, Altmann DR, Orrell RW, Howard RS, JohansenBerg H, Miller DH, Matthews PM, Thompson AJ. Source: Brain; a Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16672290&query_hl=10&itool=pubmed_docsum
•
Prospective study of occupation and amyotrophic lateral sclerosis mortality. Author(s): Weisskopf MG, McCullough ML, Morozova N, Calle EE, Thun MJ, Ascherio A. Source: American Journal of Epidemiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16269579&query_hl=10&itool=pubmed_docsum
•
Protective effect of metabotropic glutamate receptor inhibition on amyotrophic lateral sclerosis-cerebrospinal fluid toxicity in vitro. Author(s): Anneser JM, Chahli C, Borasio GD. Source: Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16820266&query_hl=10&itool=pubmed_docsum
•
Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. Author(s): Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH Jr, Bowser R. Source: Journal of Neurochemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16313519&query_hl=10&itool=pubmed_docsum
•
Psychopathology in amyotrophic lateral sclerosis: a preliminary study with 27 ALS patients. Author(s): Bungener C, Piquard A, Pradat PF, Salachas F, Meininger V, Lacomblez L. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16319025&query_hl=10&itool=pubmed_docsum
114
Amyotrophic Lateral Sclerosis
•
Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design. Author(s): Schmidt EP, Drachman DB, Wiener CM, Clawson L, Kimball R, Lechtzin N. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16258948&query_hl=10&itool=pubmed_docsum
•
Quality of life and psychosocial issues in ventilated patients with amyotrophic lateral sclerosis and their caregivers. Author(s): Kaub-Wittemer D, Steinbuchel N, Wasner M, Laier-Groeneveld G, Borasio GD. Source: Journal of Pain and Symptom Management. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14527757&query_hl=10&itool=pubmed_docsum
•
Quality of life in patients with amyotrophic lateral sclerosis: perceptions, coping resources, and illness characteristics. Author(s): Nelson ND, Trail M, Van JN, Appel SH, Lai EC. Source: Journal of Palliative Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14509487&query_hl=10&itool=pubmed_docsum
•
Quantification of hyperreflexia in amyotrophic lateral sclerosis (ALS) by the soleus stretch reflex. Author(s): Christensen PB, Nielsen JF, Sinkjaer T. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14506942&query_hl=10&itool=pubmed_docsum
•
Quantification of upper motor neuron loss in amyotrophic lateral sclerosis. Author(s): Rosler KM, Truffert A, Hess CW, Magistris MR. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11090774&query_hl=10&itool=pubmed_docsum
•
Quantitative assessment of motor fatigue in amyotrophic lateral sclerosis. Author(s): Sanjak M, Brinkmann J, Belden DS, Roelke K, Waclawik A, Neville HE, Ringel SP, Murphy JR, Brooks BR. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11676992&query_hl=10&itool=pubmed_docsum
Studies
115
•
Quantitative EEG analysis for assessment to 'plan' a task in amyotrophic lateral sclerosis patients: a study of executive functions (planning) in ALS patients. Author(s): Santhosh J, Bhatia M, Sahu S, Anand S. Source: Brain Research. Cognitive Brain Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15561501&query_hl=10&itool=pubmed_docsum
•
Quantitative evaluation of the pyramidal tract segmented by diffusion tensor tractography: feasibility study in patients with amyotrophic lateral sclerosis. Author(s): Aoki S, Iwata NK, Masutani Y, Yoshida M, Abe O, Ugawa Y, Masumoto T, Mori H, Hayashi N, Kabasawa H, Kwak S, Takahashi S, Tsuji S, Ohtomo K. Source: Radiat Med. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15940067&query_hl=10&itool=pubmed_docsum
•
Quantitative evidence for neurofilament heavy subunit aggregation in motor neurons of spinal cords of patients with amyotrophic lateral sclerosis. Author(s): Mendonca DM, Chimelli L, Martinez AM. Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15933787&query_hl=10&itool=pubmed_docsum
•
Quantitative thermal sensory testing in patients with amyotrophic lateral sclerosis using reaction time exclusive method of levels (MLE). Author(s): Deepika J, Manvir B, Sumit S, Vinay G, Trilochan S, Garima S, Padma MV, Madhuri B. Source: Electromyogr Clin Neurophysiol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16918198&query_hl=10&itool=pubmed_docsum
•
Quantitative voice analysis in the assessment of bulbar involvement in amyotrophic lateral sclerosis. Author(s): Robert D, Pouget J, Giovanni A, Azulay JP, Triglia JM. Source: Acta Oto-Laryngologica. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10587009&query_hl=10&itool=pubmed_docsum
•
Radio-sensitivity of the cells from amyotrophic lateral sclerosis model mice transfected with human mutant SOD1. Author(s): Wate R, Takahashi S, Ito H, Kusaka H, Kubota Y, Suetomi K, Sato H, Okayasu R. Source: Journal of Radiation Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15802861&query_hl=10&itool=pubmed_docsum
116
Amyotrophic Lateral Sclerosis
•
Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. Author(s): Kalra S, Tai P, Genge A, Arnold DL. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16609809&query_hl=10&itool=pubmed_docsum
•
Rapid progression of amyotrophic lateral sclerosis presenting during pregnancy: a case report. Author(s): Leveck DE, Davies GA. Source: J Obstet Gynaecol Can. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15937610&query_hl=10&itool=pubmed_docsum
•
Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. Author(s): Talbot K, Ansorge O. Source: Human Molecular Genetics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16987882&query_hl=10&itool=pubmed_docsum
•
Redox system expression in the motor neurons in amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS, superoxide dismutase 1 (SOD1)mutated familial ALS, and SOD1-mutated ALS animal models. Author(s): Kato S, Kato M, Abe Y, Matsumura T, Nishino T, Aoki M, Itoyama Y, Asayama K, Awaya A, Hirano A, Ohama E. Source: Acta Neuropathologica. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15983830&query_hl=10&itool=pubmed_docsum
•
Reply to 'Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies--a comment'. Author(s): Krasnianski A, Deschauer M, Krasnianski M, Zierz S. Source: Brain; a Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16477084&query_hl=10&itool=pubmed_docsum
•
Research advances in amyotrophic lateral sclerosis (ALS): a personal view. Author(s): Rowland LP. Source: Neurol Neurochir Pol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15735983&query_hl=10&itool=pubmed_docsum
•
Respiratory effects of amyotrophic lateral sclerosis: problems and solutions. Author(s): Lechtzin N. Source: Respiratory Care. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16867198&query_hl=10&itool=pubmed_docsum
Studies
117
•
Reticulons as markers of neurological diseases: focus on amyotrophic lateral sclerosis. Author(s): Fergani A, Dupuis L, Jokic N, Larmet Y, de Tapia M, Rene F, Loeffler JP, Gonzalez de Aguilar JL. Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16909024&query_hl=10&itool=pubmed_docsum
•
Return of the cycad hypothesis - does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health? Author(s): Ince PG, Codd GA. Source: Neuropathology and Applied Neurobiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16008818&query_hl=10&itool=pubmed_docsum
•
Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis. Author(s): Brockington A, Kirby J, Eggitt D, Schofield E, Morris C, Lewis CE, Ince PG, Shaw PJ. Source: Neurogenetics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15776280&query_hl=10&itool=pubmed_docsum
•
Sensory testing in the assessment of laryngeal sensation in patients with amyotrophic lateral sclerosis. Author(s): Amin MR, Harris D, Cassel SG, Grimes E, Heiman-Patterson T. Source: The Annals of Otology, Rhinology, and Laryngology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16900807&query_hl=10&itool=pubmed_docsum
•
Serotonergic mechanisms in amyotrophic lateral sclerosis. Author(s): Sandyk R. Source: The International Journal of Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16861147&query_hl=10&itool=pubmed_docsum
•
Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Author(s): Chio A, Benzi G, Dossena M, Mutani R, Mora G. Source: Brain; a Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15634730&query_hl=10&itool=pubmed_docsum
118
Amyotrophic Lateral Sclerosis
•
Signs and symptoms at diagnosis of amyotrophic lateral sclerosis: a population-based study in southern Italy. Author(s): Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, Lepore V, Serlenga L, Logroscino G; SLAP registry. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16834713&query_hl=10&itool=pubmed_docsum
•
Single fiber electromyography in 78 patients with amyotrophic lateral sclerosis. Author(s): Cui LY, Liu MS, Tang XF. Source: Chinese Medical Journal. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15603713&query_hl=10&itool=pubmed_docsum
•
Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? Author(s): Czaplinski A, Yen AA, Simpson EP, Appel SH. Source: Archives of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16908741&query_hl=10&itool=pubmed_docsum
•
Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosislinked superoxide dismutase mutants against unfolding and aggregation. Author(s): Ray SS, Nowak RJ, Brown RH Jr, Lansbury PT Jr. Source: Proceedings of the National Academy of Sciences of the United States of America. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15738401&query_hl=10&itool=pubmed_docsum
•
Standard equations are not accurate in assessing resting energy expenditure in patients with amyotrophic lateral sclerosis. Author(s): Sherman MS, Pillai A, Jackson A, Heiman-Patterson T. Source: Jpen. Journal of Parenteral and Enteral Nutrition. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15568293&query_hl=10&itool=pubmed_docsum
•
Stem-cell therapy in amyotrophic lateral sclerosis. Author(s): Mazzini L, Fagioli F, Boccaletti R. Source: Lancet. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15567004&query_hl=10&itool=pubmed_docsum
Studies
119
•
Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Author(s): Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S, de Bustos F, Zurdo JM, Alonso H, Puertas I, Barcenilla B, Sayed Y, Cabrera-Valdivia F. Source: Acta Neurologica Scandinavica. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15644071&query_hl=10&itool=pubmed_docsum
•
The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Author(s): Wu DC, Re DB, Nagai M, Ischiropoulos H, Przedborski S. Source: Proceedings of the National Academy of Sciences of the United States of America. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16877542&query_hl=10&itool=pubmed_docsum
•
The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. Author(s): Demestre M, Parkin-Smith G, Petzold A, Pullen AH. Source: Journal of Neuroimmunology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15652414&query_hl=10&itool=pubmed_docsum
•
The relationship between amyotrophic lateral sclerosis and frontotemporal dementia. Author(s): Ringholz GM, Greene SR. Source: Curr Neurol Neurosci Rep. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16928348&query_hl=10&itool=pubmed_docsum
•
Trial of celecoxib in amyotrophic lateral sclerosis. Author(s): Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB. Source: Annals of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16802291&query_hl=10&itool=pubmed_docsum
•
Trouble on the pitch: are professional football players at increased risk of developing amyotrophic lateral sclerosis? Author(s): Al-Chalabi A, Leigh PN. Source: Brain; a Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15713848&query_hl=10&itool=pubmed_docsum
120
Amyotrophic Lateral Sclerosis
•
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Author(s): Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Source: Science. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=17023659&query_hl=10&itool=pubmed_docsum
•
Ultrastructural change of synapses of Betz cells in patients with amyotrophic lateral sclerosis. Author(s): Sasaki S, Iwata M. Source: Neuroscience Letters. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10400070&query_hl=10&itool=pubmed_docsum
•
Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Author(s): Chung MJ, Suh YL. Source: Ultrastructural Pathology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12028652&query_hl=10&itool=pubmed_docsum
•
Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease. Author(s): Forbes RB, Colville S, Cran GW, Swingler RJ; Scottish Motor Neurone Disease Register. Source: Journal of Neurology, Neurosurgery, and Psychiatry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15548498&query_hl=10&itool=pubmed_docsum
•
Unsaturated fatty acids induce cytotoxic aggregate formation of amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutants. Author(s): Kim YJ, Nakatomi R, Akagi T, Hashikawa T, Takahashi R. Source: The Journal of Biological Chemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15799963&query_hl=10&itool=pubmed_docsum
•
Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Author(s): Heath PR, Shaw PJ. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12362409&query_hl=10&itool=pubmed_docsum
Studies
121
•
Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. Author(s): Dupuis L, di Scala F, Rene F, de Tapia M, Oudart H, Pradat PF, Meininger V, Loeffler JP. Source: The Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14500553&query_hl=10&itool=pubmed_docsum
•
Use of noninvasive ventilation in patients with amyotrophic lateral sclerosis. Author(s): Lechtzin N, Wiener CM, Clawson L, Davidson MC, Anderson F, Gowda N, Diette GB; ALS CARE Study Group. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15204018&query_hl=10&itool=pubmed_docsum
•
Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Author(s): Morgan RK, McNally S, Alexander M, Conroy R, Hardiman O, Costello RW. Source: American Journal of Respiratory and Critical Care Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15516537&query_hl=10&itool=pubmed_docsum
•
Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Author(s): Ratovitski T, Corson LB, Strain J, Wong P, Cleveland DW, Culotta VC, Borchelt DR. Source: Human Molecular Genetics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10400992&query_hl=10&itool=pubmed_docsum
•
Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Author(s): Bogaert E, Van Damme P, Van Den Bosch L, Robberecht W. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16856151&query_hl=10&itool=pubmed_docsum
•
VEGF C2578A polymorphism does not contribute to amyotrophic lateral sclerosis susceptibility in sporadic Chinese patients. Author(s): Zhang Y, Zhang H, Fu Y, Song H, Wang L, Zhang J, Fan D. Source: Amyotroph Lateral Scler. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16753977&query_hl=10&itool=pubmed_docsum
122
Amyotrophic Lateral Sclerosis
•
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Author(s): Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, Carmeliet P. Source: Nature Genetics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12847526&query_hl=10&itool=pubmed_docsum
•
VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). Author(s): Terry PD, Kamel F, Umbach DM, Lehman TA, Hu H, Sandler DP, Taylor JA. Source: Journal of Neurogenetics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15763997&query_hl=10&itool=pubmed_docsum
•
Ventilator dependence and expressions of need: a study of patients with amyotrophic lateral sclerosis in Japan. Author(s): Hirano YM, Yamazaki Y, Shimizu J, Togari T, Bryce TJ. Source: Social Science & Medicine (1982). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16263201&query_hl=10&itool=pubmed_docsum
•
Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Author(s): Miller TM, Kaspar BK, Kops GJ, Yamanaka K, Christian LJ, Gage FH, Cleveland DW. Source: Annals of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15852369&query_hl=10&itool=pubmed_docsum
•
Visualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosis. Author(s): Vielhaber S, Winkler K, Kirches E, Kunz D, Buchner M, Feistner H, Elger CE, Ludolph AC, Riepe MW, Kunz WS. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10540022&query_hl=10&itool=pubmed_docsum
•
What's in a name? Amyotrophic lateral sclerosis, motor neuron disease, and allelic heterogeneity. Author(s): Rowland LP. Source: Annals of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9629837&query_hl=10&itool=pubmed_docsum
Studies
123
•
Wheelchair economy class syndrome in amyotrophic lateral sclerosis. Author(s): Kimura F, Ishida S, Furutama D, Hirata Y, Sato T, Hosokawa T, Hanafusa T. Source: Neuromuscular Disorders : Nmd. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16487707&query_hl=10&itool=pubmed_docsum
•
Wheelchair use by patients with amyotrophic lateral sclerosis: a survey of user characteristics and selection preferences. Author(s): Trail M, Nelson N, Van JN, Appel SH, Lai EC. Source: Archives of Physical Medicine and Rehabilitation. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11239293&query_hl=10&itool=pubmed_docsum
•
When motor execution is selectively impaired: control of manipulative finger forces in amyotrophic lateral sclerosis. Author(s): Nowak DA, Hermsdorfer J, Topka H. Source: Motor Control. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12893960&query_hl=10&itool=pubmed_docsum
•
Widespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral Sclerosis. Author(s): Grosskreutz J, Kaufmann J, Fradrich J, Dengler R, Heinze HJ, Peschel T. Source: Bmc Neurology [electronic Resource]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16638121&query_hl=10&itool=pubmed_docsum
•
Withdrawing ventilator support for a home-based amyotrophic lateral sclerosis patient: a case study. Author(s): Schwarz JK, Del Bene ML. Source: J Clin Ethics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15630871&query_hl=10&itool=pubmed_docsum
•
Word retrieval in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Author(s): Abrahams S, Goldstein LH, Simmons A, Brammer M, Williams SC, Giampietro V, Leigh PN. Source: Brain; a Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15163610&query_hl=10&itool=pubmed_docsum
•
Xaliproden in amyotrophic lateral sclerosis: early clinical trials. Author(s): Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15204011&query_hl=10&itool=pubmed_docsum
124
Amyotrophic Lateral Sclerosis
•
Zinc amplifies mSOD1-mediated toxicity in a transgenic mouse model of amyotrophic lateral sclerosis. Author(s): Groeneveld GJ, de Leeuw van Weenen J, van Muiswinkel FL, Veldman H, Veldink JH, Wokke JH, Bar PR, van den Berg LH. Source: Neuroscience Letters. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14625013&query_hl=10&itool=pubmed_docsum
•
Zinc and copper in the pathogenesis of amyotrophic lateral sclerosis. Author(s): Elliott JL. Source: Progress in Neuro-Psychopharmacology & Biological Psychiatry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11474839&query_hl=10&itool=pubmed_docsum
125
CHAPTER 2. ALTERNATIVE MEDICINE AND AMYOTROPHIC LATERAL SCLEROSIS Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to amyotrophic lateral sclerosis. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to amyotrophic lateral sclerosis and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select CAM on PubMed. Enter amyotrophic lateral sclerosis (or synonyms) into the search box. Click Go. The following references provide information on particular aspects of complementary and alternative medicine that are related to amyotrophic lateral sclerosis: •
A clinical trial of therapeutic electrical stimulation for amyotrophic lateral sclerosis. Author(s): Handa I, Matsushita N, Ihashi K, Yagi R, Mochizuki R, Mochizuki H, Abe Y, Shiga Y, Hoshimiya N, Itoyama Y, et al. Source: The Tohoku Journal of Experimental Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=7597693&query_hl=1&itool=pubmed_docsum
•
A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. Author(s): Zhao Z, Lange DJ, Voustianiouk A, MacGrogan D, Ho L, Suh J, Humala N, Thiyagarajan M, Wang J, Pasinetti GM. Source: Bmc Neuroscience [electronic Resource]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16584562&query_hl=1&itool=pubmed_docsum
126
Amyotrophic Lateral Sclerosis
•
A Phase I safety study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis. Author(s): Steele J, Matos LA, Lopez EA, Perez-Pinzon MA, Prado R, Busto R, Arheart KL, Bradley WG. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15799556&query_hl=1&itool=pubmed_docsum
•
A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Author(s): Barbeito LH, Pehar M, Cassina P, Vargas MR, Peluffo H, Viera L, Estevez AG, Beckman JS. Source: Brain Research. Brain Research Reviews. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15572176&query_hl=1&itool=pubmed_docsum
•
A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. Author(s): Trieu VN, Liu R, Liu XP, Uckun FM. Source: Biochemical and Biophysical Research Communications. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10623568&query_hl=1&itool=pubmed_docsum
•
A sporadic case of juvenile amyotrophic lateral sclerosis; semi-quantitative and histoenzymatical study of the denervated muscles. Author(s): Cognazzo A, Martin L. Source: European Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=4314073&query_hl=1&itool=pubmed_docsum
•
A therapeutic trial of thymic factor in amyotrophic lateral sclerosis (ALS). Author(s): Provinciali L, Giovagnoli AR, Di Bella P, Baroni M, Dellantonio R. Source: Advances in Experimental Medicine and Biology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=3577920&query_hl=1&itool=pubmed_docsum
•
Abnormal excitability of the corticospinal pathway in patients with amyotrophic lateral sclerosis: a single motor unit study using transcranial magnetic stimulation. Author(s): Kohara N, Kaji R, Kojima Y, Mills KR, Fujii H, Hamano T, Kimura J, Takamatsu N, Uchiyama T. Source: Electroencephalography and Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=8625875&query_hl=1&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Author(s): Goodall EF, Morrison KE.
Alternative Medicine 127
Source: Expert Reviews in Molecular Medicine [electronic Resource]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16723044&query_hl=1&itool=pubmed_docsum •
Amyotrophic lateral sclerosis and hopelessness: psychosocial factors. Author(s): Plahuta JM, McCulloch BJ, Kasarskis EJ, Ross MA, Walter RA, McDonald ER. Source: Social Science & Medicine (1982). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12409126&query_hl=1&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis in an Italian professional soccer player. Author(s): Vanacore N, Binazzi A, Bottazzi M, Belli S. Source: Parkinsonism & Related Disorders. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16459125&query_hl=1&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis versus cervical spondylotic myelopathy: a study using transcranial magnetic stimulation with recordings from the trapezius and limb muscles. Author(s): Truffert A, Rosler KM, Magistris MR. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10825710&query_hl=1&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis. Clinicopathological studies of a family. Author(s): Metcalf CW, Hirano A. Source: Archives of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=5089897&query_hl=1&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis: a challenge for constant adaptation. Author(s): Stone N. Source: The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=2956338&query_hl=1&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis: integrating care for patients and their families. Author(s): Thompson B. Source: Am J Hosp Palliat Care. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=2361109&query_hl=1&itool=pubmed_docsum
•
Amyotrophic lateral sclerosis: new developments in diagnostic markers. Author(s): Dengler R, von Neuhoff N, Bufler J, Krampfl K, Peschel T, Grosskreutz J.
128
Amyotrophic Lateral Sclerosis
Source: Neurodegener Dis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16909023&query_hl=1&itool=pubmed_docsum •
Amyotrophic lateral sclerosis: recent advances and future therapies. Author(s): Nirmalananthan N, Greensmith L. Source: Current Opinion in Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16280684&query_hl=1&itool=pubmed_docsum
•
Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: implications for amyotrophic lateral sclerosis. Author(s): Cassina P, Pehar M, Vargas MR, Castellanos R, Barbeito AG, Estevez AG, Thompson JA, Beckman JS, Barbeito L. Source: Journal of Neurochemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15773903&query_hl=1&itool=pubmed_docsum
•
Burden of care in amyotrophic lateral sclerosis. Author(s): Hecht MJ, Graesel E, Tigges S, Hillemacher T, Winterholler M, Hilz MJ, Heuss D, Neundorfer B. Source: Palliative Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12822849&query_hl=1&itool=pubmed_docsum
•
Calcitonin gene-related peptide immunoreactivity in familial amyotrophic lateral sclerosis. Author(s): Kato T, Hirano A, Manaka H, Sasaki H, Katagiri T, Kawanami T, Shikama Y, Seino T, Sasaki H. Source: Neuroscience Letters. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=1667811&query_hl=1&itool=pubmed_docsum
•
Characterization of three yeast copper-zinc superoxide dismutase mutants analogous to those coded for in familial amyotrophic lateral sclerosis. Author(s): Nishida CR, Gralla EB, Valentine JS. Source: Proceedings of the National Academy of Sciences of the United States of America. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=7937915&query_hl=1&itool=pubmed_docsum
•
Controversies about amyotrophic lateral sclerosis. Author(s): Rowland LP. Source: Neurologia (Barcelona, Spain). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9011143&query_hl=1&itool=pubmed_docsum
Alternative Medicine 129
•
Cortical versus spinal dysfunction in amyotrophic lateral sclerosis. Author(s): Attarian S, Vedel JP, Pouget J, Schmied A. Source: Muscle & Nerve. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16506152&query_hl=1&itool=pubmed_docsum
•
Corticobulbar tract involvement in amyotrophic lateral sclerosis. A transcranial magnetic stimulation study. Author(s): Urban PP, Vogt T, Hopf HC. Source: Brain; a Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9648545&query_hl=1&itool=pubmed_docsum
•
Decreased electroencephalogram alpha band [8-13 Hz] power in amyotrophic lateral sclerosis patients: a study of alpha activity in an awake relaxed state. Author(s): Santhosh J, Bhatia M, Sahu S, Anand S. Source: Neurology India. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15805665&query_hl=1&itool=pubmed_docsum
•
Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. Author(s): Mazzini L, Balzarini C, Colombo R, Mora G, Pastore I, De Ambrogio R, Caligari M. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11677005&query_hl=1&itool=pubmed_docsum
•
Ethical aspects of unproved therapies in multiple sclerosis, amyotrophic lateral sclerosis, and other neurologic diseases. Author(s): van den Noort S. Source: Seminars in Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11649670&query_hl=1&itool=pubmed_docsum
•
Evoked cardiac response components in cognitive processing: differential effects of amyotrophic lateral sclerosis. Author(s): Kaiser J, Wronka E, Barry RJ, Szczudlik A. Source: Acta Neurobiol Exp (Wars). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10645638&query_hl=1&itool=pubmed_docsum
•
Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. Author(s): Cochrane Database Syst Rev. 2006;(1):CD004156
130
Amyotrophic Lateral Sclerosis
Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16437474&itool=pubmed_docsum •
Factors supporting quality of life over time for individuals with amyotrophic lateral sclerosis: the role of positive self-perception and religiosity. Author(s): Bremer BA, Simone AL, Walsh S, Simmons Z, Felgoise SH. Source: Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15454359&query_hl=1&itool=pubmed_docsum
•
Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Author(s): Trieu VN, Uckun FM. Source: Biochemical and Biophysical Research Communications. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10329446&query_hl=1&itool=pubmed_docsum
•
Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation. Author(s): Apostolski S, Marinkovic Z, Nikolic A, Blagojevic D, Spasic MB, Michelson AM. Source: Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9726810&query_hl=1&itool=pubmed_docsum
•
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. Author(s): Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, Hager C, Ludolph AC, Becker G, Osterhage J, Jost WH, Schrank B, Stein C, Kostopulos P, Lubik S, Wekwerth K, Dengler R, Troeger M, Wuerz A, Hoge A, Schrader C, Schimke N, Krampfl K, Petri S, Zierz S, Eger K, Neudecker S, Traufeller K, Sievert M, Neundorfer B, Hecht M; German vitamin E/ALS Study Group. Source: Journal of Neural Transmission (Vienna, Austria : 1996). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15517433&query_hl=1&itool=pubmed_docsum
•
Histochemical and X-ray microanalytical localization of aluminum in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Author(s): Piccardo P, Yanagihara R, Garruto RM, Gibbs CJ Jr, Gajdusek DC. Source: Acta Neuropathologica. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=2467502&query_hl=1&itool=pubmed_docsum
Alternative Medicine 131
•
Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Author(s): Ziemann U, Winter M, Reimers CD, Reimers K, Tergau F, Paulus W. Source: Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9371911&query_hl=1&itool=pubmed_docsum
•
Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. Author(s): Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, Kaddurah-Daouk R, Beal MF. Source: Journal of Neurochemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11299300&query_hl=1&itool=pubmed_docsum
•
Individual and health-related quality of life assessment in amyotrophic lateral sclerosis patients and their caregivers. Author(s): Lo Coco G, Lo Coco D, Cicero V, Oliveri A, Lo Verso G, Piccoli F, La Bella V. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16109426&query_hl=1&itool=pubmed_docsum
•
Integrating manual and movement therapy with philosophical counseling for treatment of a patient with amyotrophic lateral sclerosis: a case study that explores the principles of holistic intervention. Author(s): Cottingham JT, Maitland J. Source: Alternative Therapies in Health and Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10710808&query_hl=1&itool=pubmed_docsum
•
Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. Author(s): Garbuzova-Davis S, Willing AE, Zigova T, Saporta S, Justen EB, Lane JC, Hudson JE, Chen N, Davis CD, Sanberg PR. Source: Journal of Hematotherapy & Stem Cell Research. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12857367&query_hl=1&itool=pubmed_docsum
•
Lead content of neuromuscular tissue in amyotrophic lateral sclerosis: case report and other considerations. Author(s): Petkau A, Sawatzky A, Hillier CR, Hoogstraten J. Source: Br J Ind Med. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=4214550&query_hl=1&itool=pubmed_docsum
•
Magnetoencephalographic evidence of abnormal auditory processing in amyotrophic lateral sclerosis with bulbar signs. Author(s): Pekkonen E, Osipova D, Laaksovirta H.
132
Amyotrophic Lateral Sclerosis
Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14744570&query_hl=1&itool=pubmed_docsum •
Major stressors facing patients with amyotrophic lateral sclerosis (ALS): a survey to identify their concerns and to compare with those of their caregivers. Author(s): Trail M, Nelson N, Van JN, Appel SH, Lai EC. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15204023&query_hl=1&itool=pubmed_docsum
•
Management of amyotrophic lateral sclerosis with riluzole. Author(s): Neatherlin JS. Source: The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9791781&query_hl=1&itool=pubmed_docsum
•
Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death. Author(s): Simmons Z. Source: The Neurologist. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16148733&query_hl=1&itool=pubmed_docsum
•
Marijuana in the management of amyotrophic lateral sclerosis. Author(s): Carter GT, Rosen BS. Source: Am J Hosp Palliat Care. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11467101&query_hl=1&itool=pubmed_docsum
•
Motor cortex stimulation for amyotrophic lateral sclerosis. Time for a therapeutic trial? Author(s): Di Lazzaro V, Oliviero A, Saturno E, Pilato F, Dileone M, Sabatelli M, Tonali PA. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15134719&query_hl=1&itool=pubmed_docsum
•
My journey with amyotrophic lateral sclerosis. Author(s): Nowotny ML.
Alternative Medicine 133
Source: The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9604825&query_hl=1&itool=pubmed_docsum •
Neurodegeneration induced by complex I inhibition in a cellular model of familial amyotrophic lateral sclerosis. Author(s): Rizzardini M, Lupi M, Mangolini A, Babetto E, Ubezio P, Cantoni L. Source: Brain Research Bulletin. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16624679&query_hl=1&itool=pubmed_docsum
•
Neurophysiological features of fasciculation potentials evoked by transcranial magnetic stimulation in amyotrophic lateral sclerosis. Author(s): de Carvalho M, Miranda PC, Lourdes Sales Luis M, Ducla-Soares E. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10787113&query_hl=1&itool=pubmed_docsum
•
Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders. Author(s): Cameron A, Rosenfeld J. Source: Current Opinion in Clinical Nutrition and Metabolic Care. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12394638&query_hl=1&itool=pubmed_docsum
•
Nutritional management in amyotrophic lateral sclerosis: a worldwide perspective. Author(s): Silani V, Kasarskis EJ, Yanagisawa N. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9747929&query_hl=1&itool=pubmed_docsum
•
Optimising the detection of upper motor neuron function dysfunction in amyotrophic lateral sclerosis--a transcranial magnetic stimulation study. Author(s): Osei-Lah AD, Mills KR. Source: Journal of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15592732&query_hl=1&itool=pubmed_docsum
•
Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease? Author(s): Belli S, Vanacore N. Source: European Journal of Epidemiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15921041&query_hl=1&itool=pubmed_docsum
•
Psychological function in individuals with amyotrophic lateral sclerosis (ALS). Author(s): Brown WA, Mueller PS.
134
Amyotrophic Lateral Sclerosis
Source: Psychosomatic Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=4392415&query_hl=1&itool=pubmed_docsum •
Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Author(s): Wendt S, Dedeoglu A, Speer O, Wallimann T, Beal MF, Andreassen OA. Source: Free Radical Biology & Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11978494&query_hl=1&itool=pubmed_docsum
•
Resilience and distress among amyotrophic lateral sclerosis patients and caregivers. Author(s): Rabkin JG, Wagner GJ, Del Bene M. Source: Psychosomatic Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10772408&query_hl=1&itool=pubmed_docsum
•
Responses of masseter muscles to transcranial magnetic stimulation in patients with amyotrophic lateral sclerosis. Author(s): Trompetto C, Caponnetto C, Buccolieri A, Marchese R, Abbruzzese G. Source: Electroencephalography and Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9751293&query_hl=1&itool=pubmed_docsum
•
Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Author(s): Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH Jr, Ferrante RJ. Source: Journal of Neurochemistry. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15934930&query_hl=1&itool=pubmed_docsum
•
Spiritual well-being of the individual with amyotrophic lateral sclerosis. Author(s): Dal Bello-Haas V, Andrews-Hinders D, Bocian J, Mascha E, Wheeler T, Mitsumoto H. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11464852&query_hl=1&itool=pubmed_docsum
•
Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Author(s): Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Olivieri C, Pastore I, Marasso R, Madon E.
Alternative Medicine 135
Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=13129802&query_hl=1&itool=pubmed_docsum •
Stem cells in the treatment of amyotrophic lateral sclerosis (ALS). Author(s): Silani V, Fogh I, Ratti A, Sassone J, Ciammola A, Cova L. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=12710505&query_hl=1&itool=pubmed_docsum
•
Survey of cannabis use in patients with amyotrophic lateral sclerosis. Author(s): Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT. Source: Am J Hosp Palliat Care. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15055508&query_hl=1&itool=pubmed_docsum
•
Survival in amyotrophic lateral sclerosis. The role of psychological factors. Author(s): McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA. Source: Archives of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=8274106&query_hl=1&itool=pubmed_docsum
•
Symptomatic care of patients with amyotrophic lateral sclerosis. Author(s): Smith RA, Norris FH Jr. Source: Jama : the Journal of the American Medical Association. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=52730&query_hl=1&itool=pubmed_docsum
•
The adult neural stem and progenitor cell niche is altered in amyotrophic lateral sclerosis mouse brain. Author(s): Liu Z, Martin LJ. Source: The Journal of Comparative Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16736475&query_hl=1&itool=pubmed_docsum
•
The amyotrophic lateral sclerosis (ALS) support network of Kentucky: an informational support group using interactive video. Author(s): Kasarkis EJ, Elza TA, Bishop NG, Spears AC. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9419062&query_hl=1&itool=pubmed_docsum
136
Amyotrophic Lateral Sclerosis
•
The cortico-diaphragmatic pathway involvement in amyotrophic lateral sclerosis: Neurophysiological, respiratory and clinical considerations. Author(s): Miscio G, Gukov B, Pisano F, Mazzini L, Baudo S, Salvadori A, Mauro A. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=17078971&query_hl=1&itool=pubmed_docsum
•
The family support group in the treatment of amyotrophic lateral sclerosis. Author(s): Finger S. Source: Neurologic Clinics. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=3561383&query_hl=1&itool=pubmed_docsum
•
The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders. Author(s): Ellis AC, Rosenfeld J. Source: Cns Drugs. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15584767&query_hl=1&itool=pubmed_docsum
•
The role of the amyotrophic lateral sclerosis and motor neurone disease community in health-care resourcing. Author(s): Levvy G. Source: Int J Clin Pract Suppl. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=9691245&query_hl=1&itool=pubmed_docsum
•
The serotonin precursor 5-hydroxytryptophan delays neuromuscular disease in murine familial amyotrophic lateral sclerosis. Author(s): Turner BJ, Lopes EC, Cheema SS. Source: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14527871&query_hl=1&itool=pubmed_docsum
•
The use of alternative medicine by patients with amyotrophic lateral sclerosis. Author(s): Wasner M, Klier H, Borasio GD. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11677007&query_hl=1&itool=pubmed_docsum
•
The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS). Author(s): Vardeny O, Bromberg MB. Source: J Herb Pharmacother. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16520295&query_hl=1&itool=pubmed_docsum
Alternative Medicine 137
•
Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. Author(s): Ferrante RJ, Klein AM, Dedeoglu A, Beal MF. Source: Journal of Molecular Neuroscience : Mn. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=11665866&query_hl=1&itool=pubmed_docsum
•
Transcranial magnetic stimulation and BDNF plasma levels in amyotrophic lateral sclerosis. Author(s): Angelucci F, Oliviero A, Pilato F, Saturno E, Dileone M, Versace V, Musumeci G, Batocchi AP, Tonali PA, Di Lazzaro V. Source: Neuroreport. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15094483&query_hl=1&itool=pubmed_docsum
•
Transcranial magnetic stimulation compared with upper motor neuron signs in patients with amyotrophic lateral sclerosis. Author(s): Schulte-Mattler WJ, Muller T, Zierz S. Source: Journal of the Neurological Sciences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=10540036&query_hl=1&itool=pubmed_docsum
•
Transcranial magnetic stimulation for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Author(s): Mitsumoto H, Floyd A, Tang MX, Kaufmann P, Battista V, Hristova A, Pullman SL. Source: Suppl Clin Neurophysiol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16893129&query_hl=1&itool=pubmed_docsum
•
Transgenic models of amyotrophic lateral sclerosis. Author(s): Grieb P. Source: Folia Neuropathol. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15679043&query_hl=1&itool=pubmed_docsum
•
Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Author(s): Ashworth NL, Satkunam LE, Deforge D. Source: Cochrane Database Syst Rev. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16437474&query_hl=1&itool=pubmed_docsum
•
Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Author(s): Ashworth NL, Satkunam LE, Deforge D. Source: Cochrane Database Syst Rev. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=14974059&query_hl=1&itool=pubmed_docsum
138
Amyotrophic Lateral Sclerosis
•
Use of fiberoptic endoscopic evaluation of swallowing (FEES) in patients with amyotrophic lateral sclerosis. Author(s): Leder SB, Novella S, Patwa H. Source: Dysphagia. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15383947&query_hl=1&itool=pubmed_docsum
•
Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study. Author(s): Galbussera A, Tremolizzo L, Brighina L, Testa D, Lovati R, Ferrarese C, Cavaletti G, Filippini G. Source: Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=16897634&query_hl=1&itool=pubmed_docsum
•
Vitamin E intake and risk of amyotrophic lateral sclerosis. Author(s): Ascherio A, Weisskopf MG, O'reilly EJ, Jacobs EJ, McCullough ML, Calle EE, Cudkowicz M, Thun MJ. Source: Annals of Neurology. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=A bstractPlus&list_uids=15529299&query_hl=1&itool=pubmed_docsum
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://health.aol.com/healthyliving/althealth
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com®: http://www.drkoop.com/naturalmedicine.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
Alternative Medicine 139
The following is a specific Web list relating to amyotrophic lateral sclerosis; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Herbs and Supplements BCAAs Source: Prima Communications, Inc.www.personalhealthzone.com Branched-Chain Amino Acids Source: Healthnotes, Inc.; www.healthnotes.com Glutamic Acid Source: Healthnotes, Inc.; www.healthnotes.com Melatonin Source: Healthnotes, Inc.; www.healthnotes.com
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
140
CHAPTER 3. PATENTS ON AMYOTROPHIC LATERAL SCLEROSIS Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.13 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “amyotrophic lateral sclerosis“ (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on amyotrophic lateral sclerosis, we have not necessarily excluded non-medical patents in this bibliography.
Patent Applications on Amyotrophic Lateral Sclerosis As of December 2000, U.S. patent applications are open to public viewing.14 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to amyotrophic lateral sclerosis: 13Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm. 14 This has been a common practice outside the United States prior to December 2000.
Patents 141
•
Biomarkers for amyotrophic lateral sclerosis Inventor(s): Bowser, Robert P.; (Cranberry Township, PA), Ranganathan, Srikanth; (Pittsburgh, PA) Correspondence: Leydig Voit & Mayer, Ltd; Two Prudential Plaza, Suite 4900; 180 North Stetson Avenue; Chicago; IL; 60601-6780; US Patent Application Number: 20050148026 Date filed: October 25, 2004 Abstract: The invention provides a method for diagnosing amyotrophic lateral sclerosis (ALS) in a subject, a method for assessing the effectiveness of a drug in treating ALS, and a method for determining the site of onset of ALS in a subject. Each method comprises (a) obtaining a sample from the subject, (b) analyzing the proteins in the sample by mass spectroscopy, and (c) determining a mass spectral profile for the sample. In some embodiments, the method comprises comparing the mass spectral profile of the sample to the mass spectral profile of a positive or a negative standard. Excerpt(s): This patent application claims the benefit of U.S. Provisional Patent Application No. 60/513,930, filed Oct. 23, 2003. This invention pertains to biomarkers of amyotrophic lateral sclerosis and methods of using same. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or motor neuron disease (MND), is one of several neurodegenerative diseases of the central nervous system. ALS is the most common adult onset motor neuron disease, affecting one in every 20,000 individuals, with an average age of onset of 50-55 years. ALS is characterized by rapidly progressive degeneration of motor neurons in the brain, brainstem, and spinal cord (Cleveland et al., Nat. Rev. Neurosci., 2, 806-19 (2001)). The median survival of patients from time of diagnosis is five years. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
METHOD TO TREAT PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS AND THE LIKE Inventor(s): Rooney, Roberta Nora Malone; (North Olmsted, OH) Correspondence: Roberta N. Rooney; 6787 Warrington Drive; North Olmsted; OH; 44070; US Patent Application Number: 20040176344 Date filed: April 6, 2004 Abstract: The hepatically produced isomers, URO I and URO III, are neuroprotectors capable of halting or mitigating the nervous system destruction in common neurological disorders. URO I protects neurons of the central nervous system from damage that would otherwise ensue from the neurotoxicity associated with the hepatic heme porphyrin precursors, delta-aminolevulinic acid and porphobilinogen. A method is disclosed to increase URO I to treat amyotrophic lateral sclerosis (ALS), stroke, encephalitis, meningitis, spinal cord injury and hereditary biochemical multiple sclerosis. Increases of URO III are also used to protect neurons in the peripheral nervous system in disorders including acute immunodeficiency syndrome (AIDS) related neuropathy, Guillaine-Barre syndrome and diabetic neuropathy.
142
Amyotrophic Lateral Sclerosis
Excerpt(s): This invention relates generally to the treatment of central nervous system (CNS) and peripheral nervous system (PNS) neuropathies, especially amyotrophic lateral sclerosis (ALS), wherein the neurotoxicity associated with the porphyrin precursors, delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), is a contributing factor, and more particularly, to the use of a uroporphyrin isomer, uroporphyrin I (URO I) or uroporphyrin III (URO III) or any of their substrates as such treatment. The hepatic porphyrias are usually caused by inborn shortages of one or more of the enzymes/catalysts that facilitate heme synthesis (Nordmann Y; Puy H. 2002, Clin Chim Acta, 325(1-2):17-37), though some porphyrias, notably porphyria cutanea tarda (PCT) and porphyria turcica (Dean G. 1981, Arch Dermatol, (6):318), may be acquired. The acute (neurotoxic) porphyrias cause CNS and PNS damage, elevations of porphyrins and may cause dementia. Most cause cutaneous photosensitivity as well. (Lip G Y. et al. 1993, Br J Clin Pract 47(1):38-43). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Use of substances with immunomodulating activity for the treatment of amyotrophic lateral sclerosis Inventor(s): Schubert, Walter; (Biederitz, DE) Correspondence: Weingarten, Schurgin, Gagnebin & Hayes Llp; Ten Post Office Square; Boston; MA; 02109; US Patent Application Number: 20010009898 Date filed: March 8, 2001 Abstract: It has been discovered that, in the case of amyotrophic lateral sclerosis, usually a lethal motoneuron disease, a large number of the immune system cells expressing receptors (Fc receptors) of immunoglobulins (IgC), preferably immunoglobulins of classes 1 and 3 (Fc.gamma.RIII receptors for IgG1 and IgG3) can be found in the blood stream. Selective destruction or functional obstruction of these cells can be achieved in order to treat amyotrophic lateral sclerosis (ALS) with the following substances, or their preparations (in the form of intravenous applications or preparations), individually or in combination: a) antibodies, preferably monoclonal antibodies, which bind to Fc.gamma.RIII receptors, inactivate said receptors or individual species of this receptor family or cause the destruction of cellular forms containing said receptors, and/or are coupled to other cytotoxic substances, b) soluble Fc.gamma. receptors, preferably soluble Fc.gamma.RIII receptors, which bind to immunoglobulins, preferably G immunoglobulins of under-class 1 (IgG1) and/or 3 (IgG3), c) the protein V which binds to immunoglobulin G, obtained from Gardnerella vaginalis, and d) antisense RNA molecules which bind specifically to MRNA sequences of Fc.gamma. receptors, preferably to those of Fc.gamma.RIII receptors. Excerpt(s): The invention relates to the use of substances having a well-directed, i.e. selective, effect on a certain receptor family (Fc.gamma.R) or on those immune system cells with defined surface characteristics which express said receptor and whose presence--in examinations performed by the applicant--has been found to be specific, or its number specifically increased, in the case of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis (in the following referred to as ALS, its abbreviation) is a neurodegenerative disease of the human motoneuron system which usually takes a lethal course within 3 to 5 years, whose causes have not been determined etiologically and for which there is no, or no significant, therapy as yet. The progressive decay of
Patents 143
nerve cells of the first and second motor neurons are the cause of an increasing paralysis of the voluntary muscles, eventually leading to a total walking inability and the increasing paralysis of the respiratory musculature. It has largely been proven that cellular and humoral (antibody-mediated) immunological processes play an important role, if yet unexplained in the individual case, in the pathogenesis of ALS. Worldwide, the prevalence of this disease is 4 in 100,000 and its incidence is 1 in 100,000 inhabitants. Numerous examination results seem to imply that immunological mechanisms are at play in the pathogenesis of amyotrophic lateral sclerosis. The following findings substantiate this assumption: Cytotoxic serum activity of ALS patients in neuronal cell cultures; serum immunoglobulin G (IgG) toxicity against spinal and cortical neurons as well as voltage-dependent calcium channel proteins; cytotoxicity of the cerebrospinal fluid of ALS patients against glutamate receptors; changes of the serum concentration of IgG isotypes; immune response of peripheral blood lymphocytes of ALS patients to isolated cell membranes; detection of invasive immune system cells in the motoneuron system of ALS patients Here, these cells seem to be involved in the motoneuron damaging mechanisms (the quotations of the individual above data can be found in: Westarp, M. E. et al., Neurosci. Lett. 173, 124-126, 1994). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Keeping Current In order to stay informed about patents and patent applications dealing with amyotrophic lateral sclerosis, you can access the U.S. Patent Office archive via the Internet at the following Web address: http://www.uspto.gov/patft/index.html. You will see two broad options: (1) Issued Patent, and (2) Published Applications. To see a list of issued patents, perform the following steps: Under Issued Patents, click Quick Search. Then, type amyotrophic lateral sclerosis (or a synonym) into the Term 1 box. After clicking on the search button, scroll down to see the various patents which have been granted to date on amyotrophic lateral sclerosis. You can also use this procedure to view pending patent applications concerning amyotrophic lateral sclerosis. Simply go back to http://www.uspto.gov/patft/index.html. Select Quick Search under Published Applications. Then proceed with the steps listed above.
144
CHAPTER 4. BOOKS ON AMYOTROPHIC LATERAL SCLEROSIS Overview This chapter provides bibliographic book references relating to amyotrophic lateral sclerosis. In addition to online booksellers such as www.amazon.com and www.bn.com, the National Library of Medicine is an excellent source for book titles on amyotrophic lateral sclerosis. Your local medical library also may have these titles available for loan.
Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print®). IMPORTANT NOTE: Online booksellers typically produce search results for medical and non-medical books. When searching for amyotrophic lateral sclerosis at online booksellers’ Web sites, you may discover non-medical books that use the generic term “amyotrophic lateral sclerosis” (or a synonym) in their titles. The following is indicative of the results you might find when searching for amyotrophic lateral sclerosis (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com): •
21st Century Complete Medical Guide to Amyotrophic Lateral Sclerosis (ALS), Lou Gehrig's Disease, Authoritative CDC, NIH, and FDA Documents, Clinical References,. for Patients and Physicians (CD-ROM) PM Medical Health News (2004); ISBN: 1592486738; http://www.amazon.com/exec/obidos/ASIN/1592486738/icongroupinterna
•
Amyotrophic lateral sclerosis: Proceedings of the International Symposium on Amyotrophic Lateral Sclerosis held February 2 and 3, 1978 (Publication - Japan Medical Research Foundation; no. 8) (1979); ISBN: 0839114222; http://www.amazon.com/exec/obidos/ASIN/0839114222/icongroupinterna
•
Brain Disorders Sourcebook: Basic Consumer Health Information About Strokes, Epilepsy, Amyotrophic Lateral Sclerosis (Als/Lou Ge Karen Bellenir (1999); ISBN:
Books
145
B000LZK3TW; http://www.amazon.com/exec/obidos/ASIN/B000LZK3TW/icongroupinterna •
Brain Disorders Sourcebook: Basic Consumer Health Information About Strokes, Epilepsy, Amyotrophic Lateral Sclerosis (Als/Lou Gehrig's Disease) Parkinson's. Brain Tumors (Health Reference Series) Sandra J. Judd (2005); ISBN: 0780807448; http://www.amazon.com/exec/obidos/ASIN/0780807448/icongroupinterna
•
Cognition impaired in 30% with ALS: a small study of patients with classic amyotrophic lateral sclerosis found cognitive impairment in 30% of the patients. ): An article from: Clinical Psychiatry News Mary Ann Moon (2006); ISBN: B000I0SC8Y; http://www.amazon.com/exec/obidos/ASIN/B000I0SC8Y/icongroupinterna
•
Go Not Gently: Letters from a Patient With Amyotrophic Lateral Sclerosis (Continuing series on thanatology) Frances McGill (1980); ISBN: 0405126433; http://www.amazon.com/exec/obidos/ASIN/0405126433/icongroupinterna
•
Handbook of Amyotrophic Lateral Sclerosis (Neurological Disease and Therapy) Richard Smith (1992); ISBN: 0824786106; http://www.amazon.com/exec/obidos/ASIN/0824786106/icongroupinterna
•
Management of amyotrophic lateral sclerosis with Riluzole.: An article from: Journal of Neuroscience Nursing Jacquelin S. Neatherlin (1998); ISBN: B00098BIS6; http://www.amazon.com/exec/obidos/ASIN/B00098BIS6/icongroupinterna
•
Motor neurone disease deaths (ICD 335.2) and amyotrophic lateral sclerosis for the United States, Wisconsin by county, Milwaukee City and other selected. & analysis of health data working papers) Raymond D Nashold (1988); ISBN: B00071J440; http://www.amazon.com/exec/obidos/ASIN/B00071J440/icongroupinterna
•
Palliative Care in Amyotrophic Lateral Sclerosis (Motor Neuron Disease) David Oliver, Gian Domenico Borasio, and Declan Walsh (2000); ISBN: 0192631667; http://www.amazon.com/exec/obidos/ASIN/0192631667/icongroupinterna
•
Search for the cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam: Deposition of heavy metals and essential minerals in the central nervous system Ralph M Garruto (1985); ISBN: B00070R9RU; http://www.amazon.com/exec/obidos/ASIN/B00070R9RU/icongroupinterna
The National Library of Medicine Book Index The National Library of Medicine at the National Institutes of Health has a massive database of books published on healthcare and biomedicine. Go to the following Internet site, http://locatorplus.gov/, and then select LocatorPlus. Once you are in the search area, simply type amyotrophic lateral sclerosis (or synonyms) into the search box, and select the Quick Limit Option for Keyword, Title, or Journal Title Search: Books. From there, results can be sorted by publication date, author, or relevance. The following was recently catalogued by the National Library of Medicine15: 15
In addition to LocatorPlus, in collaboration with authors and publishers, the National Center for Biotechnology Information (NCBI) is currently adapting biomedical books for the Web. The books may be accessed in two ways: (1) by searching directly using any search term or phrase (in the same way as the bibliographic database PubMed), or (2) by following the links to PubMed abstracts. Each PubMed abstract has a Books button that displays a facsimile of the abstract in which some phrases are hypertext links. These phrases are also found in the books available at NCBI. Click on hyperlinked results in the list of books in which the phrase is found. Currently, the majority of the links are between the books and PubMed. In the future, more links will be created between the
146
Amyotrophic Lateral Sclerosis
•
Amyotrophic lateral sclerosis: proceedings of the International Symposium on Amyotrophic Lateral Sclerosis held February 2 and 3, 1978 Author: Tsubaki, Tadao,; Year: 1979; Baltimore: University Park Press, c1979; ISBN: 9780839114 http://www.amazon.com/exec/obidos/ASIN/9780839114/icongroupinterna
•
Amyotrophic lateral sclerosis in Asia and Oceania: proceedings of the Sixth Asian and Oceanian Congress of Neurology Amyotrophic Lateral Sclerosis Workshop, Taipei, Taiwan, Republic of China, November 14, 1983 Author: Chen, K. M. (KwangMing); Year: 1984; Taipei]: Shyan-Fu Chou, National Taiwan University, [1984]
•
Bibliography of amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam Author: Garruto, Ralph M.; Year: 1983; Bethesda, Md.: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1983
•
Brain disorders sourcebook: basic consumer health information about strokes, epilepsy, amyotrophic lateral sclerosis (ALS Author: Bellenir, Karen.; Year: 1999; Detroit, MI: Omnigraphics, c1999; ISBN: 9780780802 http://www.amazon.com/exec/obidos/ASIN/9780780802/icongroupinterna
•
Handbook of amyotrophic lateral sclerosis Author: Smith, Richard Alan,; Year: 1992; New York: Dekker, c1992; ISBN: 9780824786 http://www.amazon.com/exec/obidos/ASIN/9780824786/icongroupinterna
•
Molecular mechanism and therapeutics of amyotrophic lateral sclerosis: proceedings of the International Symposium on Molecular Mechanism and Therapeutics of Amyotrophic Lateral Sclerosis, Japan, 22-24 September 2000 Author: Abe, Kōji.; Year: 2001; Amsterdam; New York: Elsevier, 2001; ISBN: 9780444506 http://www.amazon.com/exec/obidos/ASIN/9780444506/icongroupinterna
•
Normal aging: a neurochemical, neurophysiological, and neuropsychological study with special reference to Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis Author: Hartikainen, Päivi.; Year: 1994; Kuopio: Dept. of Neurology, University of Kuopio, 1994; ISBN: 9789517809 http://www.amazon.com/exec/obidos/ASIN/9789517809/icongroupinterna
•
Palliative care in amyotrophic lateral sclerosis (motor neurone disease) Author: Oliver, David,; Year: 2000; Oxford; New York: Oxford University Press, 2000; ISBN: 9780192631 http://www.amazon.com/exec/obidos/ASIN/9780192631/icongroupinterna
•
Pathogenesis and therapy of amyotrophic lateral sclerosis Author: Serratrice, Georges.; Year: 1995; Philadelphia: Lippincott-Raven, c1995; ISBN: 9780781703 http://www.amazon.com/exec/obidos/ASIN/9780781703/icongroupinterna
•
Riluzole for the treatment of amyotrophic lateral sclerosis: an assessment of clinical efficacy and safety Author: Garces, Kirsten.; Year: 2003; Ottawa: Canadian Coordinating Office for Health Technology Assessment, [2003]; ISBN: 9781894620 http://www.amazon.com/exec/obidos/ASIN/9781894620/icongroupinterna
•
The Diagnosis and treatment of amyotrophic lateral sclerosis Author: Mulder, Donald W.,; Year: 1980; Boston: Houghton Mifflin, Medical Division, 1980; ISBN: 9780892894 http://www.amazon.com/exec/obidos/ASIN/9780892894/icongroupinterna
books and other types of information, such as gene and protein sequences and macromolecular structures. See http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books.
147
CHAPTER 5. MULTIMEDIA ON AMYOTROPHIC LATERAL SCLEROSIS Overview In this chapter, we show you how to find bibliographic information related to multimedia sources of information on amyotrophic lateral sclerosis.
Bibliography: Multimedia on Amyotrophic Lateral Sclerosis The National Library of Medicine is a rich source of information on healthcare-related multimedia productions including slides, computer software, and databases. To access the multimedia database, go to the following Web site: http://locatorplus.gov/. Select LocatorPlus. Once you are in the search area, simply type amyotrophic lateral sclerosis (or synonyms) into the search box, and select the Quick Limit Option for Keyword, Title, or Journal Title Search: Audiovisuals and Computer Files. From there, you can choose to sort results by publication date, author, or relevance. The following multimedia has been indexed on amyotrophic lateral sclerosis: •
Augmentative and alternative communication intervention in individuals with amyotrophic lateral sclerosis [videorecording] Source: produced by National Center for Neurogenic Communication Disorders of the University of Arizona; Year: 2000; Format: Videorecording; Tucson, AZ: Arizona Board of Regents, c2000
148
APPENDICES
149
APPENDIX A. HELP ME UNDERSTAND GENETICS Overview This appendix presents basic information about genetics in clear language and provides links to online resources.16
The Basics: Genes and How They Work This section gives you information on the basics of cells, DNA, genes, chromosomes, and proteins. What Is a Cell? Cells are the basic building blocks of all living things. The human body is composed of trillions of cells. They provide structure for the body, take in nutrients from food, convert those nutrients into energy, and carry out specialized functions. Cells also contain the body’s hereditary material and can make copies of themselves. Cells have many parts, each with a different function. Some of these parts, called organelles, are specialized structures that perform certain tasks within the cell. Human cells contain the following major parts, listed in alphabetical order: •
Cytoplasm: The cytoplasm is fluid inside the cell that surrounds the organelles.
•
Endoplasmic reticulum (ER): This organelle helps process molecules created by the cell and transport them to their specific destinations either inside or outside the cell.
•
Golgi apparatus: The golgi apparatus packages molecules processed by the endoplasmic reticulum to be transported out of the cell.
•
Lysosomes and peroxisomes: These organelles are the recycling center of the cell. They digest foreign bacteria that invade the cell, rid the cell of toxic substances, and recycle worn-out cell components.
16 This appendix is an excerpt from the National Library of Medicine’s handbook, Help Me Understand Genetics. For the full text of the Help Me Understand Genetics handbook, see http://ghr.nlm.nih.gov/handbook.
150
Amyotrophic Lateral Sclerosis
•
Mitochondria: Mitochondria are complex organelles that convert energy from food into a form that the cell can use. They have their own genetic material, separate from the DNA in the nucleus, and can make copies of themselves.
•
Nucleus: The nucleus serves as the cell’s command center, sending directions to the cell to grow, mature, divide, or die. It also houses DNA (deoxyribonucleic acid), the cell’s hereditary material. The nucleus is surrounded by a membrane called the nuclear envelope, which protects the DNA and separates the nucleus from the rest of the cell.
•
Plasma membrane: The plasma membrane is the outer lining of the cell. It separates the cell from its environment and allows materials to enter and leave the cell.
•
Ribosomes: Ribosomes are organelles that process the cell’s genetic instructions to create proteins. These organelles can float freely in the cytoplasm or be connected to the endoplasmic reticulum. What Is DNA?
DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA). The information in DNA is stored as a code made up of four chemical bases: adenine (A), guanine (G), cytosine (C), and thymine (T). Human DNA consists of about 3 billion bases, and more than 99 percent of those bases are the same in all people. The order, or sequence, of these bases determines the information available for building and maintaining an organism, similar to the way in which letters of the alphabet appear in a certain order to form words and sentences. DNA bases pair up with each other, A with T and C with G, to form units called base pairs. Each base is also attached to a sugar molecule and a phosphate molecule. Together, a base, sugar, and phosphate are called a nucleotide. Nucleotides are arranged in two long strands that form a spiral called a double helix. The structure of the double helix is somewhat like a ladder, with the base pairs forming the ladder’s rungs and the sugar and phosphate molecules forming the vertical sidepieces of the ladder. An important property of DNA is that it can replicate, or make copies of itself. Each strand of DNA in the double helix can serve as a pattern for duplicating the sequence of bases. This is critical when cells divide because each new cell needs to have an exact copy of the DNA present in the old cell.
Help Me Understand Genetics
151
DNA is a double helix formed by base pairs attached to a sugar-phosphate backbone. What Is Mitochondrial DNA? Although most DNA is packaged in chromosomes within the nucleus, mitochondria also have a small amount of their own DNA. This genetic material is known as mitochondrial DNA or mtDNA. Mitochondria are structures within cells that convert the energy from food into a form that cells can use. Each cell contains hundreds to thousands of mitochondria, which are located in the fluid that surrounds the nucleus (the cytoplasm). Mitochondria produce energy through a process called oxidative phosphorylation. This process uses oxygen and simple sugars to create adenosine triphosphate (ATP), the cell’s main energy source. A set of enzyme complexes, designated as complexes I-V, carry out oxidative phosphorylation within mitochondria. In addition to energy production, mitochondria play a role in several other cellular activities. For example, mitochondria help regulate the self-destruction of cells (apoptosis). They are also necessary for the production of substances such as cholesterol and heme (a component of hemoglobin, the molecule that carries oxygen in the blood). Mitochondrial DNA contains 37 genes, all of which are essential for normal mitochondrial function. Thirteen of these genes provide instructions for making enzymes involved in oxidative phosphorylation. The remaining genes provide instructions for making molecules called transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), which are chemical cousins of
152
Amyotrophic Lateral Sclerosis
DNA. These types of RNA help assemble protein building blocks (amino acids) into functioning proteins. What Is a Gene? A gene is the basic physical and functional unit of heredity. Genes, which are made up of DNA, act as instructions to make molecules called proteins. In humans, genes vary in size from a few hundred DNA bases to more than 2 million bases. The Human Genome Project has estimated that humans have between 20,000 and 25,000 genes. Every person has two copies of each gene, one inherited from each parent. Most genes are the same in all people, but a small number of genes (less than 1 percent of the total) are slightly different between people. Alleles are forms of the same gene with small differences in their sequence of DNA bases. These small differences contribute to each person’s unique physical features.
Genes are made up of DNA. Each chromosome contains many genes. What Is a Chromosome? In the nucleus of each cell, the DNA molecule is packaged into thread-like structures called chromosomes. Each chromosome is made up of DNA tightly coiled many times around proteins called histones that support its structure. Chromosomes are not visible in the cell’s nucleus—not even under a microscope—when the cell is not dividing. However, the DNA that makes up chromosomes becomes more tightly packed during cell division and is then visible under a microscope. Most of what researchers know about chromosomes was learned by observing chromosomes during cell division. Each chromosome has a constriction point called the centromere, which divides the chromosome into two sections, or “arms.” The short arm of the chromosome is labeled the “p arm.” The long arm of the chromosome is labeled the “q arm.” The location of the centromere on each chromosome gives the chromosome its characteristic shape, and can be used to help describe the location of specific genes.
Help Me Understand Genetics
153
DNA and histone proteins are packaged into structures called chromosomes. How Many Chromosomes Do People Have? In humans, each cell normally contains 23 pairs of chromosomes, for a total of 46. Twentytwo of these pairs, called autosomes, look the same in both males and females. The 23rd pair, the sex chromosomes, differ between males and females. Females have two copies of the X chromosome, while males have one X and one Y chromosome.
154
Amyotrophic Lateral Sclerosis
The 22 autosomes are numbered by size. The other two chromosomes, X and Y, are the sex chromosomes. This picture of the human chromosomes lined up in pairs is called a karyotype. How Do Geneticists Indicate the Location of a Gene? Geneticists use maps to describe the location of a particular gene on a chromosome. One type of map uses the cytogenetic location to describe a gene’s position. The cytogenetic location is based on a distinctive pattern of bands created when chromosomes are stained with certain chemicals. Another type of map uses the molecular location, a precise description of a gene’s position on a chromosome. The molecular location is based on the sequence of DNA building blocks (base pairs) that make up the chromosome. Cytogenetic Location Geneticists use a standardized way of describing a gene’s cytogenetic location. In most cases, the location describes the position of a particular band on a stained chromosome: 17q12 It can also be written as a range of bands, if less is known about the exact location: 17q12-q21 The combination of numbers and letters provide a gene’s “address” on a chromosome. This address is made up of several parts: •
The chromosome on which the gene can be found. The first number or letter used to describe a gene’s location represents the chromosome. Chromosomes 1 through 22 (the autosomes) are designated by their chromosome number. The sex chromosomes are designated by X or Y.
Help Me Understand Genetics
155
•
The arm of the chromosome. Each chromosome is divided into two sections (arms) based on the location of a narrowing (constriction) called the centromere. By convention, the shorter arm is called p, and the longer arm is called q. The chromosome arm is the second part of the gene’s address. For example, 5q is the long arm of chromosome 5, and Xp is the short arm of the X chromosome.
•
The position of the gene on the p or q arm. The position of a gene is based on a distinctive pattern of light and dark bands that appear when the chromosome is stained in a certain way. The position is usually designated by two digits (representing a region and a band), which are sometimes followed by a decimal point and one or more additional digits (representing sub-bands within a light or dark area). The number indicating the gene position increases with distance from the centromere. For example: 14q21 represents position 21 on the long arm of chromosome 14. 14q21 is closer to the centromere than 14q22.
Sometimes, the abbreviations “cen” or “ter” are also used to describe a gene’s cytogenetic location. “Cen” indicates that the gene is very close to the centromere. For example, 16pcen refers to the short arm of chromosome 16 near the centromere. “Ter” stands for terminus, which indicates that the gene is very close to the end of the p or q arm. For example, 14qter refers to the tip of the long arm of chromosome 14. (“Tel” is also sometimes used to describe a gene’s location. “Tel” stands for telomeres, which are at the ends of each chromosome. The abbreviations “tel” and “ter” refer to the same location.)
The CFTR gene is located on the long arm of chromosome 7 at position 7q31.2.
156
Amyotrophic Lateral Sclerosis
Molecular Location The Human Genome Project, an international research effort completed in 2003, determined the sequence of base pairs for each human chromosome. This sequence information allows researchers to provide a more specific address than the cytogenetic location for many genes. A gene’s molecular address pinpoints the location of that gene in terms of base pairs. For example, the molecular location of the APOE gene on chromosome 19 begins with base pair 50,100,901 and ends with base pair 50,104,488. This range describes the gene’s precise position on chromosome 19 and indicates the size of the gene (3,588 base pairs). Knowing a gene’s molecular location also allows researchers to determine exactly how far the gene is from other genes on the same chromosome. Different groups of researchers often present slightly different values for a gene’s molecular location. Researchers interpret the sequence of the human genome using a variety of methods, which can result in small differences in a gene’s molecular address. For example, the National Center for Biotechnology Information (NCBI) identifies the molecular location of the APOE gene as base pair 50,100,901 to base pair 50,104,488 on chromosome 19. The Ensembl database identifies the location of this gene as base pair 50,100,879 to base pair 50,104,489 on chromosome 19. Neither of these addresses is incorrect; they represent different interpretations of the same data. For consistency, Genetics Home Reference presents data from NCBI for the molecular location of genes. What Are Proteins and What Do They Do? Proteins are large, complex molecules that play many critical roles in the body. They do most of the work in cells and are required for the structure, function, and regulation of the body’s tissues and organs. Proteins are made up of hundreds or thousands of smaller units called amino acids, which are attached to one another in long chains. There are 20 different types of amino acids that can be combined to make a protein. The sequence of amino acids determines each protein’s unique 3-dimensional structure and its specific function.
Help Me Understand Genetics
157
Examples of Protein Functions Proteins can be described according to their large range of functions in the body, listed in alphabetical order: Function Antibody
Description Antibodies bind to specific foreign particles, such as viruses and bacteria, to help protect the body.
Example Immunoglobulin G (IgG)
Enzyme
Enzymes carry out almost all of the thousands of chemical reactions that take place in cells. They also assist with the formation of new molecules by reading the genetic information stored in DNA.
Phenylalanine hydroxylase
Messenger
Messenger proteins, such as some types of hormones, transmit signals to coordinate biological processes between different cells, tissues, and organs.
Growth hormone
Structural component
These proteins provide structure and support for cells. On a larger scale, they also allow the body to move. These proteins bind and carry atoms and small molecules within cells and throughout the body.
Actin
Transport/storage
Ferritin
How Does a Gene Make a Protein? Most genes contain the information needed to make functional molecules called proteins. (A few genes produce other molecules that help the cell assemble proteins.) The journey from gene to protein is complex and tightly controlled within each cell. It consists of two major steps: transcription and translation. Together, transcription and translation are known as gene expression. During the process of transcription, the information stored in a gene’s DNA is transferred to a similar molecule called RNA (ribonucleic acid) in the cell nucleus. Both RNA and DNA are made up of a chain of nucleotide bases, but they have slightly different chemical properties. The type of RNA that contains the information for making a protein is called messenger RNA (mRNA) because it carries the information, or message, from the DNA out of the nucleus into the cytoplasm. Translation, the second step in getting from a gene to a protein, takes place in the cytoplasm. The mRNA interacts with a specialized complex called a ribosome, which “reads” the sequence of mRNA bases. Each sequence of three bases, called a codon, usually codes for
158
Amyotrophic Lateral Sclerosis
one particular amino acid. (Amino acids are the building blocks of proteins.) A type of RNA called transfer RNA (tRNA) assembles the protein, one amino acid at a time. Protein assembly continues until the ribosome encounters a “stop” codon (a sequence of three bases that does not code for an amino acid). The flow of information from DNA to RNA to proteins is one of the fundamental principles of molecular biology. It is so important that it is sometimes called the “central dogma.”
Through the processes of transcription and translation, information from genes is used to make proteins.
Can Genes Be Turned On and Off in Cells? Each cell expresses, or turns on, only a fraction of its genes. The rest of the genes are repressed, or turned off. The process of turning genes on and off is known as gene regulation. Gene regulation is an important part of normal development. Genes are turned on and off in different patterns during development to make a brain cell look and act different from a liver cell or a muscle cell, for example. Gene regulation also allows cells to react quickly to changes in their environments. Although we know that the regulation of genes is critical for life, this complex process is not yet fully understood. Gene regulation can occur at any point during gene expression, but most commonly occurs at the level of transcription (when the information in a gene’s DNA is transferred to mRNA). Signals from the environment or from other cells activate proteins called transcription factors. These proteins bind to regulatory regions of a gene and increase or decrease the level of transcription. By controlling the level of transcription, this process can determine the amount of protein product that is made by a gene at any given time.
Help Me Understand Genetics
159
How Do Cells Divide? There are two types of cell division: mitosis and meiosis. Most of the time when people refer to “cell division,” they mean mitosis, the process of making new body cells. Meiosis is the type of cell division that creates egg and sperm cells. Mitosis is a fundamental process for life. During mitosis, a cell duplicates all of its contents, including its chromosomes, and splits to form two identical daughter cells. Because this process is so critical, the steps of mitosis are carefully controlled by a number of genes. When mitosis is not regulated correctly, health problems such as cancer can result. The other type of cell division, meiosis, ensures that humans have the same number of chromosomes in each generation. It is a two-step process that reduces the chromosome number by half—from 46 to 23—to form sperm and egg cells. When the sperm and egg cells unite at conception, each contributes 23 chromosomes so the resulting embryo will have the usual 46. Meiosis also allows genetic variation through a process of DNA shuffling while the cells are dividing.
Mitosis and meiosis, the two types of cell division. How Do Genes Control the Growth and Division of Cells? A variety of genes are involved in the control of cell growth and division. The cell cycle is the cell’s way of replicating itself in an organized, step-by-step fashion. Tight regulation of this process ensures that a dividing cell’s DNA is copied properly, any errors in the DNA are repaired, and each daughter cell receives a full set of chromosomes. The cycle has checkpoints (also called restriction points), which allow certain genes to check for mistakes and halt the cycle for repairs if something goes wrong.
160
Amyotrophic Lateral Sclerosis
If a cell has an error in its DNA that cannot be repaired, it may undergo programmed cell death (apoptosis). Apoptosis is a common process throughout life that helps the body get rid of cells it doesn’t need. Cells that undergo apoptosis break apart and are recycled by a type of white blood cell called a macrophage. Apoptosis protects the body by removing genetically damaged cells that could lead to cancer, and it plays an important role in the development of the embryo and the maintenance of adult tissues. Cancer results from a disruption of the normal regulation of the cell cycle. When the cycle proceeds without control, cells can divide without order and accumulate genetic defects that can lead to a cancerous tumor.
Genetic Mutations and Health This section presents basic information about gene mutations, chromosomal changes, and conditions that run in families.17 What Is a Gene Mutation and How Do Mutations Occur? A gene mutation is a permanent change in the DNA sequence that makes up a gene. Mutations range in size from a single DNA building block (DNA base) to a large segment of a chromosome. Gene mutations occur in two ways: they can be inherited from a parent or acquired during a person’s lifetime. Mutations that are passed from parent to child are called hereditary mutations or germline mutations (because they are present in the egg and sperm cells, which are also called germ cells). This type of mutation is present throughout a person’s life in virtually every cell in the body. Mutations that occur only in an egg or sperm cell, or those that occur just after fertilization, are called new (de novo) mutations. De novo mutations may explain genetic disorders in which an affected child has a mutation in every cell, but has no family history of the disorder. Acquired (or somatic) mutations occur in the DNA of individual cells at some time during a person’s life. These changes can be caused by environmental factors such as ultraviolet radiation from the sun, or can occur if a mistake is made as DNA copies itself during cell division. Acquired mutations in somatic cells (cells other than sperm and egg cells) cannot be passed on to the next generation. Mutations may also occur in a single cell within an early embryo. As all the cells divide during growth and development, the individual will have some cells with the mutation and some cells without the genetic change. This situation is called mosaicism. Some genetic changes are very rare; others are common in the population. Genetic changes that occur in more than 1 percent of the population are called polymorphisms. They are common enough to be considered a normal variation in the DNA. Polymorphisms are 17
This section has been adapted from the National Library of Medicine’s handbook, Help Me Understand Genetics, which presents basic information about genetics in clear language and provides links to online resources: http://ghr.nlm.nih.gov/handbook.
Help Me Understand Genetics
161
responsible for many of the normal differences between people such as eye color, hair color, and blood type. Although many polymorphisms have no negative effects on a person’s health, some of these variations may influence the risk of developing certain disorders. How Can Gene Mutations Affect Health and Development? To function correctly, each cell depends on thousands of proteins to do their jobs in the right places at the right times. Sometimes, gene mutations prevent one or more of these proteins from working properly. By changing a gene’s instructions for making a protein, a mutation can cause the protein to malfunction or to be missing entirely. When a mutation alters a protein that plays a critical role in the body, it can disrupt normal development or cause a medical condition. A condition caused by mutations in one or more genes is called a genetic disorder. In some cases, gene mutations are so severe that they prevent an embryo from surviving until birth. These changes occur in genes that are essential for development, and often disrupt the development of an embryo in its earliest stages. Because these mutations have very serious effects, they are incompatible with life. It is important to note that genes themselves do not cause disease—genetic disorders are caused by mutations that make a gene function improperly. For example, when people say that someone has “the cystic fibrosis gene,” they are usually referring to a mutated version of the CFTR gene, which causes the disease. All people, including those without cystic fibrosis, have a version of the CFTR gene. Do All Gene Mutations Affect Health and Development? No, only a small percentage of mutations cause genetic disorders—most have no impact on health or development. For example, some mutations alter a gene’s DNA base sequence but do not change the function of the protein made by the gene. Often, gene mutations that could cause a genetic disorder are repaired by certain enzymes before the gene is expressed (makes a protein). Each cell has a number of pathways through which enzymes recognize and repair mistakes in DNA. Because DNA can be damaged or mutated in many ways, DNA repair is an important process by which the body protects itself from disease. A very small percentage of all mutations actually have a positive effect. These mutations lead to new versions of proteins that help an organism and its future generations better adapt to changes in their environment. For example, a beneficial mutation could result in a protein that protects the organism from a new strain of bacteria. For More Information about DNA Repair and the Health Effects of Gene Mutations •
The University of Utah Genetic Science Learning Center provides information about genetic disorders that explains why some mutations cause disorders but others do not. (Refer to the questions in the far right column.) See http://learn.genetics.utah.edu/units/disorders/whataregd/.
162
•
Amyotrophic Lateral Sclerosis
Additional information about DNA repair is available from the NCBI Science Primer. In the chapter called “What Is A Cell?”, scroll down to the heading “DNA Repair Mechanisms.” See http://www.ncbi.nlm.nih.gov/About/primer/genetics_cell.html. What Kinds of Gene Mutations Are Possible?
The DNA sequence of a gene can be altered in a number of ways. Gene mutations have varying effects on health, depending on where they occur and whether they alter the function of essential proteins. The types of mutations include: •
Missense mutation: This type of mutation is a change in one DNA base pair that results in the substitution of one amino acid for another in the protein made by a gene.
•
Nonsense mutation: A nonsense mutation is also a change in one DNA base pair. Instead of substituting one amino acid for another, however, the altered DNA sequence prematurely signals the cell to stop building a protein. This type of mutation results in a shortened protein that may function improperly or not at all.
•
Insertion: An insertion changes the number of DNA bases in a gene by adding a piece of DNA. As a result, the protein made by the gene may not function properly.
•
Deletion: A deletion changes the number of DNA bases by removing a piece of DNA. Small deletions may remove one or a few base pairs within a gene, while larger deletions can remove an entire gene or several neighboring genes. The deleted DNA may alter the function of the resulting protein(s).
•
Duplication: A duplication consists of a piece of DNA that is abnormally copied one or more times. This type of mutation may alter the function of the resulting protein.
•
Frameshift mutation: This type of mutation occurs when the addition or loss of DNA bases changes a gene’s reading frame. A reading frame consists of groups of 3 bases that each code for one amino acid. A frameshift mutation shifts the grouping of these bases and changes the code for amino acids. The resulting protein is usually nonfunctional. Insertions, deletions, and duplications can all be frameshift mutations.
•
Repeat expansion: Nucleotide repeats are short DNA sequences that are repeated a number of times in a row. For example, a trinucleotide repeat is made up of 3-base-pair sequences, and a tetranucleotide repeat is made up of 4-base-pair sequences. A repeat expansion is a mutation that increases the number of times that the short DNA sequence is repeated. This type of mutation can cause the resulting protein to function improperly. Can Changes in Chromosomes Affect Health and Development?
Changes that affect entire chromosomes or segments of chromosomes can cause problems with growth, development, and function of the body’s systems. These changes can affect many genes along the chromosome and alter the proteins made by those genes. Conditions caused by a change in the number or structure of chromosomes are known as chromosomal disorders. Human cells normally contain 23 pairs of chromosomes, for a total of 46 chromosomes in each cell. A change in the number of chromosomes leads to a chromosomal disorder. These changes can occur during the formation of reproductive cells (eggs and sperm) or in early fetal development. A gain or loss of chromosomes from the normal 46 is called aneuploidy.
Help Me Understand Genetics
163
The most common form of aneuploidy is trisomy, or the presence of an extra chromosome in each cell. “Tri-” is Greek for “three”; people with trisomy have three copies of a particular chromosome in each cell instead of the normal two copies. Down syndrome is an example of a condition caused by trisomy—people with Down syndrome typically have three copies of chromosome 21 in each cell, for a total of 47 chromosomes per cell. Monosomy, or the loss of one chromosome from each cell, is another kind of aneuploidy. “Mono-” is Greek for “one”; people with monosomy have one copy of a particular chromosome in each cell instead of the normal two copies. Turner syndrome is a condition caused by monosomy. Women with Turner syndrome are often missing one copy of the X chromosome in every cell, for a total of 45 chromosomes per cell. Chromosomal disorders can also be caused by changes in chromosome structure. These changes are caused by the breakage and reunion of chromosome segments when an egg or sperm cell is formed or in early fetal development. Pieces of DNA can be rearranged within one chromosome, or transferred between two or more chromosomes. The effects of structural changes depend on their size and location. Many different structural changes are possible; some cause medical problems, while others may have no effect on a person’s health. Many cancer cells also have changes in their chromosome number or structure. These changes most often occur in somatic cells (cells other than eggs and sperm) during a person’s lifetime. Can Changes in Mitochondrial DNA Affect Health and Development? Mitochondria are structures within cells that convert the energy from food into a form that cells can use. Although most DNA is packaged in chromosomes within the nucleus, mitochondria also have a small amount of their own DNA (known as mitochondrial DNA or mtDNA). In some cases, inherited changes in mitochondrial DNA can cause problems with growth, development, and function of the body’s systems. These mutations disrupt the mitochondria’s ability to generate energy efficiently for the cell. Conditions caused by mutations in mitochondrial DNA often involve multiple organ systems. The effects of these conditions are most pronounced in organs and tissues that require a lot of energy (such as the heart, brain, and muscles). Although the health consequences of inherited mitochondrial DNA mutations vary widely, frequently observed features include muscle weakness and wasting, problems with movement, diabetes, kidney failure, heart disease, loss of intellectual functions (dementia), hearing loss, and abnormalities involving the eyes and vision. Mitochondrial DNA is also prone to noninherited (somatic) mutations. Somatic mutations occur in the DNA of certain cells during a person’s lifetime, and typically are not passed to future generations. Because mitochondrial DNA has a limited ability to repair itself when it is damaged, these mutations tend to build up over time. A buildup of somatic mutations in mitochondrial DNA has been associated with some forms of cancer and an increased risk of certain age-related disorders such as heart disease, Alzheimer disease, and Parkinson disease. Additionally, research suggests that the progressive accumulation of these mutations over a person’s lifetime may play a role in the normal process of aging.
164
Amyotrophic Lateral Sclerosis
What Are Complex or Multifactorial Disorders? Researchers are learning that nearly all conditions and diseases have a genetic component. Some disorders, such as sickle cell anemia and cystic fibrosis, are caused by mutations in a single gene. The causes of many other disorders, however, are much more complex. Common medical problems such as heart disease, diabetes, and obesity do not have a single genetic cause—they are likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. Conditions caused by many contributing factors are called complex or multifactorial disorders. Although complex disorders often cluster in families, they do not have a clear-cut pattern of inheritance. This makes it difficult to determine a person’s risk of inheriting or passing on these disorders. Complex disorders are also difficult to study and treat because the specific factors that cause most of these disorders have not yet been identified. By 2010, however, researchers predict they will have found the major contributing genes for many common complex disorders. What Information about a Genetic Condition Can Statistics Provide? Statistical data can provide general information about how common a condition is, how many people have the condition, or how likely it is that a person will develop the condition. Statistics are not personalized, however—they offer estimates based on groups of people. By taking into account a person’s family history, medical history, and other factors, a genetics professional can help interpret what statistics mean for a particular patient. Common Statistical Terms Some statistical terms are commonly used when describing genetic conditions and other disorders. These terms include: Statistical Term Incidence
Description The incidence of a gene mutation or a genetic disorder is the number of people who are born with the mutation or disorder in a specified group per year. Incidence is often written in the form “1 in [a number]” or as a total number of live births.
Examples About 1 in 200,000 people in the United States are born with syndrome A each year. An estimated 15,000 infants with syndrome B were born last year worldwide.
Help Me Understand Genetics
165
Prevalence
The prevalence of a gene mutation or a genetic disorder is the total number of people in a specified group at a given time who have the mutation or disorder. This term includes both newly diagnosed and preexisting cases in people of any age. Prevalence is often written in the form “1 in [a number]” or as a total number of people who have a condition.
Approximately 1 in 100,000 people in the United States have syndrome A at the present time. About 100,000 children worldwide currently have syndrome B.
Mortality
Mortality is the number of deaths from a particular disorder occurring in a specified group per year. Mortality is usually expressed as a total number of deaths.
An estimated 12,000 people worldwide died from syndrome C in 2002.
Lifetime risk
Lifetime risk is the average risk of developing a particular disorder at some point during a lifetime. Lifetime risk is often written as a percentage or as “1 in [a number].” It is important to remember that the risk per year or per decade is much lower than the lifetime risk. In addition, other factors may increase or decrease a person’s risk as compared with the average.
Approximately 1 percent of people in the United States develop disorder D during their lifetimes. The lifetime risk of developing disorder D is 1 in 100.
Naming Genetic Conditions Genetic conditions are not named in one standard way (unlike genes, which are given an official name and symbol by a formal committee). Doctors who treat families with a particular disorder are often the first to propose a name for the condition. Expert working groups may later revise the name to improve its usefulness. Naming is important because it allows accurate and effective communication about particular conditions, which will ultimately help researchers find new approaches to treatment. Disorder names are often derived from one or a combination of sources: •
The basic genetic or biochemical defect that causes the condition (for example, alpha-1 antitrypsin deficiency)
•
One or more major signs or symptoms of the disorder (for example, sickle cell anemia)
•
The parts of the body affected by the condition (for example, retinoblastoma)
166
Amyotrophic Lateral Sclerosis
•
The name of a physician or researcher, often the first person to describe the disorder (for example, Marfan syndrome, which was named after Dr. Antoine Bernard-Jean Marfan)
•
A geographic area (for example, familial Mediterranean fever, which occurs mainly in populations bordering the Mediterranean Sea)
•
The name of a patient or family with the condition (for example, amyotrophic lateral sclerosis, which is also called Lou Gehrig disease after a famous baseball player who had the condition).
Disorders named after a specific person or place are called eponyms. There is debate as to whether the possessive form (e.g., Alzheimer’s disease) or the nonpossessive form (Alzheimer disease) of eponyms is preferred. As a rule, medical geneticists use the nonpossessive form, and this form may become the standard for doctors in all fields of medicine. Genetics Home Reference uses the nonpossessive form of eponyms. Genetics Home Reference consults with experts in the field of medical genetics to provide the current, most accurate name for each disorder. Alternate names are included as synonyms. Naming genes The HUGO Gene Nomenclature Committee (HGNC) designates an official name and symbol (an abbreviation of the name) for each known human gene. Some official gene names include additional information in parentheses, such as related genetic conditions, subtypes of a condition, or inheritance pattern. The HGNC is a non-profit organization funded by the U.K. Medical Research Council and the U.S. National Institutes of Health. The Committee has named more than 13,000 of the estimated 20,000 to 25,000 genes in the human genome. During the research process, genes often acquire several alternate names and symbols. Different researchers investigating the same gene may each give the gene a different name, which can cause confusion. The HGNC assigns a unique name and symbol to each human gene, which allows effective organization of genes in large databanks, aiding the advancement of research. For specific information about how genes are named, refer to the HGNC’s Guidelines for Human Gene Nomenclature. Genetics Home Reference describes genes using the HGNC’s official gene names and gene symbols. Genetics Home Reference frequently presents the symbol and name separated with a colon (for example, FGFR4: Fibroblast growth factor receptor 4).
Inheriting Genetic Conditions This section gives you information on inheritance patterns and understanding risk. What Does It Mean If a Disorder Seems to Run in My Family? A particular disorder might be described as “running in a family” if more than one person in the family has the condition. Some disorders that affect multiple family members are caused by gene mutations, which can be inherited (passed down from parent to child). Other conditions that appear to run in families are not inherited. Instead, environmental factors
Help Me Understand Genetics
167
such as dietary habits or a combination of genetic and environmental factors are responsible for these disorders. It is not always easy to determine whether a condition in a family is inherited. A genetics professional can use a person’s family history (a record of health information about a person’s immediate and extended family) to help determine whether a disorder has a genetic component.
Some disorders are seen in more than one generation of a family. Why Is It Important to Know My Family Medical History? A family medical history is a record of health information about a person and his or her close relatives. A complete record includes information from three generations of relatives,
168
Amyotrophic Lateral Sclerosis
including children, brothers and sisters, parents, aunts and uncles, nieces and nephews, grandparents, and cousins. Families have many factors in common, including their genes, environment, and lifestyle. Together, these factors can give clues to medical conditions that may run in a family. By noticing patterns of disorders among relatives, healthcare professionals can determine whether an individual, other family members, or future generations may be at an increased risk of developing a particular condition. A family medical history can identify people with a higher-than-usual chance of having common disorders, such as heart disease, high blood pressure, stroke, certain cancers, and diabetes. These complex disorders are influenced by a combination of genetic factors, environmental conditions, and lifestyle choices. A family history also can provide information about the risk of rarer conditions caused by mutations in a single gene, such as cystic fibrosis and sickle cell anemia. While a family medical history provides information about the risk of specific health concerns, having relatives with a medical condition does not mean that an individual will definitely develop that condition. On the other hand, a person with no family history of a disorder may still be at risk of developing that disorder. Knowing one’s family medical history allows a person to take steps to reduce his or her risk. For people at an increased risk of certain cancers, healthcare professionals may recommend more frequent screening (such as mammography or colonoscopy) starting at an earlier age. Healthcare providers may also encourage regular checkups or testing for people with a medical condition that runs in their family. Additionally, lifestyle changes such as adopting a healthier diet, getting regular exercise, and quitting smoking help many people lower their chances of developing heart disease and other common illnesses. The easiest way to get information about family medical history is to talk to relatives about their health. Have they had any medical problems, and when did they occur? A family gathering could be a good time to discuss these issues. Additionally, obtaining medical records and other documents (such as obituaries and death certificates) can help complete a family medical history. It is important to keep this information up-to-date and to share it with a healthcare professional regularly. What Are the Different Ways in which a Genetic Condition Can Be Inherited? Some genetic conditions are caused by mutations in a single gene. These conditions are usually inherited in one of several straightforward patterns, depending on the gene involved: Inheritance Pattern Autosomal dominant
Description One mutated copy of the gene in each cell is sufficient for a person to be affected by an autosomal dominant disorder. Each affected person usually has one affected parent. Autosomal dominant disorders tend to occur in every generation of an affected family.
Examples Huntington disease, neurofibromatosis type 1
Help Me Understand Genetics
169
Autosomal recessive
Two mutated copies of the gene are present in each cell when a person has an autosomal recessive disorder. An affected person usually has unaffected parents who each carry a single copy of the mutated gene (and are referred to as carriers). Autosomal recessive disorders are typically not seen in every generation of an affected family.
cystic fibrosis, sickle cell anemia
X-linked dominant
X-linked dominant disorders are caused by mutations in genes on the X chromosome. Females are more frequently affected than males, and the chance of passing on an X-linked dominant disorder differs between men and women. Families with an X-linked dominant disorder often have both affected males and affected females in each generation. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons (no male-to-male transmission).
fragile X syndrome
X-linked recessive
X-linked recessive disorders are also caused by mutations in genes on the X chromosome. Males are more frequently affected than females, and the chance of passing on the disorder differs between men and women. Families with an X-linked recessive disorder often have affected males, but rarely affected females, in each generation. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons (no male-to-male transmission).
hemophilia, Fabry disease
Codominant
In codominant inheritance, two different versions (alleles) of a gene can be expressed, and each version makes a slightly different protein. Both alleles influence the genetic trait or determine the characteristics of the genetic condition.
ABO blood group, alpha-1 antitrypsin deficiency
Mitochondrial
This type of inheritance, also known as maternal inheritance, applies to genes in mitochondrial DNA. Mitochondria, which are structures in each cell that convert molecules into energy, each contain a small amount of DNA. Because only egg cells contribute mitochondria to the developing embryo, only females can pass on mitochondrial conditions to their children. Mitochondrial disorders can appear in every generation of a family and can affect both males and females, but fathers do not pass mitochondrial traits to their children.
Leber hereditary optic neuropathy (LHON)
170
Amyotrophic Lateral Sclerosis
Many other disorders are caused by a combination of the effects of multiple genes or by interactions between genes and the environment. Such disorders are more difficult to analyze because their genetic causes are often unclear, and they do not follow the patterns of inheritance described above. Examples of conditions caused by multiple genes or gene/environment interactions include heart disease, diabetes, schizophrenia, and certain types of cancer. Disorders caused by changes in the number or structure of chromosomes do not follow the straightforward patterns of inheritance listed above. Other genetic factors can also influence how a disorder is inherited. If a Genetic Disorder Runs in My Family, What Are the Chances That My Children Will Have the Condition? When a genetic disorder is diagnosed in a family, family members often want to know the likelihood that they or their children will develop the condition. This can be difficult to predict in some cases because many factors influence a person’s chances of developing a genetic condition. One important factor is how the condition is inherited. For example: •
Autosomal dominant inheritance: A person affected by an autosomal dominant disorder has a 50 percent chance of passing the mutated gene to each child. The chance that a child will not inherit the mutated gene is also 50 percent.
•
Autosomal recessive inheritance: Two unaffected people who each carry one copy of the mutated gene for an autosomal recessive disorder (carriers) have a 25 percent chance with each pregnancy of having a child affected by the disorder. The chance with each pregnancy of having an unaffected child who is a carrier of the disorder is 50 percent, and the chance that a child will not have the disorder and will not be a carrier is 25 percent.
•
X-linked dominant inheritance: The chance of passing on an X-linked dominant condition differs between men and women because men have one X chromosome and one Y chromosome, while women have two X chromosomes. A man passes on his Y chromosome to all of his sons and his X chromosome to all of his daughters. Therefore, the sons of a man with an X-linked dominant disorder will not be affected, but all of his daughters will inherit the condition. A woman passes on one or the other of her X chromosomes to each child. Therefore, a woman with an X-linked dominant disorder has a 50 percent chance of having an affected daughter or son with each pregnancy.
•
X-linked recessive inheritance: Because of the difference in sex chromosomes, the probability of passing on an X-linked recessive disorder also differs between men and women. The sons of a man with an X-linked recessive disorder will not be affected, and his daughters will carry one copy of the mutated gene. With each pregnancy, a woman who carries an X-linked recessive disorder has a 50 percent chance of having sons who are affected and a 50 percent chance of having daughters who carry one copy of the mutated gene.
•
Codominant inheritance: In codominant inheritance, each parent contributes a different version of a particular gene, and both versions influence the resulting genetic trait. The chance of developing a genetic condition with codominant inheritance, and the characteristic features of that condition, depend on which versions of the gene are passed from parents to their child.
•
Mitochondrial inheritance: Mitochondria, which are the energy-producing centers inside cells, each contain a small amount of DNA. Disorders with mitochondrial inheritance result from mutations in mitochondrial DNA. Although mitochondrial
Help Me Understand Genetics
171
disorders can affect both males and females, only females can pass mutations in mitochondrial DNA to their children. A woman with a disorder caused by changes in mitochondrial DNA will pass the mutation to all of her daughters and sons, but the children of a man with such a disorder will not inherit the mutation. It is important to note that the chance of passing on a genetic condition applies equally to each pregnancy. For example, if a couple has a child with an autosomal recessive disorder, the chance of having another child with the disorder is still 25 percent (or 1 in 4). Having one child with a disorder does not “protect” future children from inheriting the condition. Conversely, having a child without the condition does not mean that future children will definitely be affected. Although the chances of inheriting a genetic condition appear straightforward, factors such as a person’s family history and the results of genetic testing can sometimes modify those chances. In addition, some people with a disease-causing mutation never develop any health problems or may experience only mild symptoms of the disorder. If a disease that runs in a family does not have a clear-cut inheritance pattern, predicting the likelihood that a person will develop the condition can be particularly difficult. Estimating the chance of developing or passing on a genetic disorder can be complex. Genetics professionals can help people understand these chances and help them make informed decisions about their health. Factors that Influence the Effects of Particular Genetic Changes Reduced penetrance and variable expressivity are factors that influence the effects of particular genetic changes. These factors usually affect disorders that have an autosomal dominant pattern of inheritance, although they are occasionally seen in disorders with an autosomal recessive inheritance pattern. Reduced Penetrance Penetrance refers to the proportion of people with a particular genetic change (such as a mutation in a specific gene) who exhibit signs and symptoms of a genetic disorder. If some people with the mutation do not develop features of the disorder, the condition is said to have reduced (or incomplete) penetrance. Reduced penetrance often occurs with familial cancer syndromes. For example, many people with a mutation in the BRCA1 or BRCA2 gene will develop cancer during their lifetime, but some people will not. Doctors cannot predict which people with these mutations will develop cancer or when the tumors will develop. Reduced penetrance probably results from a combination of genetic, environmental, and lifestyle factors, many of which are unknown. This phenomenon can make it challenging for genetics professionals to interpret a person’s family medical history and predict the risk of passing a genetic condition to future generations. Variable Expressivity Although some genetic disorders exhibit little variation, most have signs and symptoms that differ among affected individuals. Variable expressivity refers to the range of signs and
172
Amyotrophic Lateral Sclerosis
symptoms that can occur in different people with the same genetic condition. For example, the features of Marfan syndrome vary widely— some people have only mild symptoms (such as being tall and thin with long, slender fingers), while others also experience lifethreatening complications involving the heart and blood vessels. Although the features are highly variable, most people with this disorder have a mutation in the same gene (FBN1). As with reduced penetrance, variable expressivity is probably caused by a combination of genetic, environmental, and lifestyle factors, most of which have not been identified. If a genetic condition has highly variable signs and symptoms, it may be challenging to diagnose. What Do Geneticists Mean by Anticipation? The signs and symptoms of some genetic conditions tend to become more severe and appear at an earlier age as the disorder is passed from one generation to the next. This phenomenon is called anticipation. Anticipation is most often seen with certain genetic disorders of the nervous system, such as Huntington disease, myotonic dystrophy, and fragile X syndrome. Anticipation typically occurs with disorders that are caused by an unusual type of mutation called a trinucleotide repeat expansion. A trinucleotide repeat is a sequence of three DNA building blocks (nucleotides) that is repeated a number of times in a row. DNA segments with an abnormal number of these repeats are unstable and prone to errors during cell division. The number of repeats can change as the gene is passed from parent to child. If the number of repeats increases, it is known as a trinucleotide repeat expansion. In some cases, the trinucleotide repeat may expand until the gene stops functioning normally. This expansion causes the features of some disorders to become more severe with each successive generation. Most genetic disorders have signs and symptoms that differ among affected individuals, including affected people in the same family. Not all of these differences can be explained by anticipation. A combination of genetic, environmental, and lifestyle factors is probably responsible for the variability, although many of these factors have not been identified. Researchers study multiple generations of affected family members and consider the genetic cause of a disorder before determining that it shows anticipation. What Is Genomic Imprinting? Genomic imprinting is a factor that influences how some genetic conditions are inherited. People inherit two copies of their genes—one from their mother and one from their father. Usually both copies of each gene are active, or “turned on,” in cells. In some cases, however, only one of the two copies is normally turned on. Which copy is active depends on the parent of origin: some genes are normally active only when they are inherited from a person’s father; others are active only when inherited from a person’s mother. This phenomenon is known as genomic imprinting. In genes that undergo genomic imprinting, the parent of origin is often marked, or “stamped,” on the gene during the formation of egg and sperm cells. This stamping process, called methylation, is a chemical reaction that attaches small molecules called methyl groups to certain segments of DNA. These molecules identify which copy of a gene was inherited
Help Me Understand Genetics
173
from the mother and which was inherited from the father. The addition and removal of methyl groups can be used to control the activity of genes. Only a small percentage of all human genes undergo genomic imprinting. Researchers are not yet certain why some genes are imprinted and others are not. They do know that imprinted genes tend to cluster together in the same regions of chromosomes. Two major clusters of imprinted genes have been identified in humans, one on the short (p) arm of chromosome 11 (at position 11p15) and another on the long (q) arm of chromosome 15 (in the region 15q11 to 15q13). What Is Uniparental Disomy? Uniparental disomy is a factor that influences how some genetic conditions are inherited. Uniparental disomy (UPD) occurs when a person receives two copies of a chromosome, or part of a chromosome, from one parent and no copies from the other parent. UPD can occur as a random event during the formation of egg or sperm cells or may happen in early fetal development. In many cases, UPD likely has no effect on health or development. Because most genes are not imprinted, it doesn’t matter if a person inherits both copies from one parent instead of one copy from each parent. In some cases, however, it does make a difference whether a gene is inherited from a person’s mother or father. A person with UPD may lack any active copies of essential genes that undergo genomic imprinting. This loss of gene function can lead to delayed development, mental retardation, or other medical problems. Several genetic disorders can result from UPD or a disruption of normal genomic imprinting. The most well-known conditions include Prader-Willi syndrome, which is characterized by uncontrolled eating and obesity, and Angelman syndrome, which causes mental retardation and impaired speech. Both of these disorders can be caused by UPD or other errors in imprinting involving genes on the long arm of chromosome 15. Other conditions, such as Beckwith-Wiedemann syndrome (a disorder characterized by accelerated growth and an increased risk of cancerous tumors), are associated with abnormalities of imprinted genes on the short arm of chromosome 11. Are Chromosomal Disorders Inherited? Although it is possible to inherit some types of chromosomal abnormalities, most chromosomal disorders (such as Down syndrome and Turner syndrome) are not passed from one generation to the next. Some chromosomal conditions are caused by changes in the number of chromosomes. These changes are not inherited, but occur as random events during the formation of reproductive cells (eggs and sperm). An error in cell division called nondisjunction results in reproductive cells with an abnormal number of chromosomes. For example, a reproductive cell may accidentally gain or lose one copy of a chromosome. If one of these atypical reproductive cells contributes to the genetic makeup of a child, the child will have an extra or missing chromosome in each of the body’s cells.
174
Amyotrophic Lateral Sclerosis
Changes in chromosome structure can also cause chromosomal disorders. Some changes in chromosome structure can be inherited, while others occur as random accidents during the formation of reproductive cells or in early fetal development. Because the inheritance of these changes can be complex, people concerned about this type of chromosomal abnormality may want to talk with a genetics professional. Some cancer cells also have changes in the number or structure of their chromosomes. Because these changes occur in somatic cells (cells other than eggs and sperm), they cannot be passed from one generation to the next. Why Are Some Genetic Conditions More Common in Particular Ethnic Groups? Some genetic disorders are more likely to occur among people who trace their ancestry to a particular geographic area. People in an ethnic group often share certain versions of their genes, which have been passed down from common ancestors. If one of these shared genes contains a disease-causing mutation, a particular genetic disorder may be more frequently seen in the group. Examples of genetic conditions that are more common in particular ethnic groups are sickle cell anemia, which is more common in people of African, African-American, or Mediterranean heritage; and Tay-Sachs disease, which is more likely to occur among people of Ashkenazi (eastern and central European) Jewish or French Canadian ancestry. It is important to note, however, that these disorders can occur in any ethnic group.
Genetic Consultation This section presents information on finding and visiting a genetic counselor or other genetics professional. What Is a Genetic Consultation? A genetic consultation is a health service that provides information and support to people who have, or may be at risk for, genetic disorders. During a consultation, a genetics professional meets with an individual or family to discuss genetic risks or to diagnose, confirm, or rule out a genetic condition. Genetics professionals include medical geneticists (doctors who specialize in genetics) and genetic counselors (certified healthcare workers with experience in medical genetics and counseling). Other healthcare professionals such as nurses, psychologists, and social workers trained in genetics can also provide genetic consultations. Consultations usually take place in a doctor’s office, hospital, genetics center, or other type of medical center. These meetings are most often in-person visits with individuals or families, but they are occasionally conducted in a group or over the telephone.
Help Me Understand Genetics
175
Why Might Someone Have a Genetic Consultation? Individuals or families who are concerned about an inherited condition may benefit from a genetic consultation. The reasons that a person might be referred to a genetic counselor, medical geneticist, or other genetics professional include: •
A personal or family history of a genetic condition, birth defect, chromosomal disorder, or hereditary cancer.
•
Two or more pregnancy losses (miscarriages), a stillbirth, or a baby who died.
•
A child with a known inherited disorder, a birth defect, mental retardation, or developmental delay.
•
A woman who is pregnant or plans to become pregnant at or after age 35. (Some chromosomal disorders occur more frequently in children born to older women.)
•
Abnormal test results that suggest a genetic or chromosomal condition.
•
An increased risk of developing or passing on a particular genetic disorder on the basis of a person’s ethnic background.
•
People related by blood (for example, cousins) who plan to have children together. (A child whose parents are related may be at an increased risk of inheriting certain genetic disorders.)
A genetic consultation is also an important part of the decision-making process for genetic testing. A visit with a genetics professional may be helpful even if testing is not available for a specific condition, however. What Happens during a Genetic Consultation? A genetic consultation provides information, offers support, and addresses a patient’s specific questions and concerns. To help determine whether a condition has a genetic component, a genetics professional asks about a person’s medical history and takes a detailed family history (a record of health information about a person’s immediate and extended family). The genetics professional may also perform a physical examination and recommend appropriate tests. If a person is diagnosed with a genetic condition, the genetics professional provides information about the diagnosis, how the condition is inherited, the chance of passing the condition to future generations, and the options for testing and treatment. During a consultation, a genetics professional will: •
Interpret and communicate complex medical information.
•
Help each person make informed, independent decisions about their health care and reproductive options.
•
Respect each person’s individual beliefs, traditions, and feelings.
A genetics professional will NOT: •
Tell a person which decision to make.
•
Advise a couple not to have children.
176
Amyotrophic Lateral Sclerosis
•
Recommend that a woman continue or end a pregnancy.
•
Tell someone whether to undergo testing for a genetic disorder. How Can I Find a Genetics Professional in My Area?
To find a genetics professional in your community, you may wish to ask your doctor for a referral. If you have health insurance, you can also contact your insurance company to find a medical geneticist or genetic counselor in your area who participates in your plan. Several resources for locating a genetics professional in your community are available online: •
GeneTests from the University of Washington provides a list of genetics clinics around the United States and international genetics clinics. You can also access the list by clicking on “Clinic Directory” at the top of the GeneTests home page. Clinics can be chosen by state or country, by service, and/or by specialty. State maps can help you locate a clinic in your area. See http://www.genetests.org/.
•
The National Society of Genetic Counselors offers a searchable directory of genetic counselors in the United States. You can search by location, name, area of practice/specialization, and/or ZIP Code. See http://www.nsgc.org/resourcelink.cfm.
•
The National Cancer Institute provides a Cancer Genetics Services Directory, which lists professionals who provide services related to cancer genetics. You can search by type of cancer or syndrome, location, and/or provider name at the following Web site: http://cancer.gov/search/genetics_services/.
Genetic Testing This section presents information on the benefits, costs, risks, and limitations of genetic testing. What Is Genetic Testing? Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. Most of the time, testing is used to find changes that are associated with inherited disorders. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person’s chance of developing or passing on a genetic disorder. Several hundred genetic tests are currently in use, and more are being developed. Genetic testing is voluntary. Because testing has both benefits and limitations, the decision about whether to be tested is a personal and complex one. A genetic counselor can help by providing information about the pros and cons of the test and discussing the social and emotional aspects of testing. What Are the Types of Genetic Tests? Genetic testing can provide information about a person’s genes and chromosomes. Available types of testing include:
Help Me Understand Genetics
177
•
Newborn screening is used just after birth to identify genetic disorders that can be treated early in life. Millions of babies are tested each year in the United States. All states currently test infants for phenylketonuria (a genetic disorder that causes mental retardation if left untreated) and congenital hypothyroidism (a disorder of the thyroid gland). Most states also test for other genetic disorders.
•
Diagnostic testing is used to identify or rule out a specific genetic or chromosomal condition. In many cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical signs and symptoms. Diagnostic testing can be performed before birth or at any time during a person’s life, but is not available for all genes or all genetic conditions. The results of a diagnostic test can influence a person’s choices about health care and the management of the disorder.
•
Carrier testing is used to identify people who carry one copy of a gene mutation that, when present in two copies, causes a genetic disorder. This type of testing is offered to individuals who have a family history of a genetic disorder and to people in certain ethnic groups with an increased risk of specific genetic conditions. If both parents are tested, the test can provide information about a couple’s risk of having a child with a genetic condition.
•
Prenatal testing is used to detect changes in a fetus’s genes or chromosomes before birth. This type of testing is offered during pregnancy if there is an increased risk that the baby will have a genetic or chromosomal disorder. In some cases, prenatal testing can lessen a couple’s uncertainty or help them make decisions about a pregnancy. It cannot identify all possible inherited disorders and birth defects, however.
•
Preimplantation testing, also called preimplantation genetic diagnosis (PGD), is a specialized technique that can reduce the risk of having a child with a particular genetic or chromosomal disorder. It is used to detect genetic changes in embryos that were created using assisted reproductive techniques such as in-vitro fertilization. In-vitro fertilization involves removing egg cells from a woman’s ovaries and fertilizing them with sperm cells outside the body. To perform preimplantation testing, a small number of cells are taken from these embryos and tested for certain genetic changes. Only embryos without these changes are implanted in the uterus to initiate a pregnancy.
•
Predictive and presymptomatic types of testing are used to detect gene mutations associated with disorders that appear after birth, often later in life. These tests can be helpful to people who have a family member with a genetic disorder, but who have no features of the disorder themselves at the time of testing. Predictive testing can identify mutations that increase a person’s risk of developing disorders with a genetic basis, such as certain types of cancer. Presymptomatic testing can determine whether a person will develop a genetic disorder, such as hemochromatosis (an iron overload disorder), before any signs or symptoms appear. The results of predictive and presymptomatic testing can provide information about a person’s risk of developing a specific disorder and help with making decisions about medical care.
•
Forensic testing uses DNA sequences to identify an individual for legal purposes. Unlike the tests described above, forensic testing is not used to detect gene mutations associated with disease. This type of testing can identify crime or catastrophe victims, rule out or implicate a crime suspect, or establish biological relationships between people (for example, paternity).
178
Amyotrophic Lateral Sclerosis
How Is Genetic Testing Done? Once a person decides to proceed with genetic testing, a medical geneticist, primary care doctor, specialist, or nurse practitioner can order the test. Genetic testing is often done as part of a genetic consultation. Genetic tests are performed on a sample of blood, hair, skin, amniotic fluid (the fluid that surrounds a fetus during pregnancy), or other tissue. For example, a procedure called a buccal smear uses a small brush or cotton swab to collect a sample of cells from the inside surface of the cheek. The sample is sent to a laboratory where technicians look for specific changes in chromosomes, DNA, or proteins, depending on the suspected disorder. The laboratory reports the test results in writing to a person’s doctor or genetic counselor. Newborn screening tests are done on a small blood sample, which is taken by pricking the baby’s heel. Unlike other types of genetic testing, a parent will usually only receive the result if it is positive. If the test result is positive, additional testing is needed to determine whether the baby has a genetic disorder. Before a person has a genetic test, it is important that he or she understands the testing procedure, the benefits and limitations of the test, and the possible consequences of the test results. The process of educating a person about the test and obtaining permission is called informed consent. What Is Direct-to-Consumer Genetic Testing? Traditionally, genetic tests have been available only through healthcare providers such as physicians, nurse practitioners, and genetic counselors. Healthcare providers order the appropriate test from a laboratory, collect and send the samples, and interpret the test results. Direct-to-consumer genetic testing refers to genetic tests that are marketed directly to consumers via television, print advertisements, or the Internet. This form of testing, which is also known as at-home genetic testing, provides access to a person’s genetic information without necessarily involving a doctor or insurance company in the process. If a consumer chooses to purchase a genetic test directly, the test kit is mailed to the consumer instead of being ordered through a doctor’s office. The test typically involves collecting a DNA sample at home, often by swabbing the inside of the cheek, and mailing the sample back to the laboratory. In some cases, the person must visit a health clinic to have blood drawn. Consumers are notified of their results by mail or over the telephone, or the results are posted online. In some cases, a genetic counselor or other healthcare provider is available to explain the results and answer questions. The price for this type of at-home genetic testing ranges from several hundred dollars to more than a thousand dollars. The growing market for direct-to-consumer genetic testing may promote awareness of genetic diseases, allow consumers to take a more proactive role in their health care, and offer a means for people to learn about their ancestral origins. At-home genetic tests, however, have significant risks and limitations. Consumers are vulnerable to being misled by the results of unproven or invalid tests. Without guidance from a healthcare provider, they may make important decisions about treatment or prevention based on inaccurate, incomplete, or misunderstood information about their health. Consumers may also experience an invasion of genetic privacy if testing companies use their genetic information in an unauthorized way.
Help Me Understand Genetics
179
Genetic testing provides only one piece of information about a person’s health—other genetic and environmental factors, lifestyle choices, and family medical history also affect a person’s risk of developing many disorders. These factors are discussed during a consultation with a doctor or genetic counselor, but in many cases are not addressed by athome genetic tests. More research is needed to fully understand the benefits and limitations of direct-to-consumer genetic testing. What Do the Results of Genetic Tests Mean? The results of genetic tests are not always straightforward, which often makes them challenging to interpret and explain. Therefore, it is important for patients and their families to ask questions about the potential meaning of genetic test results both before and after the test is performed. When interpreting test results, healthcare professionals consider a person’s medical history, family history, and the type of genetic test that was done. A positive test result means that the laboratory found a change in a particular gene, chromosome, or protein of interest. Depending on the purpose of the test, this result may confirm a diagnosis, indicate that a person is a carrier of a particular genetic mutation, identify an increased risk of developing a disease (such as cancer) in the future, or suggest a need for further testing. Because family members have some genetic material in common, a positive test result may also have implications for certain blood relatives of the person undergoing testing. It is important to note that a positive result of a predictive or presymptomatic genetic test usually cannot establish the exact risk of developing a disorder. Also, health professionals typically cannot use a positive test result to predict the course or severity of a condition. A negative test result means that the laboratory did not find a change in the gene, chromosome, or protein under consideration. This result can indicate that a person is not affected by a particular disorder, is not a carrier of a specific genetic mutation, or does not have an increased risk of developing a certain disease. It is possible, however, that the test missed a disease-causing genetic alteration because many tests cannot detect all genetic changes that can cause a particular disorder. Further testing may be required to confirm a negative result. In some cases, a negative result might not give any useful information. This type of result is called uninformative, indeterminate, inconclusive, or ambiguous. Uninformative test results sometimes occur because everyone has common, natural variations in their DNA, called polymorphisms, that do not affect health. If a genetic test finds a change in DNA that has not been associated with a disorder in other people, it can be difficult to tell whether it is a natural polymorphism or a disease-causing mutation. An uninformative result cannot confirm or rule out a specific diagnosis, and it cannot indicate whether a person has an increased risk of developing a disorder. In some cases, testing other affected and unaffected family members can help clarify this type of result. What Is the Cost of Genetic Testing, and How Long Does It Take to Get the Results? The cost of genetic testing can range from under $100 to more than $2,000, depending on the nature and complexity of the test. The cost increases if more than one test is necessary or if multiple family members must be tested to obtain a meaningful result. For newborn
180
Amyotrophic Lateral Sclerosis
screening, costs vary by state. Some states cover part of the total cost, but most charge a fee of $15 to $60 per infant. From the date that a sample is taken, it may take a few weeks to several months to receive the test results. Results for prenatal testing are usually available more quickly because time is an important consideration in making decisions about a pregnancy. The doctor or genetic counselor who orders a particular test can provide specific information about the cost and time frame associated with that test. Will Health Insurance Cover the Costs of Genetic Testing? In many cases, health insurance plans will cover the costs of genetic testing when it is recommended by a person’s doctor. Health insurance providers have different policies about which tests are covered, however. A person interested in submitting the costs of testing may wish to contact his or her insurance company beforehand to ask about coverage. Some people may choose not to use their insurance to pay for testing because the results of a genetic test can affect a person’s health insurance coverage. Instead, they may opt to pay out-of-pocket for the test. People considering genetic testing may want to find out more about their state’s privacy protection laws before they ask their insurance company to cover the costs. What Are the Benefits of Genetic Testing? Genetic testing has potential benefits whether the results are positive or negative for a gene mutation. Test results can provide a sense of relief from uncertainty and help people make informed decisions about managing their health care. For example, a negative result can eliminate the need for unnecessary checkups and screening tests in some cases. A positive result can direct a person toward available prevention, monitoring, and treatment options. Some test results can also help people make decisions about having children. Newborn screening can identify genetic disorders early in life so treatment can be started as early as possible. What Are the Risks and Limitations of Genetic Testing? The physical risks associated with most genetic tests are very small, particularly for those tests that require only a blood sample or buccal smear (a procedure that samples cells from the inside surface of the cheek). The procedures used for prenatal testing carry a small but real risk of losing the pregnancy (miscarriage) because they require a sample of amniotic fluid or tissue from around the fetus. Many of the risks associated with genetic testing involve the emotional, social, or financial consequences of the test results. People may feel angry, depressed, anxious, or guilty about their results. In some cases, genetic testing creates tension within a family because the results can reveal information about other family members in addition to the person who is tested. The possibility of genetic discrimination in employment or insurance is also a concern.
Help Me Understand Genetics
181
Genetic testing can provide only limited information about an inherited condition. The test often can’t determine if a person will show symptoms of a disorder, how severe the symptoms will be, or whether the disorder will progress over time. Another major limitation is the lack of treatment strategies for many genetic disorders once they are diagnosed. A genetics professional can explain in detail the benefits, risks, and limitations of a particular test. It is important that any person who is considering genetic testing understand and weigh these factors before making a decision. What Is Genetic Discrimination? Genetic discrimination occurs when people are treated differently by their employer or insurance company because they have a gene mutation that causes or increases the risk of an inherited disorder. People who undergo genetic testing may be at risk for genetic discrimination. The results of a genetic test are normally included in a person’s medical records. When a person applies for life, disability, or health insurance, the insurance company may ask to look at these records before making a decision about coverage. An employer may also have the right to look at an employee’s medical records. As a result, genetic test results could affect a person’s insurance coverage or employment. People making decisions about genetic testing should be aware that when test results are placed in their medical records, the results might not be kept private. Fear of discrimination is a common concern among people considering genetic testing. Several laws at the federal and state levels help protect people against genetic discrimination; however, genetic testing is a fast-growing field and these laws don’t cover every situation. How Does Genetic Testing in a Research Setting Differ from Clinical Genetic Testing? The main differences between clinical genetic testing and research testing are the purpose of the test and who receives the results. The goals of research testing include finding unknown genes, learning how genes work, and advancing our understanding of genetic conditions. The results of testing done as part of a research study are usually not available to patients or their healthcare providers. Clinical testing, on the other hand, is done to find out about an inherited disorder in an individual patient or family. People receive the results of a clinical test and can use them to help them make decisions about medical care or reproductive issues. It is important for people considering genetic testing to know whether the test is available on a clinical or research basis. Clinical and research testing both involve a process of informed consent in which patients learn about the testing procedure, the risks and benefits of the test, and the potential consequences of testing.
182
Amyotrophic Lateral Sclerosis
Gene Therapy This section presents information on experimental techniques, safety, ethics, and availability of gene therapy. What Is Gene Therapy? Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient’s cells instead of using drugs or surgery. Researchers are testing several approaches to gene therapy, including: •
Replacing a mutated gene that causes disease with a healthy copy of the gene.
•
Inactivating, or “knocking out,” a mutated gene that is functioning improperly.
•
Introducing a new gene into the body to help fight a disease.
Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under study to make sure that it will be safe and effective. Gene therapy is currently only being tested for the treatment of diseases that have no other cures. How Does Gene Therapy Work? Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein. A gene that is inserted directly into a cell usually does not function. Instead, a carrier called a vector is genetically engineered to deliver the gene. Certain viruses are often used as vectors because they can deliver the new gene by infecting the cell. The viruses are modified so they can’t cause disease when used in people. Some types of virus, such as retroviruses, integrate their genetic material (including the new gene) into a chromosome in the human cell. Other viruses, such as adenoviruses, introduce their DNA into the nucleus of the cell, but the DNA is not integrated into a chromosome. The vector can be injected or given intravenously (by IV) directly into a specific tissue in the body, where it is taken up by individual cells. Alternately, a sample of the patient’s cells can be removed and exposed to the vector in a laboratory setting. The cells containing the vector are then returned to the patient. If the treatment is successful, the new gene delivered by the vector will make a functioning protein. Researchers must overcome many technical challenges before gene therapy will be a practical approach to treating disease. For example, scientists must find better ways to deliver genes and target them to particular cells. They must also ensure that new genes are precisely controlled by the body.
Help Me Understand Genetics
183
A new gene is injected into an adenovirus vector, which is used to introduce the modified DNA into a human cell. If the treatment is successful, the new gene will make a functional protein.
Is Gene Therapy Safe? Gene therapy is under study to determine whether it could be used to treat disease. Current research is evaluating the safety of gene therapy; future studies will test whether it is an effective treatment option. Several studies have already shown that this approach can have very serious health risks, such as toxicity, inflammation, and cancer. Because the techniques are relatively new, some of the risks may be unpredictable; however, medical researchers, institutions, and regulatory agencies are working to ensure that gene therapy research is as safe as possible. Comprehensive federal laws, regulations, and guidelines help protect people who participate in research studies (called clinical trials). The U.S. Food and Drug Administration (FDA) regulates all gene therapy products in the United States and oversees research in this area. Researchers who wish to test an approach in a clinical trial must first obtain permission from the FDA. The FDA has the authority to reject or suspend clinical trials that are suspected of being unsafe for participants. The National Institutes of Health (NIH) also plays an important role in ensuring the safety of gene therapy research. NIH provides guidelines for investigators and institutions (such as universities and hospitals) to follow when conducting clinical trials with gene therapy. These guidelines state that clinical trials at institutions receiving NIH funding for this type of research must be registered with the NIH Office of Biotechnology Activities. The protocol, or plan, for each clinical trial is then reviewed by the NIH Recombinant DNA Advisory Committee (RAC) to determine whether it raises medical, ethical, or safety issues that warrant further discussion at one of the RAC’s public meetings.
184
Amyotrophic Lateral Sclerosis
An Institutional Review Board (IRB) and an Institutional Biosafety Committee (IBC) must approve each gene therapy clinical trial before it can be carried out. An IRB is a committee of scientific and medical advisors and consumers that reviews all research within an institution. An IBC is a group that reviews and approves an institution’s potentially hazardous research studies. Multiple levels of evaluation and oversight ensure that safety concerns are a top priority in the planning and carrying out of gene therapy research. What Are the Ethical Issues surrounding Gene Therapy? Because gene therapy involves making changes to the body’s set of basic instructions, it raises many unique ethical concerns. The ethical questions surrounding gene therapy include: •
How can “good” and “bad” uses of gene therapy be distinguished?
•
Who decides which traits are normal and which constitute a disability or disorder?
•
Will the high costs of gene therapy make it available only to the wealthy?
•
Could the widespread use of gene therapy make society less accepting of people who are different?
•
Should people be allowed to use gene therapy to enhance basic human traits such as height, intelligence, or athletic ability?
Current gene therapy research has focused on treating individuals by targeting the therapy to body cells such as bone marrow or blood cells. This type of gene therapy cannot be passed on to a person’s children. Gene therapy could be targeted to egg and sperm cells (germ cells), however, which would allow the inserted gene to be passed on to future generations. This approach is known as germline gene therapy. The idea of germline gene therapy is controversial. While it could spare future generations in a family from having a particular genetic disorder, it might affect the development of a fetus in unexpected ways or have long-term side effects that are not yet known. Because people who would be affected by germline gene therapy are not yet born, they can’t choose whether to have the treatment. Because of these ethical concerns, the U.S. Government does not allow federal funds to be used for research on germline gene therapy in people. Is Gene Therapy Available to Treat My Disorder? Gene therapy is currently available only in a research setting. The U.S. Food and Drug Administration (FDA) has not yet approved any gene therapy products for sale in the United States. Hundreds of research studies (clinical trials) are under way to test gene therapy as a treatment for genetic conditions, cancer, and HIV/AIDS. If you are interested in participating in a clinical trial, talk with your doctor or a genetics professional about how to participate. You can also search for clinical trials online. ClinicalTrials.gov, a service of the National Institutes of Health, provides easy access to information on clinical trials. You can search for specific trials or browse by condition or trial sponsor. You may wish to refer to a list of gene therapy trials that are accepting (or will accept) patients.
Help Me Understand Genetics
185
The Human Genome Project and Genomic Research This section presents information on the goals, accomplishments, and next steps in understanding the human genome. What Is a Genome? A genome is an organism’s complete set of DNA, including all of its genes. Each genome contains all of the information needed to build and maintain that organism. In humans, a copy of the entire genome—more than 3 billion DNA base pairs—is contained in all cells that have a nucleus. What Was the Human Genome Project and Why Has It Been Important? The Human Genome Project was an international research effort to determine the sequence of the human genome and identify the genes that it contains. The Project was coordinated by the National Institutes of Health and the U.S. Department of Energy. Additional contributors included universities across the United States and international partners in the United Kingdom, France, Germany, Japan, and China. The Human Genome Project formally began in 1990 and was completed in 2003, 2 years ahead of its original schedule. The work of the Human Genome Project has allowed researchers to begin to understand the blueprint for building a person. As researchers learn more about the functions of genes and proteins, this knowledge will have a major impact in the fields of medicine, biotechnology, and the life sciences. What Were the Goals of the Human Genome Project? The main goals of the Human Genome Project were to provide a complete and accurate sequence of the 3 billion DNA base pairs that make up the human genome and to find all of the estimated 20,000 to 25,000 human genes. The Project also aimed to sequence the genomes of several other organisms that are important to medical research, such as the mouse and the fruit fly. In addition to sequencing DNA, the Human Genome Project sought to develop new tools to obtain and analyze the data and to make this information widely available. Also, because advances in genetics have consequences for individuals and society, the Human Genome Project committed to exploring the consequences of genomic research through its Ethical, Legal, and Social Implications (ELSI) program. What Did the Human Genome Project Accomplish? In April 2003, researchers announced that the Human Genome Project had completed a high-quality sequence of essentially the entire human genome. This sequence closed the gaps from a working draft of the genome, which was published in 2001. It also identified the locations of many human genes and provided information about their structure and
186
Amyotrophic Lateral Sclerosis
organization. The Project made the sequence of the human genome and tools to analyze the data freely available via the Internet. In addition to the human genome, the Human Genome Project sequenced the genomes of several other organisms, including brewers’ yeast, the roundworm, and the fruit fly. In 2002, researchers announced that they had also completed a working draft of the mouse genome. By studying the similarities and differences between human genes and those of other organisms, researchers can discover the functions of particular genes and identify which genes are critical for life. The Project’s Ethical, Legal, and Social Implications (ELSI) program became the world’s largest bioethics program and a model for other ELSI programs worldwide. What Were Some of the Ethical, Legal, and Social Implications Addressed by the Human Genome Project? The Ethical, Legal, and Social Implications (ELSI) program was founded in 1990 as an integral part of the Human Genome Project. The mission of the ELSI program was to identify and address issues raised by genomic research that would affect individuals, families, and society. A percentage of the Human Genome Project budget at the National Institutes of Health and the U.S. Department of Energy was devoted to ELSI research. The ELSI program focused on the possible consequences of genomic research in four main areas: •
Privacy and fairness in the use of genetic information, including the potential for genetic discrimination in employment and insurance.
•
The integration of new genetic technologies, such as genetic testing, into the practice of clinical medicine.
•
Ethical issues surrounding the design and conduct of genetic research with people, including the process of informed consent.
•
The education of healthcare professionals, policy makers, students, and the public about genetics and the complex issues that result from genomic research. What Are the Next Steps in Genomic Research?
Discovering the sequence of the human genome was only the first step in understanding how the instructions coded in DNA lead to a functioning human being. The next stage of genomic research will begin to derive meaningful knowledge from the DNA sequence. Research studies that build on the work of the Human Genome Project are under way worldwide. The objectives of continued genomic research include the following: •
Determine the function of genes and the elements that regulate genes throughout the genome.
•
Find variations in the DNA sequence among people and determine their significance. These variations may one day provide information about a person’s disease risk and response to certain medications.
Help Me Understand Genetics
187
•
Discover the 3-dimensional structures of proteins and identify their functions.
•
Explore how DNA and proteins interact with one another and with the environment to create complex living systems.
•
Develop and apply genome-based strategies for the early detection, diagnosis, and treatment of disease.
•
Sequence the genomes of other organisms, such as the rat, cow, and chimpanzee, in order to compare similar genes between species.
•
Develop new technologies to study genes and DNA on a large scale and store genomic data efficiently.
•
Continue to explore the ethical, legal, and social issues raised by genomic research. What Is Pharmacogenomics?
Pharmacogenomics is the study of how genes affect a person’s response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup. Many drugs that are currently available are “one size fits all,” but they don’t work the same way for everyone. It can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience negative side effects (called adverse drug reactions). Adverse drug reactions are a significant cause of hospitalizations and deaths in the United States. With the knowledge gained from the Human Genome Project, researchers are learning how inherited differences in genes affect the body’s response to medications. These genetic differences will be used to predict whether a medication will be effective for a particular person and to help prevent adverse drug reactions. The field of pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. In the future, pharmacogenomics will allow the development of tailored drugs to treat a wide range of health problems, including cardiovascular disease, Alzheimer disease, cancer, HIV/AIDS, and asthma.
188
APPENDIX B. PHYSICIAN RESOURCES Overview In this chapter, we focus on databases and Internet-based guidelines and information resources created or written for a professional audience.
NIH Guidelines Commonly referred to as “clinical” or “professional” guidelines, the National Institutes of Health publish physician guidelines for the most common diseases. Publications are available at the following by relevant Institute18: •
National Institutes of Health (NIH); guidelines consolidated across agencies available at http://health.nih.gov/
•
National Institute of General Medical Sciences (NIGMS); fact sheets available at http://www.nigms.nih.gov/Publications/FactSheets.htm
•
National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines: http://www.nlm.nih.gov/medlineplus/healthtopics.html
•
National Cancer Institute (NCI); guidelines available at http://www.cancer.gov/cancertopics/pdq
•
National Eye Institute (NEI); guidelines available at http://www.nei.nih.gov/health/
•
National Heart, Lung, and Blood Institute (NHLBI); guidelines available at http://www.nhlbi.nih.gov/guidelines/index.htm
•
National Human Genome Research Institute (NHGRI); research available at http://www.genome.gov/page.cfm?pageID=10000375
•
National Institute on Aging (NIA); guidelines available at http://www.nia.nih.gov/HealthInformation/Publications/
•
National Institute on Alcohol Abuse and Alcoholism (NIAAA); guidelines available at http://www.niaaa.nih.gov/Publications/
18
These publications are typically written by one or more of the various NIH Institutes.
Physician Resources
189
•
National Institute of Allergy and Infectious Diseases (NIAID); guidelines available at http://www.niaid.nih.gov/publications/
•
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); fact sheets and guidelines available at http://www.niams.nih.gov/hi/index.htm
•
National Institute of Child Health and Human Development (NICHD); guidelines available at http://www.nichd.nih.gov/publications/pubskey.cfm
•
National Institute on Deafness and Other Communication Disorders (NIDCD); fact sheets and guidelines at http://www.nidcd.nih.gov/health/
•
National Institute of Dental and Craniofacial Research (NIDCR); guidelines available at http://www.nidcr.nih.gov/HealthInformation/
•
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); guidelines available at http://www.niddk.nih.gov/health/health.htm
•
National Institute on Drug Abuse (NIDA); guidelines available at http://www.nida.nih.gov/DrugAbuse.html
•
National Institute of Environmental Health Sciences (NIEHS); environmental health information available at http://www.niehs.nih.gov/external/facts.htm
•
National Institute of Mental Health (NIMH); guidelines available at http://www.nimh.nih.gov/healthinformation/index.cfm
•
National Institute of Neurological Disorders and Stroke (NINDS); neurological disorder information pages available at http://www.ninds.nih.gov/health_and_medical/disorder_index.htm
•
National Institute of Biomedical Imaging and Bioengineering; general information at http://www.nibib.nih.gov/HealthEdu
•
National Center for Complementary and Alternative Medicine (NCCAM); health information available at http://nccam.nih.gov/health/
•
National Center for Research Resources (NCRR); various information directories available at http://www.ncrr.nih.gov/publications.asp
•
Office of Rare Diseases; various fact sheets available at http://rarediseases.info.nih.gov/html/resources/rep_pubs.html
•
Centers for Disease Control and Prevention; various fact sheets on infectious diseases available at http://www.cdc.gov/publications.htm
NIH Databases In addition to the various Institutes of Health that publish professional guidelines, the NIH has designed a number of databases for professionals.19 Physician-oriented resources provide a wide variety of information related to the biomedical and health sciences, both past and present. The format of these resources varies. Searchable databases, bibliographic
19
Remember, for the general public, the National Library of Medicine recommends the databases referenced in MEDLINEplus (http://medlineplus.gov/ or http://www.nlm.nih.gov/medlineplus/databases.html).
190
Amyotrophic Lateral Sclerosis
citations, full-text articles (when available), archival collections, and images are all available. The following are referenced by the National Library of Medicine20: •
Bioethics: Access to published literature on the ethical, legal, and public policy issues surrounding healthcare and biomedical research. This information is provided in conjunction with the Kennedy Institute of Ethics located at Georgetown University, Washington, D.C.: http://www.nlm.nih.gov/databases/databases_bioethics.html
•
HIV/AIDS Resources: Describes various links and databases dedicated to HIV/AIDS research: http://www.nlm.nih.gov/pubs/factsheets/aidsinfs.html
•
NLM Online Exhibitions: Describes “Exhibitions in the History of Medicine”: http://www.nlm.nih.gov/exhibition/exhibition.html. Additional resources for historical scholarship in medicine: http://www.nlm.nih.gov/hmd/index.html
•
Biotechnology Information: Access to public databases. The National Center for Biotechnology Information conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease: http://www.ncbi.nlm.nih.gov/
•
Population Information: The National Library of Medicine provides access to worldwide coverage of population, family planning, and related health issues, including family planning technology and programs, fertility, and population law and policy: http://www.nlm.nih.gov/databases/databases_population.html
•
Cancer Information: Access to cancer-oriented databases: http://www.nlm.nih.gov/databases/databases_cancer.html
•
Profiles in Science: Offering the archival collections of prominent twentieth-century biomedical scientists to the public through modern digital technology: http://www.profiles.nlm.nih.gov/
•
Chemical Information: Provides links to various chemical databases and references: http://sis.nlm.nih.gov/Chem/ChemMain.html
•
Clinical Alerts: Reports the release of findings from the NIH-funded clinical trials where such release could significantly affect morbidity and mortality: http://www.nlm.nih.gov/databases/alerts/clinical_alerts.html
•
Space Life Sciences: Provides links and information to space-based research (including NASA): http://www.nlm.nih.gov/databases/databases_space.html
•
MEDLINE: Bibliographic database covering the fields of medicine, nursing, dentistry, veterinary medicine, the healthcare system, and the pre-clinical sciences: http://www.nlm.nih.gov/databases/databases_medline.html
•
Toxicology and Environmental Health Information (TOXNET): Databases covering toxicology and environmental health: http://sis.nlm.nih.gov/Tox/ToxMain.html
•
Visible Human Interface: Anatomically detailed, three-dimensional representations of normal male and female human bodies: http://www.nlm.nih.gov/research/visible/visible_human.html
20
See http://www.nlm.nih.gov/databases/index.html.
Physician Resources
191
The NLM Gateway21 The NLM (National Library of Medicine) Gateway is a Web-based system that lets users search simultaneously in multiple retrieval systems at the U.S. National Library of Medicine (NLM). It allows users of NLM services to initiate searches from one Web interface, providing one-stop searching for many of NLM’s information resources or databases.22 To use the NLM Gateway, simply go to the search site at http://gateway.nlm.nih.gov/gw/Cmd. Type amyotrophic lateral sclerosis (or synonyms) into the search box and click Search. The results will be presented in a tabular form, indicating the number of references in each database category. Results Summary Category Journal Articles Books / Periodicals / Audio Visual Consumer Health Meeting Abstracts Other Collections Total
Items Found 9280 151 72 6 3 9512
HSTAT23 HSTAT is a free, Web-based resource that provides access to full-text documents used in healthcare decision-making.24 These documents include clinical practice guidelines, quickreference guides for clinicians, consumer health brochures, evidence reports and technology assessments from the Agency for Healthcare Research and Quality
